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Family Planning Methods and Practice: Africa was written both for stu­
dents of medicine, nursing, and midwifery, and their instructors. Health 
wcrkers, program manageis, policymakers, and international organizations 
will also find this book useful. The individuals who prepared the book hope 
that this book will enhance the understanding and availability of family plan­
ning services within Africa. 
The partnership of Africans and Americans is a natural one for preparing 
this book. The Americans bring to the book their experience from working 
on other similar books for American audiences and from providing family 
planning services in several different successful health care systems. The 
Africans, themselves engaged in research and service delivery, bring to the 
book the wealth of their experience, working in nations where traditional 
family plarning methods have been used for centuries and where the health 
care systems are developing in response to the unique needs and challenges 
of Africa. Thus, Family Planning Methods and Practice. Africa is a compila­
tion of documented scientific research, tried-and-true common knowledge, 
and opinion derived from the expertise of those who prepared it. 
I am confident that FarnilyPlanning Methods and Practice. Africa will be 
useful to African health and family planning workers because it takes into 
account specific cultural and pragmatic factors that influence an individual's 
decisions to begin planning the birth of children, to use contraceptives, and 
to choose the most suitable contraceptive method. For example, traditions 
surrounding the naming of children frequently place pressure on couples to 
have as many children as they can have as soon as pcssible. By contrast, 
customs related to the inheritance of land in densely populated areas can, in 
fact, provide a strong incentive for couples to space and limit the'r children. 
In polygamous societies and in areas where husbands leave home to work 
as migrant laborers for extended periods of time, women may have inter­
course infrequently or irregularly and therefore may choose temporary bar­
rier methods over other methods. 
The combination of cultural and biologic factors also needs to be consid­
ered when assessing the risks and benefits of contraceptive use among 
African women. Some culturJl practices that influence the health risks asso­
ciated with the use of some contraceptives for African women include their 
diet, smoking habits, and family composition. 
Furthor considerations in chocsing the best contraceptive method for an 
African woman should include her access to medical care in case of 
complications, her practice of breast-feeding, and the possibility that she 
may have the sickle cell gene which is found in approximately 20% of Afri­
cans in Sub-Saharan Africa. The interrelationship of sickle cell anemia with 
contraception is a subject that has not been adequately studied. 
The patterns of disease to which women are exposed also may influence 
the choice of a contraceptive method. For example, malnutrition or malaria 
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and other infections that contribjute to anemia might contraindicate the 
choice of a particular contraceptive. 
Further, differences in how people live-for example, water sources,
transportation, housing, and literacy--are factors that in part determine the 
ease with which contraceptives can or cannot be used 
The types of health systems and the extenit of tlheir developmoent in­
fluence tie contraceptive methods avaifable to African wonien. Ii several 
countries, maternal and child health centers are tihe pnriary sources of con­
traceptive delivery. Ir soie courrtries, may family plarring methods,
including oral contraceptives, are available without formal medical supervi­
sion through pharmacists, patent medicine stores, and cominiLity-based
distribution systems. Other countries are much more restrictive. 
Traditionally, children are of great importance to couples throughout
Africa because they are perceived by many as an affirmation of life, a sign
of strength, and as an economic necessity. Yet, within African 
communities, there are large numbers of infertile or subfertile couples
whose neighbors have many children. Therefore, this book not only provides
guidance to help couples limit and space their children so that they have the 
number they desire when they warrnt thrll, but also deals with tire problem 
of the infertile couple. 
li acknowledgment of the con tinued desire for large families by some,
anrd in concern over the inipact of inflertility on others, African health profes­
sionals give careful emphasis to contraceptive methods that help couples 
space, rather than limit, children. As a lesult, "child spacing" is a phrase that 
is often used instead of "family planning." Oire of the limitations of this 
phrase, however, is that it doeS irot include tire concept of eithar delaying
the first child irr young adolescents until a girl is socially and medically ready
to have a child or terminating clhildbearing for any of a nurler of medical 
reasons. 
TIre underlying premise of both the Africans and Amriericans who devul­
oped this book is identical. Throughout tile world, niost couples desire to
have children and to bo part of a family. Family planning has been presented
in this book as a compleItely voluntary decision and as an important service 
leading to implove(Ihoalth. Family Planning Methods and Practice: Africa 
upholds the very first principle of family planning which remains: 
"Voluntary farnil, planning is an important health service." 
William H. Foege, M.D. 
Assistant Surgeon General 
Director, Centers for Disease Control 
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Preface 
Family planning, until recently a very sensitive subject in black Africa, is 
now being increasingly accepted as a necessary ingredient of socioeconom­
ic development. Many African leaders now accept family planning as an im­
portant health measure contributing to the health of mothers and children. 
They also accept it as an important contributor to any efforts aimed at the 
improvement in the status of women. 
Unfortunately this understanding, expressed at the national levels and at 
least on two occasions by African parliamentarians at meetings in Nairobi 
and Yaound6, is not being translated into appropriate education, infor­
mation, and services which meet the needs of women and men in Africa. 
In fact, of women of the fertile ages in Africa who need family planning, 
rather less than 10x use effective contraceptives for planning their families 
Such services as exist are often available only to the urban elite or are 
governed by such unnecessary requirements as to make the services virtual­
ly unavailable, except to a small minority. 
In 1974, after much debate in Bucharest, family planning was accepted 
as a human right of individuals and couples. Article 14(F) of the World 
Population Plan of Action states: 
All couples and individuals have the basic right to decide freely and responsibly the 
number and spacing of their children and to have the information, education and 
means to do so; the responsibility of cnuples and individuals in the exercise of this 
right takes into account tie needs of thoir livinrig and fil,ture children, and their responsi­
bilitifis towards the comno rity. 
This shouid be a clear mandate to family planners to stimulate the 
needed plans and programmes to enable rapid services to rural areas. In 
many countries there is a conspiracy of silence about these issues. Even 
doctors who should know the important contributions of family planning 
often hide behind archaic laws and practices and keep quiet. The time has 
come for all those interested in the health and welfare of children and their 
mothers and for the promotion of women's development to include family 
planning in the programmes they advocate. 
Population dynamics need to be taught in schools and out of school. The 
mneaning and implications of human sexuality knowledge should be given to 
everybody before they become biologically mature. Young people who are 
able to have children are old enough to be taught how to prevent having un­
planned pregnancies. 
These subjects should naturally be handled within social and cultural 
norms but should not necessarily be omitted because of them. It is neces­
sary to remember that the Margaret Sangers, Marie Stopes, and Ottesen 
Jenseis of the family planning movement had to face censure, prosecution, 
and even imprisonment for a cause they believed in. Such a fate hardly 
awaits any innovator in family planning today. Yet a lot of timidity is dis­
played over issues such as adolescent services, work among the unmarried, 
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and nonclinical services which will go a long way to meeting tile needs of 
the majority of persons in rural areas and in the urban fringes.
Towards this end Faily Planning Methods and Practice: Africa is avaluable aid. It seeks to pot into the hands of all health workers an authorita­
tive yet concise guide to family planning technology as it exists today. An
African edition has been found necessary, both because there are
environmental, social, aid healthi conditions which do influence other ap­
proaches to familv planning, and also to act as a stimulus for African health
,orkers to monitor family plar rring tecli nology in use under existing African 
conditions. 
US/AID has been the generous sponsor of this publication as indeed ithas been a supporter of many family planning programmes in Africa. Today, 
some African countries can really boast of good beginnings of programmes.
US/AID supplies are a major source of commodities for many countries,
saving them foreign exchange expenditure. Much still needs to be done.
The chances are that without foreign support many programmes will be
less effective. Such assistance, however, should be sensitive to all of the
really pressing iroblems of Africa, and it should not be used as an excuse 
for hectoring or for preaching the 'lagrna of population explosion andcontrol. Africans are accepting family planning as a human right and a 
health measure. That is enough for us fow. 
By 
Fred . Sai 
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Giving birth is some thing in which mankind and animals are equal....
But rearing the young, andespecially educating them formany years is some­
thing which is a unique gift and responsibility of man. It is for this reason that
it is important for human beings to put emphasis on caring for children and
the ability to look after them properly, rather than thinking only about the
number of children and the ability to give birth. For it often happens that
man's ability to give birth is greater than their ability to bring up the children 
in a proper manner 







HEALTH BENEFITS OF FAMILY PLANNING 
In Africa, the average life expectancy at birth is 49 years, infant mortaliy 
averages 149 per 1 ,000 live births, maternal mortality is estimated to ba be­
tween 110 and 647 deaths per 100,000 live births, and contraceptives arg 
used by more than 15', of married women of reproductive age in only two 
countries. Clearly, the health benefits of family planning associated with child 
spacing and the use of specific methods can play a major role in protecting 
the lives of infants, children, women, and the family as a whole on this 
continent. (See Figure 1. I.) 
In this chapter, we provide some fundamental answers to the question 
"WHY IS FAMILY PLANNING IMPORTANT TO THE HEALTH OF THE 
FAMILY?" The health benefits of family planning are obtained either as a 
result of child spacing or directly from the use of contraceptive methods. In 
both cases, all members of the family benefit.' 
Three important factors associated with family planning influence the out­
come of pregnancies: the survival, health, and development of children; the 
survival, health, and reproductive potential of childbearing women; and the 
general well-being of families. These include: 
* 	 interpregnancy interval (tile amnOUIlt of time that has passed between a 
current pregnancy and tile previous pregnancy);
 
" maternal age (the age of the woman who is pregnant); and
 
* 	 pregnancy or birth order (the number of previous pregnancies or births 
that the woman has experienced). 
SURVIVAL AND HEALTH OF CHILDREN 
FETAL DEATHS 
Fetal death rates tend to increase with birth order as shown in Figure 1.2 
(3,4). Deaths per 1,000 deliveries in the last 2 months of pregnancy and 
during the first week following birth in Tientsin, China, more than quadrupled 
for women having their third or more delivery as compared with those having 
their first or second. Fetal death rates have also been shown to increase after 
the second and third pregnancies in numerous other developing countries (5). 
The same study from Tientsin, China, and a study done in England and 
Wales demonstrate that fetal deaths are less likely to occur among pregnant 
women between the ages of 20-34 than among younger or older women as 
shown in Figure 1.3 (6). 
'Many of the examples cited inthis section come from two very UseIul 1 IhIICatIi3 
MAINE, D Family Planning Its Impact on the Health of Women and Children. New York, The 
Center for Population and Family Health, Columhia University, 1981 
OMRAN, A R., STANDLEY, C C Compilers) Family Formation Patterns and Health, Further 
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Birth orderFIGURE 1.2 Fetal deaths during the last 2 months of pregnancy and deathsduring the first week of life, by birth orde Tientsin, China, 1978. 
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FIGURE 1.3 Fetal deaths during the last 2 months of pregnancy and deaths 
during the first week of life, by age of mother Tientsin, China, 19 78, andEn­
glandand Wales, 1977. 
As demonstrated in an international collaborative study conducted in 
Colombia, Egypt, Pakistan, and Syria, the proportion of pregnancies resulting 
in stillbirths and abortions (pregnancy wastage) tends to increase with the 
age of the pregnant woman and higher pregnancy order, and decreases with 
longer periods of time between pregnancies (interpregnancy interval) (7). 
These findings --e illustrated in Figures 1.4-1.6. 
BIRTH DEFECTS 
Infants born to older women have a much greater risk of having birth 
defects than do children born to younger women. This relationship has been 
clearly established in the United States as shown in Figure 1.7 (8). 
The risk of malformations increases rapidly for infants born to women in 
their late thirties. Specific defects that increase with maternal age include 
heart defects, cleft palate and lip, and Down's syndrome (or mongolism) (9). 
INFANT MORTALITY 
The likelihood of infants dying before their first birthday is for greater for 
infants born less than 1 year after the end of their mothers' last pregnancy 
than for infants born after a longer interval (10). This tragic association, 
based on experience in India, isshown in Figure 1.8. 
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FIGURE 1.4 Pregnancy wastage by maternal age and residence. Semi-urban 
Malir/Saudabad and Nazimabad/Paposhnagar) and urban (Karachi), 
Pakistan, 19 75. 
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Zone (OUZ) andNew Settlement Zone (NSZ), Medellin, Colombia, 1975. 
Infants born to women who already have had many births are also more
likely to die in their first year than those bern to women with fewer children.
As in many other countries, after the third or fourth birth, the risk of infant 
death increased sharply in El Salvador, Chile, England, and Wales (6,1 1). (See
Figure 1.9.) In England and Wales, this pattern has remained stable over
several decades, although infant deaths are less common than they used to 
be. Therefore, although improved living conditions and medical care greatly
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FIGURE 1.6 Pregnancy wastage by duration ofpreceding pregnancy interval. 
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FIGURE 1. 7 Infants born with malformations, by age of mother, United 
States, 1973-1974. 
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FIGURE 1. 10 Association between pregnancy spacing and child mortailty 
(0-5 years of age) in Kenya -Msambweni, Kibondo, and Kasula Ethnic 
Groups. 
CHILD NUTRITION AND HEALTH 
The effect of birth order on the survival and health of children is likely to be 
influenced heavily by nutrition, particularly in those African countries that 
suffer from recurrent drought. Children suffering from acute malnutrition 
(body wasting) or chronic malnutrition (stunting of their growth and 
development) are more susceptible to measles and respiratory and other in­
fections and do not recover from parasitic infections and bouts of diarrhea as 
readily as well-nourished children (15). Consequently, mortality among mal­
nourished children who become ill can be as much as 400 times greater than 
that for well-nourished children (15). For this reason, the results from a study 
conducted in India demonstrating the relationship between birth order and 
the daily consumption of calories and protein are of grave concern with re­
spect to child survival and development. The study showed a rapid decline in 
the consumption of both proteins and calories for the third, fourth, and sub­
sequent children born to a family (16). (See Figure 1.11.) 
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FIGURE 1.11 Amount of protein and calories consumed daily, per person, by
number ofchildren in the household, India, 1968. 
CHILDREN'S INTELLIGENCE 
A number of studies in various countries have examined the relationship
between the intelligence of children, as measured through the use of IQ(intelligence quotient), and birth order and interval (7). The results of thesestudies are inconsistent and tenuous. They warrant continued investigation,
however, as do other potential associations that link the full development of 
children with child spacing. 
SURVIVAL AND HEALTH OF MOTHERS
 
BENEFITS OF CHILD SPACING
 
The death of a mother is one of the most traumatic events that can befall afamily. The loss of the mother has an immense impact on the emotional well­being of the family members that survive her. It may also affect the physicalhealth of her survivors since a third of African women earn a living and since women are directly involved in the hygiene and sanitation of children. Child
spacing can protect a woman in significant ways. During the process of re­ceiving family planning services, illnesses can be detected and treated early,which can reduce the likelihood of long-term debilitating problems. If familyplanning services are linked to other family health or maternal/child health
services, high-risk pregnancies can be detected and referred for specialassistance. Moreover, by spacing her children, a woman can avoid high-risk
pregnancies. Finally, when a women uses a contraceptive methodeffectively, she is less likely to resort to dangerous illegal abortions. 
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FIGURE 1. 12 Deaths among women from pregnancy andchildbirthand from 
all other causes, and deaths among men from all causes, by age, Matlab, 
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FIGURE 1.16 Percent of all OStetric hospitalizations attributable to 
abortion, Chile, 1964-19 78. 
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According to the United Nations' Demographic Yearbook, 1978, for theeight African countries that provided information, between 110 and 647women die for every 100,000 live births because of deliveries and complica­
tions of pregnancy, childbirth, and the puerperium (17).
These high rates of maternal mortality are partially attributed to a way ofliving that is common in developing countries: frequent pregnancies, pro­longed lactation, heavy work, and local food customs (e.g., women eat withthe children after the men have satisfied themselves). This combination pro­duces a "continuous cumulative nutritional drain" on women; their bodies donot have time to replenish stores of vital nutrients (16,18). As a result, theyare less able to combat infections associated with pregnancy, childbirth, in­complete abortions, puerperium, or everyday exposures to illness. In Figure1.12, data from Matlab, Bangladesh, illustrate that women of childbearingage have a higher risk of dying than do men in the same age groups becauseof deaths related to pregnancy and childbirth (1 9). In fact, 40"o-60% of alldeaths among women between the ages of 15-34 are associated with 
reproduction. 
Figure 1.13 from the same Bangladeshi study, conducted in 200 villages,shows that the risk of dying climbs steadily as the number of births increases.Maternal deaths from the three major complications of pregnancy in Eng­land and Wales are shown in Figure 1.14 (20). Deaths from hemorrhage
(uncontrolled bleeding) and from pulmonary embolism (blood clots in thelungs) are especially common among women having their fourth or subse­quent birth (21). Toxemia (very high blood pressure during pregnancy thatcan lead to convulsions) is approximately equally high among first and fourth­and-later births, but is much lower among second and third births. In mostparts of Africa, we suspect that the two leading causes of maternal deathsare hemorrhage and sepsis (infection often caused by retained placental
tissue or manual intrauterine intervention).
Although not conclusively documented, a large proportion of maternal
deaths related to pregnancy in Africa 
are probably associated with incom­plete abortions, whether spontaneous, self-induced, or induced by a trained
or untrained practitioner. In Kenyatta National Hospital (Nairobi, Kenya), one­fourth of all obstetric and gynecologic hospital admissions in 1981 involved cases of incomplete abortions (22). The major causes of maternal mortalityrelated to abortion are hemorrhage, sepsis, and a spreading infection that af­fects the uterus, abdominal cavity,and overall body. These conditions, which 
are caused by retained fetal or placental tissue, can lead to septic shock anddeath. Medical colleagues from 12 African countries whom we consultedduring the preparation of this book all consider abortion complications to be amajor public health problem. Data from Chile suggest that prevention of abor­tions through effective contraception can dramatically reduce the number ofmaternal deaths attributable to abortion as well as the percent of all obstetrichospitalizations that are due to abortion (23-25). (See Figures 1.15 and
1.16.) 14 
NONCONTRACEPTIVE BENEFITS OF FAM:L1 PLANNING METHODS 
In Chapters 11 through 21, we have reviewed the health risks, contracep­
tive effectiveness, and some of the major health benefits of each of the 
family planning methods. To expand on the normal perspectives from which 
family planning is discussed, wq have summarized some of the key noncon­
traceptive benefits of family planning methods in the rest of this chapter. 
They are important to keep in mind both for the benefit of the public and indi­
vidual family planning users. 
Oral contraceptives 
In the United States alone, it has been estimated that over 50,000 
hospitalizations-for conditions ranging from benign breast disease to can­
cers of the reproductive tract-are averted each year through the use of oral 
contraceptives (26). Eight diseases listed in Table 1.1 may be prevented by 
oral contraceptive use. For the first five-benign breast disease, ovarian 
cysts, iron-deficiency anemia, pelvic inflammatory disease (first episodes), 
and ectopic pregnancy-the Pill's protective effects are well documented. 
However, its effects on rheumatoid arthritis, endometrial cancer, and ovarian 
cancer need further confirmation. 
TABLE 1. 1 Rate of hospitalization prevented annually by use of oral contra­
ceptives per 100,000 Pill users, and estimated number of hospitalizations 
prevented annually, by specific disease, United States' 
Disease Rate No. 
Benign breast disease 235 20,000 
Ovarian cysts 35 3,000
 
Iron-deficiency anemia" 
 320 27,200 
Pelvic inflammatory 
disease (first episodes) 
Total episodes 600 51,000 
Hospitalizations 156 13,300 
Ectopic pregnancy 117 9,900 
Rheumatoid arthritis* 32 2,700 
Endometrial cancer 5 2,000 
Ovarian cancer 4 1,700
 
*Except where noted, figures refer to hospitalizations prevented among the es­
timated 8.5 million current users of oral contraceptives in the United States.**Episodes prevented regardless of whether hospitalizations occured. 
Based on an estimated 39 million U.S. women who have ever used oral 
contraceptives. 
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In those parts of Africa where endemic or acute drought conditions threat­
en the nutritional status of the populations, or where pelvic inflammatory 
disease, sexually transmitted infections, and infertility are prevalent (see 
Chapter 6), the value of the Pill in safeguarding the health of women should 
be weighed when deciding whether or not to use a contraceptive and when 
choosing a specific method. 
Injectable contraceptives 
In many African countries, before the public debates and newspaper arti­
cles appeared during the last few years on the controversies surrounding the 
use of Depo-Provera'", several programs reported a growing demand for that 
and other injectable contraceptives since they are effective and simple to 
use. Providers and mothers are also insearch of a method that does not inter­
fere with lactation, a factor that is of paramount importance to the survival 
and growth and development of children. Most research has found that 
Depo-Provera ", DOES NOT suppress milk production as do several other 
hormonal contraceptives (27). In fact, some studies report that Depo-
Provera"' increases milk volume and the duration of lactation for the majority 
of women (28-32). Study results have reported increased, unchanged, orde­
creased concentrations of lactose, protein, or lipids in human breast milk 
(29,30,33,34). 
Further, the development of infrequent or scanty menstrual bleeding 
(oligomenorrhea) and the cessation of menses (secondary amenorrhea) 
" during the use of Depo-Provera Imay help to decrease the likelihood of iron­
deficiency anemia among women of reproductive age who are prone to have 
this problem (35). 
Condom, diaphragm, spermicides 
The condom and diaphragm, if used correctly-particularly together with 
a spermicide-are highly effective in preventing the transmission of many 
sexually transmitted diseases (gonorrhea, syphilis, trichomoniasis, 
candidiasis, and herpes genitalis-types 1 and 2) (36-39). In addition, barrier 
methods have been shown to reduce the risk of pelvic inflammatory disease 
(PID) (40). These findings are of particular importance in areas that have high 
rates of sexually transmitted disease and PID, since untreated sexually trans­
mitted infections can lead to PID, which can in turn cause infertility. (See 
Chapters 5 and 6.) 
BENEFITS TO THE COUPLE 
There are four specific ways in which a couple benefits from family 
planning. To begin with, both the man and woman can have more relaxed 
sexual relations when they are confident that intercourse will not lead to an 
unwanted or ill-timed pregnancy. In addition, through the effective use of 
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contraception, they can postpone having their first child or subsequent child­
ren to complete their education or vocational trainiing. This freedom can 
make a significant difference in the economic future of the entire family be­
cause of improved employment opportunities. Further, if family pianning
leads to job security or a sound economic base, the couple can increase itS 
sense of self-respect by being able to provide the type of education and 
home environment (shelter, food, clothing, recreation) that it elects for its 
children. Finally, if a couple provides a positive example to its childian in 
terms of child spacing and takes the time to explain to them what family plan­
ning has meant to the couple and the family, the possibility is strong that the 
children themselves will plan their own reproductive lives and be spared the 
problems associated with an unplanned adolescent pregnancy. 
SUMMARY 
Child spacing or the timing of every birth, including the first and last, can 
improve the likelihood of survival and of good physical arid emotional health 
for the entire family at all stages of life. The risks associated with fetal death, 
birth defects, infant mortality, child mortality, and nutritional depletion for 
women and children, which can lead to an increased risk of infection, mater­
nal mortality, and unfulfilled family members, can all be reduced through ef­
fective family planning. 
In the eyes of many, these health benefits provide the principal rationale 
for family planning programs. While we do not emphasize the point in this 
book, in addition to aiding individuals and families, family planning can benefit 
the community or society as a whole in at least three ways: (1) the health 
benefits to men, women, arid children can result in a more productive labor 
force; (2) the number of unplanned pregnancies resulting ii, abortions can be 
reduced, thereby decreasing the proportion of hospital supplies and staff 
time used to treat women with incomplete, septic abortions; and (3) a basis 
for understanding how, where, and when the population will grow can 
emerge; thus, development plans carl be made in relationship to the number 
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Are you aware of any traditional approaches to regulating fertility? It is 
likely that you know of some practices based on your own professional ex­
periences in family planning, your personal experiences, or the experiences of 
your family and friends. We have grouped traditional practices into two 
categories. One involves the intentional use of locally available plants and 
substances for the purpose of controllinr f. rtility The sprnd groip rnnriqt 
of behavior that may directly or indirectly affect fertility but is not necessarily 
practiced with the intention of spacing children. 
Traditional practices have been used throughout history and are still in use 
today despite the availability of modern contraception. As a provider of 
family planning services, you must be aware that your users may be using a 
traditional practice. You need to assess the effectiveness and safety of these 
practices as well as their compatibility with the various modern methods of 
contraception available to you. In so doing, you will be more effective in help­
ing your users to determine a course of family planning action and to stay 
with it. 
WHAT ARE TRADITIONAL METHODS? 
Historically, people have used many methods to control their fertility. 
Around the world, a large number of plants and other substances have been 
used to control fertility. While we are now beginning to realize how wide­
spread traditional methods of contraception have been, the efficacy of many 
of the practices still needs to be determined. The use of these methods 
makes it evident that people believe in their ability to regulate their fertility 
and have seen a benefit in doing so for quite some time. 
The rapid rate of modernization, urbanization, and social changes exper­
ienced in many African countries makes it difficult to determine how com­
monly traditional methods of fertility regulation are still used. Reports from 
earlier in this century indicated widespread use of these methods More 
recent reports suggest their use continues, at least to some degree. How im­
portant these traditional practices are to you will depend to a large extent on 
where you provide family planning or other maternal and child health 
services. People working in urban clinics and hospitals will probably see 
fewer individuals who actively use traditional approaches to child spacing. 
On the other hand, heath workers in rural settings are more likely to be provid­
ing services to women who frequently use traditional means to regulate their 
fertility. 
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PLANTS AND OTHER SUBSTANCES 
Locally available plants have traditionally been used in a variety of waysto control fertility. The World Health Organization has been compiling infor­mation on the use of traditional contraceptives and abortifacients and hasfound references to the use of over 500 different plants and substances in 
Africa (1).
Plants are used in other ways as well. The oil of the seeds of Buchholziamacrophyl/a is said to have an estrogenic effect and has been used bywomen in Zaire to reduce menstrual flow (2). Many plants are used bywomen to stimulate the flow of breast milk. They are either drunk as teas,like Osyris wightiana in Kenya (3), or rubbed on the breasts like the poundedleaves of Hibiscus surattensis in Tanganyika (4). Other plants are used asspermicides (Saponaria officina/is or Enterolobium cyclocarpum (5), bothused in Egypt), contraceptives (Sphaeranthus cyathuloides in Tanzanyia(3)), or labor-inducing agents (Parinari exceisa in Guinea (6)).The active agents in most of these plants used to regulate fertility havenot been identified. This fact, however, may not mean that they do notwork. Laboratory experiments with some plants have shown them to beeffective. Combretodenron africanum, used in the Ivory Coast, has beenshown to have an anti-implantation effect in rats (7). The effects of Sapona­ria officinalis, used as a spermicide in Egypt, have also been demonstrated 
in controlled laboratory studies (5). 
BEHAVIOR PATTERNS 
Perhaps more important than traditional contraceptives and abortifacients are the cultural practices related to reproduction and sexuality that affectfertility. Post-partum abstinence associated with lactation is the most impor­
tant of these practices in Africa.

Breast-feeding has a clinically demonstrated contraceptive effect, primari­ly before the menses return, as explained in Chapter 3. But its importance as acontraceptive is actually greater, since many cultures discourage sexual inter­course while the mother is breast-feeding. This may be practiced to spacebirths so that each child will receive enough breast milk to survive, or becauseof the mistaken notion that semen pollutes breast milk.
Surveys indicate that lactation and post-partum abstinence are still impor­tant in their effect on fertility in some parts of Africa. A recent survey of fertili­ty in Senegal, for example, revealed little use of modern contraception. Yetthe levels of fertility were only about half of that projected for a populationwith an uninhibited fertility level (8). Lactation and post-partum abstinence,known to be practiced in Senegal, have apparently helped to keep birth inter­vals longer and fertility lower than would have otherwise been the case (9). Arecent survey in Nigeria showed that about 80% of married couples knew of 
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some form of modern contraception but only 10% actually practiced any. The 
most prevalent method of fertility control was abstinence (10). Other 
surveys, for example, in Togo (11), Nigeria (12), and Zaire (13, 14), 
demonstrated the importance of post-partum abstinence for fertility 
regulation, particularly child spacing. 
The impact of this practice on fertility was mathematically demonstrated 
in a recent study (15). The author concluded that prolonged post-partum 
abstinence is a powerful inhibitor of a population's fertility. He further sug­
gested that fertility would rise 40% if post-partum abstinence were to de­
crease from current durations to a 1-year period. 
Polygyny (the practice of having more than one wife, a form of polygamy), 
has also been important as a traditional means of controlling fertility. Polygy­
ny can reinforce effects of the post-partum abstinence by providing the hus­
band with another sexual partner or outlet, thereby decreasing the chances 
that the abstinenct will be violated and sexual relations resumed prematurely 
(16). 
In addition to abstinence after childbirth, and especially during breast­
feeding, there are other culturally mandated periods of abstinence that affect 
fertility. The value placed on virginity in many areas prohibits the beginning of 
sexual activity until a girl is married. This is true for those living in the Kasai 
and Shaba regions of Zaire, for example (16). In some areas, women are sup­
posed to abstain indefinitely from intercourse once they have become 
grandmothers. Thus, there are areas in Africa where abstinence shortens a 
woman's reproductive period at both ends of her reproductive life span, 
determining when she becomes sexually active as well as when she stops. 
When sexual activity is permitted before marriage, it is usually in a limited 
form. Coitus interruptus (withdrawal), coitus inter crura ("between a skin" or 
separated by a garment), and coitus inter femora (between the thighs) are 
methods that, if correctly practiced, provide sexual release while reducing 
the likelihood of pregnancy. 
Another practice that affects fertility and is commonly encountered in 
heavily Islamic areas of Africa is female circumcision. This procedure is per­
formed in three basic ways with different levels of severity. Some of these 
procedures merely entail removing the prepuce of the clitoris and the 
posterior, larger parts of the labia minora. More extensive is the operation 
that removes the glans and thE adjacent parts of the labia minora. This proce­
dure is called "excision" or "reduction." The most extensive procedure is 
called "excision and infibulation." In this procedure, the whole clitoris, all of 
the labia minora, and part of the labia majora are surgically removed, and the 
vaginal opening is almost entirely closed. This procedure is still commonly 
practiced in Sudan, where it is called "pharaonic circumcision" (17). 
These operations are rarely performed by medical personnel, and compli­
cations can be very severe. One of the significant long-term complications is 
the effect on a woman's sexual functioning. A study in Egypt compared 
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1,900 circumcised women with a similar group of uncircumcised women. 
Difficulty in penetrating or successfully completing intercourse or pain during 
coitus was reported by 50" of the circumcised women. Fifty-six percent of 
these women failed to achieve orgasm during intercourse. Perhaps because 
of these problems, 60", of the circumcised women experienced diminished 
coita! frequency, three times less than the level found among the noncircum­
cised group (1 7). ConseCluently, female circumcision can have an important 
effect on fertility by limiting women's exposure to sexual intercourse. 
Many of these practices, especially post-partum abstinence, were more 
important in the past than today. A recent Nigerian survey revealed a marked 
difference between wealthy urban women and poor urban or rural women in 
the duration of post-partum abstinence 1 8). Women of higher socio­
economic status tended to adopt modern contraceptives and to rely less on 
abstinence than did women of lower status. Recent anthropologic reports 
suggest that the stated duration of the period of abstinence has decreased 
noticeably with time (1 9). When the societies that practice a shorter (less 
than 1 year) period of post-partum abstinence are located on a map (Figure 
2.1), three distinctive clusters are apparent. The first cluster stretches from 
Senegal to Somalia across the Sahel. Among these ethnic groups, the decline 
of taboos can be associated with the influence of Islam. While the Qur'an 
stipulates a 2-year period of abstinence, Islamic canon prescribes a post­
partum period of only 40 days, or as long as the bleeding lasts. There are 
Moslem populations in the Sahel that maintain a longer taboo, however (from 
2 months to 1 year), and even a larger cluster in portions of West Africa that 
has maintained the long period of abstinence The impact of the Islamic 
canon appears to decrease the farther south one moves. 
A second cluster of societies with shortened periods of post-partum absti­
nence is found in East Africa, although, in many of these societies, the longer 
period of abstinence is still adhered to by polygynists. The practice of coitus 
interruptus during lactation is widespread in many of these societies and may 
be the reason for the decline in the custom of post-partum abstinence. An 
additional factor in these societies is Christianity, which reduces the practice 
of polygyny (thereby opposing the separation of husband and wife after 
childbirth) and accelerates modernization through literacy. 
The third cluster of societies with a shortened period of post-partum absti­
nence is in the Lacustrine area, where most of the societies engage in animal 
husbandry and regularly consume milk, decreasing the need to abstain from 
intercourse to protect lactation. In Rwanda and Burundi, intensive Christian 
influence may explain the decline in the abstinence practices of other 
societies. In Zaire, the period of abstinence has shrunk most along the lakes 
and in Central Zaire (among the Mongo) and least in the west and south. In 
Southern and Central Ghana, the period has shortened considerably, princi­
pally among Akan peoples (i.e., the Akuapem, Akyem, Kwahu, Ashanti, 
Brong, Fante, Nzima Sefwi, and Ga ethnic groups). 
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Figure 2.1 lists ethnic groups that appear from publishe.; reports to have 
maintained the long post-partum taboo. These ethnic groups are heavily con­
centrated in western Africa. An examination of these maps should give you 
an idea where you can expect to find traditional long periods of post-partum 
abstinence and where you can expect to see newer, shortened periods. 
WHAT TO DO? 
While traditional practices are slowly disappearing, there is ample evi­
dence that some traditional forms of fertility regulation are still fairly 
common. As one who delivers family planning services, you must be able to 
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whether she is using the method conscientiously and effectively, and wheth­
er use of the method iscausing her any problems. Only when you have these
facts will you be in a position to help her make decisions about family planning
that she will be able to carry out with con fidence. 
The rest of this chapter is intended to help you examine your users' tradi­
tional practices and how they can affect the services that you can provide
them. We will take you through a step-by-step approach that will enable you
to get the information you need and to evaluate it, arriving at a method or 
combination of methods that will be suitable for your user. 
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The first step is to determine if your user is using a traditional form of fer­
tility regulation. Answers to the following questions will give you some clues 
as to whether a woman does or does not make use of traditional methods 
and practices: 
* Is she from an urban setting?
 
* 
 Is her area strongly Islamic or strongly Christian?
 
* 
 Does she appear to have adopted modern habits of dress, language, 
and bearing? 
* Does she come from a cattle-raising ethnic group that consumes milk 
regularly? 
* Is she in a monogamous marriage? 
If the answers to all of these questions are "yes," it is likely that the woman 
is not a traditional family planner. In that case, you should suggest modern 
contraception. If, on the other hand, the answers to some of these questions 
are "no," the woman may be traditional in her fertility-related practices. Ask 
her directly if she uses any means to space her births. These questions may 
serve as a guideline: 
" Do you breast-feed your children? How long do you breast-feed before 
you begin to supplement the child's diet? How long do you breast-feed 
before weaning the child completely? 
* Do you abstain from sexual intercourse completely while you are 
breast-feeding? How long do you abstain? How long are you supposed 
to abstain? 
* Do you use any means of contraception at all, especially methods that 
you have not r3ceived from a clinic or health professional?
If the answer to the first question in each series is "no," proceed with recom­
mending modern contraception. 
If the woman answers "yes," however, and she breast-feeds and abstains 
for a substantial period of time, the woman is probably a family planner, and 
modern contraception alone may not be the best course of action. Additional 
information is needed; specifically, you must determine how reliable this 
woman is in adhering to traditional family planning practices and how effec­
tive her method of choice is. Ask her if she has intentionally attempted to 
space her births. Use these questions as a guide to getting the further infor­
mation you need: 
* How many children do you have? How many do you want to have?
 
* 
 How far apart are your children in age? How far apart should childreil be 
spaced?
 
* How long will it be before you want to have another child? 
If the woman has more children than she intended or if her children are 
more closely spaced than she had desired, recommend a modern method of 
contraception. The traditional method she has used may have required long
periods of sexual abstinence that she and her husband have found difficult. 
Modern contraception may be easier for her to use and will allow her greater 
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sexual activity. In this case, there may be indications that an IUD would be the
safest choice, as it requires the least amount of user attention. 
If the answers to these questions reveal the woman is managing to control 
her fertility to her satisfaction through the use of her traditional means, youneed to investigate the safety of her method of choice. This step may be 
more difficult. If the woman is effectively spacing her births through acombi­
nation of breast-feeding and abstinence, there is nothing safer. If this is the 
case, the best course of action is probably to recommend a barrier method ofcontraception as a backup to her traditional practices. For example, you
might recommend that the woman use foam or condoms just in, case her
resolve to abstain, or her husband's resolve, should weaken. 
Completely replacing her traditional practice with a modern method ofcontraception may not be productive. In many places, particularly in rural 
areas, there are still difficulties encountered in maintaining a consistent
supply of contraceptives. If you cannot guarantee that your user will be able 
to obtain the supplies she needs, you may be doing her a disservice by dis­
rupting her traditional patterns and replacing them with at best spotty cover­
age with modern contraceptives. Furthermore, some types of oral contracep­
tives (the combination Pills) should be prescribed with caution for lactating
women. If used improperly, they can decrease the milk yield and shorten the
period of lactation (see Chapter 3). In cases where the period of sexual absti­
nence is directly related to breast-feeding, the improper use of a combination
Pill could expose women to another pregnancy sooner than they would have 
been had they followed their traditional practice. 
In the case of traditional contraceptives and abortifacients, however, it is 
very difficult to determine how safe they are for the user. There are many
types in use and many different means of using them. Active agents have notbeen identified for many of these substances. The decision about the safety
of these methods must be yours. There are no guidelines we can offer,though we can suggest that you question the woman dbout any side effects 
she may have experienced while using these methods. While this may require
prompting and clever investigation, she will be your best source of
information. If you have any doubt at all about the safety of her 
contraceptive, recommend amodern method. 
In general, if a woman is willing to use a traditional contraceptive method,
she may be willing to use a modern method, especially one that is analogous.
For example, women who are accustomed to using traditional barrier meth­
ods that require vaginal insertion may be more willing to switch to a dia­phragm or foam. Similarly, women who use traditional methods that are
taken orally may be candidates for the Pill. Stressing the overall effects on her 
health may convince her to switch to a modern methud. 
Before you recommend such a switch, however, you should try to deter­
mine how receptive the woman is to changing her method and using modern
contraception. If she is resistant to change, try to determine the source of 
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that resistance. Consider the following questions in each case: 
" Will giving the woman contraception put her in disfavcr with her 
husband? Is he aware that she is receiving care at your clinic? 
* Will it open her to criticism from the other women inher group?

" Wi'. she be in disfavor with her mother? 
 her mother-in-law? her 
grandmother? 
* 	 Does she have the freedom to get to the clinic when she needs to, or isit 
difficult for her to leave her household? 
If the woman appears to be socially free to use modern contraception,
recommend that she do so. Even if not totally socially free, recommend that a 
woman adopt a method if she wants to space or limit the number of children 
she will have. However, in this case, your responsibility goes beyond provid­
ing contraceptive services. Counsel her about the pressures that she is
encountering, reinforce her decision to use a modern method, and help herto
develop good justifications for the use of her method. Assure her that she 
can contact the health clinic for further reassurance, for answers to
questions, or for help in discussing with others their concerns about her use 
of 	the contraceptive. It is preferable to schedule a return visit, even if her
method of choice does not require it, to check on her progress with
contraception, and to help her with any problems-medical or social-that 
she may be having with its use 
As you can see, it isdifficult to make comprehensive recommendations to
all women regarding the use of traditional family planning methods. The
preceding series of questions are intended to help you to arrive at a suitable 
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CHAP TER 3 
LACTATION 
It is likely that even now, when consideredon a globalscale, more 
births are prevented by breast-feeding than by any other method 
of contraception. 
CarlDjerassi 
The Politics of Contraception, 19 79 
If we could develop contraceptives that promoted breast-feeding, 
they would increase the birth interval and reduce the infant mor­
tality rate at the same time. 
Dr Roger Short 
RoyalSociety ofLondon- 19 76 
The majority of mothers in the world breast-feed their babies for at least 3 
months. Breast-feeding, a very natural and effective process for providing a 
growing infant with high quality, no-cost nutrition, has two distinct advan­
tages that will be described in this chapter: 
1. Breast-feeding is a valuable means of fertility control. 
2. Breast-feeding is often crucial to infant health and survival (1). 
PREVALENCE 
Traditionally, many African mothers have relied on breast-feeding as a 
method of delaying their next pregnancy. In addition, the period of breast­
feeding, or lactation, is often accompanied by a period of abstinence. The 
husband might sleep in a separate dwelling or, if he is polygamous, with 
another wife. 
The length of time that abstinence is practiced varies. Some mothers ob­
serve traditional customs that prohibit intercoursc for a lotig period nf time, 
measured by some activity of the child. For example, some cultures prohibit
intercourse until a child can carry a bowl of food to the father, lift a three­
legged stool, or walk steadily- usually at about 2 years of age. 
With changing patterns of education, job opportunities for women, 
economic circumstances, and living conditions, however, abstinence, if done 
at all, is practiced for much shorter periods. In 1977, 90% of Nigerian women 
who were studied abstained for only 1 year (2). According to a recent report,
the majority of Kenyan women stopped abstaining by 6 months after birth; 
about 50% stopped abstaining by 3 months (3). The unfortunate result of 
these changing practices of abstinence is that many breast-feeding mothers 
now rely on breast-feeding alone, without abstinence or modern 
contraceptives, to delay their next pregnancy. 
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Patterns of breast-feeding are also changing as Africa becomes more 
urbanized. Most mothers continue to breast-feed their infants for 1 to 2 
years (2,4,5). Mothers in rural areas, however, tend to breast-feed for a 
longer time than mothers in urban areas. In a Nigerian study, for example, it 
was found that rural and poor urban mothers breast-feed their infants an 
average of 18 months. More affluent urban mothers, on the other hand, 
breast-feed their infants a much shorter period of time. Only 10% of the afflu­
ent urban mothers continued breast-feeding for 18 months (2). 
Not only does the length of time a woman nurses her child differ between 
rural and urban mothers, but also other practices vary. The rural mother is 
more likely to practice "full" breast-feeding for a longer period, to carry her 
baby with her at all times as she goes about her daily activities, and to sleep 
with her baby at night so that the infant may feed on demand. 
EFFECTIVENESS OF BREAST-FEEDING 
AS A CONTRACEPTIVE 
How reliable is breast-feeding as a contraceptive? During the first month 
after delivery, the likelihood of pregnancy is low whether or not a mother 
breast-feeds her child since she is usually amenorrheic during this time. 
STUDIES HAVE SHOWN THAT AFTER MENSTRUATION RESUMES, THE 
RISK OF PREGNANCY IS SIMILAR WHETHER OR NOT A WOMAN BREAST-
FEEDS (6,7). THIS SUGGESTS THAT THE PREGNANCY-PREVENTING 
PROPERTIES OF BREAST-FEEDING ARE PRIMARILY LIMITED TO THE A-
MENORRHEIC PERIOD (6). 
However, there is no way of predicting when menstruation or ovulation will 
resume. After delivery, mothers take varying lengths of time to resume regu­
lar menstruation. In general, post-partum amenorrhea lasts longer in breast­
feeding mothers than in nonbreast-feeding mothers. For most breast-feeding 
mothers, the duration of post-partum amenorrhea depends, in part, on the 
duration and frequency of breast-feeding; in different studies the duration 
ranges from 4 months to 24 months. For most nonbreast-feeding mothers, 
post-partum amenorrhea lasts about 2 months to 3 months (8). 
But amenorrhea does not offer a completely reliable indication of the con­
traceptive effectiveness of breast-feeding. Nearly 80% of breast-feeding 
mothers ovulate before their first menstrual period (9). Ovulation may occur 
as early as 2 months after delivery. Anywhere from 3% to 7% of breast­
feeding mothers will become pregnant before they have their first menstrual 
period (8). 
On the other hand, breast-feeding does offer some protection against 
pregnancy. In areas where breast-fecding is prolonged, "expected" numbers 
of births do not occur. For example, a study in Rwanda showed that 50% of 
breast-feeding mothers became pregnant within 18 months after delivery 
compared with 50% of nonbreast-feeding mothers, who became pregnant 
by 4 months after delivery (10). In another study, only 5% of breast-feeding 
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mothers became pregnant within 9 months after delivery compared with 
75% of nonbreast-feeding mothers; and 75' of breast-feeding mothers 
were still not preonant 15 months after delivery (11). 
Not only can pregnancy rates in a population be affected by breast-feeding 
or 	not breast-feeding, but also the rates can be affected by how breast­
feeding is practiced. In Rwanda, urban mothers who breast-fed became preg­
nant 12 months to 16 months earlier than rural mothers who breast-fed (12). 
Among the factors that might explain the greater contraceptive effectiveness 
in rural women are: 
* 	 Less use of breast milk supplements 
* More prolonged breast-feeding
 
" More breast-feeding on demand (around-the-clock)
 
* 	 More simultaneous use of abstinence during breast-feeding 
We emphasize, however, that while prolonged breast-feeding is a highly 
effective contraceptive when the entire population is taken into account, it 
may be a less reliable contraceptive for the individual woman. Since the time 
when menstruation will resume varies greatly, a woman does not know when 
the protection of lactational amenorrhea will end. Further; ovulation may 
occur before menstruation resumes (9,10). Thus, it is possible that a woman 
can become pregnant while she is breast-feeding. The most effective contra­
ceptive effects of breast-feeding probably occur during the first 6 months 
when a woman is not supplementing the breast milk with other types of food. 
After 6 months, a woman would be wise to begin another contraceptive 
method to prevent pregnancy. Many experts encourage beginning appropri­
ate contraceptive methods at the 6-week post-partum examination, or even 
after delivery. The woman who desires to have maximum protection agjainst 
becoming pregnant while she is still breast-feeding her child should begin 
contraception as soon as permissible (9,11). 
MECHANISM OF ACTION 
THE PHYSIOLOGY OF LACTATION 
Successful breast-feeding depends on perinatal practices. The sucking of 
the newborn infant causes two reflexes in the mother that lead to milk pro­
duction and the prevention of pregnancy: 
1. Prolactin reflex: As the baby sucks, impulses are sent from the areola 
of the nipple to the vagus nerve and then to the anterior pituitary.The 
3nterior pituitary secretes the hormone prolactin, which stimulates 
glands in the breast to produce milk. It also produces a contraceptive 
action by decreasing the level of the leutinizing hormone necessary for 
rTgintaining the menstrual cycle (13). (See Figures 3.1 and 3.2.) 
2. 	L,3'-down reflex: As the baby sucks, impulses are sent from the areola 
to the vagus nerve and then to the posterior pituitary The posterior 
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pituitary then releases the hormone oxytocin, which causes the muscle
cells in the areola to contract and squeeze out milk. Oxytocin also helpsthe uterus contract to its normal condition. The mother's let-downreflex is also stimulated by seeing or hearing her baby. This reflex can
be inhibited,however, by stress or anxiety, making nursing difficult.Although prolactin has a contraceptive effect, lactation does not postponemenstruation ovulation indefinitely. THE LONGERor 	 A MOTHER BREAST-FEEDS, THE MORE LIKELY SHE WILL BEGIN TO MENSTRUATE OR BECOMEPREGNANT WHILE SHE CONTINUES TO BREAST-FEED. Moreover, a reduc­tion from full breast-feeding to partial breast-feeding usually causes the 
menstrual cycle to resume (6). 
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FIGURE 3. 1Anatomy of the breast and milk production in the breasts. 
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THE MILK LET-DOWN REFLEX 
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FIGURE3.2 Physiology of lactation and the milk let-down reflex. 
It is the frequency and duration of breast-feeding that most reduce the 
chance of pregnancy. The more frequent the stimulation of the breast by 
sucking (if, for example, the baby is nursed on demand and depends more on 
breast milk for its nutritional needs), the more intense will be the reflex stimu­
lation of prolactin, which causes lactation to have a contraceptive effect. 
Stimulation of prolactin is greatest when the baby sucks frequently during 
both day and night. 
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Contraceptive counseling should begin in the antenatal period. Contracep­
tive use should begin either immediately after delivery or at the 6-week post­
partum examination, depending upon which contraceptive method is
chospn. In many cases, this may be one of the few times a woman has accessto medical care. The contraceptive method chosen for a woman after child­
birth should be one that does not interfere with the mother's ability to pro­
duce breast milk in sufficient quantity and quality. Contraceptives given at
the 6-week post-partum examination or later are less likely to interfere with
breast-feeding because lactation has already been fully established by that
time. If a woman practices "full" breast-feeding (that is, frequent and
prolonged), contraceptive use may be delayed until the baby's diet is 
supplemented- usually at 6 months. 
Here are several contraceptive methods from which to choose (14, 15):
Abstinence, if practiced properly, is 100% effective in preventing
pregnancy. If the mother chooses to remain abstinent while she is breast­
feeding, this can be considered a suitable method of contraception. She
should, however, be counseled about other contraceptive methods should 
she desire to resume having intercourse. Some mothers practice abstinence
because they believe intercourse will harm their breast milk. Assure mothers
that sexual relations will in no way harm their ability to breast-feed-unless 
they get pregnant. Having been educated in this manner, the mother can 
make an informed decision concerning the practice that best suits her. 
Spermicides, such as foams, foaming tablets, creams, or jellies have no

effect on breast-feeding. These 
can be used safely in the immediate post­
partum period.
 
Barrier methods, such as 
the condom or diaphragm, have no effect on

breast-feeding. Condoms may be used safely in the immediate post-partum

period. However, the diaphragm cannot be fitted properly until the vaginal
canal returns to its normal size and shape. Fitting may be performed at the




Inert IUD's, such 
as the Lippes Loop® or Saf-T-Coil®, probably do not
affect breast-feeding, although some mothers experience mild uterine
cramping when they breast-feed while an IUD is in place. In most cases, the
cramping does not hinder the mother. Because of the high rate of expulsions
of IUD's inserted immediately post partum, the 6-week post-partum exami­
nation is probably a better time to insert the IUD. Two new IUD's do appear to
reduce the risk of expulsion after immediate post-partum insertion. The Delta 
T® and the Delta Loop® have sutures tied to their upper limbs; 1/2-cm ends
of the sutures project downward at a 450 angle (16). If available, these IUD's 
may be inserted in the immediate post-partum period. 
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Medicated IUD's are also an acceptable choice of contraceptive for the 
" breast-feeding mother. The copper on the Copper-T ;or the Copper-7 ' does 
not appear to affect the quantity oi quality of breast milk (1 7). The 
progesterone-containing IUD has only a small amount of progesterone, 
which is released slowly over 1 year. Progestins have little or no effect on 
breast-feeding. If available, progesterone-containing IUD's may be used 
safely. The disadvantage of the medicated IUD's, however, is that they need 
to be replaced every year, in the case of the progesterone-containing IUD, 
and every 3 years in the case of the copper-bearing IUD's. The best time to 
insert these IUD's is at the 6-week post-partum examination. 
Tubal ligations are an excellent method for those mothers who have had 
all the children they want. In many African nations, tubal ligations are general­
ly scheduled a month or two after delivery. However, tubal ligations can be 
performed immediately after delivery with no adverse effects on the mother. 
POST-PARTUM TUBAL LIGATION AND USE OF ANESTHESIA 
If you are considering performing a tubal ligation immediately 
after delivery, use a regional or local anesthetic if possible, instead 
of a general anesthetic. Many clinicians have observed that gener­
al anesthesia or heavy sedation during labor or immediately after 
delivery can be associated with problems in beginning successful 
breast-feeding. The sedatives carried in the breast milk may 
affect the infant's sucking response. A poor sucking response 
begins a vicious cycle of poor milk supply that again discourages 
the sucking response. The use of general anesthesia or heavy se­
dation during a post-partum tubal ligation may have the same 
effect. 
Oral contraceptive Pills are frequently prescribed for breast-feeding 
African mothers. In a global survey of physician practices, estrogen­
containing oral contraceptives were provided to lactating women by 63% or 
more of the responding physicians in developing nations and in less than 40% 
of the responding physicians in developed countries (18). The figure was 
highest in Africa (88%), and lowest for North America (26%). Many clinicans, 
however, are concerned that the oral contraceptive Pill will decrease the 
amount of milk the mother produces. In high doses, estrogen can suppress 
lactation and decrease milk supply. The dose of estrogen in oral contraceptive 
Pills can affert the milk supply, especially if the Pills are begun immediately 
after delivery or before lactation has been fully established (19). Lower-dose 
estrogen oral contraceptive Pills are believed to affect lactation less. Al­
though research still needs to be done in Africa, based on available study 
results, many experts believe that the lower-dose oral contraceptive Pills 
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(30-35 mcg estrogen) are good contraceptive choices for breast-feeding
mothers provided they are given after the mother has begun breast-feeding 
successfully 
Progesterone-only contraceptives may have little or no effect onlactation, according to studies. Some studies have shown that a decreased
milk supply results from the use of progesterone-only contraceptives but
that the quality of the milk is not affected. Other studies have shown an ap­parent reduction in the nutritional value of the milk, but this is compensated
for by an increased milk supply (19,20). IN GENERAL, THE BEST HORMONAL
CONTRACEPTIVE FOR BREAST-FEEDING MOTHERS IS ONE THAT HASPROGESTERONE ONLY (SUCH AS THE MINI-PILL OR DEPO-PROVERA, 
INJECTION) AND THE LEAST POSSIBLE ESTROGENIC EFFECT 
INA 150-MG 
(21). (See Figure 3.3.) BOTH OF THESE MAY BE GIVEN IMMEDIATELY POSTPARTUM OR WHEN THE MOTHER RETURNS FOR HER 6-WEEK POST-
PARTUM EXAMINATON. A!though their numbers are small, in the global
survey mentioned above, the percentage of African clinicians that received
complaints of decreased milk supply from women using progestin-only Pills 
was significantly smaller (0>) than the percentage receiving complaints from 





FIGURE 3.3 Progestin-only oral contraceptives appear to be a better contra­
ceptive option than estrogen-containing combined Pills for the lactating 
woman. 
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How do hormonal contraceptives affect the nursing baby? 
Experts are uncertain, although they surmise that Pills and in­
jections present no hazard if they contain 2.5 mg or less of 19­
nonprogesterone and 50 mcg or less of ethinylestradiol or if they 
contain 100 rncg or less of mestranol (22). 
Little is known about the short- or long-term effects from 
exposure to oral contraceptive drugs during infancy. Breast en­
largement in male and female infants has been reported when 
mothers had taken oral contraceptives with higher estrogen and 
progesterone doses than currently used. One study has shown 
that very little of the drugs actually passes through the mother's 
milk: about one-fifth to one-tenth of the d-norgestrel dose taken 
by the mother (20). Another study has shown that the amount of 
estradiol from a 50-mcg dose Pill has only a minimal transfer and 
that it does not exceed the transfer that occurs during physiologic 
conditions once the mother has resumed ovulation (23). Further 
research into the effects of hormones on breast-feeding infants 
is needed. 
COMPLICATIONS OF BREAST-FEEDING 
Breast-feeding is associated with relatively few complications although 
one, as noted previously, is the risk that a pregnancy can occur. The more 
commonly encountered complications for the mother involve the effects of 
breast-feeding on the breast. (See Table 3.1.) For the infant, it is diarrhea 
when fed breast milk, but not to the extent of bottle-fed babies. 
Yet another complication of major concern, along with the risk of 
pregnancy, is the toll on the mother's nutritional health if she is suffering 
from an inadequate diet. For many mothers, the added demand that breast­
feeding makes on her body can be met by her increasing the quality and 
quantity of the foods in her diet. For others, however, diet alone will not 
suffice. 
The maternal depletion syndrome, in which a mother is literally drained 
of body nutrients by a rapid succession of pregnancies, is an extreme exam­
ple of the need for child spacing. The mother's body has given so much of her 
nutrient stores to each developing fetus and nursing infant that she appears 
20 or 30 years older than she actually is. 
A more common nutritional complication of breast-feeding is anemia. 
Usually, anemia will occur during pregnancy by two mechanisms of action: 
(1) hemodilution associated with pregnancy results in a physiologic anemia 
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TABLE 3. 1. Complications ofbreast-feeding and their managemen t 









































feedings so baby is 

ravenous, allergy to 

lanolin, allergy to wool, 

nipples not kept dry.
 
Persistantly sore nip-
pies, inflammation of 
nipples and areola; baby 
has white patches in 
mouth. 
Baby not gaining 
weight; sucking notof 
interest to baby for 
more than a few 




Reassure mother this is not unusual. The pain
is related to apoorly functioning let-down 
response and will disappear within a few 
weeks. 
Mother should breast-feed frequently. 
Mother and baby should not be separated in 
early weeks after birth since breasts fill more 
rapidly at this time. 
Mother should apply moist heat to breast and 
massage the breast beginning behind the 
plugged duct ano moving toward the nipple.




Mother should fold her arms overher chest 
and press firmly toward chest wall. She 
should apply pressure directlyover nipples 
with finger or thumb. 
Mother should continue breast-feeding; the 
infection will not harm baby. Moist heat
 
should be applied to the breast, the mother
 
should be urged to drink fluids and to rest in
 
bed, and antibiotics appropriate for staph

infection should be given.
 
The mother should rest her breast for several
 
hours but not allow it to become overfull. She
 
should change positions while nursing. The
 




Treat with nystatin or 1",-21' gentian violet, if 
severe. Treat with I tsp. baking soda in 1 cup 
water for mild cases. Treat any vaginal yeast 
infections. 
Encourage complete emptying of the breast. 
The more the mother nurses, the more milk 
that is produced. Discourage supplementing 
breast milk in the first few months. 
(25) and (2) the demand the developing fetus makes on the mother's nutrient 
stores creates a genuine anemia. For example, the fetus and placenta require 
360 mg of iron more than the 450 mg of iron usually required by the adult 
(25). When the anemic mother breast-feeds, the anemia may become more 
severe. If the mother's anemia is determined to be caused by an iron or folate 
deficiency, it can be treated with supplements. 
However, the best approach to anemia is prevention. A properly balanced 
diet that includes adequate minerals, vitamins, and calories is essential. Both 
the mother and clinician should remember that maternal nutrition is aided by 
family planning. The practice of child spacing permits a woman to regain her 
strength and proper physical condition before beginning another pregnancy 
and period of breast-feeding. 
NONCONTRACEPTIVE BENEFITS OF LACTATION 
Family planning and nutrition go hand in hand. This is especially so for the 
breast-feeding mother and her child. Breast milk is the best source of nutrition 
and immunity for the growing infant. (See Figure 3.4.) 
By preventing unplanned pregnancies, family planning helps prevent mal­
nutrition in both the mother and the child. Family planning should begin even 
before childbearing is begun. Delaying the birth of the first child has several 
advantages. The future mother and father have more time to acquire 
FIGURE 3.4 Breast-feeding is best. 
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economic stability, thereby insuring resources for a better food supply.Delay­
ing the first pregnancy also serves to reduce the future mother's reproductive 
time span. 
Increased intervals between births have several advantages also. The
mother's nutrients are more fully replenished before the next pregnancy. Nu­trition experts feel that an African mother may need 2 years to gain back the 
nutritional health she had before pregnancy.
Increased birth intervals also mean that the child will have the high-quality
proteins and nutrients found in breast milk. A child who is weaned completely
at too early an age or who receives supplements (before the age of 4 months 
or before clean, nutritious alternatives to breast milk can be provided) is in
danger of having poor nutrition and poor defenses against diseases. High
infant mortality also is related to weaning at too early an age (26). Studies
have shown that, in many cases, early weaning is the result of another 
pregnancy that occurs while the mother is breast-feeding (4). Often this is be­
cause pregnancy reduces the mother's milk supply.
Hence, the wisdom of the proverb: "A second child will 'drink up' the firstchild" (27). A baby weaned before 5 or 6 months of age hasa greater chance 
of dying. Therefore, it is preferable to delay full weaning until after 9 months 
or even later. 
NUTRITION FOR THE BREAST-FED INFANT 
Breast milk provides the new infant with adequate calories and protein for
the first 6 months of life. Breast milk also offers the infant immunologic pro­
tection derived from the mother's antibodies carried in her milk. The breast­
fed infant is less likely to suffer from diarrheal diseases (28). However, to be

most protective, breast-feeding should continue for at least 
 1 year, if
possible, and be given "on demand," that is whenever the baby is hungry.
For the mother who works away from the home, prolonged breast-feeding
 
may not be possible. But she should try to nurse the infant at least twice a day
and make certain her baby is getting good protein supplements. The excellent
protein in breast milk compiements and improves the quality of other foods
given to the infant. If the working mother must give her baby bottled
formulas, she needs to realize that the formulas must be prepared and mixed
correctly. The right concentration must be made or else the baby will not re­
ceive enough calories or proteins for healthy growth.
Two serious conditions of nutrient deficiency are marasmus and
kwashiorkor. These are two extremes of a syndrome. Infantile marasmus is
often caused by too early weaning from breast milk with the substitution of
grossly inadequate bottle feedings. As the infant starves from inadequate
calories and proteins, development of the brain, muscle and fat cells, bones,
and supporting and visceral tissues ceases. The infant begins to look old with 
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hollowed temples and wrinkled skin hanging in folds from a loss of subcuta­
neous fat and potassium. The abdomen is usually scaphoid but can be dis­
tended if the child suffers frm diarrhea and potassium deficiency. 
The mortality from infantile marasmus cun be as high as 100% if 
untreated. With early diagnosis and good management, however, this figure 
can be reduced to 10% (29). Treatment requires a cautious increase of calo­
ries and protein in feedings. 
Kwashiorkor affects achild who is over 1 year of age. In general, the infant 
has been breast-fed successfully for 6 months to 18 months, but then is 
weaned to a diet that is generous in calories but deficient in proteins and 
nitrogen. These babies have severe protein losses in their liver, muscle, 
pancreas, and other organs. The condition is marked by muscular weakness, 
apathy, and irritability. Edema is usually present, either gross and generalized, 
or slight and localized to the eyelids and feet. The hair becomes sparse, 
brittle, and depigmented, turning to a grayish or reddish tint. Skin changes 
consist of erythema followed by hyperpigmentation, desquamation, 
depigmentation, and, sometimes, ulceration. The baby will frequently suffer 
from chronic diarrhea with small, greenish stools. 
Babies sick enough to receive hospital attention may have a 10%-40% 
mortality rate. The deaths in the first 24 hours of hospitalization are caused 
by acute electrolyte disturbances or irreversible biochemical changes. Deaths 
in the next 10 days are caused by sepsis. Treatment requires restoration of 
kidney function and electrolyte balance, supplementary feedings, and treat­
ment of infection (29). 
It is even more crucial to rea!;ze, however, that for every case of marasmus 
or kwashiorkor, many other children suffer more moderate forms of 
malnutrition. A malnutrition problem of this magnitude and its close associa­
tion with infant mortality can only be attacked with mass education 
programs; more widespread health services including immunization, child 
spacing, and oral rehydration therapy: general availability of protein sources; 
and economic development (29). 
NUTRITION FOR THE BREAST- FEEDING MOTHER 
The breast-feeding mother requires even more food than a pregnant 
mother. To have an adequate milk supply, a mother needs an adequate 
amount of food and water. If nothing else, the mother should have at least an 
extra potful of maize or rice or an equivalent staple each day (30). Although 
an adequately balanced diet is best, if protein sources are not readily 
available, then increased calories will help the mother retain her health. 
Ideally, the mother's diet should have not only increased calories and 
proteins, but also increased iron, calcium, and vitamins. Family planning can 
aid the mother's nutrition by preventing a rapid succession of pregnancies 




The following instructions are intended to help mothers obtain the maxi­mum benefits of breast-feeding and to 	 make breast-feeding a positive 
* 	 Use 
experience: 
a method of contraception at the appropriate time if you do not 
• 	
want to become pregnant while you are breast-feeding.
Breast-feed on demand frequently if you plan to rely on breast-feeding
to prevent pregnancy. Remember that you can still get pregnant while you breast-feed, although the chance of that happening is low. 
to Breast-feed until your child is 1to 2 years of age.
* 	 Add supplements to breast milk when your baby is 4 to 6 months of age. Good supplements include starchy household foods, sauces, 
soups, stews, and eggs.




 Use fresh and clean drinking water; get immunizations and malaria 
prophylaxis to prevent disease. 
* Conserve your energy by avoiding unnecessary work.
* 	 Ask your clinician for nutrition advice, iron supplementation, anti­
malaria pills, and vitamins, if necessary.
* Eat a balanced diet. Include green vegetables, peas, beans, and fruits. In­crease the amount of food you eat. A nursing mother should have suffi­
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CHAP TER 4 
ADOLESCENT PREGNANCY 
Pregnant adolescents suffer from more problems than pregnant adults. 
Both the medical and social risks of pregnancy are greater in the ado­
lescent than in the woman over 20 years of age (1). Rates of prematurity, 
low-birth-weight babies, maternal and infant mortality, anemia, and preec­
lampsia are dramatically higher for adolescent mothers (2-7). Recent re­
search indicates that although a large part of the excess morbidity and mor­
tality is attributable to inadequate pre- and postnatal care received by adoles­
cents rather than to the mother's age, per se, other factors are involved in the 
increased medical risks for adolescent mothers (8-9). 
If the adolescent receives poorer pre- and postnatal care partly because 
she is unable to plan ahead for her pregnancy, she will probably also be 
unable to cope with a child. Adolescent parenthood may increase the inci­
dence of child neglect, abuse, and infanticide, halt education for many young 
people, lead to potentially dangerous an illegal abortions, or may cause a 
young woman to be abandoned by her family in some traditional societies 
(10-14). 
Family planning clinicians who have worked with adolescent mothers un­
derstand how much they need guidance and support. This chapter focuses 
on ways in which family planning helps reduce the problems that arise from 
adolescent pregnancy. Delaying the first pregnancy until a young woman is 
mature enough physically and socially to care for herself and her child is the 
first step in coping with a problem that is common not only in Africa, but 
throughout the world. 
FERTILITY IN THE AFRICAN ADOLESCENT 
While more accurate data are needed, family planners are beginning to 
realize that marriage at too early an age is quite common in Africa and 
pregnancy out-of-wedlock is also becoming a major concern (15-17). 
Compared with women in the rest of the world, African women marry 
young. Marriage close to the age of menarche is common in many Islamic 
areas. According to recent data from 28 African countries, about 55% of 
women aged 15 to 19 years were married. (This average is based on figures 
ranging from 82% in Guinea, 81% in Niger, 79% in Mali, 74% in the Ivory 
Coast, 73% in Chad, 72% in Nigeria, to 32%in Ghana, 22% in Lesotho, 18% in 
Rwanda, 14% in Somalia, 14% in Botswana, and 12% in Burundi.) (17) 
Young women often marry older men which can put pressure on the 
women to become pregnant during adolescence (7). Consequently, early 
marriage is generally accompanied with early fertility. In the 31 countries 
where data are available, fertility rates among women aged 15 to 19 years 
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are high, averaging 164 births annually per 1,000 women aged 15 to 19 
(17). The countries of Sub-Saharan Africa (excluding Southern Africa and 
the islands off East Africa) have the highest levels of early childbearing of any
region of the world, averaging 50", higher than other high-fertility regions 
(17). 
These fertility rates reflect pregnancies occurring both within and outside 
of marriage. The breakdown of traditional social pressures and the loss of 
traditional methods of fertility control (see Chapter 2) have contributed to 
this problem. Traditionally, young boys or girls in many cultures were carefully
instructed by an elder relative of the importance of delaying pregnancy until 
marriage. Premarital pregnancy often was a disgrace to the parents' families, 
the ethnic groups, and the young persons involved. In place of intercourse 
were other activities that permitted young people to explore intimate 
relationships. When lost traditions are not replaced by modern systems of 
support, adolescents have no guidance and can make serious mistakes. 
Table 4.1 contains suggestions for helping reduce the rate of adolescent 
pregnancies. 
TABLE4. 1Reducing the numberof adolescent pregnancies 
a. 	Return to some of the traditional customs that discourage 
sexual intercourse before marriage. 
b. 	Discourage betrothals and marriages among the very young. 
c. 	 Provide public education and dialogue on the implications 
of childbearing in very young and unmarried girls-dialogue 
in parliaments, national assemblies, regional and city 
governments, and among local community leaders, cell­
block leaders, and village spokespersons. 
d. 	 Teach young people that the medical and social implications 
of adolescent pregnancies are serious. One thoughtful phy­
sician suggested teaching yc'rng people that sexual inter­
course is potentially dangerous because of the social and 
medical effects adolescent pregnancy may have. 
e. 	 Teach sex education in schools and in churches. 
WHAT CAN BE DONE? 
The adolescent-pregnancy problem must be addressed directly. Leaders 
must come to acknowledge the problem where it exists and redirect the 
health and other social services to deal with it directly. Although it will never 
be solved by family planning alone, contraceptives might help.
Adolescents should be educated and motivated to assume the responsibil­
ity for their choices and actions. We believe that family planners should pro­
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vide services to those adolescents who do choose to have sex. At the same 
time, family planners should make every effort to actively support and serve 
those adolescents who choose not to have sex. While contraceptives may 
not be required by sexually inactive adolescents, family planning education 
should be provided to all adolescents. When appropriate, family planning 
groups should develop programs that support the decision of young people 
to delay sexual activity. Parents and their children should learn about the im­
portance of family planning within today's society, particularly for the pur­
pose of postponing the first pregnancy of married and unmarried 
adolescents. 
Withholding family planning services from adolescents from urban or 
rural communities does not lead to a decline in the number of adolescents 
having intercourse. Rather, the results are many more unwanted 
pregnancies, each bearing a tremendous social, educational, economic, and 
emotional cost. We believe that providing contraceptives to adolescents is 
part of the solution to the prcblem of adolescent pregnancy. 
Some may argue that sex education and the availability of contraceptives 
have been responsible for the rise in the number of adolescent pregnancies. 
But research has no' shown this to be true. One study from the United States 
found that adolescent girls who had not taken asex education class had, over 
a 20-year period, more than 16 times as many out-of-wedlock births than 
those who had taken a course. The study also found that tfie adolescent boys 
who had not taken the course had about four times the divorce rate of those 
who had taken the course (18). 
Family planning can serve adolescents by: 
* 	 Providing contraceptives to those who desire them. 
* 	 Educating adolescents about issues relating to family planning, includ­
ing pregnancy, sexually transmitted diseases, abortions, and the health 
benefits of family planning. 
* 	 Reaching out to the community with family planning information. 
PROVIDING CONTRACEPTIVES TO ADOLESCENTS 
Many contraceptive methods are suitable for adolescents. 
BARRIER METHODS. If the adolescent is taught how to use barrier meth­
ods correctly, they can be both safe and effective. (See Chapters 14 and 15 
for more information.) 
SPERMICIDES. Again, if the adolescent is taught how to use spermicides 
correctly, they can be both safe and effective. (See Chapter 16 for more 
information.) 
WITHDRAWAL. Because of the high failure rate associated with this 
method, it is not highly recommended. Some traditional practices, however, 
do encourage the use of withdrawal. Certainly, using withdrawal is better 
than using no method of contraception. (See Chapter 18 for more 
information.) 
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INTRAUTERINE DEVICE. The small-sized intrauterine device (IUD), such 
as the Copper-70'', can be used in the adolescent nulliparous woman. One dis­
advantage of this method is the increased risk of pelvic inflammatory
disease. A young woman who desires children later needs to be made aware
of the increased risks of developing such inflammatory diseases should she 
use an IUD. (See Chapter 13 for more information.)
 
ORAL CONTRACEPTIVES. 
 The Pill does not harm a young woman's de­
velopment or her ability to become pregnant in the future. Nonetheless, it is
important that a young woman be given the Pill after she has begun to 
menstruate regularly. (See Chapters 10, 11, and 12 for more information.) 
MINI-PILL. The Mini-Pill is a good choice for the adolescent girl who has
reached a stable menstrual cycle. She should know that her periods may be 
scanty and that spotting may occur. (See Chapter 12 for more information.)
STERILIZATION: Neither tubal sterilization nor vasectomy is recommend­





do not have to wait until they are married 
to have a pelvic examination. This first pelvic examination should 
be performed very gently. In a healthy adolescent, a painless first 
examination is more important than a complete examination. The 
attitude the young woman develops as a result of her first exami­
nation may affect her attitude toward reproductive health care for 
the rest of her life. 
Clinicians must be prepared to perform pelvic exams on young 
women who may never have had intercourse or even used a 
menstrual tampon. Supplies of small speculae, including the 
Peterson virginal speculae, are essential. A gonorrhea culture may
be obtained digitally. However, tell the adolescent ahead of time 
what will happen to her during the examination. 
EDUCATING ADOLESCENTS 
Educating adolescents involves just that-education, giving information, not 
rules. Adolescents value their freedom as much as adults do (19), and they
will stop listening if they feel they are being lectured to. Do not cut yourself
off from them by assuming an authoritarian tone. Gain trust by being sincere
and unforced. Help adolescents sort out their complex, but normal emotions. 
Provide reassurance that their bodies, their fantasies, and their sexual feel­
ings and actions are usually normal. 
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COMMON QUESTIONS ASKED BY ADOLESCENTS 
* Am I normal? 
* Should I have sexual intercourse? 
" Should I use a method of contraception? 
* What should I do about an unplanned pregnancy? 
* How can Itell if I have an infection? 
Many adolescents already have answers to these questions. 
Their answers, however, may not have been made on the basis of 
knowing all, or the correct information. For example, a girl may re­
quest oral contraceptives, but she may not have given serious 
thought to any of the other methods. 
Patient and thorough counseling will help adolescents make sound 
decisions. Yet be certain to distinguish between deciding what is good for 
adolescents and exploring with them what may be a good decision for them 
to make. 
If you are talking with unmarried adolescents, be sensitive to those who 
still have not made up their minds about sex. Providing contraceptives may 
be seen as encouraging or condoning sexual activity. Give adolescents sup­
port to make their own decisions about what is right for them. If they choose 
not to have sex, let them know the decision is right for them and that they 
should not be pressured by others into an act with which they do not feel 
comfortable. Let them know that society as a whole sti!l values virginity at the 
time of marriage. On the other hand, when adolescents decide to have sex, let 
them know that they must be prepared to live with the consequences. Pre­
venting an unplanned or unwanted pregnancy is an important responsibility 
that goes along with the decision to have sex, but there may be other offset­
ting consequences in certain cultures which are hard to avoid. 
REACHING ADOLESCENTS 
Regardless of your efforts, a family plnning program cannot reach all of 
the adolescents in the community. Often, adolescents will not seek family 
planning services until they are concerned about a possible pregnancy. By or­
ganizing outreach educational programs, however, family planners can reach 
adolescents before the youth have made theirdecisions about sex. 
Education about contraception, health care, anatomy, and physiology can 
be offered through schools, churches, and youth groups. Adolescents them­
selves can become effective educators within a community, if given the 
chance. Not only do adolescents need education and counseling, their par­
ents do too. 
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If you are going to lead discussion groups, there are a few general rules to 
keep in mind: 
" 	 Prepare your own thoughts about sexuality, contraception, and family 
planning before leading group meetings. Find out in advance as much 
as you can about the group you will address. Find out what your listen­
ers want to learn and focus on those subjects first. 
" Investigate the facts and present them in an organized and interesting 
way. 
* 	 During the discussion, allow time for questions and comments from 
your listeners. 
* 	 Be flexible. If your listeners have many questions or comments, be 
ready to forget your prepared presentation and encourage the group's 
participation. 
* Listen. The most important aspect of talking is listening. 
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Children are the cloth of the body. Without children you are 
naked. 
Yoruba Saying (Nigeria) 
ONE WOMAN'S THOUGHTS ON HER INFERTILITY 
To live with infertility is ... 












"To joke about it. But mostly to live day by day ... and leave a 
little room for hope." 
INTRODUCTION 
Fertility is important to all societies. Infertility has traditionally been a 
source of pain, anxiety, and shame. And the more important children are to 
the fabric of a given society, the more important it is for couples to bc fertile, 
and the worse are the consequences if a couple is infertile. Families of four to 
eight living children are common and only intensify the anguish and pain of 
those who are unable to bear children (primary infertility) or those unable to 
have as many children as they would have liked (secondary infertility). African 
gynecologists are becoming convinced that infertility is a problem of such 
magnitude that it must be given a very high priority in the development of ra­
tional family planning programs (1). More and more reports on the causes 
and treatment of infertility in Africa are appearing in the literature (2-7). Fur­
ther attention to this problem is an important service and research priority for 
Africa. 
Economic and social motivation underscore the hardship imposed on a 
family by infertility. In most of Africa a man's wealth is measured, in part, by 
the number of children he has. Children are important as farm workers and as 
a source of support in old age for the parents. Male children also play an im­
portant role in certain ethnic groups where, for example, a grandchild is the 




spect to the practice of certain rituals. Similarly, a woman's value to her hus­
band may be determined by her ability to bear a healthy child who will contri­
bute to the family. A woman may be divorced summarily for her inability to
bear children (even if dhe man is the major cause of the problem). 
GLOSSARY
 
The terminology surrounding the subject of infertility is inexact and there­
fore confusing. In this book, the term "infertility" is used to mean a woman's
inability to conceive and bear a living child or a man's inability to produce a 
pregnancy. 
The World Health Organization has subdivided the term, as it relates to 
couples, as follows (1): 
PRIMARY INFERTILITY 
The woman has never conceived despite living with a man, being exposed
to the possibility of pregnancy, and wishing to become pregnant for at least 
12 months. 
SECONDARY INFERTILITY 
The woman has previously conceived but is subsequently unable to con­
ceive despite living with a man, being xposed to the possibility of 
pregnancy, and wishing to become pregnant for at least 12 months. 
PREGNANCY WASTAGE 
The woman is able to conceive but unable to produce a live birth. 
SUBIFERTILITY 
The difficulty experienced by some couples, both of whom may have re­
duced fertility, in conceiving. 
BACKGROUND 
The joining of sperm and egg to eventually produce a human being is one
of nature's miracles. There are so many steps and possible missteps in the in­
tricate sequence that we should not be surprised to learn that a certain per­
centage of couples in every society is infertile. 
In societies where unplanned and unwanted pregnarcies are prevalent,
and where family planning programs may publicize this fact, the dilemma of
those who are infertile is particularly poignant. Moreover, the diignosis and 
treatment of infertility are physically and emotionally arduous, and the out­
come of treatment remains uncertain. 
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Throughout this chapter we will be stressing how important it is that cou­
ples who come to a family planning clinic for treatment of infertility receive 
sensitive support from nurses, physicians, lay counselors, and the infertility 
specialists who may ultimately be giving treatment. 
EPIDEIIOLOGY OF INFERTILITY IN AFRICA 
There is a recognized belt of subfertility and infertility in Africa extending 
from the West African countries of Senegal, Upper Volta, Mali, Niger, and 
Northern Nigeria through Cameroon, Gabon, Congo, Central African 
Republic, Zaire, and Southwest Sudan, to the East African countries of 
Uganda, Southwest Kenya, and Tanzania (8). It is important to remember, 
however, that infertility exists in other parts of Africa, although the preval­
ence is lower than in these areas. 
It is ironic that infertility and subfertility are prevalent within the high­
fertility zones of Africa. Family planning administrators have to recognize this 
feature so that they deal sensitively with issues pertaining to fertility control 
in areas where fertility enhancement is also needed. Cameroon is a good 
example of a country divided between high- and low-fertility zones. Table 
5.1 shows fertility differential based on the percentage of childlesp women 
per given age groups in Cameroon (9). It ca,. be seen that infertility is a prob­
lem in Central, South, and East Cameroon, but much less so in other areas. 
An example of childlessness, probably as a result of pregnancy wastage, 
is found in Southwest Nigeria, where the average number of pregnancies 
recorded ranged between 5.03 and 6.50, but the number of live births 
achieved by women over45 years old was a maximum of 4.93 (10). 
TABLE 5. 1Percentage of childless women in various age groups in 
Cameroon, 1962- 1964 (9) 
Age group of Central, South, North North west 
mothers and East Cameroon Cameroon and Southwest 
1962-1964) (1962-1964) (1964) 
15-19 72 73 56 
20-24 29 27 10 
25-29 28 20 7 
30-34 30 19 6 
35-39 33 17 8 
40-44 29 13 7 
45-49 29 11 7 
Infertility is associated with marital instability. The divorce rate is high 
among infertile women. On the other hand, if there is marital instability, the in­
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dividuals may have multiple sex partners and therefore have a higher risk of
becoming infertile due to an increased likelihood of a sexually transmitted 
infection. 
PRIMARY VERSUS SECONDARY INFERTILITY 
Published clinical data seem to indicate differences in the relative inci­dences of primary and secondary infertility in Africa. Two studies from Kenya(11,12) suggested that these diagnoses are made in nearly equalproportions, unlike almost all reports from West Africa in which secondary in­
fertility is diagnosed in nearly two-thirds of the cases (13,14,15). Geaerally
speaking, the variations in the rates of primary and secondary infertility re­
flect differences in the pattern of underlying causes. 
OCCURRENCE OF INFERTILITY 
The amount of time that it takes for a couple to achieve a pregnancy whenthey are actively trying to do so varies widely. Delay in conception, in those 
not using any contraception, is influenced by the age of the mother. Table 5.2shows the age of the female and length of time it would take her to conceive 
as found in a study of 1,128 women. By 6 months, 40-73', of the womenstudied had conceived (16). Fertility was shown to be lower in women over 
35 years of age. 
TABLE5.2 Length of time wome,' have unprotected intercourse before they
become pregnant, by age (16) 
Percentage Distribution by Age Group













Less than 3 months 
3-6 Months 
6 Months- 1 year 
1-2 years 


























Number of women 
included in study (113) (438) (381) (141) (55) 
This table can be simplified by looking at what happens to any 100 cou­
ples actively trying to conceive, as portrayed in Figure 5.1. 
58 
WHAT ARE THE ESSENTIALS OF FERTILITY? 
For a union between a man and woman to be fertile, there must be a heal­
thy ovum produced by the female, which must be fert:lized by a healthy sper­
matozoon from the male.' The fertilized ovum must then be transmitted into 
a uterus that is capable of protecting it and providing the necessary 
nourishment. 
Male infertility may result from faults in the following normal physiological 
functions: 
1. Normal spermatogenesis. 
2. Ability to transmit the spermatozoa to the partner's vagina. This is 
possible through:
 
a) Possession of the necessary sexual drive,
 
b) Ability to maintain an erection, and 
c) Ability to achieve an adequate ejaculation. 
Any faults in the following normal physiological properties may be re­
sponsible for infertility in the female: 
1. 	Presence of ovulation. 
2. 	A normal vagina for reception of spermatozoa. 
3. 	Normal cervical mucus to allow passage of spermatozoa to the upper 
genital tract. 
4. Healthy fallopian tubes to permit the meeting of the sperm and ovum 
and, after fertilization, to permit migration of the ovum to the uterus. 
5. 	A healthy uterus to permit the implantation and development of the 
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FIGURE 5. 1 Occurrence of pregnancy in couples actively trying to conceive 
(allage groups) (1 7, 18) 
'Incidentally, it is the male's sperm, not the female's ovum, that determines the sex of the 
offspring. 
59 
CAUSES OF INFERTILITY 
Anything that can hinder or prevent either gametogenesis (egg or sperm 
formation) or fertilization can potentially prevent fertilization. Into this 
category fall such diverse conditions as undescended testicles, exposure to 
certain chemicals, and infrequent coitus. 
The female factor has been more widely studied in Africa than the male 
factor because it is commonly assumed that the woman is primarily responsi­
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FIGURE 5.2 Causes of infertility in women. 
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In two laparoscopic studies conducted in Kenya, tubal occlusion was diag­
nosed in 73', of cases of primary and secondary infertility (12,19). Tubal oc­
clusion is presumably a consequence of pelvic inflammatory disease (PID) 
following sexually transmitted diseases, septic abortion, or puerperal sepsis. 
The infection has traditionally been attributed to Neisseriagonorrhoeaealone 
(20). In certain ethnic groups in Uganda, up to 50.,of women are infertile asa 
result of the sequelae of gonoccocal PID (21). It is becoming evident, 
however, that repeated episodes of PID may be caused by microorganisms 
other than N. gonorrhoeae, such as chlarnydia (22, 23), although the initial 
episode nay still be caused by NV.qonorrhoeae. 
If the preeminence of tubal occlusion reported in female infertility in the 
Kenyan studies holds true in other parts of Africa, ovulation disturbance 
(which exists in 30',-40', of cases in developed countries) plays a much less 
important role than normally expected. For instance, in 1970 investigators 
suspected anovulation (the suspension or cessation of the release of an egg) 
in only 2. of the cases in Kenya (11). But when the fevv patients with healthy 
tubes were analyzed, anovulation accounted for infertility in nearly 30o (12). 
Recent availability of better equipped laboratory facilities in some African 
countries will enable more accurate estimates of contribution of anovulation 
in female infertility. 
The male factor, where studied, has been found to exist in 20'.-40' of 
the couples. In a series of 173 semen analyses completed in Kenya, 14.5Z 
were found to have azoospermia (lack of spermatozoa in the semen) (12). 
Table 5.3 presents the distribution of abnormal clinical findings for Nigeria 
(3). 
TABLE 5.3 Causes ofmale infertility from clinical findings in Nigeria (3) 
Number Percentage 
of Cases Distribution 
Hypoplastic testes 26 58 
Epididymal cyst 6 13 
Cryptorchidism 4 9 
Varicocele 3 7 
iHydrocele 3 7 
Inguinal operation 3 7 
TOTAL 45 100 
Of course, there are many different analyses of the different causes of 
infertility. Two studies from the United States and from Nigeria are summa­
rized below. When an anatomic approach to the etiology of infertility is taken, 
the sites of dysfunction among infertile couples appear with approximately 
the frequencies listed in Table 5.4: 
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TABLE 5.4 Proportional distribution ofcauses of infertility in men and 
women: recent studies from the United States andNigeria 
Male infertility (24) Female infertility 
American data (18) Nigerian data (3) 
(%))
 
Varicocele (alone o: in Tubal/peritoneal 30 66 
combination with other Ovarian 20 10 
causes) 25 Cervical 15 7
 
Ductal obstruction 7 Uterine 10 10 
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It should also be pointed out that although gonorrhea, filariasis, 
tuberculosis, a number of other infectious agents, trauma, and congenital 
anomalies can produce a number of anatomic changes in men arid women, 
not all cases lead to infertility. 
Certair patterns of sexual intercourse, marriage, arid exposure to sexually 
transmissible infections are associated with primary infertility, secondary 
infertilit\, or lower birth rates for all entire culture. Arya, Taber, and Nsanze 
studied cultural patterns in two areas of Uganda in an effort to explain re­
markably different birth rates in these two areas. Their findings summarized 
in Table 5.5 demonstrate that among women in the low-fertility area, lower 
abdominal pain, cervicitis, a tender pelvic mass, positive gonorrhea cultures, 
and positive laboratory tests (VDRL) are more common (26). 
Nasah and Cox (15) reported vascular lesions, possibly filarial, in the 
testes of infertile males in the Cameroon. These lesions were seen in 40 of 41 
males with severe oligospermia arid consisted of massive subendothelial fi­
brinoid deposits in the small- arid medium-sized vessels that led to testicular 
scarring. The investigators postulated that these deposits were a result of 
repeated formation and depobition of circulating antigen-antibody 
complexes. These antigens could be of various origins arid, in two cases, 
parasitic elements were visible histologically. It is possible that other tropical 
diseases may play a role in male infertility in Africa. 
The role of sexually transmitted diseases in male infertility has been dis­
cussed by Alausa arid Osoba (27) arid Arya, Taber, and Nsanze (26). They 
found that problems resulting from venereal infections contributed signifi­
cantly to male infertility. Their findings are summarized in the following table. 






Women ( ) () 






Lower ahdotintoril Imr 25 0 8.9 
Ce(viciti.; 30 5 125 
Tenr mast; 7 8 06 
Gonorihea nid nifimed 18 3 2.4 
VDRL posinive 25 3 12.6 
Men 
M;arri.,d 85.9 82.6 
Polygarnou, 25 5 23.3 
Never had child 24 8 3.7 
UretIhi'al(fls(h'irtlet 







Acute epididyinoorchitis 2 2 0.6 
GonOrrheidentitcnl t 8 9 4.2 
VDR. positive 388 155 
Six or mor chilrn 20 2 50.0 
Uirth rate 37, 1000 55. 1000 
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There are a number of factors that increase the likelihood of infertility.
These factors vary between geographic areas and ethnic groups resulting in 
different infertility rates P5 shown in Figure 5.4. Thus, the risk of infertility 
may also vary accordingly, even within a nation. These factors include: 
* Malnutrition 
* Prostitution 
* Multiple sexual partners for either the man or the woman 




 Preference by women to delay childbearing until their late twenties 
* Polygamy 
* Rising divorce and remarriage rates 
* Voluntary sterilization which couples later want reversed 





 Man and woman not living together 
* Increasing age at marriage 
* Septic abortions leading to infection
 
* 
 Delayed diagnosis and treatment of pelvic inflammatory disease (PID)
* Infection with certain tropical diseases (malaria, filariosis, etc.) 
-d 2S 29 IH It .Vk 
30 





FIGURE 5.4 Infert i/it yin eight nations in Africa and eight regions in Zaire. (28) 
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WHAT CAN FAMILY PLANNERS DO? 
Many organizations involved with fertility control want to meet the chal­
lenge of infertility control. Yet, the diagnosis and treatment of infertility are 
often so complex that they must be referred to specializing 
obstetricians/gynecologists, urologists, and reproductive endocrinologists. 
Nevertheless, a definite role remains for family planners. The facilities avail­
able for investigation of infertility at a family planning clinic will vary from 
place to place, depending on the availability of resources. Some clinics can 
only refer an infertile couple to an appropriate center where investigations 
can begin. Some of the initial tests might include full blood count; urinalysis 
for sugar and protein; serological tests for syphilis; cervical, urethral, and 
rectal cultures for gonorrhoea; blood group and Rhesus factor; and a Pap 
smear. We MUST take a leading role in the area of PREVENTION. We can also 
help in the areas of TRIAGE," FERTILITY COUNSELING, HISTORY TAKING, 
EXAMINATION, FIRST TESTS FOR INFERTILITY, EDUCATION TO TREAT-
MENT OPTIONS, AND DEALING WITH PERSONAL STRESS. 
PREVENTION 
The family planning clinic provides an opportunity for healthy individuals 
to have access to medical examination. In the course of this, sexually trans­
mitted diseases may be diagnosed and treated early. Certain family planning 
practices, such as the use of condoms, can also assist in reducing the spread 
of infections, such as gonorrhea, chlamydia, and trichomoniasis. On the 
other hand, contraceptives such as IUD's may increase the risk of infection, 
with consequent reduction in fertility. Family planners are not only in a unique 
position to advise men and women of such sequelae, but are also in a very for­
tunate one-that of being able to offer preventive health education. Some 
factors contributing to infertility are encountered daily by those caring for pa­
tients in family planning clinics. Listed below are some of these problems and 
the specific actions family planners might take to diminish the impact of each 
potential problem. 
PELVIC INFLAMMATORY DISEASE 
Pelvic inflammatory disease may lead to the occlusion or distortion of 
the fallopian tubes. Causes of pelvic infection include sexually transmitted 
Triage. It this clinic management technilue is being used, usually a nurse will greet all patients, 
torm a preliminary judgilient as to the nature of each )atient's prol)lenl, and refer the individual 
to the staff member hest able to help the patient In this way. the specialized skill- of physicians, 
nurses, midwives, nutritonists, and others ar. ou Ito op timi al use, time is not waste( with repeti­
tious questioning or services; and patient waiting lime is riiminized. 
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diseases and retained products of conception following childbirth, mis­
carriage, or incomplete abortion. 
ACTION: - Clinicians should be up to date in their knowledge of 
treatments. 
- Family planning health educators and administrators must 
begin or continue alliances with sex educators so that the con­
sequences of untreated sexually transmitted diseases may be 
fully understood by young people. 
- They must work with educators to ensure that minors every­
wh.re are receiving early and confidential treatment of all 
sexually transmitted diseases. 
- Family planners should be aware that of all the contraceptive
options for a woman, oral contraceptives appear to have the 
greatest protective effect against PID (30). They should en­
courage sexually active youths to use condoms. 
INTRAUTERINE DEVICES 
The intrauterine device (IUD) is associated with an increased risk of con­tracting PID. The Food and Drug Administration in the United States advises
that a 3- to 5-fold increase in risk of pelvic infection exists, and the Interna­
tional Planned Parenthood Federation suggests that a 1.5- to 4-fold increase
in the risk of pelvic infection exists in IUD users compared with non-IUD users(29). Because of this association, family planners must take a number of fac­
tors into consideration when recommending the use of the IUD since PID mayincrease the ris!. o" f :t,' infertility for the couple. (See Chapter 13.) Women
wearing an IUD that is treated with a progestin seem to be less likely to devel­
op PID than other IUD users. 
ACTION: - Be conservative in using IUD's for nulliparous women. 
- Do not use the IUD for women who may not understand or are
concerned about risks to future fertility and who are at greater
risk for sexually transmitted diseases and PID. 
- Urge further refinements in current IUD's. 
(Specifically, tailless types need to be evaluated carefully
and considered for use, particularly in areas where the inci­
dence of gonorrhea is high.) 
- DO NOT INSERT AN IUD INA WOMAN WITH AN UNTREATED 
SEXUALLY TRANSMITTED DISEASE. 
- In areas where the incidence of gonorrhea is high, consider 
giving antibiotic prophylaxis for one week after IUD insertion. 
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THE PILL 
Oral contraceptive users are at less risk of developing PID than are either 
IUD users or those who use no birth control method at all. Decreased 
menstrual flow and myometrial activity, along with a less penetrable mucus, 
may exert a protective effect against PID in the Pill user (30). 
Amenorrhea and temporary infertility following Pill use attributable to the 
oversuppression syndrome (post-Pill amenorrhea) do not appear to be seri­
ous threats to female fertility. The above symptoms are most commonly 
found inwomen who have irregular menses before beginning oral contracep­
tive therapy (31). This temporary condition is usually treatable. 
ACTION: - Educate patients to these aspects of the Pill. 
- Pills are probably as good a method as any in the prevention of 
PID and should be strongly considered as the contraceptive of 
choice for women hoping to have subsequent children. 
STERILIZATION 
The popularity of this method throughout the world continues to grow for 
both men and women. However, family planners in several parts of the world 
have expressed concern over the numbers of requests for sterilization rever­
sal and over the uncertain prognosis and high cost of such procedures. In a 
recent survey of 100 female patients (32), the following breakdown of rea­
sons for requesting reversal was obtained: 
Change inmarital status 63% 
Death of child 17% 
More children wanted 10% 
(marital status same) 
Psychological reasons 6% 
Other tragedy 4% 
ACTION: - Emphasize the permanence of the procedure and expose pa­
tients to information about the trend for requested reversals. 
- Do not sterilize childless adults unless there are extenuating 
circumstances. 
- Avoid using the term "tying the tubes" to describe sterilization 
procedures. It may sound overly simple and, by implication, 
reversible to some patients (32). 
67 
PROMPT RESPONSE TO THE INFERTILITY PROBLEM 
It is critical that the first counselor whom the couple sees immediately try
to sort out the facts of the case to determine what action needs to be taken 
to further investigate the problem. The couple should then be referred to
the appropriate person(s) for diagnosis and treatment. Speed is of particular 
importance for couples when (33): 
a) the woman is over 30. Men and women reach peak physiologic fertility
in their mid-twenties, after which fertility declines (more rapidly for tile 
woman than for tile man). 
b) tile woman reports irregular menses. This could signal sporadic
ovulation, a condition unlikely to improve spontaneously unless the 
woman is very young (an adolescent). It is also usually easy to treat. Ir­
regular bleeding may be a symptom of a disease process, thus warrant­
ing a careful examination. 
c) 	 there is a known history of disease such as mumps in the man or repeat­
ed miscarriages or PID in the woman, or when a major disability exists in 
either partner. 
Time will not improve such problems, but will steadily diminish the cou­
ple's fertility, so a remedy should be sought promptly. A person's "sixth 
sense" that something is wrong should be heeded. 
FERTILITY COUNSELING 
Ways of living as diverse as occupation, diet, and even clothing are some­
times relevant to fertility. Couples experiencing difficulty in conceiving, or 
couples using contraception who plan to have children in the future, should
learn which of their habits reduce or increase their fertility. Some examples 
include: 
FERTILITY AWARENESS 
Is the couple aware of the female fertility cycle and that sex with intent to
produce a pregnancy must occur near the time of ovulation? Is the woman 
charting her basal body temperature or checking her cervical mucus? 
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SEXUAL INTERCOURSE 
Failure to have intercourse at a time when fertilization would be possible 
(i.e., around ovulation) may be a cause of infertility. A couple should be en­
couraged to have relations frequently during the midcycle period, that is, 
about a week after the onset of menses to a week before the next, anticipat­
ed menses. Intercourse every other day, or even daily. should not be 
discouraged. Only in the case of the oligospermic (low-sperm-count) male 
should a buildup interval of 2 to 3 clays between midcycle relations be 
recommended. Rigid schedules for the performance of intercourse are 
discouraged, as this may prove psychologically stressful and counterpro­
ductive to good sexual functioning (24,34). 
LUBRICANTS 
Couples may use some lubricants for their lubricating properties. 
However, since some are also spermicides, a couple that is actively trying to 
conceive may inadvertently be practicing contraception. One researcher 
recommends that couples use saliva as a lubricant when maximal fertility is 
sought (1 7). 
DOUCHING 
While douching is an unreliable method of birth control for couples of 
average fertility, it may, where fertility is marginal, manage to kill the very 
sperm that would have fertilized the ovum. 
MEDICATIONS 
A number of medications may affect male fertility by causing impotence, 
retrograde ejaculation, or by temporarily impairing spermatogenesis. 
Narcotics, tranquilizers (such as phenothiazides), monoamine oxidase 
inhibitors, and drugs such as guanethidine and methyldopa are in the 
former class, while ambecides, antimalarial drugs, nitrofurantoin, and me­
thotrexate may affect sperm production (18,35). In utero exposure to DES 
(diethylstilbestrol) may or may not diminish the conceptive potential of 
females (36). It is claimed that rates of testicular cancer, sperm 
abnormalities, and undescended testicles are higher than usual for males so 
exposed to DES (35,37) 
EXPOSURE TO IRRADIATION 
This can affect male reproduction at several levels. The testicular germi­
nal epithelium (enclosing the seminiferous tubules) may be reversibly or irre­
versibly incapacitated for sperm production, and chromosomal aberrations 
may occur (38). 
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ATHLETIC ACTIVITIES 
Among other activities, long-distance running for women may bring onamenorrhea. Men who are in the habit of taking frequent hot showerswhirlpool treatments or may be subjecting the scrotum to high enough tem­peratures to stop or greatly reduce sperm production (34). 
TIGHT CLOTHING 
Certain tight clothing (undergarments, tight pants) may have the samesuppressive effect on sperm production as do hot showers because of hightemperatures in the scrotal region (34,39). 
OCCUPATION 




 it is thought that gross interference with conception does notoccur until near starvation is experienced (41), poor nutritional status mayexert a general debilitating effect that may indirectly hinder a couple's at­tempt to conceive. The opposite condition, obesity, may also lead to
frequent ovulation or to 
less frequent intercourse and thereby be 
less 
a con­
tributing factor to lessened fertility potential. 
SMOKING/ALCOHOL 





Exposure to toxic tumes, pesticides, and lead are presently being exam­ined on the suspicion that they cause or contribute to infertility (42). 
MULTIPLE SEXUAL PARTNERS 
Aside from the increased possibility of contracting a sexually transmitteddisease, it is now known that some women may develop an immune re­sponse to sperm over time (sperm agglutinating antibodies) and that this ismore likely to occur in women exposed to multiple partners. Regular use offoams, jellies, and condoms may prevent the development of sperm agglu­
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tinating antibodies in a woman. The use of condoms in the infertile couple 
to avoid infertility is an apparent contradiction which needs careful 
explanation. (See Chapter 1 5.) 
INFERTILITY - WHOSE PROBLEM? 
Specialists claim that infertility is a shared problem. Males and females 
each separately account for about 40 .of infertile unions arid jointly are re­
sponsible for the remaining 20 (43). 
Some clinicians advocate that the postcoital test (which involves a pelvic 
examination of the woman shortly after intercourse) precede the semen 
analysis (which requires that the man privately masturbate to produce a 
semen sample) because this ordering "avoids the stess associated with the 
semen analysis" 
However, most clinicians recommend that semen analysis be the first di­
agnostic procedure in the infertility investigation. As one scientist has 
observed, "It is still all too common to find the wife subjected to an opera­
tive procedure before it was determined that tier husband was azoosper­
mic" (not producing any sperm) (24). Other workers have expressed con­
cern over the "parallel but independent" routes which may be taken when 
the traditional woman-to-gynecologist and man-to-urologist separation 
occurs. They feel that lack of a coordinated treatment plan may slow I ie 
process and discourage the couple (44). 
We hope that it will become a generally accepted principle in infertility in­
vestigation that the couple be dealt with as a unit and that at every stage of 
diagnosis and treatment of this unit, the least invasive procedures be used. 
HISTORY TAKING, EXAMINATION, AND 
FIRST TESTS FOR INFERTILITY 
After a preliminary explanation of the above areas, the interview with the 
counselor may lead into a full history-taking session. It is best to interview the 
man and woman separately at this point in case either feels that his or her his­
tory must be kept confidential from the other partner. Very complete fertility 
questionnaires have been developed by many medical schools that can be 
used in initiating an infertility evaluation inclinics and hospitals. 
PHYSICAL EXAMINATION OFTHE WOMAN 
Visual evaluation of hair distribution and of body and breast development 
will be directed at detecting endocrinopathy or dt,,elopmental deficiencies 
such as hypogonadism, adrenal hyperplasia, hypothyroidism, ovarian 
dysfunction, and hyperprolactinemia. A complete pelvic exam (palration of 
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uterus and adnexae, speculum exam of vagina and cevixl should revealwhether uterine hypoplasia, adnexal tumors, or cervical lesions are presentand should also indicate whether dyspareunia may be a problem (25). 
PHYSICAL EXAMINATION OFTHE MAN 
Again, visual inspection of sexual -haracteristics
nopathies as 
to detect such endocri­hypogonadism or Klinefelter's syndrome (the genetic XXYanomaly often assoc.ated with infertility) is in order. The penile exam shouldbe done to detect hyposadias (displacement of the urethral opening) orphimosis (constriction of the foreskin). The testicular exam detects atrophy,tumors, epididymal cysts, cryptorchtidism (unidescended testicles),thickening or vasabsence, hydrocele (fluid accumulation in testes or alongspermatic cord), or varicocele (dilatation of the veins of the spermatic cord in
the scrotum) (25). 
DIAGNOSTIC TESTS FOR INFERTILITY 
The findings of the physical exam may indicate the direction for futureinvestigations. However, it is often appropriate to begin with five basic diag­nostic tests which, with some extra training, could be performed at selectedfamily planning clinics. Ideally and where feasible, a lot of time and moneycan probably be saved if tubal patency is established fairly early in theworkup because of the evidence of the high incidence of tubal occlusion inAfrica. In many clinics this is done before hormonal assays and complicatedcervical rnucus studies are embarked on. Only those patients with patenttubes are passed on for further tests. Those with ocUluded tubes are as­sessed for tubal surgery, and only after successful treatment are they inves­
tigated further. 
SEMEN ANALYSIS 
This test can he done immediately unless the man has had coitus in the
previous 2 days, in which case sperm count may be somewhat depleted. On
the other hand, abstinence for more than 7 days will also introduce errors ofinterpretation because the concentration of round cells will have increased.Tile specimen of semen is collected by having the patient masturbate eitherat the laboratory (or not more than a 2-hour journey from it) into either a cleanglass jar or into a polyethylene (not rubber) condom. Tha technician will belooking for directiond motility in over 60', of sperm present, 40, normaliorphology, and Counta of at least 20 million sperniml. Exceptazoospermia, inthe actual number of sperm is considered to be less criticalthan their apparent ability to move and their morphology. 
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BASAL BODY TEMPERATURE AND MUCUS 
These important indicators of ovulation are fully discussed in Chapter 9 
Again, this is a process the woman can begin immediately. 
POSTCOITAL (SIMS-HUHNER) TEST 
Within 2 to 4 hour, after intercourse (with no douching afterward), the 
woman is examined and a cervical mucus-semen sample is collected. The 
mucus-semen sample is studied to note whether sperm are p,-.sent in suffi­
cient numbers and penetrating the mucus; also the spinnbarkeit (elasticity) 
and ferning of the mucus aire observed to see whether they present the ex­
pected ovulatory qualities at midcycle. 
ENDOMETRIAL BIOPSY 
A postovulatory-phase biopsy (or premenstrual-phase biopsy) of the en­
dometrial lining may indicate whether progesterone has been produced by 
the corpus luteum in the expected amount for the time of the cycle (under 
local anesthetic). If available, plasma progesterone levels may be determined, 
which may be less painful but as valuable diagnostically as endometrial 
biopsy. Most family planning clinics would notbe able to perform endometrial 
biopsies. 
TUBAL PATENCY TESTS 
In some family planning clinics, tubal patency may be tested by tubal in­
sufflation (Rubin test). In this test, a cannula is fixed in the cervical canal and 
carbon dioxide is gently introduced and allowed to flow through the fallopian 
tubes. Although this technique is not as reliable as hysterosalpingography or 
laparoscopy procedures which are only available in hospitals, the Rubin test 
can be a useful screening tool, If as a result of this test a patient is found to 
have patent tubes and she does not conceive for up to 6 months, she should 
be referred for further tests. In no cuse should tubal surgery be undertaken 
until hysterosalpingography and laparoscopy have been done. In some cases 
the Rubin test has been followed fairly closely by pregnancy and it has been 
suggested that this test may at times be therapeutic. At other times, the 
Rubin test may be harmful, causing a flkire-up of a smouldering tubal 
in.ection. 
It has been estimated that these f,,e tests are capable of diagnosing 90" 
of infertility cases (18). Only the most sophisticated clinic will be able to per­
form tubal patency tests. The other tests could more readily be added to the 
services offe',t by a family planning clinic if resources are available. At the 
present time, it is rare for family planning clinics in Africa to offer any of the 
above five tests. 
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DEALING WITH PERSONAL STRESS
About 50%of couples who seek help for infertility may eventually report apregnancy (many in the course of preliminary investigation) (18). Howeverwithin the group that does conceive, ectopic pregnancy, miscarriage, andperinatal mortality tend to surpass what would be expected in the general
population. Therefore, 
 of the original infertile PopUlation coming fortreatment, just over half wil: eventually confront the reality of childlessness.The impact of this discovery sometimes damages a couple's relationship oran individual's self-esteem. Workers have noted typical reactions toinfertility: surprise, denial, isolation, anger, guilt, grief, and, finally, resolution 
(39).

Family planning agencies may take 
an active and complementary role inhelping infertile couples deal with personal stress. For very little extra expense 
or staff time, we can: 
1. Provide full information on adoption, with narnes and addresses oflocal agencies, and we can get those agencies to assess waiting times,if any. Where adoption agencies do not exist, we can investigate for ourpatient the means of identifying and arranging for adoption.2. Make referral for psychologic counseling if depression appears serious.The rule of thumb to follow is to do that which might help the couple deal
positively with itheir situation. 
Family planners surely will do much more to help the infertile in the future.Assistance in diagnosis and, to some degree, treatment, dealing w '1person­al stress, arid prevention are all roles in which we can expand our involvement.
Confrontation with one's infertility is something that no counselo; wvhohas not personally faced it can easily imagine. Yet, when it comes to an c:rno­tion that we have riot experienced personally and which we cannot fullyunderstand, we can still offer respect and sensitivity. 
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SEXUALLY TRANSMITTED DISEASES 
In addition to fertility control, family planning care can include the preven­
tion and trcdi,;Lnt of sexually transmitted diseases (STD). Why is the family 
planning clinic suited to treating STD's? 
* 	 The occurrence of an STD can have considerable medical and emotion­
al consequences in people's lives: infertility, pain, marital disruption, 
hospitalization, and even death. 
* 	 Certain contraceptive methods can influence a person's likelihood of 
acquiring an STD. 
STD's are a major cause of secondary infertility. (See Chapter 5.) An infec­
tion that invades the uterus or tubes can occlude the passage for -perm and 
ovum, thus preventi, g ;ertilization. Or, if fertilization does occur, the partially 
occluded passageway can lead ,c -m rctopic pregnancy STD's can also 
harm a developing fetus or a baby delivered through the birth canal of an in­
fected woman. 
In Africa, the consequences of STD's are major; and STD's, especially 
gonorrhea, have become endemic in many parts of Africa (1). In a study from 
central Africa, about 17",, of women attending family planning clinics had 
gonorrheal infections; some had no symptoms of disease (2). In a study from 
Senegal, over 21"., of the populatiomi was found to be serologically positive 
for syphilis or yaws (2). One survey inZimbabwe found a crude rate of nearly 
1,100 cases of syphilis per 100,000 population and about 2,100 cases of 
gonorrhea per 100,000 population (3). In some parts of Africa, chancroid is 
as common as gonorrhea. Other diseases that are quite common in other 
parts of the world may also be prevalent in Africa, although their prevalence 
is not well documeri ted. Some estimates have placed the prevalence of tri­
chomonas at 30".. About 60,,of urethritis is probably caused by Chlamydia 
(2). 
While some contraceptive methods help protect a ainst STD, others may 
increase the risk of infection. In areas where STD's are I,revalent, family plan­
ners need to be knowledgeable about the relationships between specific 
methods and infections. For example: 
* 	 Oral contraceptives may exert a protective elfect against the develop­
ment of pelvic inflammn atory disease (See Cha;rpter 1 1.) 
• Oral contraceptives may make a woman more prone to monilial 
infections. (See Chapter 11 .) 
• 	Barrier methods help decrease the traismissiomr of many of the STD's. 
(See Chapters 5, 14, 15 ) 
" Spermicidal preparations such as foams have chennicals that may act 
against organisms such as N. jolnorrhooae, 1 pallidum, C.albicans, C. 
trachomatis, T vagiialis (4). (See Chapter 16.) 
77 
* The intrauterine device may increase the risk of pelvic inflammatory dis­
ease in a woman who has an STD. (See Chapter 13.)
By recognizing and treating STD's and by keeping these associations in
mind when assisting a patient to choose a method, family planners can play a 
major role in preventing the spread of these infections while promoting the 
reproductive health of their patients. 
For some of the most common STD's, associated symptoms, diagnosis,
treatment, and patient instructions are summarized in Table 6.1. 
SEVERAL POINTS TO CONSIDER IN THE MANAGEMENT
 
OF SEXUALLY TRANSMISSIBLE INFECTIONS
 
1. While patients should be encouraged riot to have sexual intercourse until 
their infection is cured, condoms should be provided just in case they are 
needed and should also be considered strongly for use after the infection 
is cured. 
2. 	Patients should be urged to continue taking medications throughout the 
prescribed course of treatment even if symptoms subside or a menstrual 
period begins. 
3. Often, patients have more than one sexually transmissible infection at a 
time. 
4. Long-term use of broad-spectrum antibiotics such as ampicillin,
tetracycline, and metronidazole (Flagyl ")often predispose a woman to 
monilia. 
5. Whereas asymptomatic gonorrhea may be treated with a single dose of
penicillin (or another drug), pelvic inflammatory disease caused by gonor­
rhea or any other organism should be treated for 7-10 days with 
antibiotics.
 
REMEMBER, TO PREVENT INFERTILITY, A SINGLE SHOT OF PENICILLIN
 
IS INADEQUATE. TREATMENT FOR PELVIC INFLAMMATORY DISEASE
 
SHOULD CONTINUE FOR 7-10 DAYS.
 
6. Patients .;hou, ­ be advised to avoid iron, milk, and milk products for 1 
hour before alJ 2 hours after ingesting tetracycline as these inhibit ab­
sorption of the drug. 
7. 	Treatment of both partners is ESSENTIAL if a recurrence occurs and 
should usually be provided at the time of initial diagnosis.
8. 	Usually both partners must be treated. If one partner is treate6 by a
clinician, it would be helpful to the couple if the other partner could be 
provided with a prescription simultaneously. 
9. Always consider that there may be other sexual contacts who may not 
be treated. 
10. Trichomoniasis may be responsible for some of the cases that show a 
Class II Pap smear reading. If this is the case, recheck the Pap smear 2 
nonths aftvr treatment. 78 




Pelvic inflammatory disease 
Aodominal, pelvic, back, and or leg pain; 
fever or chills, vomiting; vaginal discharge
often beginning on the last day of menstrual 
flow or shortly thereafter; prolonged 
menstrual bleeding or menorrhagia; 
bleeding after intercourse; dysuria; pain 
with intercourse, 
BE SURE TO RULE OUT ECTOPIC 
PREGNANCY. Infectious agents associated 
with PiD and endometritis are N. gonor-
rhoeae, Chlamydia trachomatis bacteroides, 
streptococci, peptostreptococcus, clostridia, 
staphylococci, E. coli, tuberculosis, 
schistosomiasis, filariasis, and occasionally 
actinomycosis. Some clinicians find the 
erythrocyte sedimentation rate (ESR) very 
useful. Patients with peritoneal signs or 
evidence of pelvic abscess should usually be 
hospitalized. Gram stain of endocervical 
secretions, gonorrhtea culture on Thayer-
Martin medium. 
Gonorrhea 
May be totally asymptomatic in both sexes. 
Symptoms can include vaginal or penile
discharge or pain; painful urination; tender-
ness of lymph nodes in groin; lower 
abdominal pain; fever; testicular pain in male 
and irregular and painful menses in female; 
pain with intercourse and postcoital bleeding 
may also occur. 
Gram stain, culture on Thayer-Martin 
medium. Because of the possibility of 
concommitant syphilis infection, each 
patient treated for a known gonorrheal infec-
tion should have a test for syphilis, if possible. 
Chancroid 
Progression from initial vesicle-like pustule 
covered by a thin membrane to a sharply
circunicised ulcer with an irregularedge may 
take up to 2 weeks. 
The ulcer is soft and its base may be 
covered 'y a grey purulent exudate. 
Multiple lesions may occur. Lesions 
may be painful. Unilateral inguinal 
adenopathy occurs in 25%-50% of patients 
and suppurating bubos may develop. 
Destructive scarring may occur. In women 
ulcers occur most frequently on labia, clitoris, 
and vaginal introitus. In men, ulcers occur on 
penis and inside surface of foreskin. More 
common in uncircumcised men. 
Chancroid is caused by Hemophilus ducreyi, 
a small pleomorphic gram-negative rod. 
Currently no available serologic test or skin 
test exists. Diagnosis is often made on basis 
of negative darkfield exam for spirochetes
and response to sulfonamides. H. ducreyi is 
difficult to grow. When obtained from lesions, 
the organism is present in pairs and short 
chains. 




Pelvic inflammatory disease Gonorrhea Chancroid 
Objective findings: lower abdominal pain oi

rebound tenderness, decreased bowel

sounds, tenderness of uterus and or adnexa,

pain on movement of cervix, palpable mass
 
or swelling, and or a purulent vaginal

discharge. The differential diagnosis includes
 
ectopic pregnancy, endometriosis, ovarian
 
cysts, neoplasms, mesenteric lymphadeniti

uterine leiomyomata, and appendicitis.

Treatment Tetracycline 0.5 gm orally four times a day 
 Tetracycline 0.5 gm orally every 6 hours forfor 10 days (not for pregnant patients); 5 days, Local cleansing and soaks for ulcer. tetracycline should be given 1 hour before or 
or 3.5 gm of ampicillin or 3.0 gm of Sulfonamides are the antibiotics of choice.amoxicillin orally with 1 gm probenecid taken Sulfisoxazole: 1 gm orally every 6 hours for2 hours after meals. OR aqueous procaine together. (Oral treatment is a precautionpenicillin G 4.8 million units I.M., ampicillin 2 weeks. If this fails, continue the sulfa andagainst anaphylaxis with parenteral penicil-Co 3.5 gm, or amoxicillin 3.0 gin, each with 1.0 
add oral tetracycline, 500 mg every 6 hours.
C lin.) If trained appropriate personnel aregm of probenecir (particularly if gonococcal avai;able 4.8 million units aqueous procaine 
Kanamycin and gentamicin and parenteral
infection is suspected). Either regimen is cephalothin have also been used in resistantpenicillin (divided into 2 duses), given into cases. Streptomycin also treats chancroid.followed by ampicillin 0.5 gm or amoxicillin two or more sites into the gluteal muscle,0 5 gm orally four times a day for 10 days Of accompanied orally by 1.0 gm of probenecidthe above approaches. tetracycline has the should be given. NOTE: For nonpregnant
advantage of covering chlamydial infections. penicillin-allergic individuals: 0.5 gm oral
In general. IUD's should be removed if a tetracycline every 6 hours for 5 days (as
woman develops PID. The IUD 
 may be above) or 2 gm spectinomycin in a singleremoved at the time PID is diagnosed, after 2 injection. For pregnant penicillin-allergiccaysof antibiotics. or following one menstrual persons: 2 gm spectinomycin in a singleperiod, depenoing on the clinical setting, the injection or cephalexin, 500 mg 4 times atime of the cycle, and the days of the cycle day for 4 days. Treatment should includewhen intercourse has occurred. followup culture" and test for .,philis in 7-14 
days. 





Pelvic inflammatory disease 
1. Use condoms until posttreatment cultures 
are negative for both partners. 




3. Avoid milk, milk products, and large 
amounts of any food for 1 hour before and 2 
hours after ingestion of tetracycline, as milk 
inhibits tetracycline absorption. 
4. Rest in bed until abdominal pain 
subsides. 
5. ABSTAIN from sex at least 1 week. 
6. Return to your clinician on the appointed 
date so that s he can make certain your 
infection is cured. 
Gonorrhea 
1. Get your partner treated. 
2. Avoid intercourse completely until your 
clinician makes certain your infection is 
cured. If you do have intercourse, use 
condoms to prevent reinfection. 
3. Be alert for symptoms of yeas: infection if 
you take tetracycline or arnpicillin. 
4. Return to the clinic if you develop diarrhea 
while taking tetracycline or ampicillin. 
Chancroid 
1 Wash lesions carefully. 
2. Continue antibiotics for the full 2 weeks. 
3. Circumcision may be necessary after all 
lesions have completely healed. 
4. Personal cleanliness is important both in 
treatment of active infection and in pre­
vention of further infections. 
TABLE 6. 1 Symptoms, diagnosis, treatment, and patient instructions for some common sexually transmitted 
diseases- Continued 
Chlamydia Syphilis Trichomonas 
Symptoms Chlamydia can cause a range of problems 
including nonspecific urethritis, cystitis,
purulent vaginal discharges, cervicitis, and 
pelvic inflammatory disease. Chlamydia 
trachomatis can cause conjunctivitis, 
urethritis, cervicitis, s3lpingitis, proctitis,
and pneumonia of the newborn. Trachoma, 
another chlamydial infection, is nottransmittef sexually. 
PRIMARY 13 weeks after exposure): 
char.,re is an indurated, painless, red-
rimmed sore on the penis, anus, rectum, 
edge of vagina, cervix, or mouth-it will 
disappear 2-6 weeks later, even without 
treatment-
SECONDARY (about 6 weeks after [he
hEAR of t pria sfe rh.healing of the primary infection): rash,especially on the palms of hands and 
Frothy, thin, greenish-white, sometimes 
bubbly, vagiral discharge; intense vulvar 
itching, pain, and frequency of urination. The 
infection may be asymptomatic and usually
is in males, although they may have oc­
casional pain on urination and discharge
from the urethral meatus. 
soles of feet, fever, sore throat, head­
aches, arthralgia, sore mouth, anorexia, 
nausea, and or inflamed eyes. These 
symptoms may disappear in 2-6 weeks 
even without treatment. Moist, broad-
Co based, flat-topped growths (condylomata­
lata) up to 2 cm in diameter may appear 
on the warm moist areas of the body. 
TERTIARY (10-20 years): heart disease, 
brain damage, spinal cord damage, blind­
ness. One in four persons not treated 
for secondary syphilis will eventually suf­
fer incapacity or death from the disease. 
Symptoms may be absent until tertiary 
damage occurs (latent syphilis). 
Congenital syphilis, a serious infection in 
newborns, occurs frequently if pregnant 
women with syphilis are not treated. 
TABLE 6. 1 Symptoms, diagnosis, treatment, and patient instructions for some common sexually transmitted 
diseases- Continued 
Chlamydia 
Diagnosis Chlamydia is an obligate intracellular 
bacteria. Usually diagnosis is one of 
exclusion since very few centers can provide
techniques for culturing Chlamydia. 
Treatment Tetracycline 2 50-500 mg four times a day for 
10-21 days is treatment of choice. The sexual 
CA partner must be treated. Erythromycin is alsoreported to be effective. Ampicillin is usually
not effective, 
Syphilis 
Dark field examination of fluid from chancre,
VDRL (may not be positive until 2-3 weeks 
after appearance of chancre), and the 
fluorescent treponemal antibody absorption 
test (FTA-ABS); the treponema pallidum
immobilization test (very few false positives)
has been for the most part replaced by
treponemal tests (microhemagglutination 
treponemal pallidum antibody test = 
MHA-TP, or TPHA, or the TRA-ABS test), 
Penicillin: 2.4 million units benzathine 
penicillin G for primary and secondary
syphilis. The high short-term doses given for
gonorrhea will prevent development of 
syphilis if given within 10 days of exposure,
but will not cure syphilis that has progressed
to the primary stage or beyond. Alternatives: 
2.4 million units of benzathine penicillin 
weekly , 3 for early latent or tertiary syphilis.
Or, for tertiary syphilis, penicillin G procaine
600,000 to 1.2 million units I.M. daily for 15
days, ortetracycline 30-40 gm p.o. over 10-15 
days. 
Trichomonas 
Infemales the appearance of discharge and 
punctate red petechiae on cervix is helpful
but not diagnostic. Motile flagellated 
trichomonads appear on microscopic 
examination of saline wet mount. Culture.
Pathologists can detect these organisms on 
a Pap smear. Often not necessary to treat 
asymptomatic women when organisms are 
found on a Pap smear. In males culture or 
wet smear of prostatic secretions may yield
organisms, but identification of the 
trichomonad is difficult in males. 
Metronidazole (Flagyl') 2 gm p o. (single 
dose) or 500mg bid for 5 days
Provide condoms as part of treatment. 
Do not provide systemic metronidazole 
in first trimester of pregnancy--effects 
of metronidazole later in pregnancy or 
in nursing mothers is unknown. 
Metronidazole has been noted to pro­
duce leukopenia and allergic reactions. 
Metronidazole has been shown to be 
carcinogenic in mice and possibly
carcinogenic in rats. Unnecessary use 
of this drug should be avoided. 











pelvic inflammatory disease. 

Set instrL, for cystitis. vaginitis, and or 
Gardnere!la Vaginalis 
Yelio.v, to gray-green vaginal discharge, 
sometimes described as chalky white, 
Mtay be thick or watery and may cause 
Oul odor, pain on urination, vaginal 
itchin, and or painful intercourse, 
Short. rod sfiaped bacteria on wet 
mount and stippled granular epithelial 
cells "clue" cells'. Addition of KOH to 
discharge containing vaginalis releases 
amines. causing a foul fishy odor, 
Gram stain may show numerous short, 
gram-negative bacilli. Lactobacilli are 
commonly absent in the presence of G, 
vaginais. May be detected Papon 
smear May cc cultured on th:oglycolate 
broth or blood sugar culture. 
Syphilis 
1. Your partnerlsi must receive treatment 
2 Use condoms during intercourse for a 
month 
Monilia 
Thick, white cottage cheese-like 
discharge, itchino, redners of externai 
genitalia and sometimes upper thighs 
Itching may be severe 
Ten percent potassium lhydroxide or, 
discharge; Monilia is also easy to 
recognize on agram sta. Loo 7or 
hyphae and spores under microscope. 
your pathologist may note Monilia on 
Pap smear Culture in Sanouraud's or 
Nickerson's medium 
Tricl....onas 
I Nausea diarrhea, vomiting, dryness of 
:h,,mouth, or a "tinny' (metalic) taste 
may occur 
2 Use condoms throughout treatment. Your 
partner -nu t te :reated for this infection. 
2 It is not knoc',n what cancer-causing effects 
Fiagyl has on a pregnant woman or 
idevelopinq fetus 
4 is to oe treated, despite the0etter
potWelii problems caused y the drug, 









tihstfr- k- 'ulvar, cervical, or 
oen t sores or ulc rations which are 
ofter ,onteguous 'herpes" means to 
ereni pa n c interco rse, discharge. 
p'n Imay Le very severe and itching 
of vulva and pt~rei;m. Dysuria may be 
milost promintsnt symptom. 
Usuaily by clmcal judgrnent If con­
firnaton desired, Pap smear from 
s:e 5i or ies:on'si ^Askcytologist to 
look fo)r rntranUclear changes produced 
ty herpes Tissue; culture may be taken, 
and immunologtc diagnosis also ps­
sble, but difficult to obtain, 
Viralcultres (ifavailable) give accurate 
results within 48 hours. 







Oral metronidazole 500 mg bi d for 7 
days for both partners Ampicillin is a

second approach Use 500 mg q i d. for 

7-10 days for patient and partner.
Although sulfa suppositories have also 
been used in local treatment for 10-15 
days, local agents are probably not 
very effective. 
1. Partner(s) may be infected, so treatmenz 
of partner(s) is important. 
2. Use treatment exactly as prescribed; take 
full amount prescribed. 
3. Use condoms until treatment is




During examination, wash patient's
vagina carefully, sponging with 
pov~done-icdine if available Nystatin' 
vaginal suppositories once or twice a day for
15 days (longer for stubborn infections) or 
miconarolevagnal cream inaonce-a-night 
application for 7-14 days. Steroid cream will 
diminish itching. Gentian violet 
suppositories once a day for 2 weeks or by
direct application can also be used. Most 
women find it less messy to use suppositories 
at night only. A tampon may be used tokeep
vaginal suppositories in place. Bor;c acid 
(400 mgl in gelatin capsules have been used 
treat Monilia. 
1. Complete your prescription even if 

symptoms become less annoying.

2. Wear cotton underwear and avoid tight
clothing. 
3. Lose weight if you are overweight,
4. Ask for diabetes test if you have 
recurrent Monilia. 
5. You may need to take medication 
throughout one or two complete menstrual 
cycles. 
6. Consider using Monilia medication in the
future if you are being treated for other 
infections with tetracycline or ampicillin.
7. White vinegar or commercially available 
douches may help prevent recurrences of 
yeast infections. Use 1 tablespoon of vinegar
in a quart of warm water, 
Herpes Genitalis 
No specific treatment exists. Analgesics 
can be used systemically. Keep lesions clean
and dry. Avoid occlusive creams and 
ointments. Corticosteroids are contrain­
dicated. Catheterization for urinary retention. 
Treatment of superinfections may be helpful. 
1. Keep area clean to prevent superinfection.
2. Wear loose underwear. 
3. Urinate in a tub full of warm water while 
pouring warm water on vulva or penis if pain 
is severe. 
4. You should be healed in2-4 weeks. 
3. If it is easy for you to get a Pap smear, 
you should have a Pap smear every year for 
the rest of your life. 
6. Use condoms for at least 6 weeks and 
until the signs of infection are gone in both 
you and your partner. 
7. Abstain from intercourse, or use condoms 
whenever there is any sign of a recurrence. 
iOften the first sign is a tingling sensation. 
8. fell yourclinician you have had herpes if 
you plan to carly a pregnancy to term because 
there is a risk of herpes infection in the 
newborn. Active herpes infections may be an
indication iordelivery by C-section. 




Condylomata Accuminata Pubic Lice Cystitis 
Symptoms Small (2mmi to large, dry, fungating. wart- tching and lice present in pubic hair. Pain and Durning on urination, frequent
like growths on the vulva, vagina, cervix, or urnatron in 'Fery small amounts, cloudy foul­penis May cause pruritis and chronic smel .ng urine, nocturia, lower abdominaldisctharge. Vlats appear I to 3 months after npi r,,Tirar, L i, of uoetnra, pain 
exposure during lntercourse. Ilood in urine, 
Diagnosis A'Ippearance as pc.en above Be certain to Lice or eggs (nits) in pubic hair. Bacteria on urnspun urine, leukocvtes ondifferemiate betvean condylomata and urinalysis, culture and sensitivities on clean­
secondary Sylphilis. v hicir are flat moist catch urine partIcularly if there is recurrent
lesions. A test for syphilis should be drawn. infection or treatment failure), urethral 
irritation, bladder or trigone tenderness. 
NOTE Check patient for uack pain and fever. 
If present may indicate pyelonephritis lalso 
loOK for leukokuye casts in urine). Check for 
00 vaginitlis parttcui!ri/ gonorrhea, herpes,
In vaginahs, and tr!chomoniasis). Obtain clean­
catch spcc men to avoid contamination with 
vaginal descharge. Always think of PIO when
0cons'Jerts the d n ss '-f cyst1ts. 
Treatment Apply 203-251. podophyllin liquid or Gamma benzene hexachloride shampoo, ',o sf, ; :--uzj*,,mi n I 9 u-ointment to warts after protecting sur- lotion, or cream or other scabicide. for 10 14 days Sonne cfinicians report excel­rounding tissue with a lubricant jelly. Wash lent suc ess folioin .i' treatment of cystitis
off in 4-6 hous. Reapply weekly leaving it on vith just a s ngle large dose of a variety of
for progressively longer periods of time up to diffeen.............*efr 2. -46 nors if 
24 hours Often, three or more applications the burring, Da a'd sense of urgency
may be needed. 
are 
particu;at'i trc-LIesome AWarn the patient 
Tricholoracetic acid or electrocoagulation is To expect ust-coioed urine i Alternlatives:en 
used for larger or resistant lesions. Huge aomnisereto Pre'nant women, may bem asse s m ay re q u ire su rg ica l ex cisio n u n d e r a ssocist e d vo l re una o m n, m a ae 
local or gereral anesthesia. In some cases, assocJad with lowering of both plasma and
plastic surgery under general anesthesia is u inary estriol Va Ues; or tetracycline Other 
alternatives comoinaton of sulfa drugs,necesary. 
carbenicilin indanvlesoocum, and 
netroidazole Some ciiniclans recommend 
making the urine more acidic by increasing 
abscorbic acid ihtake ior intake of crsnberry
nuice). 
TABLE 6. 1 Symptoms, diagnosis, treatment, and patient instructions for some common sexually transmitted 
diseases-Continued 
Condylomata Accuminata 
Patient 1. Wash the medicine off with soap and 
instructions water after about 8 hours. 
2. Your partner may need treatment, 
3. Use condoms until all warts have 
disappeared. 
4. Too much treatment may cause nausea, 
diarrhea, vomiting, stupor, or paralysis. For 
this reason, your clinician may only treat a 
portion of the warts if you have many. 
Oor 
Pubic Lict 
1. Remove all lire and eggs that you can see. 
Wash with soap anc water. Dry with a clean 
towel, 
2. Massage lotion or cream on body from
neck down. Include scalp if lice are present 
there. Leave med;cine on overnight, 
3. Boil clothing and linen. Lice live incan 
unlaundered clothes. Eggs can live 6 days 
and lice can live 24 hours after removal from 
the body. 
4. Both you and your partner should receive 
treatment, which may need to be repeated
after 24-48 hours. 
Cystitis 
1. Drink 10-15 glasses of water each day
 
during treatment. Continue drinking 10-15
 
glasses of water a day if recurrent cystitis is 
a problem. 
2. Complete taking the antibiotics, even if 
symptoms have gone away and you are 
feeling well. 
3. Return for followup urinalysis 3-4 weeks 
after treatment is started (earlier if 
symptoms persist). Complete urologic 
evaluation may be necessary if recurrent 
infections occur. 
t4. Partner(s) mus be treated if trichomoniasis 
gonorrhea is cause of infection. 
5. Until yo ' feel better, avoid sexual inter­
course. If cystitis is a recurrent problem, 
uinate and drink a glass of water following 
sexual intercourse. Avoid coitus if too painful. 
6. If you are taking ampicill;n or tetracycline, 
return to the clinic if you develop diarrhea. 
7. If you are using the diaph;agm as your 
method of birth control and you develop
repeated bladder infections, consider the 
possibility that your diaphragm may be 
causing too much pressure against your 
urethra. 
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THE MENSTRUAL CYCLE 
A woman's fertility runs in cycles, unlike a man's fertility which is, for the 
most part, constant. An understanding of these cycles can help clinicians and 
users choose appropriate family planning methods and help individuals use 
these method; cm i ectly. In each female cycle, hormones- the hody's cheini­
cal nlessengers;tilate changes in the body. these changes gradually
build to a peak in which a Iatore egg ipens for fertilization. -he lining of the 
uterus (endometriunI) hecomes a rich, IlUtritioiLs bed in anticipation of a 
potential pregnancy. Ifthe egg is fertilized hy a speirmatozoon during the
cycle, a pregnancy deveops. But if tie egg is not fertilized, then the hormones 
gradually stop prep aring the woman's body for pregnancy. When this 
happens, the nutritious lining of the womb sheds and the cycle begins again.
Understanding a woman's cycle of fertility, called the menstrual cycle, can 
help planning for a pi egnancy, preventing one, and understanding and diag­
nosing many nedill problems. Many of the contraceptives in this book work 
by interrupting one or more of the steps in the menstrual cycle necessary for 
creating a pregnancy. 
PHYSIOLOGY 
The menstrual cycle can be divided into three parts: the uterine cycle, the 
ovarian cycle, and the functions of certain organs in the brain (1). For 
simplicity, the description of the menstrual cycle in this chapter is based on a 
28-day cycle, although a normal cycle may last anywhere from 21 to 35 
days. 
UTERINE CYCLE: 
The beginning and the end of the uterine c,cle are marked by the flow of 
menstrual blood, the shedding of the Uterine lining. After 3 to 5 days when 
the blood flow stops, about one-third of the lining is left in the uterus, where it 
will begin to repaii itself under the influence of estrogen and progesterone. 
This time of repair i' called the follicular (orproliferative) phase. The follicular 
phase lasts 1in til the middh,. of the cycle, when the hormones in the body 
cause the lining to be even further nourished by the increased stimulation 
from progesterone. This luteal (or secretory) phase begins at midcycle. The 
endometrial lining thickens, and its uterine gamds and blood vessels branch 
and multiply. 
If fertilization occurs, progesterone and subsegueiintly hu1lmall chorionic 
gonadotropin (HCG) continue to support the nutritious lining iMisupport of the 
developing pregnancy. If fertilization does not occur, the hormones stop sup­
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porting the lining. Blood vessels pinch off. Without support, tile lining of tile 
uterus sheds, creating tile bleeding and signaling the beginning of the new 
menstrual cycle. 
OVARIAN CYCLE: 
The thickening and subsequent shedding of the endomettial lining seem 
simple enough. However, this actioni is controlled by tile complex interplay of 
hormones. The key ev,mts that determine whether the uteline cycle will 
occur regularly (or il pregnancy will occur) revolve lr)imn(li ovulation--the 
releasing of a mature egg froi tie oviry. 
Each of the two ovaries contins 300,000 to 400,000 follicles Follicles 
are balls of cells with immature eggs in the cetel Il a wormai's lifetilne, 
about 300 to 500 ejgs will ma1tu1re. Illone monthly cycle, about 10 to 20 folli­
cles begin to grow u1nde.r the infl1ence Of horrrones. In most cases, only oiie 
of the follicles will mature fully and tire others will degenerate. As the follicle 
matures, it secretes estrogen arid progestelone, whiclh cause tire changes in 
tire endomet rial lining( describet above. 
Duing the follicular phase, the egg matures within the developing follicle 
andJ moves sto the surface of tile ovary until it call float away as a free egg
available for fertilizatiorn. (See -igure 7.1.) The release of an egg is called 
ovulation. Some women experience a cramping or a bloody discharge during 
ovulation. Many women will 11otice that tile cervical mUCus corMing from their 
vagina increases and becorocs slippery and more stretchable. (See Chapter 
17.) 
-. ;01 .1 1 lm j 0. 
FIGURE 7 1 Changes ill the ovry dring the menstrual cycle. Maturation of 
the follicle occurs until ovulation occurs. Under the influence of luteinizing 
hormone (LH), the cells that lite the fluid-filled follicle rearrange. themselves 
into a cluster of cells called the corpus luteum. 
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The free egg begins its 6-' -day journey through the fallopian tube. WidhinI 
a day after ovulation, the egg can he fertilized by sperm, which generally 
occurs in the outer third of the tube. After the egg is released, the follicle, now 
called a corpus lutleurn, secretes increasing amounts of progiesterone and de­
creasing amiounts of estrogen lhe lining ol t1e entersloteitis the luteal 
(secretory) IIhase Unlef the increased influence of lirogesleoile. (See Figlure 
7.2.) 
If fertilization Occurs, ie, (:()pli;liteulfi Continlueis o release progesI rne 
until the developing plkicenta )e(jis to secrete its own hormorne (HCG) to 
Continue the support of the rich endoinetrial liningl. If fertilization does not 
occur, the corpus lutetm disintegrates into a white scar tiSsue called a corpus
albicans aid no longer secretes hornones As the levels of hormones decline 
further, the endonmettial lining IS 11o longerj sup)orted, and menstrual bleeding 
begins. 
FUNCTIONS OF THE BRAIN: 
The complex interraction of hormones is controlled by organs in the brain: 
the hypothalamus and the pituitary. The hyp)othalamus is sensitive to chang­
ing levels of estrogen and progesterone. When the levels reach a certain 
point, fIe hypothalarnus signals its messenger, the pituitary gland. The pitui­
tary receives the signal "nd passes the imessage 1o the ovary, which responds 
as descrihed elow. (See Figure 7.2.) 
When estrigei levels (hop,us during the inenstrual flow, Ile hypotha­
lamus releases its 
 hirriiorie releasing factor 
(FSH-RF)--to the I)itluitafy factor 
oo nnal-follicle- tirnlating 
The releasing stimulates the pituitary to 
release follicle-stimrulating hlimmorrnne (FSH). Under the influence of FSH, the 
follicles in tne ovary begin toIrow As one of the follicles reaches maturity, it 
secretes a burst of estrogen and some progesterone. Once again, the hypoth­
alamous innterlprets Ilie corn bined levels of ew'Irogen and progesterone and sig­
nals the pituitary by releasing a second signal called luteinizing hormone 
releasing factor ([_H-RF) inaddition to more FSH-RF. In response to these 
signals, tire pituitary releases both FSH and H to stimulate the ovary The 
peak levels of FSH and Li stimulate the follicle to release the mature egg.
Ovulation occurs. Following ovu-lalion, FSH drops back to baseline levels. But 
the LH continues, at lower levels, to stinulate the empty follicle (corpus 
lu teum). As the corpus lutetum begins secreting greater amotnnts of progeste­
rone and lesser amounts of estrogen, LH slowly declines. If fertilization 
occurs, the placenta of the develeping fetus secretes HCG to contilue sup­
porting the pregnancy. If fertilization does riot occur, all hormone levels 
decline. Iiiresponse to a return to the low levels of estrogen and 
progesterone, the hypothalamus releases FSH-RF to signal the pituitary, andthe cycle begins again. 
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CHRONOLOGY 
Below is a brief chronologic sLImmary of the key activities associated with 
the menstrual cycle. 
Day 1; Menstruation begins. The lin of the uterus is shed because 
there is not enough hormone Support to keep it i place.

Day 5: Menstruation ends. Some women 
may have shorter or longer 
periods. The hyionthalamus reads the low level of hormones and 
sends a message to the pitnitary. [he pituitary releases FSH to 
stimulate the ovary to start tipening an egg. The ovary releases 
mostly estrogen and some progesterone to help build up a new 
uterine lining. 
Day 14: Ovary releases an egg. (In longer or shorter cycles, ovulation 
may occur on another day, hut almost always 14 days before 
the Itext me/Istrualperiod.)(See Figure 7.3.) Under the stimula­
tion of LH and FSH peaks, the ovarian follicle releases the egg. 
The empty follicle (corpus lutedim) secretes increasing amounts 
of progesterone and decreasing amounts of estrogen. I1the egg 
is fertilized, the corpus luteu continues secreting inrreasing 
amounts of progesterone until the placenta produces sufficient 
quantities to sustain the pregnancy. If the egg is not fertilized, 
the events continue as follows. 
Day 26-28: Premenstrual time occurs. (This varies for women with shorter 
or longer cycles.) Levels of estrogen and progesterone drop. 
Many women experience premenstrual symptoms such as 
weight gain, breast tenderness, bloating, and acne. 
Day 1: Menstruation begins. 
(. ) i) 0 ( i) i)t 
FIGURE 7.3 Timing of ovulation during the menstrualcycle. When a woman's 
cycle length varies, it is the phase before ovulation that changes in length.
The number of cycle days after ovulation remains approximately the 
same-about 14 days. 
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MENSTPUAL HISTORY 
Since many of tile contraceptive methods described in later 
chapters affect the menstrual cycle, a good menstrual history 
will help both you and your patient choose the best method of 
contraception for her. 
By asking your patient the quostions listed below, you can 
help her develop her menstrual history. 
How old were you when you started menstruating? 
When was your last menstrual period? 
How many j~ys does your menstrual bleeding last? 
Have you missed any periods? 
Do you have cramping with your periods? How severe? 
Have your menstrual periods become heavier recently? 
Do you have bleeding between periods? 
Do you experience any premenstrual depression, 
headaches, anxiety, weight gain, ankle swelling, 
breast tenderness or fullness? 
Have your menstrual cycles changed since you started using 
your present contraceptive? 




Below are three questions that patients commonly ask about the 
menstrual cycle: 
Questior, 
Can you get pregnant 





Yes. While not common, it has 
happened. It is most likely to 
happen to a woman who has 
short menstrual cycles (18-25 
days). 
Can you get pregnant 
have never had a period? 
if you Yes. A young woman can ovu­
late and become pregnant a 
couple of weeks before she 
would have had her first period. 
Are women unclean whe
have their periods? 
n they No. 
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EFFECTS OF CONTRACEPTIVES ON 
THE MENSTRUAL CYCLE 
Contraceptive methods can affect the menstrual cycle. They can alter the 
amount and duration of menstrual hleeding, the degree of premenstrual 
symptoms, flare-ups of acWne, an( interoen'1strual bleeding. Perhaps the most 
important noncontraceptive effect, are the influences on menstrual pain, or 
dysmenorrhea. 
Menstrual pain is not trcomonn. Since the ise of hormonal contracep­
tives suppresses ovJlation, many women using combined Pills, Mini-Pills, 
and long-acting progestin injections find relief from menstrual pain. IUD's are 
often associated with increased menstrual pain ard hleeding. One IUD, 
however, the progestin-releasing IUD (Progestasel- f), can suppress ute­
rine contractions, thereby decreasing menstrual pain. 
If a woman complains of menstrual pain, some of the following 
approaches may he used-
Mild menstr, al pain Severe pain 
Vigorous physical exercise Analgesics or narcotics 
Lower back, leg, or calf Diuretics 
massage Prostaglandin inhibitors 
Lying with knees to chest Birth control Pills 
One ounce of alcohol beverage Insertion of aprogestin-
Hot drinks elaborating IUD 
Aspirin for several days before Dilatation and curettage 
and during period 
Rest 
Warm hath on ;hower 
AMENORRHEA 
Amenorrhea--the failure to have a menstrual cycle-can have different 
causes. A woman may have primary amenorrhea due to abnormal 
physiology, or secondary amenorrhea in response to illness, drugs, stress or 
tumors, pregnancy, use of hormonal contraceptives, or menopause. 
A woman who has not begun tier menstrual cycle by age 17 should be 
evaluated by a specialist. A girl who has not developed breasts or female hair 
patterns by age 15 should also be evaluated. 
If a woman once iad periods but no longer has them, make certain that 
she is not pregnant. If she is not, check whether weight loss, d,pression, 
illness, or medications (including contraceptives) may be causing her 
amenorrhea. If none of these are the cause, and her periods do not resume 
with appropriate care, send ier to a specialist for an evaluation. 
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An older woman, between the ages of 45 and 55, may have begunmenopause. Menopause is the normal ending of a woman's cycle of fertility.However, a woman can still get pregnant in the early stages of menopause,because her cycle may merely be irregular before stopping completely.
Advise the woman to use a contraceptive method until 6 months to 1 year
after her periods have stopped. 
ANEMIA 
Most women of reproduction age have a borderline iron balance becauseof their monthly menstrual cycles. Heavy menstrual flow can result in anemia.However, in the malnourished woman, even normal flow may lead to anemiaif the woman has no way of replacing the iron she has lost. The average bloodflow during menstrual flow is about 30 ml. While women may vary in theamount of flow they have, various contraceptives can also affect the flow.An IUD usually makes a woman's menstrual flow heavier; thus, the IUD maynot be an ideal choice for a woman prone to anemia. On the other hand, theoral contraceptive or Mini-Pill will decrease the blood flow in many women.Encourage all women in their childbearing years to consume iron eitherthrough the foods included in their diets or by taking supplements. 
REFERENCES 




"Is this woman pregnant?" You may ask yourself this question often during 
the course of your work as a family planning professional. The answer is im­
portant for several reasons: 
* 	 You may wish to insert an IUD. However, inserting an IUD into the 
uterus of a pregnant woman can cause spontaneous abortion or sepsis. 
(See Chapter 13.) 
* 	 You may wish to administer medications. Giving some medications to a 
pregnant woman may affect her fetus. 
* 	 You should begin prenatal care if the woman is 1p.,egnarit and planning 
to remain so. Advising a patient about how to keep herself and hei" de­
veloping baby healthy is a crucial part of family planning. 
* 	 You may want to determine why a patient has missed one or more 
periods. Finding out if a woman is pregnant is the first step in evaluating 
amenorrhea. 
* 	 You may want to know if an abortion (either spontaneous or induced) 
that a patient has undergone has truly terminated the pregnancy. (See 
Chapter 22.) 
" 	 You may be concerned that a patient may have an ectopic pregnancy. 
Detecting an ectopic pregnancy before it ruptures can save a woman's 
life. 
DIAGNOSING A PREGNANCY 
In the normal pregnancy, a thorough history and a complete physical 
examination are usually adequate to make the diagnosis of pregnancy. 
During the first 6 to 12 weeks of pregnancy, awoman may have the following 
signs: (1) 
Missed periods Weight gain 
Breast tenderness or swelling Mood changes 
Nausea (morning sickness) Changes in eating habits 
Urinar,, frequency Backaches 
By the 12th week of pregnancy, the earlier signs of pregnancy may disap­
pear or persist. New signs may appear: 
Increase in breast size Vaginal discharge 
Increased facial pigmentation Fetal movements (beginning 
(mask of pregnancy, chloasma) about the 18th or 20th week) 
Protruding lower abdomen Swelling or redness of gums 
Darkening of nipples 
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While most normal pregnancies can be diagnosed and managed without 
tme use of pregnancy tests, certain situations such as those mentioned at thebeginning of this chapter are best managed by combining a thorough history
and physical examination with a laboratory test. 
The more urgent reasons for using laboratory tests to detect pregnancy 
are to help rule out the following: (2-7) 
ECTOPIC PREGNANCY
 





PREGNANCY CONTINUED AFTER ATTEMPTED ABORTION 
HUMAN CHORIONIC GONADOTROPIN 
Today, most pregnancy tests work by detecting the presence of humanchorionic gonadotropin (HCG), a hormone of pregnancy. In the normal 
pregnancy, human chorionic gonadotropin is secreted by the egg implantedin the endometrium (3). Soon after the fertilized egg implants in the
endometrium, the very sensitive tests for pregnancy can detect HCG in thepregnant woman's blood (2). In another week or two, the less-sensitive* slide
and urine tests can detect HCG in either the blood or the urine of the pregnant 
woman. 
In the normal pregnancy, the HCG levels follow the pattern shown in Table 
8.1. 
Pregnancy tests work through an immunologic reaction to human chorion­
ic gonadotropin. Since most of the commonly used slide and tube tests are in­direct tests- that is, they inhibit agglutination ­ this chapter will describe themechanism of action of these indirect tests only. Read the instructions that come with the test kit you use to determine what type of test you are using. 
(See Table 8.2.)
For performing the test, the technician adds an antibody to the patient's
urine or serum specimen. After adding the antibody, the technician adds anindicator particle which becomes visible to the naked eye if it reacts with the 
antibody.
 
If the patient is pregnant, her urine or serum will contain HCG. When the
antibody is 
 added to her specimen, the gonadotropin will bind with theantibody. No antibody will be left to react with the indicator particle that isadded. The specimen will, therefore, be clear because agglutination of the an­
tibody and the indicator particle has been inhibited. 
If the patient is not pregnant, her urine or serum will not contain HCG.Therefore, when the antibody is added to her specimen, it will not be bound 
"The sensitivity of a pregnancy test. refers to its ability to detect low Icv-ls of human chorionic 
gonadotropin. 
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but will remain free to react with the indicator particle. Thus, when the indica­
tor particle is added, agglutination-or clumping-will form and be visible to 
the naked eye (8). (See Figure 8.1.) 
TYPES OF PREGNANCY TESTS 
Three types of tests are commonly used to detect human chorionic gona­
dotropin during pregnancy: immunoassays (which include slide tests, tube 
tests, and the supersensitive tube tests), radioimmunoasssays, and radiore­
ceptorassays (2,4-7,9). (See Table 8.3.) Refer to Table 8.4 for a comparison 
of costs, sensitivity, and other requirements of tests produced by different 
manufacturers. 
IMMUNOASSAYS (SEE ACCOMPANYING INSTRUCTIONS) 
Two-minute slide tests are the most commonly used tests for screening. 
The tests are popular because they are rapid, easy to perform, inexpensive, 
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and convenient. They are, however, the least sensitive of the tests currently
used: they do not detect pregnancy until 45 days after the last normal 
menstrual period.
Two-hour tube tests are somewhat more sensitive than the slide tests and 
are generally easier to read. Oi the other hand, the test materials are more
expensive, and the test requires more time to produce results. 
TABLE 8.2 Instructions forperforming the urine slide test forpregnancy (8) 
Specimen Collection
 
Have the patient collect a specimen of the first urine
 
she voids in the morning.
 
Have the patient use a clean and well-rinsed glass or
 










Take a slide test card. 
 Fhere are circles on the card. 
Use one circle for one specimen. 
Put 1 drop of urine from a pipette in the middle of a 
circle. 
Add 1 drop of antiserum reagent to the urine. (Hold
dropper perpendicular to the slide.) 
Mix the urine and reagent with the applicator stick.
 
Rotate the card for a short time (30 seconds).
 
Add 1 drop of antigen reagent to urine and antiserum
 




Mix and spread the mixture over the entire circle.
 
Rotate the card for 2 minutes (no longer).
 




In most tests, clumping means the test is NEGATIVE.
 
The absence of clumping means the test is POSITIVE.
 
(The direct agglutination tests an
react in opposite 
manner.) 
CHECK THE INSTRUCTIONS ON THE SPECIFIC TEST 
YOU ARE USING. 
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SLIDE TEST FOR PREGNANCY 
I 	 Iii t I / f;IIIV III 
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FIGURE 8. 1Interpreting the slide test forpregnancy.(10) 
TABLE 8.3 Advanta yes and disadvantages of commonly usedpreg­
nancy tests (4,6) 
Test Advantages 	 Disadvantages 
Slide test Convenient 	 Less sensitive than tube test or 
Rapid radioinlmunnaSSay 
Centrifuging or filtering High HCG levels needed for 
of specimen not necessary positive test (1.5-2.5 IU ml) 
Specific for HCG 90 "o accuracy only after 45 days 
Minimal drlg interference has p1, ssed since last menstrual 
period 
False-negative results on urine 
with high specific gravity 
High technical error rate from 
improper mixing technique 
Occasional false-positive results 
from prateinuria 
Tube test Simple 	 Less sensitive than 
More sensitive than slide radioinimunoassay 
test High HCG levels needed for 
Less technical error rate positive result (0.5-1 lU ml) 
than with slide test 90 , 0o acCuracy only after 40 days 
has passed since last menstrual 
period 
Significant protein uia can 
produce atypical results 
Vibration or jarring can cause 
inconclusive results in some 
tube tests 
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Newer, supersensitive tube tests work in the same way as the regular tube 
tests. These new tests, however, are much more sensitive and may be a suit­
able alternative, in some situations, for the highly sophisticated
radioimmunoassays. These supersensitive tube tests may not be available in 
many areas. 
RADIOIMMUNOASSAYS 
Radioimmunoassay tests for pregnancy were developed within the past
10 years. Extremely sensitive, these tests can detect human chorionic gona­
dotropin within several days after fertilization has occurred. The use of these 
tests is limited by the availability of equipment and sustained funding and 
TABLE 8.4 Costs, sensitivity, time, and refriqeration requirements 
for pregnancy tests (1 1) 
Cost per kit Time Stability in 
(tests in kit) Sensitivity, Required Refrigerator 
FUBE TESTS 
Pregnosticon Accu­
spheres' (Organon) $1.46 (100) 
 750 2 hr 1 yr (RT)Placentex" (Roche) 1.54 (100) 1000 90 min 18 mo
Gravindex" (Ortho) 1.09 (100) 500 90 min 1 yrBeta-Stat' (Wampole) 1.78 (50) 200 1h 18 mo (RT)
Neocepr (Organon) 1.81 (50) 200 2 hr 1 yr

Sensi-Tex" (Roche) 1.75 (100) 250 90 min 
 7 mo 
SLIDE TESTS 
Pregnosticon Dri Dot' 1.20 (100) 1500 2 min 2 yr
Pregnosis (Roclie) .99 (100) 1500 2 min 2 yr




UCG Slide' (Wampole) 1.03 (100) 2000 2 rin 
 18 mo
Pregnate' (Fisher Diag.) 1.16 (50) 2000 2 min 1yr

Gravindex, ' ' (Ortho) .96 (60) 3500 2 rin 
 lyrBeta Slide' (Wampole) 1.13 (100) 500 2 min 18 mo' Sensi-Slide , (Roche) 1.20 ( 50) 800 2 min 7 mo 
SERUM TESTS 
ChorioShure" (N.M.L.) 1.35 (100) 40 90 min 6-8 wks
Chorio Quant, (N.M L.) 1.35 (100) 0-90 2.5-3 hr 6-8 wksBeta Tec", (Wampole) .72 (125) 30 1 hr 6 rNksR-hCG RIA" (Roche) .95 (100) 6-50 1 hr 8 wks
HCG-Beta 1l1",(Serono) 1.24 (125) 1 48 hr .6 wks
HCG-Beta III'" 1.24 (125)(Serono) 3 1hr 6 wks
HCG-Beta I11'" 1.24 (125) 35 30 rin(Serono) 6wks
Preg Stat, (Serono) 1.26 1 75) 25 1 hr 4 wks
Biocept-G (Wampole) 1.92 (30) 200 1 hr 5 wks 
'Milli-international units of HCG per liter of urine. 
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supplies. Radioimmunoassays require expensive, highly technologic equip­
ment and costly, relatively unstable radiologic testing materials. Because of 
their sensitivity and accuracy, radioimmunoassays, where available, are the 
tests of choice for the diagnosis of certain complications of pregnancy, such 
as ectopic pregnancy or threatened or incomplett -bortion. These tests are 
also capable of providing a quantitative measurement of human chorionic 
gonadotropin. 
RADIORECEPTORASSAYS 
Radioreceptorassays are similar to radioimmunoassays, although riot as 
sensitive. Where radioimmunoassays have not been available, radioreceptor­
assays have been the tests of choice for women with complicated 
pregnancies. Some authorities suggest that the supersensitive tube tests, 
which have similar levels of sensitivity but are simpler to perform, replace 
some of the need for the radioreceptorassay. 
(For further information about how these tests work, consult your local 
supplier.) 
USING PREGNANCY TESTS 
When you are called upon to confirm an uncomplicated normal 
pregnancy, the slide test is the test of choice (4,6). These tests can detect a 
pregnancy about 6 weeks after the last normal menstrual period (about 2 
weeks after the first missed period). Most facilities use the slide test for 
screening when the physical examination is inconclusive or if the patient 
desires laboratory confirmation. 
For pregnancies that are complicated, however, other tests are generally 
preferred, if available. For example, in an ectopic pregnancy, slide tests fre­
quently (50, percent of the time) will yield a falsely negative result (7,12). 
Tube tests less frequently (15 ' , to 35, of the time) yield a falsely negative 
result on an ectopic pregnancy (7). If available, the preferred tests include the 
radioimmunoassays, the radioreceptorassays, or the new supersensitive 
tube tests. 
For many family planning facilities in Africa, the only available test is the 
slide test. If you are in a clinic that uses only the slide test, the following guide­
lines may be helpful for managing three of the more serious complications of 
pregnancy: ectopic pregnancy, threatened or incomplete abortion, and troph­
oblastic disease. 
When the test is positive but the patient has no clinical signs of 
pregnancy, consider an ectopic pregnancy, trophoblastic disease, 
or a recent spontaneous abortion. 
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In many cases, the laboratory tests are used to confirm a clinical 
impression. Whenever the clinical impression and the laboratory test do not 
agree, BE SUSPICIOUS. Repeat the test. Refer the patient, if necessary. (See
Table 8.5 for a list of reasons why false results may occur.) 
TABLE 8.5 False results from a test forpregnancy (13) 
When a pregnancy test produces a result that does not corre­




Error in reading results of test
 
Test performed too early or too late in pregnancy
 
Urine specimen is too dilute (first morning specimen was not 
used) 
Urine specimen has been stored too long at room temperature 
Urine specimens are mislabeled (apatient's ,lame is placed on 
another woman's specimen) 
Too much antiserum is used 
The patient is taking medication that interferes with the test 
The patient has THREATENED ABORTION, MISSED 
ABORTION, ECTOPIC PREGNANCY 
False positive 
Error in reading results of test
 
Specimen container may have a detergent residue
 






Patient may be ovulatory or menopausal
 
Patient may be taking medications­




anticonvulsants or other drugs such as
 
aldomet, marijuana. 
Patient may have the following conditions­
tubo-ovarian abscess
 
persistent corpus luteum cyst
 
post-partum period (should be negative after
 






If the patient does not have acute abdominal pain but is amenorrheic and 
has a small and mobile uterus, repeat the test the next day to ruia out a falsely 
positive result. If the test remains positive, consider that the patient may have 
either an early interuterine pregnancy or an ectopic pregnancy. Follow the pa­
tient closely for 2 weeks, and advise her to contact you if she has pain, feels 
weak, or has tenesrnus, a frequent but unproductive urge to defecate (signs 
of ectpic pregnancy). If the patient has abdominal pain, refer her for surgical 
evaluation. 
ECTOPIC PREGNANCY 
REFER ALL WOMEN WITH ACUTE ABDOMINAL SYMPTOMS 
FOR SURGICAL EVALUATION. If the slide test for pregnancy is 
negative, do not be fooled into thinking the results are conclusive. 
An ectopic pregnancy may present as a mass in the adnexa. 
(See Figure 8.2.) Although ectopic pregnancies secrete human 
chorionic gonadotropin, levels are generally lower than those 
found in normal pregnancies. For this reason, the pregnancy test 
may be negative, even though the patient is pregnant. On the 
other hand, the pregnancy test may he positive, but the patient 
may not have an enlarged uterus. 
If the patient has an adnexal mass with either a positive or a 
negative pregnancy test or if she has a positive test but your clini­
cal impression is different, refer the patient. 4cute abdominal pain 
means the ectopic pregnancy may have ruptured, and the pa­
tient's life may be endangered. (See Figure 8.3.) 
FIGURE 8.2 An ectopic pregnanc ymay present as a mass in the adnexa. 
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When tho test is negative but the patient has clinical signs of pregnancy, 
consider an ectopic pregnancy, trophoblastic disease, a recent spontaneous 
abortion, or an early but normal pregnancy. Consider also that the urine speci­
men used may not have been a first morning specimen and may, theretore, 
have been too diluted. When adjusted to different levels of sensitivity, the di­
agnostic value of the test varies. (See Table 8.6.) 
It the patient does nct have abdominal pain, repeat the test in 2 weeks. By 
2 weeks' time, the pregnancy should have advanced enough to produce 
higher levels of human chorionic gonadotropin. If the patient has abdominal 
pain, refer her for asurgical evaluation. 
THREATENED OR INCOMPLETE ABORTION 
The patient is having bleeding. Her pregnancy test had been 
positive but now is riot. If he does not appear to have passed all 
tissue, refer her for an evaluation procedure. 
Depending upon when you see the patient, she may have 
either a positive or negative pregnancy test. If abortion has oc­
curred and is riot just threatening to occur, it is important to make 
certain no products of conception are left in the uterus because 
this can lead to infection. Partially retained tissue may secrete 
human chorionic gonadotropin, sometimes in levels high enough 
to be detected, other times riot. 
Could this woman 
have an 
ectopic pregnancy ? 
frl
 
FIGURE 8.3 Detecting an ectopic pregnancy before it ruptures can save a 
woman "sife. 
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When the test was initially positive but the patient is now bleeding, consid­
er a threatened abortion. Obtain another test. If two morning : "ne specimens 
are negative, this may mean the patient has aborted, is carryi'ig a dead fetus, 
or has an ectopic pregnancy. 
TIPS FOR PERFORMING ANY PREGNANCY TESTS ACCURATELY 
1 . Have trained personnel perform the tests. Provide a supervised workshop 
where the workers can actually practice pedforming the tests. Inyour own 
facility, provide clear, posted irrstrrc tion, to( the type of pregnancy tests 
you have chosen to Use. 
2. 	Instruct your patients how to obtain a (ood rine specimen. When 
possible, have them bring their first Moririilng specimen in a clean, well­
rinsed receptacle. 
3. 	 Label each urine specimen clearly. Do not separate the specimen from the 
reporting slip until results and nIarnes have been recorded. If possible, per­
form the test as soon as you receive tIhe urine specimen. 
4. 	Be certain that you have enough room imyOUr testing area. Provide room 
for the actoal testing, storing the materials, and for ecording results in a 
cILUer- free space. 
5. 	 Store tests appropriately. Many tests require refrigeration. Check the in­
structions supplied with the test. Make certain that you refrigerate the 
tests that regLaire refrigeration arId that you use tests before the expiration 
(late stamped oil the kit. (See Table 8 7 for other tips.) 
TABLE 8.6 Uses of radioinimunoassa y test adjiisted to various levels of 
sensitivity 
Test sensitivity Capabilities and limitations 
0.3 IU/ml 	 Picks up rrif,'t.c opics and threatened 
abortions; many false positives 
0.6 lU/mI Picks up some ovulatory and menopausal FSH 
and LH, i.e., false positives 
0.7 IU ml 	 Best compromise level for a sensitive pregnancy 
test 
1 lU/imI Detects HCG as e,.-',,as 4 to 7 days after miss, 
period, but there are false negatives until 
day 14 
t
5 IU/ml Detects HCG as early as 7 to 10 day ,after 
missed period; if done too early, there may 
be false negatives; when properly done, false 
positives are rarely aproblem with this test 
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TIPS FOR ORDERING PREGNANCY TFSTS 
1. Choose the type of test that has an expiration date stamped on the boxand that has a distributor who will be available to replace faulty tests, to
provide educational aids, and offer reasonable prices.
2. 	Determine what level of sensitivity you need for your purposes. Do not buythe more expensive and more sensitive tests if you do riot usually require
them at your facility.
3. 	Estimate the number of tests yo, will need before you order supplies. Thisshould prevent your running out of tests when you need them or having
tests expire because you cannot use them in time. 
TABLE 8. 7 How to get neximum accuracy from your pregnancy test

(checklist of errors and corrections in performing pregnancytests)
 
Errors Corrections 
Formation of layers Mix well 
Contamination of containers, work Reevaluate technique used 
surface, pipette tips, reagents
Too many people using a kit Give each person his or her own kitOccasional testing Have same person do the tests all the 
timePatient error; someone else's urine Sample given on the spot
Labeling error Devise foolproof system 
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CHOOSING A CONTRACEPTIVE: 
EFFECTIVENESS, SAFETY, AND 
OTHER CONSIDERATIONS 
Family planning decisions should be made on a completely volun­
tary basis, but also on the basis of thoroughly informed choice on 
the part of individuals and couples. A decision about childbearing 
cannot be called voluntary if individuals and couples have not 
been previously educated and informed about the meaning of 
family planning to their lives and the lives of their children and 
about the methods of fanilyplanning that are available. 
Dr Fred T Sai 
DEVELOPING A REPRODUCTIVE LIFE PLAN 
This chapter is about choosing. It is a part of everything we do in life. Each 
society emphasizes helping young people and adults plan their lives. We 
often do not spend nearly enough time planning our families, so it should be 
no surprise that the family as an institution is being challenged in many areas 
of the world. In view of the importance of fertility, infertility, childbearing, and 
family, it might be wise for most of us to consider how we could help others, 
particularly adolescents, think clearly and creatively about their own repro­
ductive life plans: 
* 	 When would I like to have a child? How many do I really want? Am I able 
to plan for a healthy, happy childhood for them? 
* 	 How should I space my children? Should I use acontraceptive? 
* 	 What contraceptive would be best for me? The most effective? The 
safest? 
Every person, whether from a traditional or modern culture, already has at 
least a partially developed reproductive life plan. Cultural expectations about 
when to marry, when to bear children, and how many children to have can be 
strong and can form a person's future. In the process of accepting or chal­
lenging these expectations, one is actually forming a reproductive life plan. 
(See Figure 9.1.) 
CHOOSING A CONTRACEPTIVE 
If there were a perfect method of birth control, we would not need this 
chapter. A perfect contraceptive would be 100% effective, totally safe, 
available to everyone, inexpensive, completely without side effects, instantly 
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*1 
FIGURE9. Development of a reproductive lifeplan. 
QUESTIONS FOR USERS 
The following questions are intended as aids in developing a reproductivelift
plan They should be answered privately by the user alone, when p.)ssible(Many of these questionsrCan also aid inen in developing a reproductive life 
plan I 
FOR UNMARRIED WOMEN WHO HAVE NOI YE -HAD CHILDREN1 Would I like to w'lit intil airnarri ed hefiire having SeXual irlercourse?, 2 At what age would I like to Ie rfIalrdiN if I COLIld (Otmarried whenever I 
wanted to
 
3 Would I like tohawve children sorneiay

4 Ilow oll would I like 
 I be when I nave my first i:h(li .

5 How many children woUld I IliI.hlilLy alLi 1In
6 What are the hilfl(ISthat I would like to achieve imst in life, and by when7 Of all the tlinlgs iat Icoull i(iiI life irhahihly lle nest Important wouldbe to accollilis
h tills 
8 This life gnatl 1ViUld dIHh(I ( r iff tectrihby) childbeilarni j In the follow-
Ing ways 
9 How conicereliw would I lheif I were to hecoile pregiant before I was 
rea d ? 
10 What would I (ito if I we ra to brecomre Ilrellinairt Irtfore I wanrted to have a 
(aniother) child' 
I 1 I-low compatille is ity life plan thus farwith my religious beliefs, withwhat I personally feel God .Ilah would wml me to be doing, wih what IPerSonally feel Is ",(In" or",NiMr "and with what is expected of me bythose who are IlllrIpor
dll ti line 
FOR MARRIED OR UNMARRIFD WOMEN WI fH CHILDREN 
I Would I like to have ioe chlildrer one day 1

2 
 How many chijlren woriuFlIIe hap V having3 What are the things that would like to achieve most inlife, and by when ?4 
 Of all the things thalI crould do in life, probably the most Iriportant would

be to accomlitsh ths
 
5 This life goal would iffect (or be at fected by) child earing in the following 
ways 
6 How ol) would Ilike to Ie when I have my last child?7. How concieirneld woitld I I) if I wonrerto becomer pregnant again before I was 
ready?
8 What would I do f I were to bicorni pregnant before I wanled to have a 
(anotfher)child? 
9. How compatible is my life plan thrus far with my religious beliefs, with whatI personally feel God Allah would wart me to be doing,wrtt wihat I persoi.ally feel is "right"or "wrong," and with what is expected to me by thosj
who are imoportant to ine? 
114
 
reversible, and easy to use. It would not interfere with intercourse in any way 
and would require no advice or care from a clinician. There is no such method 
today, and, according to research experts, there are no likely prospects for 
the near future. 
In the absence of a perfect method, two considerations rise to the top as 
the most important in the minds of couples considering contra­
ceptives- effectiveness and safety 
EFFECTIVENESS 
Patient questions about effectiveness 
No one would bother with a contraceptive were it not felt to be effective. 
One hears many questions about effectiveness: 
"Which is the most effective method?" 
"Which do you think would be the most effective method for me?" 
"Why did one doctor tell me diaphragms were 98% effective and another 
say they were 80% effective?" 
"Can you get pregnant if you take your Pills every day?" 
"Will the method I'm considering really work?" 
Providing fair answers ah out effectiveness 
"Will it work?" is the question asked first and most frequently about any 
birth control method. We suspect that those who ask "Will it work?" are in 
fact asking, "How well will it work for me?" Since this query cannot be an­
swered for an individual woman, most clinicians feel it wise to provide two 
answers. They provide an effectiveness rate for women who use the method 
consistently and correctly (method effectiveness), and they provide a rate of 
effectiveness for typical users of the method (user-effectiveness). Different 
reliable researchers may report different effectiveness rates for the same 
method. This is largely caused by differences in how they conducted their 
studies and in the groups of women they studied. To avoid confusing users 
while still explaining to them both the method- and user-effectiveness of dif­
ferent methods, we suggest using Table 9.1. The rates reported in this table 
are widely accepted by researchers and clinicians. As these user­
effectiveness rates were derived largely from studies conducted indeveloped 
countries where family planning and other services are relatively easily 
available, use these rates as guidelines-not as an absolute statement of the 
user-effectiveness in the geographic area you serve. 
Predicting user-effectiveness for the individualuser 
The authors of Contraceptive Technologyare aware that the effectiveness 
rates in Table 9.1 can vary. Method-effectiveness rates change along with 
115 
changes in the technology of contraceptives, such as lowering the amount of
estrogen or progestin in Pills or adding copper or progesterone to an IUD.
Actual user-effectiveness rates for any one method may vary for many 
reasons. 
An individual's acceptance of a method is partially conditioned by his or
her attitudes and the attitudes of others toward the method, and contracep­
tion in general. Figure 9.2 is included to help users establish their true feelings
about methods under consideration. 




Failure Rate in 
Typical Users ** 
Chance (no method of birth control) (1) 70 70 
Tubal ligation (2) 0.04 0.04 
Vasectomy (3) 0.15 0.15 
Injectable progestin (4, 5) 0.25 0.25 
Combined birth control Pills (6-8) 0.5 2 
Progestin-only Pill (9, 10) 1 2.5 
IUD (6, 11, 12) 1.5 4 
Condom (6, 7, 13) 2 10 
Diaphragm (with spermicide) (6, 7, 14, 15) 2 13 
Cervical cap (16) 2 13 
Foam, creams, 'ellies, and vaqinal
suppositories (7, 17, 18) 3-5 15 
Coitus interruptus (19) 16 23 
Fertility awareness techniques (6, 7, 20, 21)
(basal body temperature, mucus (22, 23)
method, calendar, "rhythm," and douche 
(24-26)) 2-20 20-30 
Designed to complete the sentence: "Of 100 women who start out the yearusing a given method, and who use it correctly and consistently, the number
who will be pregnant by the end of the year will be _ ." 
**Designed to complete the sentence: "Of 100 typical users who start out the year
using a given method, the number who will be pregnant by the end of the year 
will be _ ." 
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FIGURE 9.2 Questions. u'ind,'viduals considering use of a specific method of 
birth control. 
The tollowing questions have been developed so that every "yes" re­
sponse indicates to the potential user of a method of birth control a factor 
that might lower the effectiveness of a given method. When possible, users 
should be encouraged to answer these questions for themselves, in private. 
Or you may find it useful to select some of these questions to pose and dis­
cuss with them. 
BACKGROUND: For each method of birth control there is a rate of failure 
or an estimated number of pregnancies that can be expected ifthat method is 
used perfectly. Since you will be using your method of birth control to avoid 
an unplanned pregnancy, you want to get just as low a pregnancy rate as 
possible, You want to be able to use your method CORRECTLY and 
CONSISTENTLY. Obviously, the rate of pregnancies, or failure rate, goes up 
if for any reason you don't use the method or if you fail to use it exactly as it 
was designed to be used. The following questions were developed to help 
you decide if the method you are considering is a good choice or a poor 
choice for you. 
METHOD OF BIRTH CONTROL YOU ARE CONSIDERING USING: 
Have you had trouble with this method before? Yes No
 
If yes, what were the problems?....................-

PLEASE ASK YOURSELF THESE QUESTIONS 	 Yes No 
1. Am lafrad ofusing thismethod? 
2. Would Ireally rather notuse this method? 
3. Will I have trouble remembering to use this method' 
4. Will I have trouble using thismethod correctly?
 
5 Do Istill hi'vo unanswered questions about this nethod
 
6. Do., this method cost more than I can afford 
7. Isthis method known to have serious complications? 








10. AmI fusing this method without my partner's knowledge? 
11. 	 Will use of this method embarrass my partner or others who areim­
portant to me?
 
12. Will use of this method embarrass me?
 
13 Will I enjoy sex less because of this method?
 
14. Will thismethed interfere with lovemaking?)
 
15 Hasa midwife, nurse, or doctor ever told me not to use this method?
 
16, Is there anything about iry personality which would cause me not to
 
use this method correctly? 




18. Do I know what I should do if I have problems with the use of this 
method? 
TOTAL NUMBER OF YES ANSWERS: 
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When answering the questions in Figure 9.2, most persons will have sever­al "yes" responscs, indicating, unfortunately, that potential problems do lie instore for peoplc using almost any method of birth control. If you have anumber of "yas" responses, you may want to discuss some of these with 
your clinician, counselor, partner, or friend. This may help you to decidewhether to use this method or how to use it to its maximum effectiveness. Ingeneral, the more "yes" answers you have, the less likely you are to use this 
method consistently and correctly. 
SAFETY
 
Just as no contraceptive is 100, 
 effective, no contraceptive is withoutrisk. In fact, there are a variety of risks one might expose oneself to by using amethod. First, there are the risks related to the inherent dangers of themethod How often might the method be associated with death,hospitalization, loss of fertility, hysterectomy, pain, infection of the genitouri­nary tract, etc.? Secondly, there are potential risks in terms of inconvenience.
Does the method make sexual intercourse less pleasant or even unpleasant,
is there great expense, lost time from work, or partner dissatisfaction or em­barrassment associated with the method? Finally, there are risks associated
with pregnancy sh,-ld the method fail (or should the couple make a mistakeusing the method). How often does pregnancy occur? What are the dangersof pregnancy to this woman? Would pregnancy cause the family hardship?All too often, a method is classified as completely harmless because theinherent medical dangers of the method are minimal, while the inconve­
niences of the method and the very real risks associated with the pregnanciesthat can occur using the method are overlooked by the person considering 
the method. 
Risks in everyday life 
When it comes to death, the most serious risk of a contraceptive, the ab­solute level of risk is very low-indeed, so low that most people have little ap­preciation of the magnitude of risk involved. Wher we use the phrase, "it is a one in a million possibility," we usually mean ti imply that it almost never
happens. But, of course, for that one person who suffers a complication, it is




Some women are more likely than others to encounter problems with a 
specific method of birth control. Contraindications to the methods are an im­
portant consideration for a woman making a birth control choice. A contrain­
dication is a medical condition that renders inadvisable or unsafe a course of 
treatment that might otherwise be recommended. 
Clinicians usually rank contraindications on three levels: 
1. Absolute contraindicaions: you ffust not try to use the method. 
2. 	 Strong relative contraindications: you will be strongly advised not to use 
the method. However, if other factors rule out the use of alternative 
methods, then this method would be acceptable if you are carefully fol­
lowed for early signals of trouble. 
3. 	 Other relative contraindications: you may be able to try the method if you 
know that you may have problems with it and are willing to assume re­
sponsibility for seeking help the moment early danger signals appear. 
Most of the serious complications of Pills and IUD's could be avoided by 
not giving the methods to women for whom they are contraindicated. 
Using contraceptives cautiously- dangersignals: 
When helping a woman choose the method she can use safely as well as 
effectively, you must be able to teach the individual the danger signals of the 
method she is considering. If a danger signal does appear, the informed user 
can quickly seek help. This is particularly important should the method she is 
considering be the Pill or the IUD. 
BY TEACHING WOMEN THE PILL AND IUD DANGER SIGNALS,
 




OTHER CONSIDERATIONS IN CHOOSING A METHOD 
Pattern ofsexualactivity 
Regarding their contraceptive choice, women and men should be and are 
influenced by the number of partners they have had and their frequency of 
intercourse. For example, a woman who has several partners might find 
condoms, foam, or a diaphragm relatively inconvenient even though they
might be quite desirable in terms of preventing infection. Very infrequent in­
tercourse might make a person not want to expose herself to the risks of Pills 
or an IUD. The risk of infection to a woman with a number of partners would 
make one advise against the IUD rather strongly. 
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Access torn edical care 
Because of high levels of method and user effectiveness-if users are
properly screened for contraindications-the IUD and the Pill are both good
choices for most women. (See Chapters 1 1 and 13.) Most complications re­
sulting from either method are medically treatable. However, 70, of the 
populati n in Africa is rural, and at this point in the development of the health 
services of most countries, health facilities are riot easily accessible for a
large portion of women in their childbearing years. Consequently, trained 
health personnel are not readily available to treat complications from either 
contraceptives or from pregnancy or childbirth. 
When weighing the ardpros cons of providing Pills or IUD's in hard­
to-reach areas, keep i mind that the risk of pregnancy-related mortality is 
very great in Africa, whereas the risk of mortality associated with the use of 
contraceptives has been found to be low in developed and developing coun­
tries alike. (See Table 9.2.) 
Even if a community-based distribution system has been established, the
usefulness of the Pill for rural women is compromised unless the system pro­
vides for dependable resupply of oral contraceptives. Women are typically
given one to three cycles of Pills to start with and are asked to ri.turn to reple­
nish their supply. If upon return, packets of Pills are not available, these 
women will return home unprotected and will run the risk of becoming 
pregnaant. 
The IUD is an miportant contraceptive method for rural women if adequate
screening is done and venereal diseases or other risk factors associated with
pelvic inflamnrvatory disease (PID) are riot prevalent in the program area. The 
IUD is particularly convenient since the user usually needs to be motivated 
only once, However, the IUD should riot be used indiscriminately because its 
use significantly increases the likelihood of PID. (See Chapter 13.) Therefore,
strict criteria and thorough screening before the IUD is inserted are required.
Given the limitations of both the Pill and the IUD, long-acting progestin injec­
tions may I)e a very attractive option to consider 
Cost of contraceptive 
Most ministries of health in Africa do not charge for maternal and child
health services, including family planning. Private physicians, clinics, and 
family planning associates customarily do charge for services. In both cases, 
women invest their time, loss of wages, and travel money in obtaining family
planning services. A woman should be told in advance what her ongoing in­
vestment will be while using a particular method. If this will prove to be a 
major hardship, then an alternative contraceptive, or a means of obtaining
the desired contraceptive without hardship, should be found. 
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TABLE 9.2 Putting into perspective the risks of mortality associated with contraceptive use (29,30) 
Dpaihs r 
44 100,000NOT RELATED TO REPRODUCTION lomn' 15-- ,ovr y,.r 
(Men and Women) of e posuih . rh U S A 
Smoking (1 pack per day) 500.0 
Cancer 18.0 
Automobile Driving 16.7 
Heart Disease 7.3 
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Cooperationbetween men and women 
Certain methods cannot be used over time without the man's cooperation.
Condoms, foam, and often the diaphragm fit into this category. Fertility 
awareness methods, with attendant long periods of abstinence, require a
stable relationship and mutual trust. Although IUD's, Pills, and injectable
hormonal contraceptives can be used by a woman without a man's 
knowledge, it is more likely that she will continue to use the method effective­
ly over time if tile man is knowledgeable about family planning and the 
method and is supportive. 
HOW EFFECTIVE ARE CONDOMS?
 
DOES THE ANSWER AN INDIVIDUAL RECEIVES
 
DEPEND ON WHICH PERSON IN YOUR CLINIC IS ASKED?
 
A woman 'sneeds during tte reproductive life 
As a provider of services, yoL, are accustomed to recommending a change
in method if a woman develops side effects or if danger signals appear. In 
addition, you should expect, and in some cases encourage, women to use dif­
ferent contraceptive methods at different points in their reproductive life. For
instance, if a young couple wants to postpone havino their first child for a few 
years, a dependable temporary contraceptive like the Pill or diaphragm might
be the method of choice. After the first child, the couple may choose to 
resume use of the same method or may decide to use a different one 
(condom and foam, natural methods) to space other children. If the parents
reach a point where they are uncertain about having more children, a long­
term method such as the IUD or an injectable contraceptive might be
 
adopted. Once the couple decides that they do not 
want to have more
 
children, either the man 
or the woman may elect to have a sterilization per­
formed or to continue using (or use) an injectable method.
 
Choosing method for a program 
Choosing the aporopriate contraceptive methods to provide to women of 
different reproductive experiences and ages who live in ecologically and cul­
turally different areas within a country is complex. Making appropriate deci­
sions often involves seeking acompromise between: 
• The medically sound. Prevalence of disease that contraindicates the 
use of a method, availability of adequate sanitation to permit the use of 
some methods, prevalence of marital arrangements that result in multi­
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pie sex partners, risk of serious side effects and their relative 
importance, etc. 
* 	 The practical Method-specific continuation rates, cost of methods, 
transportation, shelf life, storage requirements, the need for sophisti­
cated or costly equipment -nd supplies, complexity of training, etc. 
* 	 The politically desirable. Positions held about specific methods by in­
fluential interest groups, scientific opinion of international organizations 
and experts, other commitments that could limit the ability to develop 
an adequate delivery mechanism for aspecific method, etc. 
We can only recommend that those of you who are faced with making 
these decisions take into consideration some of the epidemiologic facts 
available in Table 9.2 and elsewhere in this book or other sources (relative 
risks, mortality and morbidity rates) so that the public health impact of your 
decisions is carefully weighed. 
DEALING WITH METHOD FAILURES 
What would yotr patient do were she to have a contraceptive failure? 
If 1,000 women are using the Pill exactly as instructed, only 5 would be ex­
pected to become pregnant. Out of 1,000 perfect users of condoms or the 
diaphragm, 20 pregnancies would be expected. A woman who is totally Lin­
comfortable with the possibility of a method failure might find the use of two 
contraceptives simultaneously (e.g., condoms arid foam) an attractive option. 
INFORMED CHOICE 
The importance of informed choice in family planning has three bases: the 
pragrmatic, the ethical, and the legal. Pragmatically, a user who thoroughly un­
derstands her/his contraceptive method may well be able to use it more 
safely and effectively. Ethically, every user has a right to have complete infor­
mation about her/his method. The physician should provide adequate infor­
mation in assisting the patient to reach a reasonable and informed decision 
about family planning medications and procedures. 
At present, the whole subject of informed choice is not as widely debated 
and discussed in Africa as it is in America. However, it is of increasing interest 
to staff members working in hospital-based and large urban family planning 
clinics in Africa, and for this reason it is included in this book. 
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The Elements of an Informed Choice 
The simple mnemonic, BRAIDED, may prove useful in remember­
ing (1) what information needs to be provided to users and (2)
some key points for the individual to consider in making a choice: 
Benefits of the method (1).
Risks of the method (all major risks and all common 
minor risks) (1).
Alternatives to the method (including abstinence and no 
method) (1). 
Inquiries about the method are the patient's right and 
responsibility at any and all times (2).
Decision to withdraw from using the method should be 
accepted by staff without disapproval.
Explanation of the method should cover how to use 
the method, what to expect, and what to do if there 
are danger signs (1). 
Documentation of the above (2). 
COMPETENCE TO CHOOSE 
It is the responsibility of the health professional to ascertain that each 
person who obtains a family planning method has sufficient information onthe proposed treatment and that this person is competent to make a choice.
Sometimes it is very difficult to judge just who is and who is not competent tounderstand the information being provided about modern contraceptives. 
The basic criteria for competence to choose are:
* Is the user capable of understanding the proposed method, the 
alternatives, and the risks? 
* Is the user capable of balancing the pros and cons of alternatives and of 
arriving at a conclusion? 
In some situations the individual's competence is quite difficult toevaluate. The very young adolescent, the mentally retarded, and tile mentally
ill user are examples of such situations. As difficult and uncomfortable as it 
may be to apply these criteria to specific cases, we must be prepared to do sosince we are or may be called upon to sit in judgment. If there is any doubt
about the competence of the person to choose to plan a family through the use of contraceptives, consult with other professionals to determine the ap­propriate course of action. This consultation must be in the person's record. 
In America, a number of family planning programs have begun to use con­sent forms as an important part of patient education and now provide each
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SEC TION I/I 
CONTRACEPTIVE TECHNOLOGY 
CHAPTER 10 
HORMONAL CONTRACEPTIVES: AN OVERVIEW* 
Hormonal contraceptives are the most popular and most effective non­
surgical methods of child spacing and fertility control in the world. In Africa 
where many women associate family planning with "birth control Pills," the 
Pill has become the most accepted contraceptive method. Unlike the IUD, the 
barrier methods, and the natural family planning methods, hormonal contra­
ceptives have no traditional uses in history, since they are fairly new additions 
to the family planning field. Most of the serious work with hormonal contra­
ceptive development began in the 1950's. 
Hormonal contraceptives consist of synthetic compoLds made to resem­
ble actual hormones within a woman's body. These hormones, estrogen and 
progesterone, are essential for the functioning of the menstrual cycle (see 
Chapter 7) and, hencc, for ovulation which is required for fertilization to 
occur. Early researchers believed that if they could interrupt the menstrual 
cycle with the synthetic compounds they could then prevent ovulation and 
implantation. (See Table 10.1 .) 
The first Pills marketed were combined ones, which contained hoth estro­
gen and progestin (or laboratory-produced progesterone). In the early 
1960's, the combined Pills contained about 100 to 150 mcg (micrograms) 
estrogen arid about 1 to 10 mg (milligrams) progestin. The Pills were ex­
tremely effective. But studies showed that the use of these Pills was associat­
ed with serious cardiovascular side effects in some women. Further, annoying 
minor side effects caused many women to stop using the Pills. 
When it became clear that estrogen was the primary cause of the side 
effects, researchers began to lower the close of estrogen in the Pills arid to de­
velop progestin-only contraceptives. (Refer to Chapters 11 arid 12.) Today, 
the dose of estrogen in combined Pills is between one-third to one-fifth the 
dose in the earlier combined Pills. Most Pills provided to today's users contain 
only 30 to 50 rncg of estrogen arid 1 mg or less of progestin. The progestin­
only contraceptives include the Mini-Pill, long-acting progestiri injections 
(such as Depo-Provera ), plastic IUD's filled with progesterone, and 
progesterone-containing silastic capsules arid cervical rings. (Refer to Chap­
ter 12.) Although extensive studies still need to be conducted, some evidence 
suggests that the lower-dose combined Pills arid the progestin-only contra­
ceptives cause fewer side effects than the earlier Pills which have been 
studied. 
Spcific references documenting the central points made in this overview that are available in 
Chapters 1 1 and 12 have not been reported in this chapter. 
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WHAT ARE SOME OF THE SIDE EFFECTS OF THE PILLS?
 
As with all the other methods, one risk is that of failure and the resultingrisk of pregnancy. (Refer to Chapter 9, Table 9.2.) The most serious side
effects, howevei, are cardiovascular. Yet, these effects (high blood pressure,blood clots, heart attack, and stroke) occur primarily in the woman who isolder than 35 years and smokes orthe woman who has an underlying diseasethat contraindicates the use of the Pill. For the rest of the female population,the risks of these serious complications are quite low. Moreover, the risk ofdeath from any cause is lower in Pill users than in women who go through afull-term pregnancy and delivery. Some of the minor side effects fromhormonal contraceptives include nausea, weight gain or bloating from water 
retention, and changes in menstrual bleeding. 
WHAT ARE SOME OF THE BENEFITS OF THE PILLS? 
These include an extremely high rate of effectiveness, relief from symp­toms of the menstrual cycle, a decrease in iron-deficiency anemia associated
with a heavy menstrual flow, some protection against the development ofpelvic inflammatory disease, reduction in endometriosis, and a decrease inovarian cysts, benign breast tumoi s, cancer of the uterus, and cancer of the 
ovary. 
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TABLE 10. 1How does the Pillprevent pregnancy? 
Demonstrated mechanisms of action 
OVULATION is inhibited. The hypothalamus cannot detect a pattern of 
change in estrogen levels and thus does not stimulate release of FSH and LH, 
which are required for the ovary to release an egg. Pills containing less than 
50 mcg estrogen probably only suppress ovulation 95 -98% of the time. 
*OVULATION may be inhibited. Subtle changes in progesterone levels may 
modify the midcycle surge of FSH and LH to alter the hypothalamic­
pituitary-ovarian axis. 
*IMPLANTATION is inhibited. High-dose estrogens work against the pro­
gestational effects on the uterus, alter the normal secretory development, 
and cause marked edema with areas of dense cellularity.This action has been 
shown with postcoital estrogens: ethinyl estradiol given iti four to seven 
times the dose in combined Pills and DES in 500 to 2,000 times a comparable 
dose in combined Pills. Progestins may alter the FSH and LH peaks enough to 
decrease the progesterone released by the corpus luteum to prepare the en­
dometrium for pregnancy. The decreased progesterone leads to a resting, 
atrophic lining. 
*THICK, HOSTILE CERVICAL MUCUS associated with the use of proges­
tins hampers sperm transport. The cervical mucus is scanty but thick and 
cellular,with decreased ferning patterns and spinnbarkeit. 
Theoretical mechanisms of action 
*OVUM TRANSPORT is accelerated by estrogen, as shown in animal 
studies. However, this is not known to be an important mechanism in prevent­
ing pregnancy. Ovum transport is slowed by progestins. Slowed transport 
may cause a partially degenerated ovum to implant in the uterus, resulting in a 
defective fetus. It may increase the risk of ectopic pregnancy. 
*CAPACITATION is inhibited. Capacitation, the activation of hydrolyLic 
spermatic enzymes in the head of the sperm, is required for the sperm to 
penetrate the cells and macromolecules surrounding the ovum. 
LUTEOLYSIS may occur. The degenerating corpus luteum cannot maintain 
normal serum progesterone levels required for normal implantation. 
*The mechanisms of action of progestin-only methods have not been demonstrated. The items 
marked with asterisks are suggested mechanisms of action. 
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CHAPTER 11 
COMBINED ORAL CONTRACEPTIVES: "THE PILL" 
The most important contribution that the Pill, together with 
the various IUDs, has made worldwide is to teach people that 
reversiblecontraception can be completely separated from coitus 
by a method that for the first time permits the woman herself to 
decide whether and how to control her own fertility. 
CarlDjerassi 
The Politics of Contraception, 19 79 
HISTORY, MECHANISM OF ACTION, AND 
EFFECTIVENESS 
HISTORY 
The oral contraceptive Pill has been in use for about 20 years. As studies 
began to show an association between the use of oral contraceptives and 
certain side effects, researchers gradually reduced the dose of hormones, 
particularly estrogens. These lower-dose Pills have been shown to be safer 
than the earlier higher-dose Pills. 
Oral contraceptive Pills are now used by some 50 million to 100 million 
women throughout the world. In many African countijes, the Pill is the most 
popular method of contraception. Its effectiveness and relative safety have 
made the Pill not only an accepted, but often a preferred method of contra­
ception for many women. 
In this chapter, you will learn guidelines to help you reduce the risk of seri­
ous complications developing in Pill users. By not giving the Pill to women 
who have contraindications and by teaching users the Pill's "danger signals," 
you can help make the Pill an even safer method. 
MECHANISM OF ACTION 
How do combined oral contraceptives work? Estrogenic agents may have 
contraceptive effects by influencing normal patterns of ovulation, or ovum 
transport, implantation, or placental attachment. 
The progestins also have a number of potential contraceptive effects. 
Normally, progesterone (pro=on behalf of; gestation=pregnai,..y) prepares 
the endometrium for implantation and maintains pregnancy. Progestation 
agents also may have several contraceptive effects. (See Chapter 10.) 
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v, 'U , 
EFFECTIVENESS 
The Pill and injectable contraceptives have the highest effectiveness rate
of all nonsurgical contraceptive methods. In theory, the effectiveness of thePill should be close to 100%. However, the actual effectiveness rate is diffi­
cult to determine because many factors influence effectiveness. Does the woman use her Pills correctly and consistently? Does she have a reliable 
means of obtaining resupplies? Does the family planning program make it easy for patients to comply? Many pregnancies occur when women discon­
tinue Pill use but fail to begin another method of contraception and therefore
have unprotected intercourse. Although rare, pregnancies can also occur 
even though the woman has taken all of her Pills. The Royal College studyreported that for every 300 women using the Pill in agiven year, one pregnan­
cy could be expected (1). 
CONTRAINDICATIONS TO 
ESTROGEN-CONTAINING PILLS 
Although the Pill is a safe contraceptive method, it is not appropriate for 
every woman. 
Listed below are some of the contraindications to Pill use. When consider­
ing use of the Pill for women with strong relative contraindications (see Chap­
ter 9), it is extremely important to weigh both its risks and benefits. Alterna­
tives to the Pill must be considered by both the clinician and the patients. 
CONTRAINDICATIONS TO COMBINED BIRTH CONTROL PILLS 
CONTAINING BOTH AN ESTROGEN AND A PROGESTIN 
Absolute contraindications 
1. Thromboembolic disorder (or history thereof) 
2. Cerebrovascular accident (or history thereof) 
3. Coronary artery disease (or history thereof)
4. Known impaired liver function at present time 
5. Hepatic adenoma (orhistory thereof)
6. Malignancy of breast or reproductive system (or history thereof) 
7. Known pregnancy 
Strong relative contraindications 
"8. Severe headaches, particularly vascular or migraine
"9. Hypertension with resting diastolic blood pressure of 90 or greater on
three or more separate visits, or an accurate measurement of 110 or 
more on a single visit 
10. Diabetes 
11. Prediabetes or a strong family history of diabetes 
"12. Gallbladder disease, including cholecystectomy 
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13. 	 Previous cholestasis during pregnancy, congenital hyperbilirubin 
(Gilbert's disease) 
14. 	 Mononucleosis, acute phase 
•15. Sickle cell disease (ss) or sickle C disease (sc) 
"16. Undiagnosed, abnormal vaginal bleeding 
"17. Elective surger/ planned in next 4 weeks or major surgery requiring 
immobilization 
18. Long-leg casts or major injury to lower leg
 
*19. Over 40 years of age
 
*20. History of heavy smoking and over age 35
 
21. 	 Impaired liver function within past year 
Other relativecontraindications 
A. May contraindicate initiation of Pills:
 
*22. Termination of term pregnancy within past 10-14 days
 
23. Weight gain of 10 pounds or more while on Pills 
"24. Failure to have established regular menstrual cycles 
*25. Patient with profile suggestive of anovulation and infertility problems: 
late onset of menses and very irregular menses 
"26. Cardiac or renal disease (or history thereof) 
*27. Conditions likely to make patient unreliable at following Pill instruc­
tions (mental retardation, major psychiatric problems, alcoholism, his­
tory of repeatedly taking Pills in orrectly) 
"28. Lactation (oral contraceptives may be initiated after lactation is fully 
etablished) 
B. May initiate Pills for women with these problems and observe carefully 
for worsening or improvement of the problem: 
"29. Depression 
"30. Hypertension with resting diastolic blood pressure at a single visit of 
90-99 












37. 	 History of hepatitis but results of liver function tests have been normal 
for at least 1 year. 
"Contraindicatioi to estrogen-containing Pills, which may not be a contrain­
dication to progestin-only Pills. 
"Several reviewers of this book strongly feel this should be listed as an abso­
lute contraindication to Pill use. It remains here since we cannot in a simple, 
straightforward manner define "abnormal." If you, the clinician, feel that the 
patient's bleeding pattern is "abnormal," do not provide her with birth control 
Pills. 
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PROVISION OF COMBINED PILLS 
HELPING A PATIENT CHOOSE THE APPROPRIATE PILL 
Since Pills first became available, there have been numerous Pill prepara­
tions from which clinicians and patients can choose. The decision regarding
which Pill to prescribe for a particular user is complex, since all Pills are not 
the same. This section is intended to help you make this decision. 
Pills containing an estrogen and a progestin (combined Pills) may
be an excellent initial contraceptive choice for healthy women 
early in their reproductive years, for post-partum women after 
they have stopped nursing their babies, and for women who have 
had a miscarriage or an induced abortion. Effective use of Pills 
and high Pill-continuation rates tend to occur when the Pill user is 
conscientious and can get thoughtful answers to questions and 
concerns about Pills; when family planning workers are suppor­
tive of this method; when supplies are available to users at the 
time of a followup visit; and when the user enjoys noncontracep­
tive effects of the Pill, such as a reduction of menstrual cramping 
or in heavy menses. 
Assumptions 
Once the patient and her clinician have decided that a combined Pill is the 
desired means of birth control and the various contraindications to Pills have 
been eliminated, the clinician must recommend aspecific Pill. 
The assumptions upon which the clinicians might make this recommenda­
tion are as follows: 
1. The Pill provided should minimize the risk of the patient's developing 
major or minor side effects. 
2. 	 It is currently very difficult to predict which women will develop serious 
Pill-associated complications. 
3. 	The estrogenic component of the Pill is responsible for most of the 
major Pill-associated complications and also for most of the minor side 
effects which can lead to discontinuing its use. 
4. The progestin component of the Pill is responsible for some of the 
minor side effects that can lead to Pill discontinuation, but to a lesser 
degree than is the case with est t'gens.
5. 	The cost and availability of oral ,ontracentives may be important to per­
sons using, and to public family planning programs providing Pills. 
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Checklist For Use Before Dispensing Oral Contraceptives 
Check the following (starting from the head and working down) 
Head 
1. Do you have severe headaches? 	 Yes/No 
2. Do you have problems with severe depression? 	 Yes/No 
3. Do you have seizures or convulsions or epilepsy? 	 Yes/No 
Chest 
4. Do you ever have severe chest pain? 	 Yes/No 
5. Do you get very short of breath after walking or 
after light work? Yes/No 
6. Have you ever had a lump in the breast? 	 Yes/No 
7. Are you nursing a baby who is under 6 weeks of age? Yes/No 
Abdomen and Pelvis 
8. Do you think you could be pregnant now? 	 Yes/No 
9. Have you missed a period recently? 	 Yes/No 
10. Have you missed a period and then started bleeding? Yes/No 
11. 	Do you have bleeding between periods or after 
sexual intercourse? Yes/No 
Le gs 
1 2. Do you have severe Ig pains or painful varicose veins? Yes/No 
1 3. Do you have swelling or warmth (heat) in your legs? Yes/No 
14. Have you ever had aclot in your legs? 	 Yes/No 
Other 
15. Do you smoke? 	 Yes/No 
16. Are you over 35 years of age? 	 Yes/No 
1 7. Have you ever been treated for high blood pressure? Yes/No 
18. Have you had any operation in the past 2 weeks? 	 Yes/No 
19. Have you ever had sugar in your urine? 	 Yes/No 
20. Do you have sickle cell disease? 	 Yes/No 
If all the above answers are "No," the woman may be given oral 
contraceptives. 
If any are "Yes," it may be desirable for a woman to be seen by a doctor,nurs­
ing sister, or nurse. If you do decide to give oral contraceptives, you may need 
to arrange for the woman to be seen by a family planning worker within 2 
months. 
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COMBINED PILLS AVAILABLE IN AFRICA 
Table 11.1 lists the combined Pills currently available in Africa. The pyra­
mid (Table 11.2) shows the relative estrogens and progestational strengths 
of various Pills. 
TABLE 11. 1 Characteristics of combined oral contraceptives 
Proprietary No. of
Name Manufacturer tablets Estrogen mg Progestrogen mg 
"Anovlar Schering 21 EE'* 0.05 Norethisterone 4.0 
acetate**
28 EE 0.035 Norethindrone 0.5
"Brevicon', Syntex 
*Conovid-E- Searle 20 Mestranol 0.10 Norethynodrel 2.5*Demulon" Searle 21 or 28 EE 0.05 Ethynodiol 1.0 
Enavid E, Searle diacetate20 Mestranol 0.075 Norethynodrel
Eugynon 50. Schering 21 
5.0 
or 28 EE 0.05 Norgestiel 0.5Gynovlar 21'-? Schering 21 EE 0.05 Norethisterone 3.0 
acetate
21 EE 0.02 Norethisterone 1.0 
Loestrin 20 - Parke, Davis 
acetate 
', 
EE 0.05 Lynestrenol 2.5
*Lyndiol, Organon 22 
Metrulen 501 Searle 2 Menstranol 0.10 Ethynodiol 2.0 
"Microgy- Schering diacetate21 or 28 
 EE 0.03 Le,.onorgestrel 0.15 ,non 30('
Minilyn' Organon 22 EE 0.05 Lynestrenol 2.5"Minovlar' Schering 21 or 28 EE 0.05 Norethisterona 1.0 
acetate*Neogynon"; Schering 21 or 28 EE 0.05 Levonorgestrel 0.25"Nordioll' Wyeth 21 or 28 EE 0.05 Levonorgestrel 0.25*Nordette', Wyeth 28 EE 0.03 Levonorgestrel 0.15"Norminest-F Syntex 28 EE 0.035 Norethindrone 0.5Norinyl-1/50 Syntex 21 or 28 Mestranol 0.05 Norethisterone 1.0' *Norlestrin Parke, Davis 21 or 28 EE 0.05 Norethisterone 2.5 
acetate*OrlestV Parke, Davis or 2821 EE 0.05 Norethisterone 1.0 






 21 Mestranol 0.08 Noresthisterone 1.0 
1/80
"Ortho-Novum Ortho 21 Mestranol 0.10 Norethisterone 2.0 
2 mg®
*Ovstate Organon 22 or 28 EE 0.05 Lynestrenol 1.0*Ovral' Wyeth 21 or 28 EE 0.05 Norgestrel 0.5Ovrane Wyeth 21 EE 0.05 Norgestrel 0.5Ovranetteb Wyeth 21 EE 0.03 Levonorgestrel 0.15Ovulen® Searle 21 or 28 EE 0.05 Ethynodiol 1.0 
diacetate"Ovulen® Searle 21 or 28 Mestranol 0.10 Ethynodiol 1.0
 
diacetateOxysmen21® Ortho 21 E 0.035 Norethisterone 0.5 
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TABLE 11.1 Characteristics of combined oral contraceptives -Continued 





























*Known to be available in Africa 
**EE = Ethinyl-estradiol 
***Norethisterone = Norethindrone and Norethisterone acetate = Norethynodrel 
TABLE 11. . The relative potency of estrogens and progestins in currently avail­
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ESTROGENIC AND PROGESTATIONAL ACTIVITY OF PILLS 
The relative estrogenic and progestational activity of various oral contra­
ceptives is an incredibly complex subject. Table 11.2 is a pyramid adapted
from a table developed by Heinen (2). It is admittedly simplistic in that it pro­
vides a picture of hormone strength for when the estrogen or the progestin is
used alone. Actually, estrogens and progestins are used in combination when 
one provides combined birth control Pills. It is only when we provide Mini-Pills 
(progestin-only Pills) that we provide the progestins alone. None of the cur­
rently available contraceptive agents provides estrogens alone as an ongoing
oral contraceptive. Several of the important qualifications of this are: 
1. Progestins vary as to their inherent estrogenicity. For example, norethy­
nodrel (in Enovid' )is a relatively strong estrogenic compound. Norgestrel (in
Ovral') has no estrogenic effect. The relative estrogenic potency of the vari­
ous progestins is as follows (3): 
Progestin Estrogenic effect 
Norethynodrel (Enovid) 2.08
Norethindrone (Noriny*,and Ortho Novum .
 0.25 
Norethindrone acetate (Norlestrin 1 0.38 
Ethynodiol diacetate (Demulen' and Ovulen ") 0.86
Norgestrel (Ovrall) 0.0 
2. Progestins also vary as to their anti-estrogenic effects. Norethindrone 
acetate (in Norlestrin ')and norgestrel (in Ovral') have strong anti-estrogenic
effects, whereas norethynodrel (in Enovid )has no anti-estrogenic effects,
and ethynodiol diacetate (in Demulen- and Ovulen'0) has relatively low anti­
estrogenic effects. The relative anti-estrogenic effect of the various proges­
tins is as follows (4): 
Progestin Anti-Estrogenic effect
 
Norethynodrel (Enovid ) 
 0.0 
Norethindrone (Norinyl," and Ortho Novum ) 
 2.5 
Norethindrone acetate (Norlestrin) 25.0 
Enthynodiol diacetate (Demulen ," and Ovulen , ' ) 1.0 
Norgestrel (Ovral) 18.5 
3. Progestins vary in their androgenic potency. Norethynodrel (in Enovid®)
has no androgenic effect. Ethynodiol diacetate (in Demulen®", and Oulen®)
has very low androgenic effect, while norgestrel (in Ovral6) has relatively 
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strong androgenic effect. The androgenic potency of the various progestins 
is as follows (5): 
Progestin Androgenic effect 
Norethynodrel (Enovid®) .0 
Norethindrone (Norinyl® and Ortho Novum) 1.6 
Norethindrone acetate (Norlestrin"'b) 2.5 
Ethynodiol diacetate (Demulen ' and Ovulen" ' ) 1.01 
Norgestrel (Ovra®'1) 7.6 
4. In some women, endogenous estrogen production may be less 
suppressed, particularly as the dosage of exogenous estrogen is lowered. 
This means that in some women the total estrogen effect will be the result of 
estrogen from an oral contraceptive, in addition to endogenous ovarian 
estrogen. 
5. Estrogens affect many different organ systems and produce a broad 
range of symptoms. Organ systems have different responses to different 
estrogens and to estrogens in combination with different progestins. 
INITIAL PILL CHOICE 
1. Avoid giving Pills to women who may he harmed by them. Look over the 
contraindications to estrogen-containing Pills in this chapter. There are now 
many alternatives women may be able to choose among if one of the con­
traindications to Pills exists. Women who have already made up their minds 
to use the Pill can often be encouraged to use the Mini-Pill if they have a con­
traindication to combined Pills. 
2. Prescribe .05 mg or less cf estrogen when initiating use of an estrogen­
containing Pill. The use of .05-mg Pills seems to be associated with a mini­
mum of troublesome breakthrough bleeding and missed menses. Most 
public family planning programs in both the United States and Africa use 
either Norinyl 1 + 508 or Ortho Novum 1/50® as their initial Pill of choice, al­
though some programs are beginning to use more sub-50 Pills as their initial 
Pill of choice. 
3. In general, we recommend giving three packets of Pills at the initial visit. 
Of the 30%to 50% of women who do not continue using the Pill after 1 year, 
many stop because they find visits for resupply inconvenient or because they 
were given a very small supply of Pills and ran out before they could obtain 
more. 
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CLINIC PROCEDURES iN MANAGEMENT OF PILL USERS 
1. We recommend that six packets of Pills be provided after awoman has 
used the Pills for a year, if she is having no problems and wants to continue 
the Pills. After a woman has used the Pills for 2 years, we recommend that 
consideration be given to providing her with a full year's supply of Pills. Pill 
discontinuation is greatly increased if women have to return repeatedly for 
supplies. 
2. The danger signals for Pills are the most important health education 
message to convey to women. These are described in Figure 11. 1. 
3. The storage of contraceptive supplies is discussed in Chapter 23. 
SIDE EFFECTS AND COMPLICATIONS 
The Pill affects virtually every organ system. (See Table 11.3.) Pill compli­
cations which become worse over time (see Table 11.4) deserve our constan. 
attention as we ,rovide Pills to more women who have used those Pills for 
periods of 5-15 years. 
What are some of the risks of using the Pill? The most notable are cardio­
vascular side effects. Heart attack and stroke have been found to occur more 
often in women who use the Pill than in women who do not, according to 
studies in Britain and the United States (6-9). However, these cardiovascular 
side effects generally occur only in a small segment of Pill users. Women 
most at risk of developing cardiovascular side effects related to Pill use are
those who have other characteristics that serve to increase their risk: they
smoke, are over 35 years of age, or have other health problems such as 
hypertension, diabetes, or a history of heart or vascular disease. 
Conversely, nonsmokers who are healthy and younger than 35 can use 
the Pill safely, with very little risk of developing serious complications (6). The 
Royal College of General Practitioners Contraception drug study, a corner­
stone study of risks of the birth control Pill, showed that a woman using the 
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FIGURE 11. 1Early danger signals of the Pill. 
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2,000 if she smoked and 1 in 6,700 if she did not, but awoman younger than 
35 years of age had an excess annual risk of only 1 in 10,000 if she smoked 
and 1 in 77,000 it she did not %6). 
One might assume that African women have less risk of developing cardi­
ovascular disease from using the Pill than do European or American women. 
The African woman is less likely to have the characteristics that would serve 
TABLE 11.3 Side effects of the Pill 
FAIRLY MINOR 
Nausea (try taking the Pill with your evening meal if this is a problem; if you
vomit within 2 hours of taking the Pill, take another one because your 
original Pill may have no effect). 
Weight gain, fluid retention, breast fullness or tenderness.
 
Mild headaches (return to clinic if severe).
 
Spotting (bleeding) between periods.
 
Decreased menstrual flow (not always a nuisance).
 
Missed periods. 
More problems with yeast infection, vaginal itching, or discharge.
 
Depression, mood changes, fatigue (return to clinic if severe).

Decreased sex drive (rare: women on the Pill often enjoy 
an increased 
libido). 
Acne (again, more women notice adecrease in acne problems). 
Chloasma, or the "mask of pregnancy" (skin darkens on upper lip, under 
eyes, or on forehead; sun may make it worse; it may become 
permanent). 
SERIOUS 
Gallbladder disease, with upper abdominal pain, indigestion and the devel­
opment of gallstones. 
Hypertension (high blood pressure attributable to Pills is usually reversible 
very quickly; but it can, if high enough, lead to permanent 
complications). 
POSSIBLY LIFE-THREATENING 
Blood clots in the legs, pelvis (lower abdomen), lungs, heart, or brain. 
Hardly anyone dies from blood clots without warnings. Signs of 
trouble- possibly serious- may be headaches, blurred vision or loss of 
vision, flashing lights, severe leg pains, severe chest pains, or shortness 
of breath. The risk of heart attack is increased, particularly in women 
over 40. This risk is highest in women over 40 who smoke. 
Rupture of the capsule of the liver (a rare occurrence), extensive bleeding, 
and even death may be caused by benign tumors of the liver,which, al­
though rare, are shown to be more common in women who use the Pill. 
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to increase her risks: she is less likely to smoke, more likely to get physical 
exercise, is less likely to be obese, and is less likely to have a diet high in 
cholesterol. The African woman's risk of death from using the Pill is probably 
about 1 per 100,000 Pill users. On the other hand, the risk of death from 
pregnancy is many times greater, generally between 200-1,200 per 
100,000 births (10, 11). 
Fortunately, most of the complications women have from taking birth con­
trol Pills are riot serious. About 40"', of Pill users do have side effects of one 
kind or another; however, the vast majority have only minor side effects. 
The most serious complication of Pills can be minimized or avoid­
ed completely by following these steps: 
1. Do not give the combined Pill to women for whom they are 
contraindicated. 
2. 	Teach the individual the early Pill danger signals. 
3. 	 Be willing to use rionestrogen-containing Pills (Mini-Pills) or 
other contraceptive alternatives, when indicated. 
Cardiovascular complications are less common among Pill users who are 
young, do riot smoke, have normal weight, and do riot have Type B blood. 
Over the past years, the authors of Contraceptive Technology have devel­
oped the accompanying TIME FRAMEWORK for the occurrence of Pill 
complications and the side effects by hormone etiology. (See Tables 11.4 
and 11 .5.) These tables have proven useful in teaching clinicians about possi­
ble problems from oral contraceptives. 
MODIFICATION OF PILL DOSAGE 
While your program may have fewer brands of Pills available than the full 
range discussed below, you can successfully assist Pill users in finding the 
formulation that they can best tolerate through the use of medium- (1+50), 
low- (1+35), and no-estrogen (Mini-) dosage Pills. 
1. Spotting, early or late. From a medical point of view, spotting is gener­
ally notan ominous sign in young women and may usually be managed with a 
"watch-and-wait" approach for several months. Spotting can sometimes be 
controlled by having the patient take her Pill at exactly the same time each 
day. The .02 mg and .03 mg Pills appear to be associated with higher rates of 
breakthrough bleeding and/or spotting. Spotting is a potential problem with 
all the .05 mg Pills and sub-05 mg Pills. After 2 or 3 months, one might try 
switching to Ovral', Norlestrin 2.5"', or Demulenj,-. Rarely is it necessary to 
switch to a higher-estrogen Pill, siuch as Ortho Novum 1 + 80" orNorinyl 1 + 
80". 
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TABLE 11.4 Time framework: The progression ofPill side effects over time 
Worse in First 3 Months 




*Pelvic vein thrombosis 
*Retinal vein thrombosis 
3. Cyclic weight gain edema 
4. 	 Breast fullness, tenderness 
5. Breakthrough bleeding 
6. *Elevated serum lipid 
Ic.,els even to the extent 
of pancreatitis 
7. 	*Abnormal glucose toler-
ance test 
8. Contact lenses fail to fit 
because of fluid retention 
9. 	Abdominal cramping 
10. 	 Suppression of lactation 
11. 	 Pregnancy if the user fails 
to understand correct 
use of oral contraceptives 
Over Time: Steady-Constant 
1. Headaches during the 3weeks 
that Pills are being taken 
2. 	*Arterial thromboembolic 
events, blurred vision, stroke 
3. Anxiety, fatigue, depression 
4. Thyroid-function studies 
Elevated protein bound iodine 
Depressed T3 resin uptake 
5. Susceptibility to amenorrhea 
after the Pill is discontinued 
6. Decrease in libido 
7. Autophonia, chronic 
dilatation of eustachian 
tubes rather than cyclic 
opening and closing 
8. 	Acne 
*May be irreversible or produce permanent damage. 
Worse Over Time 
1. Headaches during week Pills 

are not taken 

2. Weight gain 
3. Monilial vaginitis 
4. 	Periodic missed menses while on 
oral contraceptives 
5. 'Chloasma 
6. *Myoc.rdial infarction 
7. Spider angiomata 
8. 	Growth of myoma 
9. 	Predisposition to gallbladder disease 
10. 	 Hirsutism 
11. 	 Decreased menstrual flow 
12. 	 Small uterus, pelvic relaxation 
cystocele, rectocele, atrophic 
vaainitis 
13. 	 Cystic breast changes 
14. 	 Photodermatitis - sunlight 
sensitivity with 
hypopigmentation 
15. 	 One form of hair loss 
(alopecia)
16. *Hypertension 
17. 	 *Focal hyperplasia of liver 
and hepatocellular adenomas 
Worse After Discontinuing 
1. 	-Infertility, amenorrhea; 
hypothalamic and 
endometrial suppres­
sion and miscalculation 
of expected date of birth 
2. One form of acne 
3. Hair loss (alopecia)
4. 	 Depression (in some 
women) 
**N.B. To avoid this complication in many patients desiring to be pregnant, discontinue Pills 3-6 months before desired pregnancy.Another possible way to avoid this problem is to avoid prescribing Pills for women with a history of very irregular menses. 
TABLE 11.5 Side effects from estrogen and progestin in oral contra­
ceptives 
Estrogen 	 Progestin Androgen 
Excess 	 Excess Excess
 
1. Nausea, dizziness 1. Increased appetite and 1. Increased appetite 
2. Edema and abdominal or weight gain (noncyclic) and weight gain 
leg pain with cyclic 2. Tiredness and fatigue; 2. Hirsutism 
weight gain, bloating feeling of weakness 3. Acne 
3. Leukorrhea 3. Depressions and decrease 4. Oily skin, rash 
4. 	 Increase in leiomyoma in libido 5. Increased libido 
size 4. Oily scalp, acne 6. Cholestic jaundice
5. Chloasma 	 5. Loss of hair 7. Pruritis 
6. Uterine cramps 6. Cholestatic jaundice 
7. Irritability 	 7. Decreased length of 




9. Cervical ectropia 9. Headaches during week 
10. Contact lenses do not fit when Pills are not taken 
11. 	 Telanglectasia 10. Moniliavaginitis, cervicitis 
12. 	 Vascular type headache 11. Increase in breast size 
13. 	 Hypertension (aleolar tissue) 
14. 	 Lactation suppression 12. Breast tenderness 
15. 	 Headaches while taking 13 Decreased carbohydrate 
Pills tolerance 
16. Cystic breast changes 14. Dilated leg veins 
17. 	 Breast tenderness 15. Pelvic congestion 
18. 	 Increased breast size syndrome 
(ductal and fatty tissue 
and fluid retention) 
19. 	 Thrombophlebitis 
20. 	 Cerebrovascular accidents 
21. 	 Myocardial infarction 
22. 	 Hepatic adenoma 
23. 	 Cyclic weight gain 
Estrogen 	 Progestin 
Deficiency 	 Deficiency 
1. Irritability, nervousness 1. Breakthrough bleeding 
2. 	Hot flushes, vasomotor and spotting
 
symptoms 2. Heavy menstrual flow
 
3. 	 Uterine prolapse, pelvic late in the period and clots 
relaxation symptoms 3. Delayed onset of menses 
4. 	 Early and midcycle 4. Dysmenorrhea
 
spotting 5. Weight loss
 




6. 	 No withdrawal bleeding 
7. Decreased libido 
B. Diminished breast size 




10. 	 Headaches 
11. 	 Depression 
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As we provide women with lower and lower dose Pills in the inter­
est of safety, we can predict and anticipate higher and higher
rates of spotting and missed menses. We should warn women 
about these problems in advance. Ingeneral, however, spotting is 
NOTan ominous sign in young women and may usually be ma~i­
aged with a "watch-and-wait" approach for several months. 
2. Failure to have withdrawal bleeding; missed menses. Initially,
switch to a higher-progestin Pill such as OvralP, Demulen®, or Norlestrin 2.5® 
or to a higher-estrogen Pill such as Norinyl 1 + 80® or Ortho Novum 1 + 80®. 
Try to avoid.1 mg Pills (estrogen-containing ones). 
3. Nausea. Use 0-.05 mg of estrogen. 
4. Weight gain caused by fluid retention. This type of weight gain is usu­
ally at its worst late in the cycle. Use 0-.05 mg of estrogen.
5. Weight gain caused by increased appetite. Consider using a low­
androgen Pill, such as Micronor® or Nor-Q.D., or another Pill relatively low in 
anabolic effects. Df.nulen" would be a good choice of the .05 mg Pills. (See
section in this chapter on "Estrogenic and Progestational Activity of Pills" for 
relative androgenic strength of Pills.) 
6. Hypertension. The association between hypertension and the use of
oral contraceptives is not conclusively established or understood; neither is 
the role that progestin or estrogen may play (12,13). If a woman develops
hypertension while using a combined Pill, suggest that she switch to the Mini-
Pill (low-dose, progestin-only Pill) or a nonhormonal method. If she still is 
hypertensive while using the Mini-Pill, and if the risks associated with use of 
an alternative are less important than those associated with hypertension,
recommend that she discontinue use of all hormonal contraceptives and 
switch to an alternative method. REMEMBER, PILL-INDUCED HYPERTEN-
SION ISUSUALLY REVERSIBLE. 
7. Oily skin or scalp; acne. Provide a low-progestin, low-androgen Pill,
preferably with .05 mg of estrogen. Initially use Demulen®, Norinyl 1 + 50®, 
or Ortho Novurn 1 + 50®.Any Pill may cause acne to become worse, but this 
may be particularly bothersome with Ovral®, which is the most androgenic of 
the .05 mg Pills. If acne does not improve, try Enovid-E® because of its very
low androgenic effects. The high estrogenic cuntent of Enovid-E® may also 
be helpful in improving acne. 
8. Hirsutism. Use a low-androgen Pill with 50 mcg of estrogen or 
less: Demulen®, Norinyl 1 + 50, Ortho Novum 1 + 50®, Norlestrin 1®,
Zorane 1 + 50®, Loestrin 1.5 + 30®, Zorane 1 + 20®, or Modicon®. 
9. Depression. This condition is complicated as depression may be attri­
butable to high estrogen levels (fluid retention), to high progestin levels, or 
even to estrogen levels that are too low. Initially, try Norinyl 1 + 50® or Ortho 
Novum 1 + 50®. Depression may improve. If it becomes worse, consider 
switching to a no-estrogen Pill, such as Nor-Q.D.®, Micronor®, or Ovrette®, or 
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,to a .03-to .035 mg Pill, such as Brevicon ', Lo-Ovral,", Ovcon-, or Modicon-. 
Some clinicians have noted that depression may be diminished by a dosage
increase to greater than .05 mg of estrogen. Pill-induced depression has also 
been managed by treatment with vitamin B6, 25 mg/day. Depression can 
become much mote severe or may be remarkably improved while using birth 
control Pills. Each Pill user must be questioned carefully.
 
Some women 
have used the Pill for years only to realize, after discontinuing 
it, just how depressed they had been while taking it. This is a potential justifica­
tion for discontinuing the Pill for a "rest period" every 3 years or so. However, 
the authors feel that, in most instances, the risks of the "rest period" approach 
far exceed the benefits. 
NONCONTRACEPTIVE BENEFITS 
It is important to remember that women often experience benefits other 
than effective contraception from oral contraceptives. Several of these 
beneficial effects of birth control Pills, along with some adverse effects, are 
presented in the bar graph (see Figure 11.2) derived from the Royal College 
Study (1). 
In this study, combined oral contraceptive users frequently experienced a 
relief of symptoms of their menstrual cycles. The Pill minimizes menstrual 
cramps, decreases the number of days of bleeding and the amount of blood 
loss, produces regular menstrual periods, and eliminates the pain of mittel­
schmerz in most instances. Also, iron-deficiency anemia is decreased in Pill 
users. Other women notice that their premenstrual tension, anxiety, or de­
pression may be diminished while taking oral contraceptives. Extra Pills from 
a separate package may be taken to avoid menses on weekends, on 
vacations, or when menses are not wanted for whatever reason. 
There is extensive evidence that the Pill provides a protective effect 
against pelvic inflammatory disease (PID). Users of the Pill are less likely to de­
velop PID than users of all other contraceptive methods (1 4,15). 
The simptoms of estrogen deficiency are often controlled by oral 
contraceptives. Women over age 35 are at greater risk of serious complica­
tions from use of oral contraceptives than younger women; therefore, 
women over age 35 should consider other combinations to remedy estrogen 
deficiency. 
The Pill has been used in the treatment of such medical conditions as en­
dometriosis and idiopathic thrombocytopenic prupura (ITP). In addition, there 
is a decreased incidence of functional ovarian cysts, rheumatoid arthritis, 
fibrocystic breast disease, and fibroadenomas of the breasts in women who 
use the Pill (16). 
An acne condition is often improved in women taking oral contraceptives. 
Some women gain weight or notice an increase in their breast size while they 
are using the Pill (which can be either a beneficial or an adverse effect). Some 
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women and men experience an increased enjoyment of sexual i'.iercourse, 
more probably because the fear of pregnancy is diminished. 
USER INSTRUCTIONS 
Patients should be instructed in the following way:
1. There are three satisfactory ways to start taking your Pills. You should 
use the approach suggested by your doctor, nurse, or clinic: 
FIRST APPROACH: 
TAKE THE FIRST PILL FROM YOUR FIRST PACK ON THE FIRST DAY 
YOU BEGIN BLEEDING DURING YOUR PERIOD 
SECOND APPROACH: 
START YOUR FIRST PACK ON THE FIRST SUNDAY (OR FRIDAY) 
AFTER YOUR PERIOD BEGINS. (See Figure 11.3.) 
THIRD APPROACH: 
START YOUR FIRST PACK ON THE FIFTH DAY AFTER YOU START
YOUR MENSTRUAL PERIOD: THE FIRST DAY OF BLEEDING IS DAY 1. 




























FIGURE 11.2 Comparison of the incidence of various conditions in current 
users oforalcontraceptives. 
149 
Swallow one Pill a day until you finish the pack. If you are using a 
21 -day pack, stop for 1 week, and then start your new pack. If you are 
using a 28-Pill pack, begin a new pack immediately. (See Figure 11.4.)
2. Try to associate taking your Pill with some regularly scheduled ac­
tivity like going to bed, eating a meal, or brushing your teeth. This may
make it easier to remember. Pills work best if you take one about the 
same time every day in order to keep a relatively constant level of drug
in your system. This is especially important if you have bleeding be­
tween periods. 
3. Check your packet of Pills each morning to make sure you took 
your Pill the day before. 
If you miss one Pill, take the forgotten one (yesterday's Pill) as soon 
as you remember it, and take today's Pill at the regular time. You proba­
bly won't get pregnant. Just to be sure, you could use your backup 
method. (See Figure 11.5.) 
If you miss two Pills in a row, take two Pills as soon as you remem­
ber and two the next day. Here is an example: You forget your Pills on 
Saturday and Sunday evenings, but remember on Monday morning.
What do you do? Take two Pills on Monday and two on Tuesday. You 
may have some spotting. Use another means of contraception until you 
finish that pack of Pills. (See Figure 11 .6.) 
If you miss three or more Pills in a row, ask yourself, "Am I a good
Pill user?" The chances are great that your ovaries will produce an egg
(you will ovulate) and that you may get pregnant. So start using a 
second method of birth control immediately. Throw away your old pack
of Pills. Start a new packet the Sunday after you realize you have 
missed three or more Pills, even if you are bleeding. Use your second 
method of birth control while you are off Pills AND for the first 2 weeks 
that you are on your new pack of Pills. Consider using a method you can 
use more consistently, unleFs you are sure missing Pills will not become 
a habit. (See Figure 11.7.) 
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FIGURE 11.4 Twenty-eight-day combined birth control Pill package. There 
are no days without Pills. 








28-Day Combined Birth Control Pill Package 
FIGURE 11. 5 If you miss one Pill. 









28-Day Combined Birth Control Pill Package 
FIGURE 11.6 If you miss two Pills. 
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If you miss one or more Pills and skip a period, start using a 
method of birth control other than birth control Pills and cntact your
clinic to see about a pelvic examination or a pregnancy test to determine 
if you are pregnant. The family planning worker will help you de-termine 
when to start using the Pill again, if you have stopped.

If you miss no Pills but skip 
a period, you probably should not 
worry too much. You may be pregnant, but it is very unlikely. It is rather 
common for women taking birth control Pills to miss periods
occasionally. If you are worried, call the clinic. You are fairly safe and 
can start a new package of Pills at the regularly scheduled time. (See 
Figure 11.8.) 
4. Tell people you are using Pills whenever you are seen for any medi­
cal problems. (See Figure 1 1.9.) 
WNHEN YOU ARE SEEN BY A DOCTOR FOR OTHER PROBLEMS, 
BE SURE TO MENTION THAT YOU ARE USING BIRTH CONTROL 
PILLS. THIS IS PARTICULARLY IMPORTANT IF YOU ARE ADMIT-
TED TO THE HOSPITAL. 
5. The most important instruction of all is to contact the person who 
provided your Pills if you develop one of the five danger signals. 
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28-Day Combined BirthControl Pill Package 
Restart takuiln Pill oil the sarne 
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[lot OCCLII0(J. 
FIGURE 11.8 Ifyou miss no Pills but skip a period. 
6. Danger Signals: Which Aches and Pains May be Warnings of Serious 
Trouble? 
Danger Signals Possible Problem 
Abdominal pain (severe) Gallbladder disease, hepatic 
adenoma, blood clot, 
pancreatitis

Chest pain (severe) or 
 Blood clot in lungs or myocardial 
shortness of breath infarction (heart attack)
Headaches (severe) Stroke or hypertension or 
migraine headache
 
Eye problems: blurred 
 Stroke or hypertension or 
vision, flashing temporary vascular problem 
lights, or blindness of many possible sites 
Severe leg pain (calf Blood clot in legs 
or thigh) 
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These symptoms may mean serious trouble. Learn them well. Note that the 
first letter of each symptom spells out the word "ACHES." 
These symptoms have been experienced by some women for weeks 
or even months before they sought help. Do not ignore these problems. Do 
not wait to see if these problems go away. Call the clinic or your doctor 
immediately and explain your problem. You should be seen in the family plan­
ning clinic or in the emergency room right away. Using birth contro: Pills can 
28-Day combined Birth control Pill Package 
Pills NOT ADVISED because of 
PLANNED ELECTIVE SURGERY 






Progestin-Only Pill or Mini-Pilll ackage 
MINI-PILL MAY BE USED the 
month prior to elective surgery 
FIGURE 11.9 Inform your doctor that you are taking the Pill whenever you re­
ceive care for medicalpro b/ems. 
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be made safer if you use them wisely and if you seek help early when prob­
lems arise. 
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Start next package immediately 
28-Day Combined Birth Control Pill Package 
Iron added to final seven Pills. An 
excellent nutritional advantage. 
FIGURE 11. l0Adding iron supplements. 
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28-Day Combined Birth Control Pill Package 
NO! NO! NO! None of our current 
Pills aie for men. Not at the time of 
sexual intercourse, not for the en­
tire month, not at any time. We 
hope one day there will be Pills 
for men. Now there are no hor­
monal Pills for men. 
FIGURE 11. 11 Pills are not formen. 
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0 000 	 1 Ifyou have severe 
diarrhea for eight
@Q 	 or00more days... 
0000000 
0000000 
28-Day Combined Birth Control Pill Package 
FIGURE 11. 12 If you ever have diarrhea for 8 consecutive days while taking 
the Pill, the diarrhea may reduce the contraceptive effect; use a backup con­
traceptive to ensure protection. 
ENCOURAGING CONTINUED USE OF THE PILL 
Generally, anywhere from 30" to 70% of women who start rombined Pills 
will still be using them after 1 year. Groups having low continuation rates 
include adolescents and women who were provided only a single pack of 
Pills. Most women who discontinue the Pills do so for nonmedical reasons, 
that is, not because they have developed a complication or major side effect. 
In writing this edition of Contraceptive Technology, we solicited sugges­
tions as to how continued use of the Pill might be increased. Among the sug­
gestions we received are the following: 
1. Develop community-based distribution systems that would provide 
Pills to women in their own homes; continue followup in homes. 
2. When Pills are provided in clinics, followup may be done through a 
community-based distribution system. Pills can be brought to the 
user's home every 1 to 3 months. 
3. Eliminate the need for so many revisits to the clinic by providing 6 to 12 
packages of Pills to a woman who has used the Pills for a year or more 
and is having no problems. 
4. 	Consider making Pills a nonprescription drug available to women 
through pharmacies and patent-medicine practitioners. 
5. 	Make Pills available through a broad range of health and nonhealth 
agencies, including agricultural extension agencies, clinics a. places of 
work (factories, cooperatives, offices), Maternal-Child Health/Family 
Planning Clinics, hospitals, private physicians, nurses, midwives, and 
school health programs. 
6. 	Provide better counseling so that patients really understand how to 
take the Pills and what problems they are to watch out for. 
7. 	Provide educational materials for distribution in community-based and 
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CONTRACEPTIVE INJECTIONS AND 
OTHER PROGESTIN-ONLY CONTRACEPTIVES 
Up to 10 million women have used the drug Depo-Provera,' 
(DMPA) at some time, and inore than one and a quarter million 
use it at present. It is registered as a therapeutic agent in the 
treatment of cancer in nearly all countries, and as a contracep­
tive agent in more than 80 developed and developing countries. 
International Planned Parenthood Federation, 1980 
PROGESTIN INJECTIONS 
HISTORY, MECHANISM OF ACTION, AND EFFECTIVENESS 
History andmechanism ofaction 
Contraceptive injections of long-acting progestins are now bJi.-,g used in 
at least 80 countries throughout the world, including several countries in 
Africa (1-3). The most commonly used injectable progestins are medroxy­
progesterone acetate (Depo-Provera or DMPA) and norethindror, ,nanth­
ate (NET). Just like the progestins in combined Pills, the progestins in the 
injectables prevent p,-egnancy by stippressing ovulation, inducing a thin, 
atrophic endometrial lining, and producing a thick cervical mucus that is dif­
ficult for sperm to penetrate. 
While the many benefits of injectable progestins have gained them popu­
larity and acceptance among providers and users, the possible side effects 
have raised some concern. People who encourage the use of injectables 
find the method is well accepted by users and enjoys high continuation 
rates, high effectiveness rates, and low complication rates. People who dis­
courage the use of injectables believe the method needs further study to 
document its safety. 
The use of injectable progestins has been effective and popular in a 
number of African countries. Reasons given by users and family planning 
workers for the great popularity of injectables were convenience, privacy af­
forded by the method, and the traditional belief that injections have a great­
er effect than oral medications (1). Higher continuation rates are associated 
with less frequent visits to the provider. This was shown in a 1978 study 
comparing the use of 150-mg DMPA given to 500 women every 3 months 
with the use of 450 mg given to 500 women every 6 months. At 6 months, 
the continuation rates were higher in women choosing the 6-month regi­
men, 73.2%vs 57%. However, amenorrhea, headaches, and a bloated abdo­




A 	number of studies of DMPA have shown that for every 400 women 
who use DMPA in a year, one will become pregnant (4). One of the reasons 
DMPA injections are so effective is that each 150-mc injection actually pro­
vides more than 3 months' protection. Thus, a woman using "the shot" as 
her contraceptive has a 4- to 6-week "grace period" during which she can 
be late for her next shot but probahly stil; be protectfcd. The pregnancy rate 
for NET is somewhat higher than for DMPA Further, study evidence sug­
gests that the contraceptive effect of NEI lasts for less than three months 
(5) 




For your own country and population, you should weigh the advantages 
and disadvantages of using( the injectables. The following chart summarizesseveral reports of the pros and cons of injectable progestins (6,7). These 
will be described in detail later in the chapter. 
AD V4NTAGES: DISAD VANTAGES: 
* 	does not have tine serious 0 may produce amenorrhea;
 
complicati )ns associated with 
 some women may want
 
estrogen-containinc, Pills 
 reassurance from menstrual 
flow that they are not 
* 	 high!y effectve pregnant and are still capable 
of becoming pregnant 
* 	 long-acting; need be provided
 
only at 3- or 6-month intervals 0 delays the return of fertility
 
* 	 effectiveness corntnLies even * may cause menstrual
 




0 studies on animals suggest
* offers privacy to user; need injectables may affect a fetus 
not be kept at home if used during pregnancy and 
may be associated with 
* 	 may produce amenorrhea; cancer of the endometrium 
may help decrease anemia and breast 
* 	 acceptable to women who 
prefer injections to oral 
medications 
* 	 does not suppress lactation 
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The United States Food and Drug Administration (FDA) has not yet ap­
proved DMPA for general use in the United States. This has caused some 
concern and touched upon the political sensitivities of certain African coun­
tries that have used the drug. The FDA gave four reasons for not approving 
the use of DMPA in America: DMPA produces breast tumors in beagles; it 
may be teratogenic if used during pregnancy; there was no evidence that 
DMPA was needed in America since sterilization is widely available; and the 
use of supplemental estrogens to control bleeding could be hazardous (8). 
CONTRAINDICATIONS 
The absolute contraindications to combined oral contraceptives have his­
torically been applied io contraceptive injections. (See Chapters 9 and 11 .) 
However, unlike the Pill, progestin-onlv injections have never had a docu­
mented association with increased risk of thromboembolic disease. (See 
Chapter 1 1 for the list of contraindications for both combined oral contra­
ceptives and progesterone-only contraceptives.) 
LONG-ACTING PROGESTIN INJECTIONS MAY PRODUCE
 
IRREGULAR MENSTRUAL BLEEDING PATTERNS.
 
THEREFORE, UNDIAGNOSED ABNORMAL GENITAL BLEEDING
 
NEEDS TO BE EVALUATED CAREFULLY
 
BEFORE PROGESTIN CONTRACEPTIVES ARE USED.
 
While it dons not appear that women have extensive post-DMPA infertility 
problems, return of fertility does appear to be delayed until the effects of the 
injected progestin have elapsed (9-1 0). Thus, some programs rhoose not to 
provide injectable contraceptives to women planning to become pregnant in 
the future. Others provide injectables to women who have three or more 
children. 
PROVISION 
Contraceptive injections are especially useful in the following situations: 
1. 	When a woman desires no more children but does not want to be 
sterilized. 
2. 	 When a woman is approaching menopause but does not want to 
be sterilized. (Older women are at greater risk of developing compli­
cations with the use of the combined Pill, a commonly available al­
ternative method, than are younger women.) 
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WOMEN OVER 35 ARE AT A GREATER RISK OF DEVELOPING 
CARDIOVASCULAR COMPLICATIONS IFTHEY TAKE 
COMBINED PILLS. YOU SHOULD CONSIDER INJECTABLE 
CONTRACEPTIVES FOR THIS AGE GROUP. 
3. 	When a woman wants a safe, effective method for a short period
of time before she is sterilized: for example, if she is a post-partum
patient who is unable to schedule tubal ligation for several months. 
4. When a woman is living under conditions where personal hygiene
is difficult. Injectable contraceptives are advantageous from both a 
hygienic and from a contraceptive standpoint.
5. When a woman has received a rubella vaccination and must be pro­
tected against pregnancy for 3 months. 
6. 	When a woman has sickle cell disease and she is not a good candi­
date for a combined Pill. 
7. When an alternative means of contraception is needed for a 
woman who has become pregnant while attempting to use another 
method or who has experienced complications with other methods. 
8. 	When a woman has a particularly high risk of developing cardio­
vascular complications from estrogen-containing birth control Pills. 
9. When a woman has developed estrogen-related complications
while taking combined oral contraceptives, and a nonhormonal ap­
proach to birth control is not satisfactory for her. Such complica­
tions of oral contraceptives include: 
* 	 high h :od pressure 
" 	headaches
 
* 	 leg pain 
* 	 chloasma 
The settings in which injectable contraceptives are least likely to be con­
1. 	When a woman has 
sidered are as follows: 
never been pregnant or is an adolescent. This 
is because return of fertility may be delayed. Inthe long run, howev­
er, return of fertility is excellent. 
2. When a woman does not like receiving injections. Women who 
faint or have had repeated vaso-vagal reactions when they received 
injections of other medications are not candidates for injectable 
contraceptives. 
3. 	When a woman has a history of breast cancer or a strong family 
history of this disease. 
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4. 	When a woman has a history of a breast mass (this is a considera­
tion, but not an absolute contraindication, to use of DMPA). 
5. 	 When a woman has had an abnormal glucose tolerance test, with a 
history of gestational diabetes or with a strong family history of 
adult-onset diabetes. 
6. 	When a woman has menorrhagia or metrorrhagia. 
SIDE EFFECTS AND COMPLICATIONS 
To our knowledge, women using injectable contraceptives are not ex­
posed to an increased risk of any lethal complication, although definitive 
long-term studies are not available at this time. 
EXCESSIVE ENDOMETRIAL BLEEDING AND AMENORRHEA
 




Women using injectable contraceptives may have breakthrough bleeding. 
If a woman is bothered by this, the bleeding can be managed by giving.her 1 
or 2 cycles of an oral contraceptive. However, usually this is not necessary, 
nor is the provision of any other exogenous estrogen. Occasionally, women 
using injectable contraceptives bleed extensively. If a woman is experiencing 
numerous days of bleeding each month, check to see if she is anemic. Con­
sider discontinuing DMPA or treating the woman with iron if her hematocrit 
drops 5 points or moie. 
AMENORRHEA IS TO BE EXPECTED AFTER 
9-12 MONTHS OF USING DMPA. 
Many women consider amenorrhea a desirable effect of DMPA; others 
clearly do not. Amenorrhea was the most common reason for discontinuing 
DMPA (14.1%) among 400 women provided this contraceptive in Ibadan, 
Nigeria (11). Pregnancy may result if a woman in her forties misinterprets 
prolonged amenorrhea as "menopause," assumes she is "sterile," and dis­
continues contraception. One could continue administering injectable pro­
gestins until the patient is age 50 if she experiences no problems. 
NET produces substantially !ess amenorrhea than does DMPA (5), which 
may make NET more acceptable in some populations. Rates for other types 
of bleeding problems caused by NET appear comparable to those for DMPA. 
Post-DMPA infertility for 6-12 months occurs in a fair number of 
women. However, fertility does return in over 80% of women within 1 year 
after DMPA is stopped. The mean interval for return of fertility is about 10 
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months. Extensive studies of DMPA throughout the world indicate thatwhile fertility takes a number of months to return after the use of DMPA, in­fertility is not a serious complication (1 9,10).

Decreased 
 libido, depression, headaches, dizziness, weight gain, and al­lergic reactions are complications of DMPA most commonly encountered.The effect of long-acting progestins on carbohydrate metabolism is stillbeing investigated. Consider periodically evaluating carbohydrate metabo­lism in long-term DMPA users, especially when a marked weight gainoccurs and when the clinician and ptient wish to continue this form of 
contraception.
 
The effect of injectable progestin 
on blood pressure is minimal. In onelarge study, DMPA had no effect on blood pressure (12). While the number ofDMPA Depo-Provera" users is still too small to be sure that all of its complica­tions have been discovered, there is no evidence of thrornboembolic phe­nomena or other circulatory diseases, as have been seen with estrogen­
containing oral contraceptives (7,12).
Toxicologic studies of DMPA in beagle dogs showed that treated dogsmanifested more mammary gland tumors; some of the tumors becamemalignant (13). Because of these studies, there has been concern over thepossibility of breast cancer in women using DMPA. Investigators in theUnited States have conducted a case-control study of breast cancer amongcontraceptive users in a program that has provided over 7,000 women withDMPA from 1969-1978 (14); however, the study showed no increased riskof breast cancer in DMPA users compared with other contraceptive users.Because of this concern over the possible development of breast cancer inDMPA users, you may wish to practice utmost caution by performing periodicbreast examinations and by teaching patients to examine their own breasts. 
NONCONTRACEPTIVE BENEFITS 
There is some evidence that at least one of the injectable progestins
(DMPA) does not suppress lactation and may even 
increase the duration of
lactation (11,15). This would be a major advantage in many areas of Africa
where successful and prolonged breast-feeding is of critical importance tothe health of infants and young children. While it is known that DMPA doesget into the breast milk in small quantities, no long-term effect on babies is
known at this time (15).
DMPA has been used in the treatment of endometriosis and dysmenor­rhea and may be a preferred contraceptive method in anemic women. It iscurious that although DMPA has been implicated in the development of endo­
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metrial and breast cancer in animals, it is used to treat these same conditions 
in humans. In Africa, where iron-deficiency anemia is very common, the de­
creased menstrual blood loss produced by DMPA is an important noncontra­
ceptive benefit of this approach to contraception. 
USER INSTRUCTIONS 
1. Use an additional contraceptive method for the first 2 weeks after 
your first injection or whenever your clinician instructs you to. 
2. 	Return to the clinic every 3 months for another injection. 
3. 	Go back to the clinic if you have longer periods, spotting between peri­
ods, irregular periods, or no periods at all. (See Figure 12.1.) Most of 
the time, the change in your periods does not mean that there is a 
problem. But if the bleeding is bothering you, go back to the clinic to 
get a blood test for anemia or to change your method. 
4. 	Remember that you may not be able to become pregnant immediately 
after you stop using the injection. Although it is usually possible to 
become pregnant after using the injection, it may take as long as 
12-18 months before your periods are regular and you can become 
pregnant. 
5. See your clinician if you develop these symptoms: decreased sex 
drive, weight gain, headaches, or dizziness. (See Figure 12.1.) The in­
jection is a fairly new method, and it is not yet known whether it will 
cause an increased risk of blood clots. Watch out for severe head­
aches, blurred vision or partial blindness, severe leg pains, and chest 
pains. CONTACT YOUR DOCTOR OR CLINIC IMMEDIATEL" if any of 




[1 	 Weight gainCAUTION [Headaches 
U Heavy bleeding 
L] Depression 
11 Frequent urination 
Conti(t us if you develop inly 
of thf? aibove fro/leins. 
FIGURE 12. 1Depo-Provera dangersignals. 
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THE MINI-PILL OR PROGESTIN-ONLY PILLS* 
The Mini-Pill has been marketed since the early 19 70's. These Pills contain
small doses of the same pro )#'stins available in combined oralcontraceptives. Ovrette® provides O.075-mg norgestrel, which is 15% of the
dose in Ovral"®, while Nor-Q.D.®' and Micronor®11 provide 0.35-mg
norethindrone, which is one-third of tne dose in Norinyl 1 + 50® and Ortho
Novum 1 + 50'. (See Table 12.1 for the names of other progestin-only Pills 
available in Africa.) 
Just how much safer (or more dangerous) Mini-Pills are than combined
Pills has not been demonstrated. Theoretically, the absence of art estrogen
would make the Mini-Pill considerably safer. Thus, because of the theoreti­
cal relative safety of the Mini-Pill, family planning workers might feel com­
fortable prescribing a full year's supply at one visit. 
EFFECTIVENESS 
While taking Mini-Pills, approximately 40% of women consistently have
ovulatory cycles, and 20% shift back and forth from ovulatory to anovula­
tory. The way in which progesterone in the Mini-Pill acts to prevent pregnan­
cy is described in Chapter 11. 







 Tablets Progestogen mg 
PROGES TIN-ONL Y PREPARA TIONS: 
Exluton ' Orqanon 35 Lynestrenol 0.5Femulen 0.5' Searle 28 Ethynodiol 0.5 
diacetateMicrolui' Schering 35 Levonorgesirel 0.30Micronor' Ortho 35 Norethisterone 0.35Micro-Novum' Ethnor 35 Norethisterone 0.075NJoriday (Norod) Syntex 28 Norethisterone 0.35
OvrettoW Wyeth 28 Norgestrel 0.075 
The thaoretical rate of effectiveness of the Mini-Pill is slightly less than
that of combined oral contraceptives, falling more into the effectiveness 
rangc of the IUD. Theoretical failure rates for Nor-Q.D. and Micronor® 
have been reported at about 1.25 pregnancies per 100 women using the 
method in 1 year. 
'Inthis book, the tern- "Mini-Pill" refers only to progestin-only preparations and never applies to 
sub-50 mg-combination Pills. 
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Pregnancy rates are highest in the first 6 months of using the Mini-Pill. 
Ideally, a second method, such as a condom or spermiides, may be used as 
a backup during the first 1 or 2 months. However, this practice is not essen­
tial and should not be enforced if it would interfere with the user's continued 
use of the Mini-Pill. 
CONTRAINDICATIONS 
Since relatively few studies have been done on the use of the Mini-Pill, it 
is safest to assume that the absolute contraindications to the use of 
estrogen-containing Pills (see Chapter 11) also pertain to use of the Mini-
Pill. However, it is not known at this time if there actually is an increased risk 
of thromboembolic disease associated with progestin-only contraceptives. 
As a result of the irregular bleeding produced by the Mini-Pill, undiagnosed 
abnormal genital bleeding is one of the more important contraindications to 
its use, especially in women over 35 years old. Progestin-only Pills should 
also be avoided in pre-diabetes (gestational diabetes), women with acute 
mononucleosis, women with irregular menses, and women with a history of 
an ectopic pregnancy. 
PROFILE OF PATIENTS WHO MIGHT CHOOSE THE MINI-PILL 
The Mini-Pill may be the initial oral contraceptive of choice for 
women who are over 35 or for women who have a history of 
headaches, hypertension, (see the section in this chapter on Pill 
dosage modification), or varicose veins. 
If a hormonal method of contraception is to be used by a 
lactating woman once breast-feeding has been established, the 
Mini-Pill or a progestin birth control injection should be 
prescribed. 
The Mini-Pill is most often provided after a patient has experienced one 
of the estrogen-excess side effects from the combined Pill. The most 
common estrogen-related side effects dictating a change in method to the 
Mini-Pill are headaches, hypertension, leg pain, chloasma, weight gain, and 
nausea. Depression and weight gain may be either estrogen-excess or 
progestin-excess side effects. Moniia vaginitis, weight gain, and acne are 
progestin-excess side effects that may be improved by switching to the 
Mini-Pill. It is important to remember that the Mini-Pill contains no estrogen
and contains a smaller amount of the progestin than does the combined Pill 
(se, pyramid of estrogen and progestin potency in Chapter 11). Both long­
ac, -gprogestins and the Mini-Pills seem to increase the length of time that 
a woman may successfullynurse, and both are preferable to combined Pills, 
which may decrease the flow of brea, t milk. 
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HEADACHES, HYPERTENSION, AND LEG PAIN-

THE MOST COMMON SIDE EFFECTS OF THE COMBINED
 
PILL-MIGHT DICTATE A SWITCH TO MINI-PILLS.
 
COMPLICATIONS 
Irregular menses, decreased duration and amount of menstrual flow,
spotting, and amenorrhea are the major complications of the Mini-Pill. Hea­daches are less common than with the combined Pill. Al increased risk ofthrombophlebitis in 	 users of the Mini-Pill has not been established. Drugcirculars include side effects experienced in other body systems, such asedema, hirsutism, and alterations in hepatic function tests, metapyronetests, and pregnanediol determination. Because the estrogen in combined
Pills is thought to be associated with cardiovascular disease and the Mini-Pill
only contains progestin, it is theoretically safer than combined Pills, but we
do not have long-tarm scientific studies proving this. 
NONCONTRACEPTIVE BENEFITS 
Dysmenorrhea is diminished in some users of the Mini-Pill, although not sopredictably as with combined oral contraceptives. The total blood loss in 
Mini-Pill users is also diminished. 
USER INSTRUCTIONS 
1. Take one Pill every day. As soon as you finish one packet of Mini-Pills, 
go right on to the next packet the very next day. Nevermiss a day if you 
aretaking Mini-Pills. 
2. 	 If you miss one Pill, take it as soon as you remember, and take your
next Pill at the regular time. Use a second method of birth control until 
your next period.
3. If you miss two Pills, take one of the missed Pills as soon as you
remember, as well as your regular Pill for that day. Take the other for­
gotten Pill plus the regular one the next day. Use a second method of 
birth control until your next period.
4. If you do not have a period within 45 days of your last one, it needs to
be determined immediately if you are pregnant. Expect changes in the
time between pei iods and in the length of your periods.
5. 	 You may have some spotting between periods. Some women have 
perfectly regular, normal cycles using the Mini-Pill. Many, however, ex­
perience irregular :,,cles. Some women have very infrequent periods
(1 or 2 per year) while on the Mini-Pill. 
6. 	 Ideally, to improve the effectiveness of the Mini-Pill, you should use asecond method for the first 2 months a,,d for those women who are




CURRENTLY IN THE RESEARCH STAGE
 
SUBDERMAL SILASTIC CAPSULES CONTAINING PROGESTINS 
These have been used experimentally as a means of providing reversible 
long-term contraception. It is hoped that single silastic capsules might pro­
vide effective contraception for 5 yeai.- or longer. A major problem is that 
the silastic capsules must be removed. 
VAGINAL RINGS IMPREGNATED WITH PR )GESTINS 
Vaginal rings, worn by women for 21 days at a time during clinical trials, 
have provided effective (98() contraception protection and have avoided 
the coitus-related inconveniences associated with diaphragms. They are 
not yet available commercially. A ring slightly smaller than a regular dia.. 
phragm (50-60 mm) is placed into the vaginal vault each month after 
mensps like a diaphragm and left in place for 21 days. The ring releases pro­
gestins that are systemically absorbed and that may also have local effects. 
Rings that can be left in place for a full 3 months are being evaluated by the 
World Health Organization in several research centers throughout the 
world, including the center in Ibadan, Nigeria. 
IUD'S THAT RELEASE A PROGESTIN 
These IUD's have been used as a means of increasing IUD contraceptive 
effectiveness and of decreasing uterine cramping and total menstrual blood 
loss. Several progestins, including progesterone, have been used in these 
IUD's. A norgestrel-releasing IUD that may be used continuously for 6 years 
is now being evaluated by The Population C .... ncil, a private American 
organization. 
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May I repeat, too, that this method is not suitable for every 
doctor, nor is it suitable for every woman. We must differentiate 
very carefullybetween individualcases. 
Dr Ernst Graefenberg 
Inventor of the Graefenberg ring- 1931 
Development of the modern IUD began in 1909 when Richter (R.) and 
Graefenberg devised intrauterine devices made of silkworm gut. Since then, 
IUD's have been made in various shapes including rings, spirals, T-shapes, 7­
shapes, and others. The Lippes Loop'" remains the most widely used IUD 
throughout Africa and, indeed, throughout mob' 2f the rest of the world. 
Today, IUD's are used by some 60 million women throughout the world. 
The materials used to make the devices have also varied and have included 
silver, copper, and plastic. Some devices contain progesterone; the majority 
do not. (See Table 13.1.) 
MECHANISM OF ACTION (1-5) 
Several mechanisms of action have been suggested for IUD's: 
1. Immobilization of sperm. 
2. Increased motility of the ovum in the fallopian tube. 
3. 	Local foreign-body inflammatory responses causing lysis of the blasto­
cyst and/or prevention of implantation. 
4. Mechanical dislodging of the implanted blastocyst from the 
endometrium. 
5. 	Impairing implantation by disruption of the proliferative-secretory 
maturation process by progestin-elaborative IUD's. 
6. 	Increased local production of prostaglandins, which inhibit 
implantation. 
7. 	Competition of with causing inhibition ofcopper zinc carbonic 
anhydrase and oossibly alkaline phosphatase activity. Copper may also 
interfere with estrogen uptake and its intracellular effects on the 
endometrium. 
EFFECTIVENESS 
The method effectiveness of IUD's is between 97% and 99% (1). The dif­
ferences in effectiveness for different IUD's can be attributed to such IUD 
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TABLE 13. / Physical characteristics of IUD's, IUD strings, and IUD insertion mechanisms 
Length* Width* Inserter Barrel Color of Number of Other StringType IUD 	 (mm) (mm) Widest Diameter (mm) Strings Strings Characteristics 
Lippes Loop A 33.0 22.5 5.26 Blue 1 or 2 1 thick; 2 thinLippes Loop B 34.0 28.0 5.30 Black 1 or 2 1 thick; 2 thinLippes Loop C 35.0 30.0 5.30 Yellow 1 or 2 	 1 thick; 2 thinLippes Loop D 36.0 30.0 5.33 White 1 or 2 	 1 thick; 2 thin 
Small Saf-T-Coil 21.5 25.5 3.76 Green 2 	 Thin stringsMedium Saf-T-Coil 32.0 30.0 4.50 Green 2 	 Thin stringsLarge Saf-T-Coil 33.0 38.0 4.50 Green 2 Thin strings 
* Small Dalkon Shield' 20.5 22.0 18.50 Black 1 Knot on thick string
*-Standard Shield' 21.5 24.9 19.48 Black 1 Knot on thick stringCopper-7 ' 	 36.0 27.0 3.07 Black 1 	 Thin stringCopper-T' 	 36.0 31.5 5.96 Light Blue 2 Thin strings 
(variable) 
Progestasert-T 36.0 32.0 6.0 	 Translucent 2 Thin strings (one 
precut at 9 cm) 
*Measured to nearest 0.5 mm. The length of the Loop series of IUD's increases after the IUD has been drawn into the inserter
 
barrel and expelled. These are post-expulsion measurements.
 
-Dalkon 	 Shields' are no longer marketed. Because of risks of infection, spontaneous abortion, and maternal death occurring in userswho become pregnant with the Shield in utero, it is recommended that all users have their Dalkon Shields' removed. 
characteristics as size, shape, presence of copper or progesterone (see Table 
13.2), and to a number of other variables such as age and parity of the IUD 
user. One of the major advantages of the IUD is that its range of actual effec­
tiveness for users (about 90' -96 effective) is quite comparable to its 
method effectiveness rates since patients can make relatively few errors (see 
Chapter 9). The user-effectiveness of IUD's depends on a number of 
administrative, patient, and medical variables, including ease of insertion, cli­
nician experience, the possibility that the patient will not detect whether the 
IUD has been expelled, and the user's access to medical services. 
CONTRAINDICATIONS TO IUD INSERTION (1,6,7) 
Some women are restricted frori using IUD's because of severe medical 
conditions. The contraindications listed below are meant as guidelines only; 
not all family planning clinicians are in agreement with them. Some clinicians 
believe that in the absence of strongy documented evidence for some of the 
contraindicatrons, the contraceptive benefits warrant easing of the restric­
tions for IUD use. Others believe that because of the possibility that certain 
medical probleris niay arise from its use, it is better to restrict the UD use to 
those women who have easy access to medical services. Still other authori­
ties believe that limited access to medical services will probably not create a 
dilemma as long as women are initially screened to eliminate those who are 
predisposed to risks. 
One of the main concerns about the use of the IUD is that women who use 
it are more likely to develop PID than women who do not use it (7). Because of 
the high rate of PID arid sexually transmitted diseases in certain parts of 
Africa 	(see Chapters 5 and 6), this association may be of major concern arid 
needs to be considered carefully. 
ABSOLUTE CONTRAIN DIACTIONS 
1. 	Active, recent, or recurrent pelvic infection (acute or subacute), including 
known or suspected gonorrhea. 
2. Pregnancy (known or suspected). 
STRONG RELATIVE CONTRAINDICATIONS 
3. 	Cervical or uterine malignancy (known or suspected), including unre­
solved Pal)smear. 




infection following an abortion that occurred
 
within the past 3 months,
 
purulent cervicitis, until controlled,
 
impaired response to infection
 
(diabetes, steroid treatment, etc.),
 
recurrent history of gonorrhea.
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1976 Alza Corp. 2.5 (Nullip) 
1.9 (Multip) 
7.5 
3.1 9.7 79.1 
Nylon tail 
*Per 100 woman years. 
5. Abnormal uterine bleeding. 
6. History of ectopic pregnancy.
7. Impaired coagulation response (idiopathic thrombocytopenic purpura, 
anticoagulant therapy, etc.). 
OTHER RELATIVE CONTRAIN DICATIONS 
8. Valvular heart disease (potentially makes patient susceptible to subacute 
bacterial endocarditis; some clinicians recommend prophylactic antibio­
tics in this situation).
9. Abnormal uterine shape (leiomyomata, endometrial polyps, bicornuate). 
10. Cervical stenosis. 
11. Small uterus. 
12. Severe dysmenorrhea." 
13. Severe menorrhagia." 
14. Anemia. 
15. Past history of severe vaso-vagal reactivity or fainting.
16. History of impaired fertility with desire for future pregnancy. 
17. Endomelriosis (possible). 
18. Allergy to copper (known or suspected) or diagnosed
 
Wilson's disease (copper ILID's only).
 
TYPES OF IUD's 
There are two types of IUD's: those that are medicated and release hor­
mones or copper and those that are not medicated. The IUD's currently
available in Afrirm are shown inFigure 13.1 ; their physical characteristics are 
outlined in Table 13.1. 
"Lippes Loops', are tIhe most commonly used IUD's throughout Africa.
They come in either prepackaged sterile units or in less expensive packages
containing 100 Loops that must be sterilized with an iodine (1:2,500 for
Betadine(!.) or benzalkonium antiseptic solution for a period of 30 minutes 
before use. 
"Saf-T-Coils come in separate, sterile packages that contain an IUD, an
inserter, and, in some instances, a plastic sound. They are easy to insert and 
remove. Insertion may be done by either the plunging or the withdrawal tech­
nique since the outer plastic ring on the inserter barrel isadjustable. The inser­
ter barrel is a bit narrower than the Lippes Loop ' inserter. 
**The Copper-T" (or Tatum-T ,,) is more popular than the Copper-7', in 
most areas of Africa. This IUD comes in presterilized packages. Insertion is
accomplished using the plunging technique in much the same manner as is
used for the Lippes Loop 1.At first, it is difficult to fold the upper limbs of the 
"T" down into the inserter barrel; but this becomes easier with practice.
*The Copper-7- (or Gravigard") comes in separate presterilized pack­
ages with an inserter. Insertion may be done by the push technique or by the 
Progestasert IUD may be thearpeutic. 
Known tobe available in Africa 
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withdrawal technique, as the cervical stop oil the inserter is adjustable. TheCopper-7' has the narrowest inserter barrel mechanism of all IUD's. Apr,.oxi­
mately halfway through the actual insertion by tile withdrawal technique (or
after a snap is felt when the Lipper limb of the Copper-7 pops out of tileinser ti tube), the insertion rod may ie gently pushed Lip toward the top ofthe funIdus to ensure higlh fmndal lacemert. The withdrawal technique is
then completed. This IUD appears to be used most in francophone Africa.
*The Progestasert-T comes in separate presterilized packages and has awide inserter barrel diameter at the end narest the nonmovable plastic
.'~I~:lt-e. The inserter narrows clown so that the end that must go through
the internal cervical os is a good bit narrower. The Progestasert -T must be 




G iavigard Proesasur -T' 
Copper-T '"or 
Taue tL" 
FIGURE 13. 1 Five IUD 's corren tly a vailable in A frica. 
FACTORS TO CONSIDER IN CHOOSING AN IUD 
In selecting an IUD, it is importan ... ,emenber the following: PROBABLY
THE SINGLE MOST IMPORTANT FACTORS ARE THE COMPETENCE OFTHE DOCTOR, NURSE, OR MIDWIFE AND HIS OR HER FAMILIARITY WITH 
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THE !UD SELECTED. It is better to master the use of one type of IUD than to 
use all of them with less competence. Table 1 3.3 is designed as a guide for 
clinicians in choosing an IUD. It is based on the assumption that all of the 
IUD's mentioned are available to the clinician and that the clinician is conmpe­
tent at inserting all IUD's. 
IUD's can be inserted by a broad rang.e(1of traned (IersoieL Studies from 
developed and develop)ing CoLinitres show tlhit riSC;S, rnnse-mrdwives, pihy­
sician assistants, paramedical personnel, ond even Inial village riidwives can 
perform rontine IUD insertion (8,9). Careful analyses have demonstrated that 
the apparent difference ii performance between one IUD and another is 
often not as great as the differencus between one clinical center and another. 
This means that the skill of the IIJD iserltr, the (juality of counseling, 
selection, rea.ssLirance, and follownp are l iruhably more importanl thail IstruiC­
tural differences between IUD's. Fhere is debate as fi) how miany IUD's a 
nurse or midwife might insert before she is competent to insert IUD's iin a 
rUral health setting; howevr, it is prot),l)ly wise to hrave pIetormed 15-20 in­
sertions before Joiig out on one's own. A pirMIr who has inserted oinly four 
to six IUD's most likely will rlot liive ra.i sot t1icii expeUrie ce with difficult ill­
sertions to start wor king tiu )upervisel- iii ,i clhnic 
INSERTION OF THE IUD 
When during the ineestrnal cycle should the IUD b inserted' Just about 
any time r:rin tll cycl -- inltess l)re(ng ancy is possiblh If pregnancy is a 
possibi!ity, IU) risertlii)i slhoulM be delayerd until the next menstrual flow, 
Vhich usually indicates that the wormi is not plegirarit (10O) 
MUST A WOMAN BE MENS [RUA I-ING IN ORDER 10 HAVE AN 
IUD INSER FED? NO! IUD's MAY BE INSERTED FOR WOMEN 
WHO ARE NOT MENSTRUATING (see Fignre 102). A womnin 
who is NOT inonstrmaing may rave al IU Inserted ill the follow­
ifg situations. 
- If she is i)ost pitull, Ifls hald nio irlenses, ami( frls ilot had 
sexual iriterciurse since delivery of her haby 
- If she is post I)irtui arid has hard nt(ofcor1e which was 
protected every time try condoris oi vrgiial i;pelmicides. If 
the Uter us is colsi( r d to be rord ro, rmiy wantt mw to 
perform a prewgraircy 'Ic,! Il Ir1 .;iuNitio to detelnine if 
sthe is pregiai 
- If a llrlemist rtiatillj WOian haSI tint hil !;(xNIr irit.rciuirse 
since her last il e si.( 
- If a wom inmFurs heni risil I h fith comith(l Pills consistently or 
another method roeliahly, one nay 'iset air IDI) on any day 
of the cycle. 
- Immediately aft er he, mineiis . 
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TABLE 13.3 Choosing an IUD for an individual patient 
Questions to help determine which IUD to use 
Is the patient using the IUD for termination 
of childbearing or for spacing of children' 
Has the patient ever been pregnant? 
Does patient have history of painful or 
heavy menses? 
Assumptions: 
'I) Cu-7",Cu-T".Progestasert-T Lippes Loop-, and Saf-T-Coil' are available.(2, Clinician is competent and familiar with insertion technicLue for each of these IUD's.(3) Patient and clinician have decided that an IUD is the method of choice. 
(4) No contraindications to IUD use exist 
(5) The IUD is an option for some nulligravid w.nmen 
Answer to question for 
the individual patient 
Termination Iwants no 
more children), 
Spacing. 
No, nulligravid patient. 
Yes: il) post-therapeutic
abortion 
12) post full-term 
delivery, uncomplicated. 
(3) post full-term 
delivery, C-section. 
Yes, painful menses. 
IUD(s) which may be used or should not be used 
Use an IUD that need not be removed and replaced at 
any set interval Lippes Loops or Saf-T-Coils may be left in 
place deflnitely in the absence of complications. The 
12-month limit on the Progestasert-T' is a strong de­
torrent to Is use on a routine 
P! IUD's acceptable 




faciltate IUD insertion. 
3.07 mm 
3.76 mm 
Consider using a paracervical block but carefully ob­
serve toxic hrlnits of agents used. 
Use fairly small or medium-sized IUD: Cu-7 . Cu-T',small or medium-sized Saf-T-Coil'. Lippec Loop A ' or 
B orC . 
Most !UD s a cceptable. 
Consider using an IUD which may be inserted using 
withdrawal technique rather than expulsion technique: 
Saf-T-Coil- or Cu-7 -. Lippes Loop is perfectly suit­
able after careful sounding of uterus. 
Consider using Progestasert-T'. Be sure not to insert 
too large an IUD. 
Questions to help determine which IUD to use 
How large is the uterus? 
Are there other social, medical, or 
personal factors which might indicate 
or contraindicate using a specific IUD? 
Answer to question forthe individual patient 




Uterus sounds less than 
4.5 cm. 
Uterus sounds 4.F-6.5 cm. 
Uterus sounds 6.5-9.9 cm. 
Uterus sounds 10.0 cm or 
more. 
Allergy to copper or his-

tory of Wilson's disease.
 








Patient wiil have 
difficulty returning for 
annual exams. 
Patient specifically 
requests a certain IUD. 
IUD(s) which maybe used orshould not be used 
Consider using Progestasert-T'. Of other IUD's, Cu-7
 
and Cu-T' may produce less augmentation of
 
menses than Lippes Loops or Saf-T-Coils '.
 
No current IUD lkely to be well tolerated. 
Use IUD with vertical length less than 3.0 cm; small

Saf-T-Coil- is 2.2 cm long.
 
Most fUD's accrp hie. 
The large Saf-T-Coil , largeLippes Loop Cu-7S,
 
Cu-T', Progestasert-T5 . Strongly urge backup
 
method of contraception. 
Avoid use of Cu-7" or Cu-T'. 
Use Cu-7 or Cu-T. 
Use a more rigid IUD, such as a polypropylene Lippes Loop5 . 
If too large an IUD has been used in small uterus, mayneed smaller IUD.

i; too small an 
 IUD has been used in large uterus, may 
need larqer IUD.
The Progestasert-T has been used with some success 
fo!lowing multiple expulsions of other IUD's. 
Avoid IUD which must be rep!aced at certain intervals 
,;uchasCu-7 -Cu-T .orProgestasert-T-. 
Try to provide the Z.Z;-.'- patiert requests. Never use 
an IUD the patient specifically does not want. 
*Cu-7 Copper 7 *Cu-T = Copper T 
IFYOUR EXAMINATION 
AND TEST SHOW 
THAT YOU AREN'T I HESO. 
PREGNANT, E'LL A FMIL EPY'ICISEPT THE IUD S AYPLAY7 TODAY JUNY 
SERFpCLINIc A 
T KiIo M 
FIGURE 13.2 If you can determine that the woman is not pregnant, an IUD 
cat be insertdevn if she is n s syat ­struating 
IN RURAL AREAS OF AFRICA AND IN SOME URBAN CLINICS, WOMEN 
MAY NEED TO TRAVEL A LONG TIME TO GET TO A FAMILY PLANNING 
CLINIC. THE INCONVENIENCE TO TIIE PATIENT CAUSED BY A POLICYTHAT DICTATES WHEN IN THE MENSTRUAL CYCLE IUD'S ARE TO BE IN-
SERTED CAN BE AN IMPORTANT OBSTACLE TO LAUNCHING AN EFFEC-
TIVE IUD PROGRAM. 
Case History: A patient who was 3 rion ths post parti1 carne to the family
planning clinit wanting to ose an IUD as her method of birth control. She
had been 1urSill(, tier bahy, anid she had not had sexual intercourse. Phlysi­
cal examini on revealed that thle Uiternus was firm and nonitenider and was
invoIltino( well. Oin the basis of the above history, thle decision was made 
to insert anl IlJ D.The insertion was easy as the post-parturni period is a par­
ticul)arly easy time to insert an IUD. Tile p~atient was provided with anl ap­
pointment for 6 weeks later at which time the( st rings to thle IUD were seenl 
at the cervical os. There was no uterine tenderness. I-lie woman's mienlses 
retuirned at 11 mlonlths 1)ost I)artuLn1. 
ONE MUST TRUST THE HISTORY GIVEN BY WOMEN IN A FAMILY PLAN-
NING CLINIC. THIS IS A BASIC PRINCIPLE IN PROVIDING THOUGHTFUL,
DIGNIFIED FAMILY PLANNING SERVICES. 
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Move slowly and gently during all phases of IUD insertion. Refer to Figure
13.3 for the minimal equipment required for IUD insertion. Insertion differs 
slightly for the various IUD's, depending on the size and shape of the IUD and 
uterus (see Figure 13.4), the inserter barrel and plunger, packaging, and the 
strings. The following are instructions that would apply to inserting all IUD's. 
FOR CURRENT INFORMATION, ALWAYS READ THE INSTRUC-1 
TIONS ON IUD INSERTION WRITTEN BY THE MANUFACTURER 
1. Explain the procedure of IUD insertion to the patient to help her relax. 
2. 	 Perform a careful birmn lal exam to rule out pregnancy and active pelvic
infection and to diagnose the position of the uterus. When the tract of IUD 
perforations is located, it is almost always at 900 to the axis of the fundus. 
When the uterus is retroflexed-and this is not recognized-there is a 
greater possibility of uterine pe,foration at the time of IUD insertion. 
3. After inserting a warm speculum (see Figure3 13.5 and 13.6) and viewing
the cervix, wash the cervix several times (three or more) with an antiseptic
solution such as a 1:2,500 solution witl iodine. If iodine is present in the 
antiseptic solution, ask the patient if she has a history of allergy to iodine. If 
she does, then use a benzalkonium chloride solution, hexachlorophene 
solution, or saline solution. 
4. 	In some instances, intracervical local anesthesia may be injected at this 
point. 
5. 	 Grasp the anterior lip of the cervix with a tenaculum about 1.5-2.0 cm 
from the os. Close the single-tooth tenaculum slowly, one notch at a time. 
Use of a teflaculum is not always necessary, but it may be very helpful if 
there is stenotic internal cervical o, OR if there is sharp flexion of the 
fundus anteriorly or posteriorly. 
6. 	 Sound the uterus slowly and gently. Place a cotton swab at the cervix 
when the sound is ill tile way in. Remove sound arid swab at the same 
time. This permits measurement of the depth of tile fundus to within 0.25 
cm. 
7. 	 Load th;n IUD into tile inserter barrel under sterile conditions. 
8. 	Apply 'teady, gentle traction on the tenaculurn, and introduce the inserter 
barrel through the cervical canal into the fundus. 
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THE TWO CARDINAL RULES FOR IUD INSERTION: 
1. EVERYTHING DONE AT THE TIME OF IUD INSERTION CAN BE 
DONE SLOWLY AND GENTLY. 
2. EVERYTHING DONE AT THE TIME OF IUD INSERTION 
SHOULD BE DONE SLOWLY AND GENTLY. 
Alliqat oi F or cps 
" .... ... . T enal




UtWi ina SoUnd 
FIGURE 13.3 Minimal eq,ipment for IUD insertion. 
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FIGURE 13.4 IUD fit for asmall uterus, the Copper- 7", andSaf-T-Coi[,. 
I-gihr 

B"  -- " x
KitIt-it,-t" - ' :' lV' 
Pilirc i gbm - rI ring (g:nccyX 
Vowf i \m 
FIGURE 13.5 Side view of the pelvis. 
-- - h t~ h ood 
FIGURE 13.6 Cervix and os as seen through the speculum. 
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9. 	Insert the IUD into the cavity of tie uterus by either plunging the inner 
plunger into the outer barrel (push technique) (see Figures 13.7 and 
13.8) or by retracting the outer barrel over the )lunger (withdrawal 
technique). [he withdrawal tecnlliquie is slightly preferred. Insertion 
should he done slowly and is usually i)osible without Iruch foCe. (See 
box oii post-partLIll insertion of IUD.) 
10. Clip the strings. Leave about 5 cm (or Int er it hem dloe immediately 
after an ahorton).It /s a/ways possible to trim strings at a later date. 
11. Some clinicians have the platient feel for the strings of her IUD before she 
leaves the ex;iiirin] room. InIailly case, this proceilure he explainedcan 

is pal t i the couin:elqllo reirct(!,;!; after the insertioll
 
12. Caution sholuild he eier Ct. vvher IiS ttlI() liDS for rIIllipIriNus women 
as they are ioe likely to exl)leerce vaso-vmi;il attacks and l)ostinser­
tion pain rrecessitatinql imrlnediate rerirvil of the IUD These problems 
are liore cominmlii t)ln rIll'parnrrIu WOMrl who have arxiety, at narrow 
cervicall carril, a simll titerirre cavity, ai eml)ty stomach, or a history of 
syrcolal attacks Geiitleiress, t:aretul exllaiation, a warml and friendly 
environmnllt, use of a .irrall bivalve speculuir, moving slowly, and jLdi­
cious use of parIcervical iri.nstlhesia may he of hell) in avoiding these two 
problerirs. Since the _il)Ipes Loo ) is the no1110widely used IUD ill many
African countries, we have iocluded tIre fOllowirrg inrstLuctions for 
insertion. Its insertion is; usually done fly tI pliuIn'll technique, as the 
plastic plhalantle on the inserter barrel is fixed. Insertion is usually fairly 
easy to teoich removing the entire strinl from the inserter Iarrel is very 
inlportat if a 4.- to 5-cm tail is qoiill he left (f-5(rll out from cervicalto 
os) tie strrlul is cut by some cliniiciaons al tIe trlle the Lilpes Loop' is 
(Irawil nto the inserter, mid hefore ilsertlnll. ihis inSLres cuttillg the 
sttlnq il it llrrlxilral lerrgtli 1h inr;sertion ali)llratus may he reused by 
washing the outer iilserlor barrel anid the ruler pltntler and placinlg them 
111to tre sare solritiOll as used for slerilizing the Lippes Lo I) 
(21 
(3) 
FIGURE 13. 7 Pulling Lippes Loop-, through use of strings, into insertion 
nechaisn. 
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FIGURE 13.8 Lippes Loop'" being inserted into the uterus using the plunging 
technique. 
PARACERVICAL ANESTHESIA OR PARACERVICAL BLOCK 
Some procedures performed in a family planning clinic are painful, and 
local anesthesia may be used. A paracervical block using no more than 4 ml 
of 1"o lidocaine without epinephrine is recommended to prevent pain from 
IUD insertion or difficult removal. PARACERVICAL ANESTHESIA IS PARTIC-
ULARLY BENEFICIAL AT THE TIME OF INSERTION IF THE WOMAN HAS 
NEVER BEEN PREGNANT OR IF A WOMAN HAS A HISTORY OF VASO-
VAGAL REACTIONS. Because of the possibility that the local anesthetic may
be 	mistakenly injected into the vascular space, paracervical blocks should 
only be performed where facilities are available for resuscitation. Remember 
to ask the patient if she has any known allergies, especially to iodine or any 
local anesthetic. 
A suggested procedure for performing a paracervical block follows: 
1 . Following bimainual pelvic examination, the clinician inserts a speculum 
into the vagina to obtain good visualization of the cervix. 
2. 	Clean the cervix and vagina witl, antiseptic soaks. 
3. 	Ask the patient to inform you if she experiences nausea, dizziness, ringing 
of the ears, or tingling of the lips from this procedure.
4. Apply the tenaculumn to the upper lip of the cervix. Before doing this, some 
clinicians inject 1-cc of lidocaine at the tenacUIlurn site. 
5. 	 Different clinicians use different placements of injections around the 
cervix. ONE TECHNIQUE IS TO INJECT 1-2 cc OF 1", LIDOCAINE AT 4 
O'CLOCK AND ANOTHER 1-2 cc AT 8 O'CLOCK (A TOTAL OF 2.4 cc).
6. 	The needle is inserted Just under the mucosa in the connective tissue. 
Since most of the smaller blood vessels and capillaries are in this region,
this method assures rapid and adequate distribution of the anesthetic. 
Aspirate lightly with each injection to avoid direct intravenous injection.
7. 	 Be aware of symptoms of toxic reactions as stated in instruction 3 above 
and treat accordingly. 
8. 	Anesthesia occurs in 2-5 minutes. 
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IMMEDIATE POST-PARTUM IUD INSERTION
 
Uterine perforation and high rates of expulsion, the major prob­
ferns associated with immediate pust-partunm IUD insertion,
 
appear to have been overcome hy hanrid insertion of a Lippes
 
Loop to which have been tied three biodegradable sutures (2).
 
These three sutures project at a 45' antgle from the Utpper limb of
 
the Lippes Loop and temporarily becone enihedded, preventing
 
expurlsion VVhile the patient is still iII the delivery room, the sterile
 
Lippes Loop held )etween the index aid middle fingers, is intro­
(Luced into the vacira, Ipast the cervix aild to the hlnLus oftihit(;t 

the uterus. Care: mLust )e taken riot to dishilace the IUD while 
directingj the 10-inch nionofilament nylon tail toward the cervix 
Kanial, et at., at the CaIro UIiversity in Egypt found a 1.2 ,expul­
sion rate at 3 months ariong 86 women provided with this IUD 
(2). Disappearance ot the thread in (4 of cases is the renaining 
enlineering plohleri with this ;Ipproich to imminediate post­
part urni 'tn t ra ,,ption :
 
SIDE EFFECTS AND COMPLICATIONS 
The rates of some of the complications from IUD use are listed in Table 
13.2. 
Eight potential complications from IUD's are listed in order of increas­
ing severity. 
SERIOUS COMPLICATIONS FROM IUD'S ARE PREVENTABLE.
 
WHEN IN DOUBT, FAKE AN IUD OU T.
 
1 Spotting, bleeding, hemorrhage, and anemia 
Approximately 15 of vonen will have their IUD's removed because 
of bleedingj 0r S)otting B3leeding is Often heavier for women with IUD's. 
They nwy experience inoe lays of hdeedin, persistent bleeding, spotting 
belween cycles, and even pallor or weakness. II addition to PID, the dif­
ferential dimniosis mist Inclu(e a1partial expulsion of the IUD, dysfunc­
tional titerlo ,bleettin (lire to inieritocrt-we imhalmice, cancer of the cervix 
or en(dllomietlmlim, c vil or uterlie polyps, aiinormal perimneropausal 
tbleedimig, leiomyo mt ),1. list) tatspottirln,a itll 
If bleeding is; ri;;trml tothe 11), here ae seveal guidelines as to when 
to remov the IUD 
as:'rlat* IfHleeding i,; ed with enihouettiti 
* Whleniever ttie paltent wants it nni.Hove(t 
* If there isan hienatociit fall of 5 
* If the patient hasa iemntoctit level of 30-32 
* If the UD has heen partially expelled 
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IRON SUPPLEMENTATION IS 	WISE FOR ALL IUD USERS WHO 
MAY BE AT RISK OF DEVELOPING AN IRON-DEFICIENCY 
ANEMIA. 
2. 	Cramping and pain 
MAY BE CAUSED BY OR 
BE ASSOCIATED WITH ... 
Sounding the uterus during the 
process of insertion 
Cramping immediately after 

insertion, for a day or so 





Partial expulsion of an IUD 
Pelvic inflammatory disease 
Severe port-insertion pain, 
vaso-vagal reaction, syncope, 
seizures, and even cardiac 
arrest (very rare) 
Too large IUD 
Spontaneous abortion 
Ectopic pregnancy 
IUD that does not unfold correctly 
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WHAT TO DO... 
Sound siowly, gently; use 
smaller sound if meeting 
resistance. 
If severe, may necessitate IUD 
removal; if mild, provide 
aspirin (2 or 3 tablets) 
or prostaglandin 
synthetase inhibitor. 
Remove IUD. If no infec ton, 
may reinsert another IUD. 
Remove IUD, treat infection 
and wait 3 months before 
cunsidering reinsertion of 
another IUD Provide 
alternative contraception. 
Atropine 0.4 or 0.5 mg 
intramuscular (or in 
paracervical block solution 
before insertion); pain 
medication; maintenance 
of cardiac output; remove 
IUD if necessary. 
May remove IUD and perhaps 
insert smaller one. 
Diagnose pregnancy, remove 
IUD, evacuate uterus, 
rule out ectopic 
pregnancy. 
Refer toi immediate surgery. 
Remove IUD and reinsert
 
or insert a different IUD.
 
Wheneve: evaluating pe!vic pair. in a woman with an IUD in 
place, it is essential to rule out the possibility of a . ectopic 
pregnancy. Vaginal discharge repeatedly surfaces as an early 
warning symptom that might have served as a clue to more seri­
ous complicatiori; 
3. IUD expulsion: partial and complete 
From 5 -20 of 100 users spontaneously expel an IUD within the first 
year (1). The symptoms of IUD expulsion may include unusual vaginal 
discharge, cramping or pain, intermenstrual spotting, postcoital spotting, 
dyspareunia (male or female), lengthening of the IUD string, ability to feel 
the hard IUD at the cervical os or in the vagina, or passage of the IUD itself 
from the vagina. IUD expulsion may cause penile pain or irritation. 
IF EXPULSION IS NOT NOTICED, T HE FIRST INDICAT!ON THAT 
SOMETHING IS WRONG MAY BE A MISSED MENSTRUAL 
PERIOD, THE SYMPTOMS OF PREGNANCY, OR INABILITY TO 
FEEL THE STRINGS OF THE IUD. 
The objective findings to look for include seeing the IUD at the cervical 
os or in the vagina, lengthening of the IUD string (partial expulsion), ab­
sence of the string (complete expulsion), inability ,o locate the IUD using 
various technirlues of probing the uterine cavity, and absence of the IUD 
on ultrasound o- on an X-ray film of the pelvis and abdomen The differen­
tial diagnosis of the lost IUD is discussed in the next section. If partial ex­
pulsion occurs, the IUD should be removed. It may be reinserted right away 
(if there is no infection and no possibility of pregnancy) or after the next 
period. If the expulsion is complete, a new IUD may be inserted. Often, it is 
helpful to try a different size or shape IUD. The Progestasert-T" may not 
be expelled when other IUD's have been expelled repeatedly. 
4. Lost IUDstrings and other string problems 
The patient may complain of on inability to feel her strings, gradual 
shortening of her strings, or irritation of her partner by IUD strings. 
However, the problem is more commonly detected during a followup visit 
to the clinic. There are two major reasons why clinicians become con­
cerned if the IUD string is no longer detectable or is lost: 
* The IUD may have been expelled; or 
" The IUD may be in the abdominal cavity. 
However, the IUD string may merely have been drawn up into the ute­
rine cavity. The clinician should attempt to locate the IUD strings to rule 
out the above two complications. Use a sonogram first (to locate the IUD) 
if the method is available. A helix can be used to retrieve the strings in 
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some cases (see Figure 13.9). Examination often reveals that the strings 
are right where they should be, in which case the patient should be taught 
in the examialation room to feel for the strings. Sometimes exploration of 
the cervical canal with a pair of narrow forceps, such as alligator forceps 
(see Figure 13.3), locates the strings immediately. Pregnancy must be ex­
cluded before further evaluation of lost IUD strings proceeds. The IUD may 
be felt with a uterine sound or removed with a variety of instruments, 
including alligator forceps, hooks, or forceps used at the time of 




 Posterior to anterior and lateral of the pelvis following insertion of a 
marker IUD 
* Fosterior to anterior and lateral of the pelvis with a metallic sound 
introduced into the uterus 
* hysterosalpingogram 
If the strings are visible, the patient shoulca be taught to feel them. If the 
strings are entirely within the endometrial cavity, it is usually desirable to 
remove the IUD and consider inserting another one, either the same or a 
different type. Because of its insertion mechanism, the Copper-7 has 
FICURE 13.9 Helix used to retrieve lost IUD strings. 
189 
more string problems than other IUD's. A lost, shortened, or elongated
string needs to be interpi ated carefully. 
Clinicians need to know flw to interpret changes in string length. 
a. The "loop of string" may come out of the endometrial cavity, cause 
concern to the patient, require a clinic vsitand a pelvic exam, and re­
quire the time of a physician or nurse practitioner to trim the string.
b. If the "loop of string" comes Out and is trimmed as per "a" above, it 
may slip back up Into the uterus, lea viny the patient and the clinician 
with the pioblem of "lost IUD strings" 
c. If the clinician cannot find the lost IUD str ii i;, the patient nay need 
to be hospitalized to locate or remove the IUD. This is of particular
importance with copper-bearing IUD's. 
d. When the !UD string that comes out of the cervical os lengthens,
usually "a" (above) has occurred, i.e., the intrauterine "loop of
string," originally drawn up into the uterus, has come down from the
uterine cavity. This has generally been found to be more common 
with the Copper-7 SOMETIMES, HOWEVER, THIS IS THE 
WRONG INTERPRETATION, and what has actually happened is tnat 
the IUD has been partially expelled into the cervical canal. If a misin­
terpretation oc,:tis, the string may be trimmed and the patient sent 
out of the oftic willh a PARTIALLY EXPELLED IUD. PREGNANCY 
MAY OCCUR AS A RESULT OF THIS MISINTERPRETATION. 
5. IUDremoval 
Removal of the Copper-7 is occasionally difficult because it has a
sharp angle that must be drawr thriugh the internal cervical os. It may be
complicated if the string lops over 'the top of the Copper-7 IUD (see
Figure 13.10). Removal may be painful. Unless emcedded, Saf-T-Coils"and Lippes Loops are associated with moderate to minimal pain or
cramping upon removal. Ifa woman has had her IUD in place for 5 or more 
years, pain tends to he slightly worse because of embedding or narrowing
down of the cervical canal. THE FOLLOWING TECHNIQUES MAY HELP IN 
THE REMOVAL OF IUD'S: 
a. Removal during menses is somewhat easier 
b. AVOID BREAKING THE STRINGS BY APPLYING GENTLE, STEADY 
TRACTION AND REMOVING THE IUD SLOWLY. If the IUD does not 
not come out easily, sound the uterus for 30 seconds and then 
rotate the sound 90" slowly. 
c. If gentle traction still does not lead to IUD removal, dilate the cervix 
with dilators (which should always be available in a clinic managing
IUD complications). A paracervical block may be performed before 
cervical dilation to diminish pain. The cervix may also be dilated for
difficult IUD removals through use of a laminaria tent. Use of a tena­
culumn to steady the cervix and straighten the anteversion or retro­
version may assist renoval. 
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d. If the strings are not seen, probe for them in the cervical canal with 
narrow forceps. 
e. When the IUD (witn or without its strings) is in the uterus, the eildio­
metrial cavity may be probe.,d with alligator forceps (with which thestrings or the IUD itself may he grasped), a hook. uterine packing
forceps, or a Novak curette Proficiency at enoval of the ILID with one of these instruIments wlhen the strings are absent or enirelywithin the uterine cavity can prevent unnecessary hospitalizations.
If a woman has had Jntercotuse at nlidcycle and the IUD was her onlymeans of contraception, ther iwfova', of that IUD may resull il inplanta­
tion fo!lowing a conception that has already oscurred. Therefore, an IUDshould usually [iot be reIMo1JIed in midcycle it ihe woman has had 1iler­course in the last 4-5 days, Io'.eSS foam or co-n-iis were used as abackup rnethod. If the woman has serious pelvic in flanImatory disease, it may be considered best to remove the IUD right ;Avway even if this increases 
her risk of pregnancy (see Figure1 3.1 1) 
6. Pregnancy with IUDstill in place
Approximately one-third of IUD-related pregnancies are attrihutable toundetected partial or complete expulsions. But pregnancies may occur 
even if the IUD is in utero. 
'I 
FIGURE 
A kink in the 
13. 10 Potential problem in removin.y the Copper- 7. 
upper limb of the Copper-7 is caused when the "loop of string" whichcomes out of the inserter barrel remains in p/ace over the upper limb of theIUD. At the time of removal, pulling the string forcefully distorts the IUD inthe manner shown above. When this occurs, the remova/is very painlul. 
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FIGURE 13.11 Remove the IUD with the first episode ofpelvic inflammatory 
disease. 
Pregnancy is one of the important complications that can occur with an 
IUD in place. There are two important reasons why the IUD should be re­
moved if pregnanc is diagnosed. First, there is approximately a 50% 
chance that a spontaneous abortion will occur if the IUD is left in place. 
This compares with approximately a 25' chance if the IUD is removed 
(11 .The second reason is the possibility of serious infection. 
When pregnancy is diagnosed and the strings of the IUD can be locat­
ed at the cervical os, the IUD should be removed immediately. If strings 
are seen, remove the IUD with gentle traction, telling her that there is 
about a 25", chance of a spontaneous abortion and informing her to 
return should bleeding, cramping, or signs of infection he noted (2). 
If the patient wants to continue the pregnancy and does not want her 
IUD removed, she should be warned that (1) the risk of a spontaneous 
abortion is increased two- or threefold with the IUD in utero (to about 
50%); (2) the likelihood of her pregnancy being ectopic is about 5%; and 
(3) the risk of a septic spontaneous abortion may be increased. The com­
bination of infection and pregnancy, although very rare, is potentially 
fatal for an IUD user (1). In a pregnant woman with an IUD in place, some 
infections do not begin with the more typical symptoms (pain, discharge, 
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bleeding) but may present with nonspecific flu-like symptoms, such as 
fever, myalgias, headaches, nausea, cr vomiting. The clinician must 
remember that a high percentage of these pregnancies with IUD's in 
place are ectopic (5'), and therefore the tissue should be caiefu!ly exam­
ined at termination. 
FLU-LIKE SYMPTOMS PLUS PREGNANCY IN A WOMAN WITH 
AN IUD VERY LIKELY MEAN SEPSIS. THINK "SEPSIS" NOT 
"FLU" WHEN A PREGNANT WOMAN WITH AN IUD PRESENTS 
WITH FEVER, CHILLS, MYALGIA, AND HEADACHES. 
7. Uterine perforation, embedding, and cervical perforation 
The exact incidence of uterine perforations varies greatly from program 
to program and from clinician to clinician. It is further complicated by the 
fact that perforations are often "silent,' occurring without bleeding or 
pain (other than the several hours immediately after insertion). Rates of 
perforation vary widely with the type of IUD and the expertise of the 
inserter. At the low end of the spectrum are the Copper-T" and the Lippes 
Loop,'"; the Dalkon Shield' is at the high end of the spectrum. Many provid­
ers of Lippes Loops'- say the incidence of perforation is about 1 in 2,500 in­
sertions (5). The symptoms of uterine perforation may include pain at the 
time of insertion, gradual disappearance of the IUD strings over several 
weeks to several months, bleeding after the insertion, and pregnancy. Ob­
jective findings include the absence of IUD strings, inability to withdraw 
the IUD if the strings are still present, and demonstration of the displaced 
IUD by radiology, hysteroscopy, or ultrasound. Cervical perforations may 
occur as an IUD is being expelled, and the IUD may be seen at the time of 
the speculum exam in one of the fornices. If the IUD is perforating the 
cervical canal, it may be grasped with alligator forceps, pushed back up 
into the endometrial cav.ty and then removed through the cervical canal. If 
the IUD is embedded in the uterine muscle (or is partially perforating the 
uterus), it may be possible to remove the device using the techniques de­
scribed above. If the IUD is extrauterine and the patient is not pregnant, 
removal of the IUD with a laparoscope or following a laparotomy is usually 
feasible. If there is a pregnancy, it may go to term before the exact location 
of the IUD is known. Uterine perforation with the Dalkon Shield may be 
particularly treacherous, as this IUD may be missed completely on an 
X-ray examination of the pelvis, particularly in an obese patient. While the 
Dalkon Shield" has been removed from the market, there are still some 
shields in place in women. 
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8. Pelvic inflammatorydiseases 
These are the most serious complications related to IUD use. Thesymptoms caused by pelvic inflammatory disease, objective findings, thedifferential diagnosis and its treatment are outlined in detail in Chapter 6. 
PREVENT CHRONIC PELVIC INFLAMMATORY DISEASE: 
REMOVE THE IUD WITH THE FIRST SIGNS OF PELVIC INFLAM-
MATORY DISEASE. 
Generally it is best NOT to try to treat pelvic inflammatory diseasewith the IUD in place, in spite of the fact that this is possible in someinstances. If the IUD is left in place, followup maybe inadequate and asmoldering infection may persist that can progress from endometritis 
to a more generalized infection. In this way the more serious IUD-related
problems, such as tubal occlusion, abcesses, peritonitis, and sepsis, maybe more likely to occur. Once an infection has occurred, it is wise to wait 3months before reinserting a second IUD. Some recommend waiting a
full year following one episode of pelvic inflammatory disease before rein­serting an IUD. Following an episode of pelvic inflammatory disease,women wanting sub'.,Cluent children should be encouraged to use amethod other than an IUD. Pelvic infection and pregnancy may be ex­
tremely dangerous as noted in Chapters 6 and 8. 
Some physicians and nurse practitioners do try to treat pelvic inflam­matory disease while leaving the IUD in place. If this is done, be sureto give
a full 10-14 days of antibiotics arid reexamine the patient at 10-14 days. 
A CHRONIC FOUL VAGINAL DISCHARGE IN AN IUD USER IS
PELVIC INFLAMMATORY DISEASE, UNTIL PROVEN 
OTHERWISE. 
WHAT SHOULD A PROGRAM DO AT THE TIME OF AN IUD INSERTION
IF 10% OR MORE OF WOMEN IN AN AREA HAVE A POSITIVE CERVICAL 
CULTURE FOR GONORRHEA? 
There are areas of Africa where 110-15" of all asymptomatic women
have a positive cervical culture for gonorrhea (12). This raises an important 
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question as to what practices should accompany the ,nsertion of IUD's in this 
setting. Several approaches come to mind: 
1. 	One approach would be to culture all women for gonorrhea, have the 
patient return at a sutl)seuerlt date, and insert tile IUD when it is deter­
milled that the culture is negative. If women travel from afar, however, 
this approach may not be practical. 
2. 	 The very mininum that should be done in a setting where gonorrhea is 
very common is to carefully evaluate the patient clinically for signs of 
gonorrhea. This would include questioning the patient about pain 
during irtercourse, lower abdominal pain, and the presence of a vaginal 
discharge in recent dais or weeks, and then looking carefully on physi­
cal examinaLion for possible signs ol infection suAch as lower abdominal 
pain, pain on cervical motion, and purulent discharge. Al IUD should 
not be put in if there is presence of lower -bdominal pain, of course, 
and, in general, shouloC not be put ill if the woman has a purulent dis­
charge suggestive of gonorrhea. 
3. 	A third approach would be to insert the IUD if there were not any appar­
ent contraindications, take a culture at the time of insertion, and have 
the woman return for treatment and possible removal of the IUD if the 
culture is positive. This approach can he used where adequate facilities 
and supplies are available. Ii areas where pelvic inflammatory disease 
and sexually transmitted diseases are prevalent, clinicians should care­
fully screen potentiai IUD users. If screening is not practical, then the 
contrac3eptive benefits of the IUD should be carefully weighed against 
the reproductive health problems that may arise. 
4. 	In the future, several technological advances might provide IUD's with 
advantages narticularly important in an area with a high infection rate. 
An IUD that would elaborate a progestin for 6-10 years (this would de­
crease menstrual blood loss and produce a thick, difficult-to-penetrate 
cervical mucus) might diminish the risk of infection (although this 
possibility has not been confirmed). Al IUD which would release an an­
tibiotic capable of killing gonorrhea organisms might have certain 
benefits. A tailless IUD might deter ascent of gonorrhea organisms 
along the cervical string of the IUD. A tailless IUD may reduce the risk of 
pelvic inflammatory disease by eliminating the pathway for bacterial as­
cension into the uterus (see box). 
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THERE IS A CAFS~ FOR TAILLESS IUD's (13-14) 
Two recent reports from England indicate that the endometrial 
surfaces of IUD users may contain bacteria if the IUD has a thread 
attached which reaches down through the cervical canal into tile 
vagina. This finding directly contradicts uarlier findings of Mishell, 
et al., who found tile endonietrial cavity to be sterile if the device 
had been in place for more than 30 clays. Sparks, et al., examined 
the uteri of 50 women riot using IUD's following hysterectomies 
(15). All uterine cavities were sterile. However, bacteria were cul­
tured from the endometrial surfaces o, 14 out of 16 uteri re­
moved from IUD users who had no clinical pelvic inflammatory 
disease. No bacteria were isolated from the endometrial surfaces 
of four women using IUD's that had no tails. 
For an individual physician or a program to c')nsider use of tailless 
IUD's, the clinicians following patients must have the necessary 
equipment and competence to remove IUD's that have no tail 
hanging down through tte cervical os. 
If all IUD is inserted in an area where rates of gonorrhea are high, it is par­
ticularly important that women be taught the IUD danger signals (most of 
which are early signs of pelvic infection) and told to return to the clinic im­
mediately shoulc these symptonis occur. 
NONCONTRACEPTIVE BENEFITS 
Proile of Patients Who Might Choose to Use an IUD
 
An IUD may be an excellent option for a woman who has had all
 
the children she wants and who, for any reason, finds steril;zation 
(male or female) an unattractive choi.e or difficult to obtain. 
An IUD may be agood choice for the woman who has a fear of 
the Pill, cannot remember to take them, has difficulty in obtaining 
additional supplies, or has had a complication from Pills. Safe,
effective, long-term use an canof IUD be recommended to a 
woman who has no history of pelvic inflammatory disease, has 
only one sexual partner, and, preferably, if she has access to 
medical care shouid she develop one of the IUD danger signals. 
With the exception of progesterone-releasing IUD's which tend to de­
crease menstrual blood loss and dysmenorriea, IUD's have relatively few 
noncontraceptive advantages. IUD's have beer, employed to prevent adher­
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ence of the two walls of the uterus by synechiae (Asherman's syndrome). 
Clinicians have also noted that women with post-Pill amenorrhea may begin 
to menstruate fairly regularly after IUD insertion. 
INSTRUCTIONS FOR PATIENTS RECEIVING AN IUD 
YOU ARE ITHE CAPTAIN OF YOUR OWN HEALTH TEAM; YOUR 
IUD IS YOUR IUD; LEARN THE IUD DANGER SIGNALS WELL 
(See Figure 13.12) 
Before you have your IUD inserted, here is d suggestion that may be of 
help to you: 
Some women have a fair amount oi pain or nausea immediately after 
their IUD is inserted; if you are going to have to walk a long distance 
after your IUD is inserted, you may want to cone to the cliiiic with 
your husband, partner, or friend, in case you need someone to assist 
you. It is preferable to return home ' y vehicle when possible.
 
After your IUD has been inserted, here are six important instructions:
 
1. Before you leave the office or clinic, it is important to learn how to feel 
the strings that protrude 2 inches or so into the vagina. Your IUD Inay 
not be working if you cannot feel the strings or if you can feel the plastic 
part. If this happens, use an1ther method Lntil you can get to the clinic 
to have your lUD checked. 
2. 	You can expel an IUD without knowing it. Check for the strings fre­
quently during the first months you have the device, then after each 
period or any time you have abnormal cramping while menstruating. 
3. 	Nuisance side effects of the IUD most commonly reported are in­
creased menstrual flow, menstrual clamping and spotting, and in­





FIGURE 13. 12 Early IUD danlersignals. 
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IUD, you can always have it removed. Heavier menstrual bleeding may 
be serious if you are anemic. However, a small increase in the menstrual 
flow is normal with the use of an IUD, especially during the first two­
three periods. 
4. 	If at any time after getting an IUD you have fever, pelvic pain or 
tenderness, severe cramping, or unusual vaginal bleeding, contact your 
doctor immediately. These may be signs of infectioi. Infections from 
IUD's can be very serious and, if untreated, can lead to hysterectomy 
(removal of the uterus) or even death. 
5. 	 If you miss a menstrual period, con tact your family planning worker 
immediately. 
6. 	Do not remove an IUD yourself, Jnfd do not let your partner pull on the 
strings. lhe clinician will have a better idea of the angle at which it went 
in. It should come out the same way. 
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DIAPHRAGMS AND CERVICAL CAPS 
The growing interest in vaginal contraceptives among women 
has not found its counterpart in the medical profession. Many 
physicians ha ve lit tle experience in the fit ting of diaphragms and 
even if they have such experience, theyimay consider the time re­
quired for proper instruction of the patient excessive and 
nonremunera tive. 
Christopher Tietze, 1981 
THE DIAPHRAGM 
HISTORY, EFFECTIVENESS, AND MECHANISM 
OF ACTION OF THE DIAPHRAGM 
HISTORY 
Invented in 1838 by the German physician Dr. Frederick Wilde, diaph­
ragms made of rubber were popularized in the early 1880's when they were 
dramatically described in Germany by C. Hasse, writing under the pseudonym 
of Wilhelm P.J. Mensigna. Because of its popularity in Holland, the diaphragm 
has also been called the "Dutch cap" or "Dutch pessary." A variety of chemi­
cals have been used with diaphragms in addition to the modern spermicidal 
agents including cocoa butter, vaseline, salt, and vinegar. Some societies 
have even used a partially shelled-out half lemon. The effect of the lemon and 
its acidic juice may have offered couples a means of control quite comparable 
to a modern diaphragm filleJ with spermicide. 
EFFECTIVENESS 
The diaphragm becomes a much more effective method if its use is asso­
ciated with an education program and with careful fitting and prescribing 
procedures 1-5). For maximum effectiveness, the use of a spermicidal agent 
inside the diaphragm is recommended. 
Clinical researchers have reported a wide range of use effectiveness rates. 
Failure rates following diaphragm use have ranged from 2.0 pregnancies out 
of 100 diaphragm users per year (2) to 17 pregnancies out of 100 diaphragm 
users per year (5). 
MECHANISM OF ACTION 
The diaphragm is a dome-shaped rubber cup with a flexible rim. It is insert­
ed into the vagina before intercourse so that the posterior rim rests in the 
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posicrior fornix and the anterior rim fits snugly behind the pubic bone. The
dome of the diaphragm covers the cervix, and spermicidal cream or jelly,
placed in the dome before insertion, is held in contact with the surfac:, of the 
cervix. The contraceptive effect of the diaphragm depends partly on its func­
tion as a barrier, decreasing the degree of contact between semen and the 
cervix, and partly on its function as a spernicide holder. The use of a sper­
micidal agent inside the diaphragm is essential for satisfactory effectiveness. 
CONTRAINDICATIONS TO USE OF A DIAPHRAGM 
The medical and social conditions that may make the diaphragm a poor
contraceptive choice fora woman are as follows: 
I. 	Allergy to rubber (latex) or sperrmicide. 
2. 	 Repeated urinary tract infections following its use. There is some evi­
dence that diaphragm users develop cystitis and urethritis more fre­
quently than women who use o' her contraceptives (6).
3. 	 Abnormalities sL..Il as uterine prolapse, cystocele, rectocele, extreme 
arid fixed uterine retroversion, vaginal fistulae, arid vaginal septa may
make diaphragm fitting difficult. It may be worthwhile to attempt a fit­
ting with each of the rim types availabe, but in some cases, a satisfac­
tory and stable diaphragr liacernent cannot be achieved. 
4. Lack of trained personnel to fit the diaphragi arid or lack of time to ad­
equately instruct the woman in its use. 
5. 	 Inability of user or partnir !o le iri 	correct insertion technique.
6. 	Lack of privacy for insurtion or lack &f e;nap and water for washing the 
diaphragir. 
FITTING THE DIAPHRAGM 
Diaphragns are available in a range of sizes (the size refers to the rim
 
diameter, in millimeters). Diaphragms are available in three rim styles (Figure

14.1 ) which differ in the inner construction of the circular metal rim. Products 
currently available are listed below:
 
The Flat Spring Rim is 
a thin, delicate rim with gentle spring strength. A 
woman with a very firm vaginal muscle tone (generally a nulliparous woman)
and or a sh-Illow notch behind the pubic bone arch may find the flat spring 
more corfortable than the coil or arcing rims. The flat spring folds flat for
 
insertir One example is the *Ortho-White Diaphragm , sizes 55-95, latex.
 
The Coil Spring Rim is a sturdy rim with 
a firm spring strength. Most 
women with averaqe vaginal muscle tone arid average pubic arch notch find 
the coil spring comfortable. It folds flat for insertion and can be used with a 
plastic introducer. Examples are the *Koroniex Diaphragm , sizes 50-105,
latex; the Ortho Diaphr'-grn (coil spring), sizes 50-105, latex; arid the 
"Ramses Flexible Cushioned Diaphragm (coil spring), sizes 50-95, gum 
rubber. 





FIGURE 14. 1 Three basic diaphragms currentlyavailable in Africa. 
The Arcing Spring Rim isa very sturdy rim with firm spring strength. Most 
women are able to use the arcing rim comfortably and find that when folded, 
the diaphragm's arc shape makes correct insertion easier. The arcing rim can 
often be retained comfortably despite a rectocele, a cystocele, or lax vaginal 
203
 
muscle tone. Examples include the Koroflex Diaphragm-, sizes 60-95, latex;
AlIflex Diaphragm' (Ortho), sizes 55-95, latex; and the Ramses Bendex 
Diaphragm", sizes 65-95, gum rubber. 
Some arcing diaphragms (such as the AlIflex ) fold at any point along the
rim and are slightly less sturdy than the Koroflex" (Holland Rantos) or the 
Ramses Bendex' (Schmid) products. The Koroflex and Bendex fold at two 
points only (a hinge or bow-bend construction). Many women find that the 
bow-bend rim is easier to insert because the fold creates a narrow leading
edge, and the two stiff halves of the "arc" can be held in the folded position
close to either end of the arc, whereas theAlIflex must be held in the middle. 
A woman with a retroverted uterus or a very long, firm nulliparous cervix 
may find that correct insertion of an arcing spring diaphragm is much easier 
than is insertion of a coil or flat spring type. Many clinicians choose an arcing
style for most patients and reserve the coil or flat spring types for women 
with very firm vaginal tone or those who do not find the arcing style 
comfortable. 
A common error in diaphragm fitting is choosing a size that is too small. 
Vaginal depth increases during sexual arousal (3-5 cm in nulliparous
women), and a too-small diaphragm may fail to maintain its pcsition covering
the cervix. A diaphragm that is too large, however, may also cause problems
such as uncomfortable vaginal pressure, abdominal pain or cramping, vaginal
ulceration, or recurrent urinary infection. 
The goal in fitting the diaphragm is to select the largest rim size that is 
comfortable for the patient. (See Figure 14.2.) The choice of size and rim 
FIGURE 14.2 Graduated fitting rings and ti,oir storage. Graduated fitting
rings are used to determine the correct diaphragm diameter Sample diaph­
ragms may also be used for fitting. If clinics can provide women with the di
aphragm they will be using during the clinic visit, they can practice inserting
and removing their own diaphragm under the supervision of a famiy planning 
worker 
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type will depend both on the depth of the vagina and on the muscle tone of its 
walls. The importance of muscle tone explains why the diaphragm alrnost 
always seems to be a tighter fit when it is first inserted by the clinician and a 
looser fit several minutes later, after the patient has inserted it herself and is 
more relaxed. It is often necessary to choose a slightly larger size once the 
user's insertion technique has been checked. 
Although diaphragm manufacturers produce sets of fitting rings (sample 
diaphragm rims with no dome), it is probably preferable to use whole sample 
diaphragms for fitting since the patient thencan practice insertion and 
removal with an actual diaphragm. Fitting rings are not adequate for patienis 
to practice with. Because different products differ somewhat in rim-spring 
strength, it is advisable to prescribe precisely the same brand and rim type as 
was used in fitting. Coil and arcing diaphragms are widely available; flat 
spring diaphragms may be harder to find commerciahy. Sampie diaphragms 
used for fittingj should be washed with soap and water and then immersed in 
a 70 -alcohol solution for at least 20 minutes after each use. 




The diaphragm is a very safe contraceptive (7). However, there are some 
problems that a woman may encounter while using the diaphragm. These 
include: 
1. Allergic reactions to rubber (latex) or spermicidal agents. 
2. 	 Skin irritation in the woman or her partner caused by the spermicidal 
agent. 
3. 	 A foul-smelling, profuse vaginal discharge is produced when the diaph­
ragm is left in place too long. This would occur with any foreign body 
left in the vagina. 
4. Monilia vaginitis can recur if the diaphragm is not well cleaned and dried 
between uses. (Some womeni prefer to have two diaphragms available 
to permit time for each to dry after use.) 
5. 	 Recurrent cystitis can be cused by the upward pressure of the ri'n of 
the diaphragm against the urethra 
NONCONTRACEPTIVE BENEFITS OF 
THE DIAPHRAGM 
The diaphragm and spermicide combination probably confers some pro­
tection against sexually transmissible infections. The diaphragm also may be 
used during menstrual flow to provide a barrier so that blood does not escape 
during intercourse. In addition, the diaphragm may have some protective 
effect against the development cf cervical dysplasia. 
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PATIENT INSTRUCTIONS 
You must use the diaphragm for it to be effective. 
Use the diaphragm whenever you have intercourse, even dJring 
your period. Don't try to "guess" about your fertile times. 
Plan to insert the diaphragm in plenty of time before intercourse. 
You can put it in just before intercourse or any time up to 6 hours 
beforehand. 
If you find it difficult or impossible to follow the time rules established
above, it is better to use the diaphragm anyway than to leave it in the drawer. 
1. To apply contraceptive jelly or contraceptive cream: Hold the diaph­
ragm with the dome down (like a cup). (See Figure 14.3.) Squeeze thejelly or cream from the tube into the dome (use about one tablespoon);
spread a little bit around the rim of the diaphragm with your finger. 
FIGURE 14.3 Placement of spermicides in the diaphragm. The sperm-killingcream orielygoes inside the dome of the diaphragm. It should be spread in a
smooth layerover the ent,re inner surface, including the rim. 
2. To insert your diaphragm: With one hand hold the diaphragm domedown (spermicide in the dome) and press opposite sides of the rimtogether so that the diaphragm folds. Spread the opening of yourvagina with your other hand, and insert the folded diaphragm into yourvaginal canal. This can be done standing with one foot propped up (on 
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the edge of a chair, a bathtub, or a toilet), squatting, or lying on1you­
back. Push the diaphragm downward and back along the back wall of 
your vagiia as far as it will go. Then tuck the front rim up along tile roof 
of your vagina behind your pubic bone. Once it is in place properly, you 
should niot be able to feel the diaphragm except, of course, with your 
fingers. If it is uncomfortable, then most likely it is not in the correct 
position; take it out and reinsert it. 
3. To checl< the placement of your diaphragm When it is correctly 
placed, the back rim of the diaphragm is below and behind the cervix, 
and the front edge of the rim is tucked up behind the pubic b)one. (See 
Figure 14.4.) Often it is not possible to feel the back rim. You should 
check to be sure that you can feel that your cervix is covered by the soft 
rubber dome of tile diaphragm aid that tile front rim is snugly in place 
behind your pLbi( bone. The spermicidal cream (inside the dome of the 
diaphragm) should be next to your cervix. 
FIGURE 14.4 Checking for proper diaphragm placement. To check forproper 
diaphragm placement, women should be 'aught to feel for the firm cervix 
through the dome of the diaphragm. 
4. 	After intercourse, leave tile diaphragm in place at least 6 hours, then 
remove it whenever it is convenient for you. If you have intercourse 
more than once within the 6-hour period, you may want to use an addi­
tional application of contraceptive cream or jelly each time. Do not 
remove the diaphragm: use the plastic applicator to insert fresh jelly or 
cream in front ot the diaphragm. If you wear the diaphragm 
continuously, remove and wash it at least once a day; but remember to 
allow the minimum of 6 hours after intercourse. 
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6. 	 To remove the diaphragm: Place your index finger behind the front rim 
of the diaphragm and pu!l down and ,uit. (See Figure 14.5.) Be careful 
not to puncture the diaphragm with a fingernail. If you find it hard to 
hook your finger behind the diaphragm, try a squatting position and 
push downward with your abdominal muscles. In other words, bear 
down as though you were having a bowel movement. Some women 
find it easier to remove the diaphragm by inserting a finger between the 
diaphragm and the pubic bone to break tile suction created by the di­
aphragm in contact with the vaginal wall Practice inserting and remov­
ing the diaphragm several times during the first week, until you can do 
so easily and are confident about checking its position. 
FIGURE 14.5 Removing the diaphragm. In teaching women to remove the 
diaphragm, they should learn to hook the rim with one finger and pull 
down ward. 
6. 	After you remove the diaphragm, wash it with mild soap and water, 
rinse it, and dry it with a towel. Store it in its plastic container. Do not use 
talcum powder or perfumed powder: it may damage the diaphragm or 
may be harmful to your vagina or cervix. 
7. Do not use vaseline or other petroleum products when you are using 
your diaphragm; they can cause the rubber to deteriorate. If you need 
extra lubrication, you can use contraceptive jelly or saliva. 
Tile above guidelines for using tile diaphragm have been suggest­
ed by manufacturers on tile basis of clinical judgment rather than 
studies. Keep in mind that tile published effectiveness rates are 
based on studies using these guidelines. But above all, be flexible 
so that your patients do not abandon the use of the diaphragm 
when they cannot follow tile guidelines exactly, as it is better to 
use it imperfectly than not at all. 
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THE CERVICAL CAP 
Currently, there are very few cervical caps available for contraceptive use 
in Africa. For this reason, the cervical cap is described only briefly in this 
chapter. 
The cervical c;ap is a thimbl,-snaped cuip (a miniture diaphragm with a tall 
dome) that fits over the cervix and is held in place by siction between its firm, 
flexible ri:,i and the surface of the cervix ot cervical-vgqin l junction. Cervical 
caps developed nd popularized 20 to 40 years aigo were constructed of 
silver or gold (nore recently, inpermeable plastic has beeni used), and were 
lef in place for as long as 3 to . weeks 
In some soplisticated medical centers, an Impermeable plastic cap intend­
ed foi artificial insemination Is available and Ls been used for contraception 
on a very limited basis by some chnicians More conmmonly used are soft 
robber caps, available in two styles manntafdcthured in England for contracep­
tive use. Very limited accounts indicate that some women find the firm plastic 
cap to be uncomfortable (See Figure 14.6 for the three styles.) Yet I soft 
rubber cap is not suita ble for pmoloiiged vaginal retention in most women be­
cause a stron odor develops after it has been in the vagina 24 to 36 hours. 
Miex Siwill Cai) 
' "Prenit Caviy R1ni Crtv:ial Cip 
/ \h 
VinmuhiSpurn Cap /j 
f if 
FIGURE 14. 6 Three cervical caps. 
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Manufacturers' recommendations that accompany the rubber cervical caps
suggest use of spermicide inside the cap (to fill one-third of the cup) and indi­
cate time rules for insertion and removal that are almost identical to standard 
recommendations for use of the diaphragm with spermicide.
A cap that fits snugly Unough to maintain suction between the cap rim and
the cervix or vaginal vault is chosen by trying the various sizes available. (See
Figure 14.7.) An opportunity for tile patient to practice insertion and removal
of her cap is essential. Most patients find that inserting a cap is somewhat 
more difficult than inserting adiaphragm.
Removal can also be difficult. One clinician asks each patient to try the cap
first during a low-fertility time in her cycle to verify that it remains in position 
after intercourse (8).
The "Prentif" Cavity-Rim Cervical Cap" linternal diameter-22mm,
25mm, 28mm, 31 mm) is a deep, soft rubber capwith a firm rim and agroove
along the inner circumference of the rim to provide good suction. It can be
fitted even when the cervix isquite long. (Manufactured by Lambert's, Ltd.)
The Vimule Cap" (outer dianeter-42mm, 48rm, 54mm) is a shallower,
soft rubber cup that clings to the vaginal vault rather than the cervix itself. It is
useful for women with a very shallow cervix or cervical scarring.
(Manufactured by Lambert's, Ltd.)
The Milex Sperm Cap' (internal diameters-28mni, 30mm, 32mm,
34mrii, 36ram, 38rm) is a very firm, impermeable plastic cup.
(Manufactured by Milex Products, Inc.) 
FIGURE 14. 7 Cervicai cap in position co vering the calv*x. 
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With relatively high quality condoms now available, the major
problem in effectiveness is clearly not the condom itself, but the 
user, who should be encouraged to be wore consistent and care­
ful in contraceptive practice if he wishes to pre vent pregnancy. 
JohnJ. Dunum, Phyllis T Piotrow, 
and/sabelA. Dalsimer 19 74 
HISTORY, MECHANISM OF ACTION, 
AND EFFECTIVENESS 
HISTORY 
Mechanical harriers coverinc the penis have been used for centuries for 
protection against pregnancy and infection, for decoration, and occasionally 
to produce penile or vaginal Stimulation. A sheath worn over the penis can be
traced back as far as 1350 B.C., when Egyptian men wore decorative covers 
for their penises. The great Italian anatomist Fallopius described the use of 
linen sheaths in 1564. Protective devices from animal intestines soon 
followed. It was not until the 18th century that penile sheaths were given the 
name "condom" and popularized by the libertines of the day as a means of
"protection from venereal disease and numerous bastard offspring."
Casanova (1725-1798) was among the first to popularize the condom as a 
coltraceptive (1). With the advent of vulcanized rubber in the 1840's came 
mass production of condoms (or "rubbers") from synthetic materials (2,3). 
MEC;ANISM OF ACTION 
Condoms are rubber or processed collagenous tissue-sheaths that fit over
the erect penis and act as a barrier to the transmission of semen into the 
vagina. Only about I ', of condoms are made from the caecum of young lamb 
intestines. 
When the sizes of several different condoms were compared, each had 
approximately the same length (19.0 cm) and the same width (2.5 cm). 
EFFECTIVENESS 
For consistent users, or those who usei. the condom exactly as directed
with each act of intercourse, the failure rate is 2 pregnancies per 100 woman 
years. This is the method failure rate. If 100 couples were to use the condom 
during a given year, 10 women are likely to become pregnant. (See Table 9.1 
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in Chapter 9.) The user effectiveness rate approaches that of the Pill when 
foam is used in conjunction with the condom. The high failure rate is often 
duc to users' dissatisfaction because of decreased sensation and interrupted
lovemaking. Very low failure rates with the condom have been reported from 
studies conducted in the United Kingdom (Table 15.1). 
CONTRAINDICATIONS 
Some men cannot retain an ereciion if a condom is used. Very rarely, men 
or women have been allergic to the rubber in condoms. 
DISTRIBUTION OF CONDOMS 
Because of several advantages of condoms, they are an important method 
of birth control for various populations. The condoms known to be available 
in Africa are listed in Table 15.2. Unfortunately, there are many rural areas in 
Africa where they are virtually unavailable at present. The following advan­
tages of condoms should be kept in mind as countries consider if and how 
distribution of condoms could be increased. 
1. The use of condoms allows participation of males in birth control 
responsibilities. 
2. Condoms are a relatively inexpensive birth control method. 
3. Condoms can be made readily available to most people. They can be 
purchased in the market, drugstores, and family planning clinics or 
from distributors. 
4. Condoms are effective protection against the transmission of 
venereal disease; for this reason theyshould be encouraged among
adolescents and among women who plan to delay childbearing for 
a number of years. This is especially true if these women will 
probably have several sexual partners before bearing a child. In 
areas of Africa where sexually transmitted infections are associated 
TABLE 15. 1 Condom failure rates per 100 couples using the method 
per year in five recent United Kingdom studies (4-8)
Name of Chief Method User 
Investigator Year Failure Rate Failure Rate 
Peel (4) 1969 0.8 3.10 
Peel (5) 1972 1.6 3.90 
John (6) 1973 0.4 4.80 
Glass (7) 1974 - 4.00 
Potts (8) 1975 0.83 
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with high rates of infertility and sterility, the routine use of condoms 
might assist greatly in decreasing infections of the uterus and the fallo­
pian tubes. 
5. Clinicians feel that use of the condom may prevent cancer of the cervi.,. 
TABLE 15.2 Condoms known to be available it? Africa 
Atlas Hygex;-' 
Con-form Lord Hygex 
Conture" Prime-
Crepe de Chine' R3 Aktiv-feucht 
Durapac . R3 Excellent 
Durex R3 Med'.. 
Durex Black Shadow R3 Naturcontact,'-
Durex Fetherlite R3 Plus 
Durex Fiesta"- R3 Superfeucht" 
Durex Gossamer Sagami Wet"l 
Durex Nu-form, Samoa' 






SIDE EFFECTS AND COMPLICATIONS 
The major complaint of condom users is that the condom reduces 
sensitivity. Some men are unable to enjoy intercourse or even to maintain an 
erection while wearing condoms. To increase sensitivity, natural­
skin-textured or lubricated condoms may be used. Some people object to in­
terrupting foreplay to put on the condom. In this instance, the female can be 
encouraged to put the condom on the male as part of foreplay. A very smal 
number of people are allergic to rubber condoms; they should try using
natural-skin condoms instead. The nost common recurrent mistake that dis­
courages couples from adopting the condom as their standard method is fail­
ure to use the condom consistently: this can lead to pregnancy. 
NONCONTRACEPTIVE BENEFITS 
In addition to providing protection against pregnancy, other benefits of the 
condom are: 
1. Sex therapists occasionally recommend the use of condoms in the 
treatment of premature ejaculation, as they reduce sensitivity of the 
glans during intercourse (9). 
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2. 	Some women and men do not wish to have the penis in direct contact 
with the vagina. The condom is an effective barrier that may make inter­
course more pleasurable if this concern exists. 
3. 	Occasionally, men unable maintain an erectionare to during 
intercourse. This often occurs in older men or in those who have had 
certain lower abdominal operations. The rim of the condom may have a 
slight tourniquet effect, helping to maintain an erection. 
4. Lubricated condoms can reduce mechanical friction and irritation of the 
penis or vagina. 
5. It has been found that, in some infertile couples desiring pregnancy, the 
woman's body makes antibodies to her partner's sperm. In such 
couples, the use of condoms for 3-6 months (the length of time 
depends on the level of the antibody titer and how long it remains 
elevated) can prevent the release of sperm :otigens into the vagina. 
6. 	Women have very occasionally been allergic to their partner's sperm 
ancl.or semen; urticarial and even anaph,!h:Li'; reactions have 
occurred. Condoms would obviously prevent these ailergies. 
7. Condoms clearly can )lay a major role in the r.revem lion of sexually 
transmitted diseases. 
8. 	By diminishing sexually transmitted infections, condoms may diminish 
the likelihood of infertility or cervical cancer insome women. 
Although condoms are currently used in most Africm Countries only to a 
limited extent, interest is incrieasing in their use (10, 1 1). Perhaps condoms 
would be a great deal more popular in Africa if some of the lioncontraceptive 
benefits received greater emphasis, theroby offsetting the stigma often asso­
ciated with condom use (e.g., promiscuity, )rOstitition). 
USER INSTRUCTIONS 
1. USE CONDOMS EVERY TIME YOU HAVE INrERCOURSE. When 
condom-using couples have an unplanned pregnancy, it is almost 
always because they did not use condoms correctly each time they had 
intercourse.
 
2. 	You or your partner should put the condo n on the penis before the 
penis is put in the vagina. Roll the rim of the condom all the way to the 
bottom of the penis. Leave about one-half inch of empty space-not 
filled with air-at the tip, or buy condoms with nipple tips to hold the 
semen. (See Figure 15.1.) 
3. 	After intercourse, hold onto the condom as you withdraw the penis, 
taking care not to spill semen anywhere near the opening to your part­
ner's vagina. The penis should be withdrawn soon after ejaculation be­
cause if you lose your erection, the condom can slip off and pregnancy 
can result. 
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4. Try not to carry your condoms near to your body as body heat can dete­
riorate the rubber You may want to lubricate the outside of your
condom to help the penis enter the vagina. DO NOT use petroleumn jelly,
as it might cause the rubber to deteriorate. Contraceptive foam, saliva, 
or other lubricants should definitely be used if you have a tendency to 
tear your condom during intercourse. Condoms will stay good for about 
2 years if stored away frorn heat. If condoms are kept ina relatively dry
enviro, ment, they can last more than five years (12).
5. To increase the effectiveness of condoms, use contracep~tive foam at 
the same time. 
FIGURE 15. 1 When putling on a condom without a reservoir end, pinch the 





1. 	 CASANOVA, J. Memoires de Jacques Casanova de Seingalt. Tome quatrieme 
(Casanova's memoirs). Brussels, J Rosez, 1872. 
2. 	 DALSIMER, I. A.. PIOTROW, P T., DUMM, J. J. Condom-an old method meets a new 
social need. Population Reports Series H. No 1, 1973 
3. DUMM, J. J., PIOTROW, P. T., DALSIMER, I. A. The modern condom-a quality product for 
effective contraception. Population Reijorts Series H, No. 2, 1974 
4. 	PEEL, J. A male-orientated fertlity control expemnent. Practitioner 202 677-681,1969. 
5. PEEL, J. The Hull family survey. II Family pl;anning in the first five years of marriage. Journal 
of Biosocial Science 4 333-346, 1972 
6. 	JOHN, A. P K. Contraception in a practice community. Journal of the Royal College of 
General Practitioners 23: 665-675, 1973. 
7. 	 GLASS, R., VESSEY, M., WIGGINS, P Use-effectiveness of the condom in a ';eiected 
family planning clinic population iii the United Kingldom Corntraception 10(6): 521-598, 
1974. 
POTTS, M., MCDEVITT, J A use-effectiveness trial of sperrnicioally lhricated condoms. 
Contracelition 11(6): 701-710, 1975. 
9. 	 MASTERS, W H ,JOHNSON, V. E.Ilun i sxua.l response. Boston, Little, trown, arid 
Company, 1966 
10. 	LAMPTEY, P, NICHOLAS, D 0), AMAAH, S 0 . LOURIE, I. M Ai evaluation of male contra­
ceptive at ceptance in rural Glhina Studies iii Family Plawting Vol 9 N-8. August 1978. 
11. 	 HUBER, S. C., PIOTROW, P T, POTTS. M, ISAACS, J. D., RAVENHOLT, R T. Contracep­
live distribution- taking supplies to villages and households Population Reports Series J, 
No. 5, 19 75. 
12. 	 NEWMAN, D (Uirited States Agency for hiternational Develonment, Development Support 









HISTORY, MECHANISM OF AZTION,
 
AND EFFECTIVENESS 
 OF SPERM ICIDAL AGENTS
 
For over 5,000 years, women have tried to use 
combinations of barrier
methods and spermicidal agents to protect themselves against pregnancy.
Their innovative attempts have been remarkable. The diaphragm-shaped
lemon, with its own built-in spermicidal juices, is still used as acontraceptive;
its modern replacement is the diaphragm filled with a spermicidal agent.
Sponges with various spermicidal additives have been used for centuries. 
Colloid sponges containing spermicidal agents (like nonoxynol-9) are a new
version of an old approach. Patentex' suppositories have been produced in 
Germany for 80 years and were distributed extensively by Margaret Sanger, 
a leader in the American birth control movement in the 1920's, only to resur­
face with use of a "new" spermicide (nonoxynol-9) in 1970.Spermicides consist of two components--an inert bsse (usually foam, 
cream, or jelly), which carries the spermicidal agent in the vagina against the
cervix, and a spermicidal chemical, which kills the sperm. Foam is placed
deep in the vagina in the vicinity of the cervix. Coital movements spread the 
spermicide over the cervix, mechanically blocking the os and preventing
entry of soerm into the cervix. The chemical effect of the spermicidal agent 
immobilizes and kills the sperm. 
Since foam is the most widely used spermicide, it is discussed first and in 
most depth. (Aerosol foams known to be available in Africa are listed in Table
16.1.) With foam, there is a wide gap between the actual user effectiveness 
and theoretical effectiveness rates. Confusion over the actual effectiveness 
of contraceptive foam is widespread. During a 15-year period of study, failure 
rates of 1.55 to 29 pregnancies per 100 woman years of use have been 
reported (see Table 9.1 in Chapter 9 and Table 16.2 in Chapter 16). 






Foam users must be taught to use this method correctly and consistently 
to maximize its effectiveness High failure rates are a reflection of both the 
inherent likelihood of method failure and careless use. The mistakes a foam 
user can make include: 
" Using too little 
* Failing to shake the foam container vigorously enough 
* Failing to recognize that the foam bottle isempty
 
" Failing to have the bottle available
 
* Failing to interrupt intercourse to use foam 
* Douching too soon after intercourse
 
" Forgetting to use the method altogether
 
TABLE 16.2 Reported failure rates for spermicidal foams 
Investigator No. of Months Pregnancies Year 
Reported Patients of Use (per 100 woman years) Reported 
Carpenter (1) - - 1.55 1970 
Bushnell (2) 130 2,737 1.80 1965 
Bernstein (3) 2,932 26,073 4.30 1974 
Kleppinger (4) 138 1,116 7.60 1965 
Mears (5) - 722 16.60 1962 
Tietze (6) 779 ? 28.30 1967 
Paniagua (7) 142 1,723 29.00 1961 
Some of the most effective users of foam obtain it not from family plan­
ning clinics or private physicians but from drugstores. Foam can be used as 
the only method of birth control by some couples. Occasionally, . clinician 
will have a patient who has used foam as the only method of contraception 
without a failure for 5, 10, or even 15 years. Some couples will use foam in 
combination with condoms; if both methods are used correctly and 
consistently, the resulting effectiveness rate is extremely high. Douching 
should not be considered a reliable contraceptive even if a spermicide is in 
the douching solution, because sperm simply enter the cervical canal too 
quickly (as soon as 1 5 seconds after ejaculation). If a vaginal spermicide has 
been used as a method of contraception, douching after sexual intercourse 
should be delayed 6-8 hours. 
CONTRAINDICATIONS 
* Allergy to foam 
* Unwillingness to use foam at the time of intercour a 
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IMPORTANT USES OF CONTRACEPTIVE FOAM 
The advantages of foam are its safety, ready availability without a 
prescription, and effectiveness. The following are settings in which foam 
may be of help to your patients. 
1. As a contraceptive alone or in combination with condoms. 
2. 	 As a contraceptive to use while waiting to begin the first pack of birth 
control Pills , nd during the first month of Pill use. 
3. 	As a backup method in case a woman stops using Pills or runs out of 
Pills. 
4. As the contraceptive to use for several months after a woman stops 
Pills and before she tries to become pregnant. 
5. 	 As a midcycle contraceptive to increase the effectiveness of an IUD, 
condoms, or natural family planning, 
6. 	As the backup contraceptive method to have in case an IUD is expelled.
7. 	 As a contraceptive method for the diaphragm user who has intercourse 
a second time before tier diaphragm can be removed. (Foam should be 
added without removing or dislodging the diaphragm.)
8. 	As a backup method in case a condom breaks. An application of foam 
should be quickly inserted in this instance. This is the best you can do in 
a very discouraging situation. It may not help at all since sperm get up 
into the cervical canal very quickly. 
SIDE EFFECTS AND COMPLICATIONS 
1. 	Foams may produce rare allergic reactions. 
2. 	Foams may produce vaginal irritation and a vaginal discharge. 
NONCONTRACEPTIVE BENEFITS 
1. Foam decreases the tran.!..,ission of gororrhea and trichomoniasis. 
2. 	Foam provides vagin,.; lubrication. 
USER INSTRUCTIONS 
1. Shake the can vigorous'v before using so that there will be plenty of 
bubbles for the barrier and the spermicide will be mixed with the foam. 
(See Figure 16.1.) 
2. 	 See Figures 16.2 and 16.3 for the correct and incorrect placement of 
the applicator. 
3. 	 If you want to douche after intercourse, wait at least 6 hours. 
4. Wash the applicator with soap and lukewarm water. 
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5. Keep a spare container of foam on hand. With most brands, there is no 
way to tell when you are about to run out. 
6. 	The effectiveness of foam in preventing pregnancy can be increased if 
it is used with another method of birth control, such as condGms. 
After shaking the bottlk of foam 
20 times, insert bottle into applicator. 
Tilt ii applicator to one side, and the 
foam will fill applicator automatically. 
FIGURE 16.1 Using foam. 
4-T' 1" 
FIGURE 16.2 Correct placement 
of foam de'p in the vagina, 
FIGURE 16.3 Incorrect placement 
of foam. 
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SPERMICIDAL SUPPOSITORIES, CREAMS, AND JELLIES 
The following table is fairly representative of the spermicidal preparations 
that a-e currently available. 
TABLE 16.3 A vailable sperm icidal preparations 
Known to be 
available in Africa Other 
Foaming lablets 
suppositories 














Creams, jellies, or gels Delfen Crearn Lorphyn Jelly'",
Ortho-Cream" Preception Gel',
Ortho-Gynol Creme' Certane Vaginal Jelly",
Koromex-A Immolin Vaginal Cream-Gel", 
Preceptin' Emko Cream " 
Patentex' Koromex Vaginal Jelly'




. Copper Cream 
Tablets and suppositories must dissolve for a period of 10-30 minutes 
after being placed in the vagina before sexual intercourse occurs. In general,
this is not the case with creams, jellies, or aerosol foaming agents. In some 
instances, a suppository or pellet will riot dissolve completely and can cause 
increased friction, a penile or vaginal irritation, and/or decreased 
effectiverass. Sonic of the suppositories are difficult to remove from their 
foil packets. The suppositories or tablets may mistakenly be used rectally or
orally. While this practice is completely ineffective inpreventing pregnancy, it 
is not usualy harmful. 
Neo-Sampoon is a fairly new spermicidal foaming tablet that is available 
through a number of family planning programs in Africa. It contains the sper­
micide menfegol (p-niethanylphenyl polyoxyethylene 8.8 ether). Clinical 
studies have reported that out of every 100 women who use Neo-Sampoon'. 
in a year, 5 can be expected to become pregnant (8). Small-scale multiclinic 
studies of Neo-Sampoon" are also being conducted by the Family Health 
International. To date, 418 women have entered into these studies, and *he 
6-month cumulative pregnancy rate for Neo-sampoon'' users was 4.9 per
100 women or 7.6 pregnancies per 100 woman years (9). 
223 
REFERENCES 
1. 	 CARPENTER, G, MARTIN. J Clinical Evaloation of a Vaginal Contraceptive Foam, Ad­
vances in Planned Parenthood New York. Excerpta Medica ForidatiOn 1970. pp 
170-178. 
2. 	 BUSHNELL, L. F A practical and effective method of contraception Pacific Medical and 
Surgical Journal 73 353, 1965 
3. 	 BERNSTEIN, G S Clinical eofcctivee' s of an aIerosol contracepttive foam Contraception 
3:37. 1970 
4. 	 KLEPPINGER, II K A va(piil coiirll II rl fl lfI!IcltVp!trail OJr heprodihctivo Fertility 4. 337. 
1962 
5. 	 MEARS, E Chemical ionrtraceptive trailII Journal of Fleprodutive Fertility 4 337, 1962 
6. 	 TIETZE, C., LEWI1, S COIMpaNor if tfhree contraceptive inethoda (diaplhra ln with iolly or 
cream, vaginal foi, a narid10lly cream liliie JOUrnal of Sex Research 3 295, 1967 
7 PANIAGUA, M. E, RIO PIODRIAS. P R . VAL IIAN . A B, GAM[I.E, C J Field tral of a con­
traceptive foam iii Puerto Rimco Journaol or the'American Medical As;ociation 177 125. 
1961 
8 ISHIHAMA, A, INOU. T Clinical field test of a iiw cioiitraci:eptive vaginal foamrtablet Con­
traceptio 6 401. 1972 




NATURAL FAMILY PLANNING METHODS 
INTRODUCTION 
Periodic abstinence, rhythm, natural family planning (NFP), and fertility 
awareness methods are terms often used synonymously to describe birth 
control methods based on the cyclic pattern of fertile and infertile phases 
during the menstrual cycle. The "natural" in natural family planning does 
not refer to the naturalness of sexual ahslne-ec n, is it intinrirr tn imnl 
that taking one's temperature is natural. It refers to the monitoring of natural 
physiological signs and symptoms to determine the fertile period. 
The International Federation for Family Life Promotion states that "NFP 
methods are means by which tihe couple uses the daily observation of signs 
and sympt.)ms of the fertile and infertile phases of the menstrual cycle to 
guide the timing of intercourse according to their desire to achieve or avoid 
a pregnancy" M1). (Implicit in this d'finition is the fact that couples will ab­
stain from sexual intercourse if the-y wish to avoid pregnancy.) 
NFO zopeals to persons who wish tc capitalize on knowledge of the fertile and in­
fertile phases of the menstrual cycle for their approach to the timing of 
prognancy, or to those who do not wish to use drugs or devices either because 
they,are concerned about their side effects or for religlious or other reasons. NFP 
can be used to help avoid or achieve pregnancy. 
Recently there have been several reviews of nethods based on perindic 
abstinence (1 2,3,4). Currently thaie are three main methods of NFP which 
are being promoted: the basal body temperature method (BBT); the cervical 
mucous method (CMM), or the Billings ovulation method; and the sympto­
thermal method (S-TM). Their physiological bases have been studied by 
numerous investigators and are documented in several recent publications 
(1,3,4,5). 
There has been a great deal of contr'oversy over the use of NFP methods 
despite their advantages in terms of lack of side effects, nonphysician 
delivery, and educational value. The reluctance of many family planning ad­
ministrators to include NFP methods in their programs usually stems from 
three concerns: (1) Although the method effectiveness is high, the use ef­
fectiveness is generally lower than desired; (2) Belief that these methods 
would be unacceptable and difficult to learn; and (3) Belief that the costs 
and utilization of service provider time would be higher than for many other 
methods if NFP was to be incorporated into existing services. Nevertheless, 
there does appear to be a renewed scientific and political interest in NFP. 
CERVICAL MUCOUS (BILLINGS OVULATION) METHOD 
Mechanism of Action 
The cervical mucous method (CMM) is based on the woman's observa­
tion of a sequence of changes in the quality of cervical mucus. Under tile in­
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fluence of estrogen, produced during the follicular phase of the menstrual 
cycle, the endocervical glands are stirnulated to secrete mucus. (See Chap­ter 7.) Before follicular development, the woman experiences a sensation of
dryness around the genital area. As the tollicle(s) begins to develop and prc­
duce estrogen, the woman experiences a sticky sensation and cloudy or
opaqle, flaky or thick mucus may he ohbserved on the und;f clothing or ol 
tissue paper applied to the vulva. 
As the time of ovulation apprcoaclhes and the estrogen concentration in­creases to its highest level in the cycle, the mucus thins out and produces awet, slippery, lubricati ,e sensation and appears as a clear, egg-white-like
substance which, when placed between the fingers, stretches so as to hang
in strings (spinnharkeit) without breakin(. 1he last (lay of the wet, slippery
sensation, which is identified retrospectively, is called the "peak" day(highest point of ferility). Followiun ovulation, the progesterone produced
by the corpus Ilteum, even in the presence of estrogens, inhibits the pro­
duction of the mucus, especially the type observed on the "peak" day.
Thus, women can learn to predict and detect the time of ovulation and the
fertile period throug1h careful daily observation of the cervical mucus. A de­
scription of mucous changes is found in Table 17.1 
TABLE 17.1 Characteristics, of cervical mIcuIls in various phases of the n1ormal menstrual
cycle and the corresponding rules for ijtecu-ourse
 
Appiu 'ilare 
Pharr;r of Numbier of Days Charac:teristics 
Rules
Menrstrual illIdealized 




Phasr;i I Mei troiatoui 
 - ! Muo', indiciirng the Wet and Abstain, since type
onel of the feloh perifod, hotircl~ihve of mulculs,ifally, 
el:}y ol beor may cannot ie ascertained 
i) IIf'tlbL  IS O) VAU;lil 
lbyilellstual flo.,Phase 2 Postmeistrual 2-4 No nucus C"diytly1" Dry Coitus isIpermiltted 




Course may obscure 
lie ilUcUS; 
Muctis present ill Sticky aild or Ali.tamu
 
Phase 3 Earlypre- smallarounts pfOIt
2 CIoudy, yellow orwhite, Sticky id or A)st,,,'i




Phase 4 hInnediyly 3-5 Clear,Siippry, wet, Ild l ilmctliv Abstin
lefoe aI. stretlry, withitile id f.Vlt 
and after coisistency lifralweti. 
ovulation white (Last day of liw. 
tphlase is kiowin i th
"peak sylluptoinr ")Phase 5 Ilnliredlie 0-3 Snall ailIounlIts uthillilyf Sticky and'or Colitusispermitted
tllstovulalory sticky rnecl'S loist beginning ott tire or 




No irrucluS Dry last day of wet, 
Phase 6 Postovulatory 7- 12 stretchy mucus.Usually rio mucus, dr',' Dry Coitus permitted 
if'rtile d ys
Phase 7 Late post- 0-3 Clear ard watery Sticky arid or Coitis permitted.
ovulatory 




'Adapted from Figurr 4. reference 1 
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User Instructions 
One of the most striking findings of the World Health Organization's 
(WHO) prospective five-country study of the ovulation method (6) was that 
93. of women, representing a wide range of cultural, educational, and soci­
oeconomic characteristics, were able to recognize and record the cervical 
mucous symptom during the first cycle following instruction in the method 
by an experienced teacher. What is particularly interesting was that 48. of 
the women in the El Salvador center were illiterate, yet they learned the 
method as quickly as the 11' and 8, of the women from the New Zealand 
and 	Ireland centers who had university degrees.
 
A simplification ot the rules of the ovularion Method states:
 
If you want to have a 'hhi: 
1. 	 Watch for the days of strort'hy, wer, md slippery IMiC:. These may not occur 
in every cycle. 
2. 	 Have intercourse on tlho dys wier the wornn;m is rmost aw;are of the feelino of 
mucous wetness. 
3. 	 Abstain for a (Jay or two before ealch coiitw to enhance hus;mnd's fertility. 
If you do not wish to have a child: 
1. 	 Abstain durin(i menstruation hecause 1hedin(U mi(rhnt Mask thMe iucous 
discharge, particularly in short cycles. 
2. 	 Abstain on days when mucus is present and for at leiast three days afterwards. 
3. 	 Abstain on days of internnenstrual bleeling and for at feast three days 
afterwards. 
4. 	 While learning the method, abstain on alternate "dry" days prior to the onset 
of the feeling or ob|servation of mucus (to minimize difficulty in recognizing the 
onSet Of MUCOUS secretion becat+e of tih t)resernce f) seminal fluid). 
Teachers of the Billings method stress tIhat digital examination of the 
vagina and, or cervix is not necessary. They also state that the quantity of 
mucus produced is less important than the quality of the mucus (sticky, 
stretchy, thin, watery) and that the individual nature of the mucus should be 
described in the users ovn terms whenever possible. 
A special, simple start)p system was developed, particularly for illiterate 
women, for keepiug a record of the menstrual cycie and cervical mucous 
discharge. Literate women can use tire same system but are encouraged to 
write a couple of words describing the mucus each day. Alternatively, a 
plain lead or colored pencil car) be used to indicate the daily observations 
with symbols devised by tie woman herself or her instructor. 
Effectiveness 
The effectiveness of NFP depends (peatly upon the woman's diliigence in observ­
ing and recording the signs and symptoms of the fertile and infertile phases of the 
menstrual cycle, the motivation of the couple and their joint cooperation in ab­
staining from sexual irntercourse, the couple's family planning intention, the quali­
ty of the instruction )rovided and, to a lesser extent, the regularity of the phe­
nomena monitored to identify the fertile period. The effectiveness of the cervical 
mucous and synpto- thermal methos is not as affected by irregular cycles as is 
the calendar-rhythr riethod. User failures can occur because sonie couples may 
find the length of abstinencc to be unacceptably long and may be tempted to take 
chances during the fertile tphase, thereby reducing the effectiveness of all NFP 
methods. 
In the WHO prospective multicenter trial of the cervical mucous-ovulation 
method (7), the unplanned pregnancies were classified as being related to 
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the method itself, inadequate teaching, inaccurate application of
instructions, conscious departure from the rules, and uncertain. Using these 
categories, the pregnancy rates reported for the 725 subjects who learned
the method and entered a 13-cycle effectiveness cycle study were 2.8, 0.4,
3.5, 15.4, and 0.5 pregnancies per 100 woman-years (modified Pearl
index), respectively (7). The use-effectiveness of CMM, regardless of
subclassifications, usually ranges from 5 to 40 pregnancies per 100 
woman-years (1). (See Appendix A) 
BASAL BODY TEMPERATURE (BBT) METHOD 
Mechanism of Action 
BBT still remains the most quantitative of all available techniques which 
can be used in the home to detect ovulation. However, it has no value in
predicting ovulation. Ovulation is detected by identifying a shift in tempera­
ture (0.2-0.5"C or 0.4-1 0'F) from a relatively lower level during the follicu­
lar phase of the menstrual cycle to a relatively higher level during the luteal 
phase. This temperature shift can be defined as one that occurs within 48
hours, and in which three consecutive daily temperatures are at least 0.2'C 
(0.36"F) higher than the last six daily temperatures before the start of the 
shift (9). 
User Instructions 
These four rules should be follovied to assure accurate BBT readings:
1. Take the temperature in the morning, after a night's rest, immediately afterawakening and before rising or drinking anything;
2. 	 Use a certified clinical or expanded scale (fertility) thermometer; the tempera­
ture can be 	measured rectally or vaginally for 3 minutes or orally for 4-5 
minutes;
3. 	 Note any deviations from the normal routine (hours of sleep, fever, change of 
thermometer, etc.); and 
4. 	 If the mercury stops between two temperatures Qllrfaduatjols), record the 
lower temperature as the BBT reading. 
There are several different ways of identifying a shift in temperature to

define the beginning of the postovulatory infertile period, e.g., the use of a

"'coverline" drawn 
 0.05'C above the highest of the lower temperatures
(excluding the first four days of the cycle and including at least six normal 
temperatures) and counting three consecutive temperatures above this 
coverline. 
Producing and interpreting temperature charts equires considerable 
care. Body temperature can be altered by illness or emotional stress, and 
temperature levels may vary from cycle to cycle in the same woman. 
Furthermore, BBT may rise in different ways-abruptly, gradually, in a step­
like pattern, the rise may be preceded by a sharp drop, and/or, less 
frequently, the rise may resemble a saw -tooth pattern (see Figure 17.1 ).
It is recommended that to produce an easily interpretable curve, the tem­
perature should be charted on a scale where the distance covered by two
days on the horizontal axis is equal to the distance covered by 0.10C on the
vertical axis. Figure 17.2 shows the same temperatures charted on three dif­
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ferent scales. Although the expanded scale (2:1 ratio) graph (P?.,Iel C) is the 
easiest to interpret, the 1:1 scale (Panel B) is acceptable and I- the one most 
frequently used by NFP programs. 
Several studies have been undertaken on the occurrence of monophasic 
temperature curves in hormonally ovulatory menstrual cycles. These studies 
have postulated that in about 10-20 of ovulatory cycles, biphasic tern­
perature patterns are riot observed (5). 
However, in a study conducted by Vollman (10), 7.2",, of the 14,852 
cycles observed (621 women) were monophasic. Vollman demons':-a-ted 
associations between cycle length and age, and the incidence of monophas­
ic patterns. In short menstrual cycles (7-17 days), 57.1 . of cycles were 
monophasic. The rate decreased with the increase in length of the menstrual 
cycles and dropped to 5.8 at cycles of 24 days. In menstrual cycles of 
25-32 day-, the proportion of rnonophasic curves was lowest (1.8-4.8> ). 
With menstrual cycles of 33 days and longer, the proportion of monophasic 
BBT curves steadily increased again and finally reached 41.3', in cycles of 
60 days and longer. Since the length of menstrual cycles is known to vary 
with age, it is riot surprising that Vollnan found that monophasic cycles 
showed ao age-dependent distribution. He concluded that, although 
monophasic BBT curves occurred at all ages, they characterize the adoles­
cent and preciimacteric phases of a woman's reproductive life and are 
found at an average of 2 in Mrature, fertile women. 
Effectiveness 
For women who are willing to take and record their temperatures daily 
and to abstain regularly for more than half of the menstrual cycle, the tem­
tfTL . INFEIIII 
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FIGURE 17. Common basal body temperature patterns. Adapted from 
Figure 3, reference 1. 
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perature method, when used alone, appears to be more effective than other 
periodic abstinence techniques. Pregnancy rates in early studies ranged
from 0.3 to 6.6 per 100 woman-years of use when intercourse was restrict­
ed to the postovulary phase of the cycle (10).
The major drawback of the temperature method alone is that abstinence 
is necessary for the entire preovulatory period. Furthermore, when ovulation
does not occur, as is common around menairche, during lactation, and 
Maround menopause, BBT does not rise and ,hstinence throughout the cycle 
is required. 
The resu'. ,,. studies are represented in Table 17.2. 
CALENDAR (RHYTHM) METHOD 
Mechanism of Action 
The calendar method, comnionly called the rhythm method, is the oldest 
NFP technique. It came into )eing in the 1930's after Drs. Ogino arid Knaus 
independently published their findings that ovulation occurs about two 
weeks before menstruation (10). The calendar method is designed to pre­
dict the fertile period based on the duration of previous cycles. The method, 
as it was traditionally taught, requires knowledge of the lengths of the past 
6 to 12 cycles. 
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FIGURE 17.2 The same biphasic basal body temperature curve drawn on 
three different temperature scales. 
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Almost all NFP providerh consider this method outdated. They believe that it 
should not be taught alone because, unlike the newer NFP methods, it does 
no: reflect physiological changes associated with ovulation and fertility. Any 
unexpected wide variation in a woman's cycle length could resuit in a miscal­
culation of the safe period which would greatly increase the chance of an un­
planned pregnancy. Furthermore, the method is useless in women with prol­
onged periods of anovulation such as occurs during the post-partum period es­
pecially with lactation. 
Information is provided here on this method because it can be used in 
combination with other NFP methods. 
Calculation of the fertile period is based on three assumptions: (1) on 
average, ovulation occurs 14 clays (plus or minus 2 days) before the onset 
of the next menstruation; (2) sperm retain their fertilizing capacity for about 
2-3 days (but sometimes up to 7 or 8 days ) and (3) the ovum retains its 
ability to be fertilized for no more than 24 hours following ovulation. 
User Instructions 
Use a standard calendar or a menstrual diary. Record the length of each 
menstrual cycle over the most recent or next 6 to 12 cycles. The first day of 
bleeding is Day 1 in each cycle. The earliest day on which you are likely to 
be fertile is computed by subtracting 18 to 21 days from the length of your 
shortest cycle; "Minus-20" is most frequently used. Subtracting 8 to 11 
days from the length of your longest cycle determines the first day on 
which you are no longer likely to be fertile; "Minus- 10" is most frequently 
used, Therefore, the two numbers that result from these calculations repre­
sent the beginning of the fertile phase and the beginning of the postovula­
tory safe phase. 
If, for example, you are practicing tlte rhythm method as it is most fre­
quently used and your menstrual records show that your shortest cycle was 
27 days and your longest cycle was 30 days, the first fertile day wil: be Day 
7 of your cycle (27-20=7) and your first safe day will be Day 20 
(30-10=20). See Appendix B for the calculation of the interval of ferti~ity. 
The decision on whether or not the woman is taught to substract 18, 19, 
20, or 2 1 from her shortest cycle length and 8, 9, 10, or 11 from her lon­
gest cycle length should be based on the couple's motivation to have more 
'rABLE 17.2 Selected stu(li;s of the effectiveness of the teinperature (BBT) methd' 
No. of 
No. of No, of Unplanned 
Author Country Date Women Cycles Pregnancies Failure Rate 
OiSirl 	 16, 13 5GUy and Guy M ', 1965 1,49 I 	 112 8.03 
Bartzen U S A 1967 	 296 4,824 79 195 
Doring W. Germrh ,, 1967 	 689 ,18.214 125 3 1 
3 0 1t 11,352 8 03 
Marshz'l UK 1968 	 255 3.545 57 19.3 
3211 4,749 26 6.6 
*Modification of Table 1, reference 10. tlntercourse restricted to postovulatory phase only. 
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days available for intercourse and a little less method effectiveness or moreeffectiveness and less intercourse. Obviously, with a wider calculated fertileperiod, abstinence increases and tile method will be more effective. 
The wider the variation in cycle length, tne longer the
required. 
 period of abstinenceThis method is somewhat inapplicable for women who have irregular
cycles. 
Effectiveness 
Recently, little attention has been paid to teaching the calendar methodalone. Therefore, no recent studies have been conducted on itseffectiveness. The failure rate of the rhythm method is usually quoted asabout 14-50 pregnancies per 100 woman-years based on studies conduct­
ed between 1937 and 1968 using retrospective analyses (10). 
SYMPTO-THERMAL METHOD (S-TM) 
Mechanism of Action
 
Approaches to identifying the fertile 
period which use BBT measure­ments to detect ovulation in combination with changes in cervical mucus,calendar calculations, and/or other parameters to pre-,ct ovulation arecalled the sympto-thermal method (S-TM). With this multiple-indicesapproach, if a woman cannot clearly interpret one sign, she can double
check her interpretation with another. A thorough review of these methodswas prepared by Parenteau-Carreau (11) and Population Reports (1).

Different NFP organizations have developed their own 
instructions andcharts for the S-TM. The S-TM rules set forth in the World Health Organiza­tion NFP curriculum call for abstinence beginning either when calendar cal­culations so indicate (shortest cycle minus 20) or when the cervical mucoussymptom is first observed, whichever comes earlier. The end of the fertileperiod beg;ns either on the fourth day after the peak mucous symptom oron the evening of the third day of consecutive higher temperatures above acoverline-whichever comes later. Some S-TM organizations teach reliance
only on calendar calculations or 




Other symptoms can be used to help identify the fertile period, but they
are 
 less common, less consistent, and less specific than cervical mucouschanges and the BBT rise. They include intermenstrual pain (mittelschmerz,which can be interpreted as a pain in the lower back, abdomen, or side), in­termenstrual bleeding, breast tenderness, and several other symptoms such 
as edema and mood changes.
Self-observed changes in the position, texture, moistness, and dilation ofthe cervix through digital examination appears to be a relatively accuratemethod of assessing the fertile phase of the menstrual cycle. The cyclicchanges in the cervix appear to occur relatively consistently and they maybe especially useful to detect the onset of fertility in the post-partum period. 
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However, some women may find this approach unacceptable. No informa­
tion is available on the percentage of women who are able are to discern 
cervical changes. 
Among supporters of NFP, there is debate as to the advantages or disadvantages
of single index (e.g., cervical mucus alone) or multiple-indices (e.g., S-TM)
methods. Some teachersNFP insist that the use of cervical mucus alone is
sufficient, stating that combining it with other indicators of ovulation may be less 
reiable than mucus only. Another argument put forward by those who advocate 
the cervical mucous method alone is that taking and interpreting daily tempera­
tqre readings makes th& combined method too complicated for many women ir 
devaloping countries. 
The promoters of the S-TM believe that the more indices monitored, the more ef­
fective the method. They also believe that the BBT shift is usually a ;,iore objec­
tive and reliable method for identifying the end of the fertile phase. In addition,
when first learning NFP, it is claimed that the monitoring of several signs and 
symptoms will help the user to gain confidence in her ability to detect the fertile 
and infertile phase of the menstrual cycle. Results of effectiveness studies indi­
cate thbt the multiple-indices methods may be somewhat more effective than 
single-index methods. Finally, while most providers of the cervical mucous 
method recommend total abstinence during the first cycle of learning, with the 
S-TM, intorcourse can take place following the temperature shift in the first cycle. 
Effectiveness 
The effectiveness of S-TM was assessed in a number of clinical trials 
conducted since the mid-1 970's and ranged from about 5 to 35 pregnan­
cies per 100 woman-years (1). 
The first international prospective study of S-TM was reported by Rice 
(12). The study was undertaken by NFP associations in five countries: 
Canada, Colombia, France, MauritiL's, and the United States. Since the form 
of the S-TM practiced in each country varied, a standardized procedure was 
adopted. There were 723 volunteers who used the S-TM only; 299 other 
volunteers reported using another method of contraception during the 
fertile days in one or more cycles. The method failure rate was 0.75 preg­
nancies per 100 woman-years (range between centers: 0.45-2.58). 
However, the total mean use-effectiveness rate was 7.2 pregnancies per 
100 woman-years (range between centers: 4.9-18.1). Life table pregnancy 
rates ranged from 3.3-15.6% (mean 8.2). 
The results of selected other studies are presented in Table 17.3. 
TABLE 17.3 Selected studies of the use-effectiveness of the sympto-thermal method* 









McCarthy U.S.A. 1981 496 NA 45 10.7(a ) 
MAdina Colombia 1980 286 1882 54 19.1( a ) 
34.4(b) 
Wade U.S.A. 1980 590 3399 47 11.2(01 
16.6 (b) 
'Adapted from Table 2, reference 1. l'aLife Table Rate, (bPearl Index. 
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FERTILITY AWARENESS 
A popular term receiving widespread use, especially in the United States, 
is fertility awareness methods. Activities such as learning about the repro­
ductive processes and sexual function, observing basal body temperature, 
cervical mucus and other symptoms of ovulation, making graphs and keep­
ing records, trying to determine if ovulation took place and even identifying 
the phases of maximum fertility and infertility are aspects of fertility
Fwareness. Furthermore, the term is used in a neutral sense because the 
manner in which fertility awareness can be incorporated into a family plan­
ning regimen is left up to the woman 'couple. That is, sexually active people 
can choose to abstain during the fertile period (natural family planning) or 
they can choose to use a barrier method (contraception). 
It appears that there has never been a prospective, use-effectiveness, ac­
ceptability study conducted in couples whc v'.'ish to combine fertility aware­
ness with the use of barrier methods Juring the rartile phase. The only ef­
fectiveness data for such a regimefn were obtained indirectly from couples 
enrolled in NFP studies who admitted to using barrier methods or coitus in­
terruptus during periods of prosciibed abstinence. Such studies, reviewed 
by Klaus (3), showed that CCM combined with barrier methods resulted in 
user and method failure rates of 6.8 and 0.2 pregnancies per 100 woman­
years, respectively. The combination of the BBT method with barrier meth­
ods resulted in a user failure rate of 8.9 and a method failure rate of 1.4 
pregnancies per 100 woman-years. It must be realized, however, that when 
using fertility awareness combined with barrier method it is almost impossi­
ble to determine if a resulting unplanned pregnancy was caused by the fail­
ure of the barrier method or the fact that an assumed infertile day was actu­
ally a fertile day. Carefully kept records of a0 acts of intercourse, unprotect­
ed and with barrier methods, would help to alleviate some of this problem. 
Program administrators who wish to recommend to appropriito clients the possi­
bility of combining fertility awdreness with barrier methods during the fertile 
period should: 
1. 	 First ensure that the woman is able to identify the fertile period. 
2. 	 Suggest that only condoms be used if the woman is monitoring her fertility 
with the cervical mucous method only-the presence of soermicidal gel, 
cream or foam (with or without a diaphragm) could very well interfere with the 
woman's ability to identify the mucous characteristics. 
3. 	 Inform the couple that the method effectiveness of the combined approach is 
not as high as abstinence during the fertile period. 
ADVANTAGES AND DISADVANTAGES 
Since use of NFP does not employ drugs or devices, the only potontial 
medical side effect is the risk of unplannr" pregnancies with the attendcnt 
possibilities of maternal mortality. Although there has been some anxiety 
expressed about the possibility of an increased risk of spontaneous abortion 
and congenitpi defects among the offspring of NFP failures, IPPF reviewed 
the literature on this subject and concluded that "the present evidence does 
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not suggest that the risk, if any, is appreciable" and that there is "no need to 
warn prospective users of this hypothetical risk" (4). 
When the rules of the newer NFP methods are followed, particularly 
those pertaining to sexual abstinence, the methods are highly effective in 
preventing unplanned pregnancy. 
Advantages 

No physical side effects. 

Acceptors can be trained by 

paraprofessionals and lay 
volunteers. 
After initial training and fo;lowup, 
many users are able to practice the 
method without additional 
assistance and at almost no 
expense. 

Training increases awareness and 
knowledge of reproductive 
functions. 
May help couples achieve 
pregnancy. 
Responsibility for family planning is 
shared by both partners, which may 
lead to increased communication 
and cooperation. By requiring 
collaboration between partners, 
periodic abstinence can contribute 
to more equitable, cooperative 
marital relationships in areas wider 
than just family planning. 
Acceptable to people who do not 
believe in "artificial" contraception. 
.Approved by the Catholic Church. 
May be esthetically more 
acceptable than other 
coitus-related methods (condoms, 
spermicides, and withdrawal), 
NFP availability may increase the 
number of initial family planning 
acceptors. 
Disadvantages 




Relatively long initial instruction.
 




Requires strong commitment and
 












Without use of volunteer teachers
 




Using NFP to avoid pregnancy,
 
intercourse must be confined to a
 




Cervical mucus (alone): 
-learners: 1/2 of the days of 
the cycle. 
-experienced users: up to 2/3 
of the days of the cycle. 
8BT (clone). 7 tu 13 days per 
cycle. 
Calendar (alone): depending on 
cycle length and variability, 
may be as few as 1 to 3 days 
or as many as 10 to 20 
days per cycle. 
Sympto-Thermal: depending on 
the combination of 
techniques used, from 
1/3 to 1/2 of the 





1. 	 LISKIN, L.Periodic abstinence: How well do new approaches work? Population Reports, 
Series I, No. 3, 1981.
 
POPULATION CRISIS COMMITTEE. 
 Natural family planning: Periodic abstinence as a 
method of fertility control. Population, No. 11, 1981. 




4. 	 KLEINMAN, R.Periodic abstinence for family planning. International Planned Parenthood 
Federation. London, IPPF medical publications, 1983 
5. 	SPELER, J.Self-detection of ovulation and the fertile Deriod In. J Cortes-Pricto, A. 
Campos de Paz and M. Neves-e-Castro (eds.). Research on Fertility and Sterility.
Lancaster, England, MTP Press Limited, pp. 35-51. 1981 
6. WORLD HEALTH ORGANIZATION. Task force on methods for the determination of the 
fertile period. A prospective rnulticentre trial of the ovulation mathod. I. The teaching
phase. Fertility and Sterility 36.152, 1981. 
7. 	WORLD HEALTH ORGANIZAr!ON. Task force on methoo, for the determination of the 
fertile period. A prospective multicentre trial of the ovulation r'hod. II.The 
effectiveness phase. Fertility and Sterility 36:591, 1981. 
8. 	 WORLD HEALTH ORGANIZATION. Biology of fertility ccntro, by periodic abstinence.
 
Report of a World Health Organization scientific group. TRS No. 360, Geneva, 1967.
 
9. 	 VOLLMAN, R.F. The menstrual cycle. Philadelphia. W. B.Saunders, 1977.
10. 	 ROSS, C., PIOTROW, P. Birth control without contraceptives Population Reports, Series 
1,No. 1, 1974 
11. 	 PARENTEAU-CARREAU, S.The sympto-thermal methods. International Seminar on 
National Family Planning. Dublin, Cahill Prineis, pp 60-78, 1979. 
12. 	 RICE F.J. et al.Effectiveness of the sympto-thermal method of natural family planning:
An international study. International Journal of Fertility:26:222-230, 1981. 
CHAPTER 18 
COITUS INTERRUPTUS OR WITHDRAWAL 
Coitus interruptus, or the withdrawal method of birth control, has long 
been used as a contraceptive technique in Africa. It has been an important 
traditional method of fertility control in many communities throughout the 
continent. (See Chapter 2 ) A couple using the withdrawal method may have 
intercourse in any way acceptable to them until ejaculation is about to occur, 
at which point the male withdraws his penis from the vagina. Ejaculation 
occurs completely away from the vagina and external genitalia oT time [emiile, 
thus preventing any possibility of conception. 
As a method of birth control, withdrawal has distinct advantages over 
most other methods. It requires no devices, involves no chemicals, and is 
available at no cost. It does, however, have one strong disadvantage. The fail­
ure rate of withdrawal ranges from 10 pregnancies per 100 women per year 
(if withdrawal is used consistently) to 23 pregnancies per 100 women per 
year among actUal users (1).
 
This failure rate is a result of 
 several factors. Even when practiced 
faithfully, there is an inherent source of error in this method. There is a small 
possibility that preliminary ejaculatory fluid (often said to be semen stored in 
the prostate or penile Liethra or in the Cowper's glands) can escape before 
the penis is withdrawn. The likelihood of failure caused by the release of pre­
liminary ejaculatory fluid increases if multiple male orgasms occur within a 
short span of time since this fluid contains more sperm after a recent 
ejaculation. Another reason for contraceptive failure of coitus interruptus is 
the lack of self-control demanded by this method. The man may attempt to 
achieve deeper penetration at the time of impending orgasm and may not 
withdraw in time to prevent sperm from being deposited on his partner's ex­
ternal genitalia. 
Lack of ejaculatory contr( (or premature ejaculation) is a con­
traindication to the use of the withdrawal method of birth control. 
Among couples who use withdrawal, some use it consistently and prefer it 
to other methods, some use it sporadically, and sonic use it as an adjunct to 
other methods during midcycle when ovulation is most likely to occur. 
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CHAPTER 19 
PROMISING NEW METHODS 
Four promising new methods of birth control include the contraceptive 
sponge, long-term progestin-elaborating IUD's, tailless IUD's, and contra­
ceptive vaccines. A fifth, a male birth control pill called gossypol, has at­
tracted a lot of attention. 
CONTRACEPTIVE SPONGE 
Vaginal contraceptive sponge 
Natural sea sponges have been used since antiquity for contraception. In 
the 1970's, interest in the sponge concept led to the development of natural 
collagen and synthetic sponges and to the incorporation of spelrnicide in 
the sponge (1). 
In 1983, the Food and Drug Administration (FDA) approved the first vagi­
nal contraceptive sponge for marketing in the United States. This product is 
a small, pillow-shaped polyurethane sponge that contains 1 gram of 
nonoxynol-9 spermicide. The sponge has a concave dimple in one side 
which fits over the cervix and decreases the chance of dislodgement during 
intercourse. The other side of tile sponge incorporates a woven polyester 
loop used to facilitate removal. 
The sponge is available in one size without prescription. Prior to use, the 
sponge is moistened with tap water and inserted deep in the vagina. Once in 
place, the sponge provides continuous protection for up to 24 hours and 
Spongje in 
place over i 
t 




Woven KW ~ I 
handle 
Vagina 
FIGURE 19. 1 Contraceptive sponge. 
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does not require any additional measures for repeated intercourse during 
that time. After use, the sponge is discarded. 
The sponge exerts its contraceptive effect by (1) providing a barrier be­
tween sperm and the cervix; (2) trapping speirm within the sponge; and (3) 
releasing spermicide contained within the sponge to destroy sperm. 
Several studies of vaginal sponges have been reported. Small studies of 
collatex sponge users in other countries have found pregnancy rates from 
1.1 to 3.6 for the first 6 months of sponge use (2), Data from a multicenter 
study in the United States comrparinq the sponge with the diaphragm found 
an 	overall 12-nionth pregnancy rate of 16.6 for sponge users and to 11 .4 
for diaphragm users (3). Although the difference between sponge and di­
aphragmn effectiveness in this study was statistically significant, the rates in­
dicate that the effectivitess of the sponge is clinic;lly similar to that of the 
diaphragm. 
Contradications to using the sIoilge incIude (1) allergy to polyurethane 
or nonoxynol- 9; (2) inability to !earn correct insertion technique or to 
remember to use the method consistenitly, (3)anatomic abnormalities such 
as 	 uterine prolapse, cystocele, rectocele, extreme uterine retroflexion or 
vaginal septum ihat interfere with proper placement or retention of the 
sponge; (4) history of toxic shock syndrome or vaginal colonization with 
Staph ylococcus aureus. 
There are relatively few side effects amd complications associated with 
the use of the sponge: (1) irri. tion or allergic reactions; (2) difficulty in 
removing the sponge (6'. of users in the United States); and (3) objections 
from partner (uncomminion). 
Althou,', not %et documented, it is likely that benefits associated with 
spermicide use also accrue to users of the spermicide-containing sponge: 
(1) spernicides decrease the traismission of sexually transmitted infections 
including gonorrhea and trichomoniasis; and (2) spermicides may offer 
some protection against cervical neoplasia. (In addition, some sponge users 
find that absorption of vaginal secretions and ejaculate is a desirable side 
effect.) 
IMPORTANT INSTRUCTIONS FOR SPONGE USERS 
I. Use your sponge whenever you have intercourse. 
2. 	 Plan to insert your sponge in plenty of time before intercourse 
and when you have water available. 
3. 	 Do not Use your sponge while you are having menstrual bleeding. 
4. 	Toxic shock has not been a problem for sponge users so far, but 
watch for the early symptoms of toxic shock whenever you use 
your sponge.
 
5. 	 If you find that the sponge is not in proper position after 
intercourse, then you may want to adopt another method of 
birth control. 
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PROGESTIN- ELABORATING IUD's 
In the late 1970's, the Alza Corporation began to market the first 
progestin-elaborating IUD in the USA. Tile perceived advantage of this inno­
vation was that it would enlist the aid of progesterone to prevent implanta­
tion without systemic effects (4). This IUD (called the "Progestasert 
System") has proven to have two additional remarkable advantages: It de­
creases the total amount of blood lost during the menstrual period, and it di­
minishes tile amount of menstrual pain experienced by the user. The main 
drawback of the Progestasert System is that it must be removed and re­
placed in what many consider to be an unacceptably short period of 
time- one year. 
Research is now underway to test IUD's which would release either pro­
gesterone or a inore powerful pro.estin, norgestrel. It is entirely possible 
that one o, these two IUD's will be available in the United States within the 
next ten years. Both norgestrel- and progestin-elaborating IUD's are being 
marketed in Europe today. 
TAILLESS IUD'S 
In our discussion of IUD's (Chapter 13), the case is made that much of 
the infection associated with IUD's may be attributable to the ascent of 
bacteria up the tail of the IUD (5,6,7). As infection is by far the most serious 
problem associated with IUD use, the elimination of the tail should minimize 
the risk of complications associated with infection, thereby constituting a 
major advance. Were we to move in this direction, we would be returning to 
an older approach but one which is widely and successfully used today in 
China (5,6,7). 
The major disadvantage of a tailless IUD is that it leave us with the inabili­
ty to readily identify the location of the inserted IUD. When available, simpli­
fied ultrasound techniques might easily overcome this difficulty. 
Another problem with a tailless IUD is its removal. See the section in the 
IUD chapter relating to removal of an IUD when the tail is lost for sugges­
tluns as to how this second problem might be managed. 
VACCINES 
Throughout the world, mortality and morbidity rates have been pro­
foundly reduced by vaccination. If the theory of vaccination also applies to 
the human reproductive system, it is possible that some day vaccination 
may be responsible for falling fertility rates as well (8). 
For years, the possibility of a vaccine against pregnancy has been 
hypothesized. In time, some of the many naturally occurring ("self") anti­
gens in the male or fernale reproductive systems might be induced through 
the process of vaccination to produce antibodies, thus preventing 
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pregnancy. We are, however, probably a number of years away from devel­
oping an effective, safe, inexpensive contraceptive vaccine. 
GOSSYPOL (MALE PILL) 
Gossypol (extracted from cotton plants) is a yellow phenolic compoundwhich in tablet form has been clinically tested as a male antifertility agent(9). It has been noted in China during the 1 950's that cooking with crushed
cottonseed oil could lead to infertility and affected men more than women.Since 1972, over 4,000 men have been treated with gossypol in Chinafor periods of at least 6 months; more than half of these have been ob­served longer than 2 years. The initial dosage was 20 mg daily, and it usually
took 2 mcnths to produce infertility.

The drug has been found to 
have two effects. It suppresses sperm
production. Also, it alters the structure arid motility of sperm in theepididymis, including damage to the acrosomal cap and swelling of the 
mitochondrial sheath. 
Pctential side effects include weakness, lowered potassium levels in theblood, a decrease in libido, change in appetite, epigastric discomfort, 
nausea, and cardiac irregularities (with high doses).
Because only minimal research has been conducted, effectiveness rateshave riot yet been determined. It is known that normal sperm counts are re­stored for only 75", of men within months of gossypol's discontinuation 
(10). 
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CHAPTER 20 
PREVENTION AND MANAGEMENT OF 
COMPLICATIONS ASSOCIATED WITH 
MISCARRIAGE OR INDUCED ABORTION 
Complications of illegal abortion account for 4 to 70 percent of maternal 
deaths in developing country hospitals and an unknown number ofadditional 
deaths outside ofhospitals. 
Laurie S. Liskin (1) 
Clinicians who provide maternal health and family planning care will 
almost surely be called upon to evaluate or treat women who are having or 
have recently had an abortion, either spontaneous (miscarriage) or induced. 
(See Table 20.1.) This chapter has been included to meet the needs of clini­
cians who are called upon to manage complications from abortion. 
PUBLIC HEALTH IMPACT OF 
PREGNANCY TERMINATION 
MOST ABORTIONS CAN BE PREVENTED BY THE SAFE AND EF-
FECTIVE USE OF CONTRACEPTIVE METHODS. 
Pregnancy and pregnancy termination are probably the most important 
health risks that women face during their reproductive years in traditional and 
developing societies. As the transition from a traditional to a developing 
society occurs, the risks of childbirth diminish dramatically, but more women 
face the risks associated with induced abortion and ectopic pregnancy. Ex­
perts reviewing these problems in Africa conclude that: 
Although the real status of induced abortion is not known, it is generally 
accepted that as the underdeveloped communities become involved in the 
transitional process of development, an increasing incidence of induced 
abortion occurs. 
Today, in the capitals of some African countries, societies are rapidly 
changing and entering the transitional process, so that induced abortion 
with all its associated risks, including complications and death, may be ex­
pected to increase in incidence (2). 
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TABLE 20.1Number of admissions in African hospitals for abortion 
complications, selectedstudies, 1970-1979 (1) 
Country Hospital 	 Year 
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TABLE 20. 1Numberof admissions in African hospitals for abortion 
complications, selected studies, 1970-1979 (1)- Continued 
No. of Abortion-















































Clinicians concerned about health care for women inAfrica must therefore 
expect to face increasing problems with the dilemma of abortion (3). Devel­
oping countries in other areas of the world have already experienced this seri­
ous problem. Studies in Latin America have demonstrated that complications 
of illegal abortion accounted for as much as 30% to 40% of maternal deaths 
(1). Similar rates have also been reported for some African urban hospitals. In 
the Lagos University Teaching Hospital, 51% of maternal deaths between 
1966 and 1972 were attributed to abortion-related complications (4). In a 
1980 study at Kenyatta National Hospital in Nairobi, the number of hospital 
admissions for septic abortion increased 100% between 1973 and 1978; 
septic abortion carried a high death rate (two deaths for every 1 000 septic 
abortion patients admitted) (5). 
Because it is usually so difficult to gather accurate statistics on induced 
abortion, there are few comprehensive studies documenting complication 
rates. Worldwide experience does show, however, that abortion complica­
tions can be a substantial burden for limited health care facilities, blood bank 
supplies, and trained medical personnel (3,6). 
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Moreover, one recent survey of 60 developing nations throughout the 
world estimated that 13.7 million abortions were induced in 1976, yielding a 
ratio of 207 abortions per 1,000 live births. An estimated 70,000 to 
140,000 women died in 1976 in these 60 developing countries from abor­
tion complications, including between 600 and 6,000 women in Africa (7,8). 
WHAT CAN YOU DO? 
Clinicians will be called upon to provide the followin-] important iealth 
services: 
1. To recognize and manage the medical complications of abortion and 
teach patients the danger signs, so that problems can be id6ltified and 
treated early. 
2. 	 To be prepared to provide treatment or referral for women who have 
complications. Tie exient of clinical services available for treating
complications will depend, to some degree, on whether they are being 
delivered in a hospital or primary care center. 
3. 	To provide contraceptive information and services. Women who have 
spontaneous abortions need time for full recovery before attempting 
another pregnancy. Women who have had induced abortions are likely 
to appreciate help and become eftective contraceptive users. Acceo­
tance rates as high as 90", have been reported by programs offering 
contraception to women after treatment ;or abortion (3). Effective con­
traception can prevent the occurrence of future abortions and their 
complications. 
4. To keep careful statistical records so that the extent of abortion-related 
public health problems can be assessed and appropriate public health 
remedies can be considered. 
COMPLICATIONS AFTER ABORTION 
Complications can occur after any type of pregnancy termination. With 
spontaneous abortion (miscarriage), the most common problems are: 
" 	 infection; 
* 	 retained pregnancy tissie; 
* 	 bleeding. 
These three problems are also common after induced abortion, particularly
illegal induced abortion. With induced abortion, however, additional problems 
must also be considered, especially when illegal or nonphysician abortion is 
suspected: 
* 	 continuing pregnancy (despite the abortion procedure); 
* damage (trauma) to the uterus and cervix;
 
" toxic reactions to chemicals or drugs used to induce abortion.
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Whenever symptoms suggest miscarriage or induced abortion, it is impor­
tant also to think of ectopic 'usually tubal) pregnancy. The early signs of 
ectopic pregnancy may be similar to the signs of abortion complications. A 
woman with, an ectopic pregnancy may have pain, irregular bleeding, breast 
tenderness, nausea, or a recently delayed or skipped menstrual period. (See 
Chapter 8 for more information on ectopic pregnancy.) The complications 
listed above are more thoroughly described in the fol;owing pages. 
MANAGEMENT OF ABORTION COMPLICATIONS 
INFECTION 
Signs of infection are: 
1. pain in the abdomen or pelvis 
2. cramping or backache 
3. fever and chills 
4. foul-smelling vaginal discharge 
5. prolonged bleeding or spotting 
6. weakness, lethargy, or muscle aches 
7. tenderness of the uterus and adnexae during pelvic exam or tenderness 
with cervical motion
 
Patients should be taught to watch for these signs and 
to seek help im­
mediately if anyof these occur, even in mild form after a spontaneous or in­
duced abortion. Most often, signs of infection appear 2 or 3 days after 
abortion, but infection can begin earlier or as long as several weeks later. 
Treatment depends on the severity arid extent of the specific infection. It 
is essential to be sure that no pregnancy tissue remains in the uterus. If an in­
complete spontaneous abortion (misca'iiage) or an illegal induced abortion is 
suspected, then special care is needed to be sure that the uterus is empty. 
This should be done at the earliest opportunity. 
If the patient is severely ill with weakness, low blood pressure (shock), 
or infection that extends beyond the uterus to involve the tubes (parametritis 
or salpingitis) or abdominal cavity (peritonitis), then urgent hospital care will 
be needed. Intravenous or intramuscular antibiotics and fluids should be start­
ed and immediate arrangements made to remove any remaining pregnancy 
tissue. Suction or sharp curettage of the uterus should be used and should 
not be delayed until hospitalization. Intravenous antibiotics are continued 
until the patient improves (remains afebrile for at least 24 hours, for example) 
and is able to change to oral treatment. If a hospital is fa. away, then antibiot­
ics can be given intramuscularly or orally until the patient arrives at the hospi­
tal for intravenous administration. In other words, antibiotic therapy ought 
not be delayed. 
If the infection is mild and involves only the uterus and no evidence of 
tissue remains in the uterus (continue to suspect it if, for example, the os is 
still widely dilated, the uterus is large, or cramping or bleeding persists), then 
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hospitalization may not be necessary. Antibiotics can be given by mouth, and
the patient can be advised to rest at home. If there is satisfactory improve­
ment when the patient is examined 2 or 3 days later (less pain, less uterinetenderness, no fever), then D&C or vacuum curettage of the uterus may not
be necessary. If symptoms persist, worsen, or the uterus is tcnder orenlarged, then a D&C or vacuum curretage may be needed to be certain that 
no tissue remains in the uterus. 
RETAINED PREGNANCY TISSUE 
Signs of retained tist Je after spontaneous or induced abortion are: 
* abdominal or pelvic pain 
* backache or cramps

" heavy or persistent bleeding, which may lead 
to shock (rapid pulse;
sweaty, clammy skin; fainting or lightheadedness) 
* an enlarged, soft, tender uterus noted at pelvic examination
 
* 
 tissue visible at cervical os (opening)

Infection very often accompanies 
 the problem of retained pregnancy
tissue because the tissue is an ideal environment for bacterial growth.
Retained tissue is common after spontaneous abortion or after illegally in­duced abortion, when surgical techniques are not optimal. It is not as 
common when vacuum aspiration is used to induce abortion, occurring usual­ly less than 1 in 25 times. Vacuum abortion ;s infrequently followed by a relat­
ed problem, accumulation of blood clots n the uterus after surgery. This 
occurs once in 200 to 300 times. This can occur rapidly, causing very severe
cramping pain that worsens within the first few hours after an initial vacuum
aspiration. Examination shows a quite large, tense uterus that is very tender,
with little or no bleeding at the cervix. In this situation, remove retained tissue or blood clots with vacuum aspiration or D&C and consider giving methyler­
gonovine (Ergometrine ,) or other oxytocics to help maintain firm uterine 
muscle tone and to expel any remaining tis.'lie or clots. 
BLEEDING 
Some bleeding is to be expected after any termination of pregnancy.
Often bleeding is scant (or absent) tor the first 24 to 36 hours, and then in­
creases somewhat as the uterine lining loses the hormone support that pregnancy provides. Moderate bleeding, similar to a menstrual period, then 
may occur and continue intermittently for as long as 6 weeks. 
Bleeding heavier than that which occurs during a menstrual period, or that
persists longer than 3 or 4 weeks needs to be evaluated. Initially, heavy bleed­ing may be caused by retained pregnancy tissue or by trauma to the cervix,
vagina, or uterus from instruments or chemicals. Some anesthetics, such ashalothane, may also cause immediate uterine hemorrhage as they interfere
with normal oterine contraction. Prolonged bleeding may indicate retained 
pregnancy tiss,' 
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Hemorrhage can also be caused by disruption in the normal blood-clotting 
sequence. This problem (disseminated intravascular coagulopathy - DIC) is 
rare but can be triggered by an instillation of hyperosmolar agents or a D&C 
for abortion in the second trimester, by a spontaneous abortion that is 
delayed (missed abortion), when a dead fetus remains in the uterus for days 
or weeks before spontaneous uterine contractions begin, or by severe 
infection. 
Initial treatment for hemorrhage, such as repair of a cervical tear or remov­
al of retained tissue, is often successful. If bleeding is very heavy or the pa­
tient shows signs of shock (rapid pulse, decreasing blood pressure, 
weakness, or faintness), then uterine massage to maintain firm muscle tone 
and oxytocics or ergometrine may be started while arrangements are made 
for further care, such as intravenous fluids, blood transfusion, and surgery. 
DAMAGE TO THE CERVIX OR UTERUS 
Damage to the vagina, cervix, and uterus is a very important problem, es­
pecially after illegal abortion or when abortion is self-induced. Uterine perfo­
ration and damage to intestines can result from an attempt to insert a foreign 
body (such as a stick) into the uterus. Vaginal injuries can also occur if tile c!i­
nician fails to locate the cervix, or if caustic chemicals such as harsh soap or 
potassium permanganate are used. If induced abortion is suspected, it is im­
portant to watch for early symptoms of internal hemorrhage and intestin3l 
injury. Rapid pulse, weakness, faintness, or decreasing blood pressure may 
be a warning that serious internal bleeding is occurring, possibly as a result of 
damage to the large uterine blood vessels in the broad ligaments adjacent to 
tile uterus. Pain, vomiting, abdominal tenderness or rigidity, and decreased 
bowel sounds may be signs of intestinal injury. 
Damage to the cervix or uterus is much less common during the course of 
vacuum aspiration abortion, but it can occur. More common are tears of the 
cervix from the clamp (tenaculum) used to stabilize it during surgery. Uterine 
puncture (perforation) is less frequent. If the perforation is caused by the ute­
rine sound, then the uterine wound may close and heal without treatment. 
When such an injury is suspected, careful observation is required for the first 
24 hours or so to watch for signs of intestinal injury and internal hemorrhage. 
If the uterus is perforated by a sharp instrument or by the vacuum curette, 
then surgery may be required to find and repair damage to the uterus, 
intestine, or bladder. 
Cervical injury can occur as a result of forceful uterine contractions during
late abortion induced with intra-amniotic prostaglandin, prostaglandin vagi­
nial tablets, or intra-amniotic saline augmented with oxytocin. In a small frac­
tion of patients cervical dilation fails to keep pace with the force of uterine 
contraction. The result is a spontaneous tear in the lower uterine segment 
(usually in the posterior fornix of the vagina, just below the cervix) through 
which the pregnancy is expelled. This problem can occur undetected with 
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surprisingly few symptoms, but examination with a speculum shows a"ragged" defect. The tear should be carefully sutured so as to avoid problems 
in future pregnancies. 
TOXIC REACTIONS TO DRUGS OR CHEMICALS 
Women who have attempted to induce abortion may also show toxic
signs of poisoning "ith herbs, cathartics, or other drugs; symptoms depend 
on the specific agent used. Watch for kidney damage (anuria or oliguria) and
for liver damage (upper abdominal pain, jaundice). Clinicians may also sus­
pect attempted abortion if the vagina shows ulceration or bleeding from
caustic chemicals, such as potassium permanganate or harsh soap.
Ergonovine poisoning can cause vomiting, diarrhea, thirst, itching,
numbness, and tingling of the extremities, and can lead to confusion, cold 
skin, a rapid weak pulse, unconsciousness, and death (lethal dose, 26 mg by
mouth) (9). Chloroquine poisoning causes headache, disturbances in vision,
gastrointestinal upset, itching, and in some cases, rash. Toxic doses of cIji­
nine cause stomach pain, nausea, vomiting, and diarrhea, ringing in the ears,
dizziness, and vision disturbances. Severe central nervous system effects of
quinine poisoning include headache, fever, confusion, delirium, faintness, de­
pressed respiration, coma, and death (lethal dose, 8 gm by mouth) (9).
These and many other drugs and herbal preparations are commonly
viewed as abortion options. None, however, provides reliable termination of 
pregnancy, arid serous toxic complications are frequent. 
On occasion (1 to 3 in 1 000) (10,11), the attempt to induce abortion
using vacuum aspiration is not successful. This problem is more common
when an abortion procedure is performed before the seventh week of gesta­
tion (counting from last menstrual period) and may also be a problem when 
less than optimal abortion methods are used.
 
Signs of continuing pregnancy 
 include persisting symptoms of
 
pregnancy, such as nausea, breast tenderness, fatigue, arid continuing or in­
creasing uterine enlargement. In this situation it is important to think of tubal

(ectopic) pregnancy, twin pregnancy, or pregnancy in a bicornuate uterus. In
 
most cases, however, the intrauterine pregnancy was simply not evacuated
 
during the initial abortion attempt. 
LATE EFFECTS OF ABORTION 
When complications occur following induced abortion, they can cause a range of long-term medical problems including chronic pelvic infection,
which can lead to an increased risk of ectopic pregnancy and infertility. Due 
to the lack of studies that provide for long-term followup for uneventful 
abortions, the possible long-term medical risks are not yet known for cases
when abortion is induced under satisfactory medical circumstances and no 
immediate complications occur. 
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The recent scientific literature from tJ- United States is inconsistent 
about whether one abortion, or even multiple abortions, is associated with in­
creased rates of adverse reproducive outcomes (miscarriage, prematurity, 
low birth weight) in subsequent desired pregnancies (12). Among current 
studies, two have demonstrated a significant association between a single in­
duced abortion and problems of s ibsequent childbearing (13,14); the others 
have found either no association or such a small level of risk that chance 
could have accounted for the difference (14-21). 
FACTORS THAT INFLUENCE (OR INCREASE)
 
THE RISK OF ABORTION COMPLICATIONS
 
Many factors influence the risk of abortion. The risk of complications is 
highest under the following circumstances: 
1. The woman is in poor health. 
2. 	 The abortion occurs late in pregnancy. 
3. 	The uterus is evacuated under unsterile conditions. 
4. The clinician who performs the abortion is incompetent. 
5. 	The woman is poorly educated to danger signs she should watch for 
after abortion. 
6. 	Aftercare is poor if problems arise after abortion. No followup exam is 
performed after the abortion (2 weeks) to be sure that the uterus has re­
turned to normal size and is not tender and that there are no other signs 
of continuing pregnancy, infection, or bleeding. 
7. 	The tissue removed is not examined following the procedure so that 
the possibility of incomplete abortion, ectopic pregnancy, or molar 
pregnancy can be recognized at the time of surgery. 
8. 	The woman has gonorrhea or other pelvic infection. 
DANGER SIGNS AFTER ABORTION 
* 	 Fever 
• 	 Chills 
* 	 Muscle aches 
* 	 Tiredness 
* Abdominal pain, cramping, or backache
 
" Tenderness (to pressure) in the abdomen
 
o 	Prolonged or heavy bleeding 
* 	 Foul vaginal discharge 
* 	 Delay (6 weeks or more) in resuming menstrual periods 
Abortion is a traumatic event for everyone concerned: the woman, the 
family, and the clinician. Ideally, abortion can be prevented by the effective 
use of contraceptive methods. 
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"Do not have any more children, " the supervising physician ad­
vised two women who, along with thirty other women, hadcome 
for family planning services. Sterilization facilities were not 
available. Since the nurse-midwife providing the contraceptives 
had a prejudice against the IUD, she gave the two women a 
supply of Pills. The women used the Pills until they could get no 
more because of a stock-out at the supply depot. They therefore 
stopped using the Pilland became pregnant. Both women died in 
childbirth. 
Mana, Mali1981 (1) 
WHAT IS STERILIZATION? 
Voluntary sterilization is a surgical operation for permanent contraception.
In women, the sterilization operation involves blocking or cutting both fallopi­
an tubes to prevent the passage of ova and sperm, in this manner, fertilization 
is prevented. Inmen, the sterilization operation-called a vasectomy- blocks 
the vas deferens to prevent the passage of sperm. The effect of sterilization 
operations on the hormonal feedback between the pituitary and the gonads
has been studied extensively (2-4). Levels of luteinizing hormone (LI), follicu­
lar stimulating hormone (FSH), testosterone and estrogen remain within the 
normal range after sterilization. Levels of serum progesterone are slightly re­
duced after tubal sterilization, according to recent reports (5,6). Even though
the sterilization operation can be reversed in some cases, it should be consid­
ered permanent. Because of its permanence, the method is best for couples
desiring no more children because their family is complete, or for couples
who, for medical reasons, should not have any more children. It is important
that couples choosing to be sterilized realize that the operation must be con­
sidered irreversible. 
THE ADVANTAGE OF STERILIZATION 
The operation has several advantages that add to its popularity:
* It is more effective than any other method of contraception. Studies 
from Singapore have shown cumulative failure rates of 0.47% at 12 
months, 0.81 2 at 24 months, and 0.85%at 36 months following tubal 
sterilization (7). 
" It can be easy to perform, depending upon the approach chosen. 
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* It carries only a one-time risk of complication, as opposed to the ongo­
ing risks of other contraceptive methods. 
* It can be performed not only at an elected point in time between 
pregnancies, but also post-partum and post-abortion.
* It is relatively safe with a very low mortality rate (8), in fact, much lower 
than that of pregnancy (See Table 21.1 ). 
TABLE 2 1. 1 Estimated mortality associated with pregnancy, childbirth, and





Developmental Status pregnancies or procedures)
 
Developed countries 






 0 0 
Developing countries (advanced) 






 0 0 
Developing countries (less advanced) 






 0.1 0.1 
Note: As the results from studies of maternal mortality and sterilization safety become
available, these estimates will need to be revised. The data from two recentstudies suggest that female sterilization mortality in less advanced developing
countries is even lower than estimated here, while male sterilization mortality
is higher (9, 10). 
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THE DISADVANTAGES OF STERILIZATION 
Disadvantages of sterilization are: 
* 	 It must be considered irreversible. Many disappointments may be 
prevented by carefully educating the patient about the permanence of 
the operation. The reversal operation requires a special skill and tech­
nologically advanced equipnent, and it carries its own risk of 




 It may not be accepted in all cultures. Again, education is helpful in 
gaining understanding and support. 
" It carries a risk of complications, a!though the complication rate is 
low and carl be further reduced througn careful medical screening. The 
complication rate depends significantly upon the skill of the surgeon. 
Complications of anesthesia are lower with the use of local, rather than 
general, anesthesia. 
STERILIZATION IN THE MALE 
VASECTOMY 
Vasectomy is a simple procedure that can be performed safely even in 
remote areas, provided the procedure is done carefully. A good history and 
physical examination are important steps in making sure that the operation 
goes smoothly. Specifically, you should: 
* 	 Obtain a history of current medications and past illnesses and 
surgeries. Ask especially about any bleeding disorders or allergies to 
local anesthetics or pain medications. In a review of systems, ask about 
hypertension, heart disease, kidney or bladder infection, diabetes, 
phlebitis, anemia (including sickle cell), liver trouble, and venereal 
disease. 
• 	 Examine the patient for local infections (which should be treated before 
the operation is performed), inguinal hernia or previous surgery for a 
hernia, a fixed and undescended testicle, hydrocele or varicocele, and a 
thick, tough scrotum or scrotal lesions. These physical conditions can 
make vasectomy more difficult to perform. 
• 	 Some surgeons suggest preoperative tests for hemoglobin and possi­
bly clotting times. But in most cases, a well-oriented history and physi­
cal examination can be enough. 
Preoperative preparation 
The patient's hair is cut from his scrotum and around his penis. The area is 
then bathed with soap and water, just before the surgery. The patient should 
prepare to rest for up to 2 days after the operation. 
Procedure 
Sterile technique is used to perform the procedure. The patient is placed in 
the supine position, the scrotum cleaned, and the area draped. The vasa (two 
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tubular structures, one on each side of the scrotum) are anchored with an 
atrautmatic instrument or fingers. (See Appendix C for kit of vasectomy 
equipment.) One-percent lidocaine is infiltrated into the area to be incised. 
The skin and muscle overlying the vasa are incised. Through this small 
incision, the vasa are isolated and occluded and, in most cases, resected (see 
Figure 21 .1). The same procedure is performed for the vas on the other side. 
The incisions are closed with absorbable suture. If possible, the patient 
should rest 15 minutes to half an hour, or longer if needed, before tie leaves 
the examination room. 
Complications 
The complication rates for vasectomy are very low in comparison with the 
contraceptive methods used for women. Most of the complications are short 
term and minor, such as swelling, discoloration, and discomfort. These may 
be reduced by the use of ice packs, rest from strenuous exercise for a day or 
two, and scrotal support. Aspirin can u5ually relieve discomfort. With the ex­
ception of rare rtports of serious infections, no major long-term clinical side 
effects have complicated vasectomy. (See Table 21.2.) Although millions of 
vasectomies have been performed throughout the world, deaths have been 
Y 
FIGURE 21.1 Sites of vasectomy incisions. A vasectomy is usuallyperformed 
using local anesthesia. Once the vas is located (upper left), an incision is 
made in the anesthesized area (upper right), and a section of the vas is lifted 
out of the incision (lower left). Vasectomy may be performed using either 
one or two incisions, both of which are shown in the lower right-hand 
diagram. 
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rare. Most of the complications of vasectomy that do occur can be prevented 
by using aseptic technique and advising restraint from strenuous exercise for 
a day or two. Hematomas are also prevented by carefully stopping bleeding 
from blood vessels during the operation. 
Infection is prevented by using sterile technique and sterilized equipment 
and by having the patient keep the incision clean. Should infection occur, it 
should be treated with antibiotics. Granulomas generally subside 
spontaneously. Those that persist can he treated with ice packs, bed rest, 
and, if needed, anti-inflammatory medication. Granulomas that increase in 
size and are painful may need to be removed surgically. Epididymitis usually 
subsides in a week This condition can usually be treated with heat and scrotal 
support. 
About one-half to two-thirds of men will develop sperm antibodies follow­
ing vasectomy. Although there has been rather widespread publicity and 
worry about this finding, no physiologic evidence points to any pathologic 
complication arising from the condition (1 1,12). Two studies performed on 
vasectomized monkeys (13,14) indicated that the monkeys developed athe­
rosclerotic plaques in the blood vessels at a greater rate than nonvasecto­
mized monkeys. The development of the plaques was attributed to the cir­
culating antibodies. These studies, however, have limitations: the number of 
animals studied was small, the groups of nonkeys were not treated in the 
same way, and there is no evidence that monkeys and men respond in the 
same manner 
TABLE 2 1.2 Summary of meedical complicationsof vasectomy (11) 




Epididymi tis 1.4% 
Granuloma 0.3o 
Failures 0.4% 
Re versibilit y 
The operation for reversing vasectomy has mixed success and requires 
special training and sophisticated equipment. Success in rejoining the tubes 
and leaving an open pathway for the passage of sperm (reanastomosis) 
ranges from 40.,, to 90',. However, success in restoring the ability to con­
ceive only ranges between 18", and 60" (15). Successful reanastomosis of 
the vas depends on the initial surgical procedure: the length of the piece of 
vas removed, where the incision was made, whether or not coagulation was 
used, the type of ligation material used, and the amount of time that passed 
between the vasectomy and the reversal procedure. 
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Postoperational instructions forthe vasectom ypatient
1 Following the surgery, you should return home and rest for about 2
days. If possible, you should keep an ice pack on the scrotum for at least
4 hours. This will reduce the chances of swelling, bleeding, and
discomfort. You may be able to resume your normal activities after 2 or 
3 days. 
2. Avoid strenuous physical exercise for a week. Strenuous exercise 
means hard physical exertion to which you are normally unaccustomed 
or lifting or straining that could bring pressure to the groin or scrotum. 
3. Do not shower or bathe for the first 2 days after the vasectomy.
4. The stitches will dissolve and do not have to be removed. (Note: this in­
struction must be modified if a permanent suture such as silk is used.)
5. You may resume sexual intercourse after 2 or 3 days if you feel that itwould be comfortable- but remember, you are not sterile immediately.
For most men, sperm has not been cleared from the tubes until after at
least 10 ejaculations. Until then, use another method of birth control to 
prevent pregnancy. The ber. way of finding out if you are still sterile is 
to have the doctor look at your semen under a microscope. Take a
specimen of your semen to the doctor for a sperm count after you have 
had 10 ejaculations. 
QUESTIONS COMMIONLY ASKED BY MEN 
QUESTION ANSWER
Is vasectomy the same as No. Vasectomy cuts only the
 
castration ? 
 passageway for your sperm. Your
 
testicles will be unhurt.
 
How will vasectomy affect my 
 Vasectomy does not affect

manhood? 
 manhood. You will have the same 
ability for sex and other manly 
functions, 
Will I still enjoy sex? The operation should have no effect 
on your ability to enjoy sex. It merely 
prevents sperm from being 
released. 
What happens to the sperm? Your body absorbs the sperm 
Are there any long-lasting effects There are no proven long-lasting
from vasectomy? effects that have been seen in 
vasectomized men. Some report 
that their wives enjoy sex rore 
since they are no longer w,)rried 




Tubal sterilization operations may be performed just after delivery or abor­
tion or at any point between pregnancies. Since we presume that the demand 
in Africa for post-partum and interval procedures is greater than the demand 
for post-abortion ones, we are restricting our discussion primarily to these 
two. 
The effectiveness of tubal sterilization is similar whether performed post 
partum or in the interval period. Although postoperative morbidity following 
a post-partum procedure may be slightly higher, several advantages of per­
forming the post-partum procedure during this time may offset the 
disadvantages: 
1. 	The woman can make a decision in private; none of her neighbors need 
know she is having a sterilization; 
2. 	 Childbirth is one of the few times many women have access to or make 
use of medical services; 
3. 	 The procedure performed in the post-partum period is a simple and effi­
cient operation and can be done with local anesthesia; 
4. 	The post-partum procedure may be more convenient for the woman as 
she need not travel or make arrangements for a return visit to the hospi­
tal or clinic nor make additional child-care arrangements for her 
newborn; 
5. 	The procedure performed post partum eliminates the additional ex­
pense of another hospitalization and travel. 
Once the decision is made to perform the operation, other decisions must 
be made as well: which approach to use, what anesthesia to use, and what 
occlusive method to use. Basically, tubal sterilization requires the blocking of 
the fallopian tubes. Blocking of the tubes can be accomplished by several 
techniques: 
* 	 Ligation and division -the Pomeroy procedure is a commonly used 
technique in which the tubes are ligated with an absorbable suture and 
divided; 
* 	 Ligation, division, and further separation-the Irving procedure is a 
variation that involves ligating the tube, dividing it, then burying the 
medial stump; 
* 	 Coagulation -the tubes are coagulated with an electrocauterizing 
instrument. Bipolar coagulating instruments are safer than unipolar coa­
gulating instruments; 
* 	 Mechanical occluslui -the tubes are blocked mechanically with 
clips, bands, or rings. The use of these occlusive techniques allows 
somewhat more hope for reversibility of the sterilization. Nonetheless, 
these techniques must still be considered permanent. 
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The fallopian tubes may be approached in two ways: through the abdo­
men or through the vagina. The abdominal approaches include laparotomy,
mini-laparotomy, and laparoscopy. The vaginal approaches include colpoto­
my and culdoscopy. These approaches will he discussed in detail later in the 
chapter.
 
Either general or local anesthesia 
 may be used for the sterilizationprocedure. In the najority of mini-la'arotomy cases, local anesthesia is used.Local anesthesia may also be used successfully in both the post-parturn inci­sion procedure and the laparoscopic procedure If local anestilesia is used,
tile patient should he adequately sedated so that she will be relatively painfree and caln enough to cooperate during the ,)peration. Sedatives andanalgesics may be used such as Demerol (ineperedine) and Valium
(diazapam). Given that much of the morhidity associated with the operationactually results from comrnlications of the general anesthetic or excessive
aniounts of local anesthetic, v.'eUrge that anesthesia be used by personswith aderluate training(I 'id with appropriate eclui)[1e1t and supplies for 
resuscitation in the event of a respiratoiy arrest, 
ABDOMINAL APPROACHES 
Most physicims are familiar with the fenia!, pelvic anatomy as seen from
the abdomen (see Figure 2 1 .2). The suspende,-ature of the oviducts makes
them easy to manipulate, bring into view, and then ligate, occlude, orcoagulate. Over 100 variations of abdominal tubal ligation have been devel­oped (16, 17). In this section, we describe thre. lajor methods: the post­partum incision, the mini-laparotomy, and the laparoscopy. The first two donot require highly specialized training or expensive and sophisticated
equipment. Laparoscopy, however, requires both of these. 
Preoperative preparations 
* Obtain a history concerning pelvic disease or adhesions, last menstrual
period, previous problems undergoing anesthesia, bleeding problems,
allergies, current medications, activity limitations, and current contra
ceptive use. Some clinician,, recommend that IUD's be removed at thetime of surgery to reduce the risk of infection. Oral contraceptives
should be discontinued for at least a month before any elective surgery
to reduce the risk of thromboembolism, During this time the patient
who discontinues oral contraceptives for this reason should use anoth­
er form of contraception, such as a barrier method.
" Examine the patient to identify any medical conditions that may make
the operation more difficult. Obesity increases morbidity and makes
both mini-laparotomny and laparoscopy harder and lengthier to perform.
* Mini-laparotomy patients: Check for adhesions from endometriosis or
pelvic infections; treat completely any local infections before perform­
ing the operation. Also, rule out the possibility of pregnancy. If, during
the operation, you find any adnexal pathology or abnormality that re­
quires corrective surgery, widen the incision to allow for adequate 
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* 	 Laparoscopy patients: Check for severe cardiac or pulmonary disorders 
as the pneumoperitoneum may complicate these conditions. Since it 
may also exacerbate a hernia, it is important that you check for antece­
dents of hernia. Note any extensive scarring adhesions or leiomyomata 
that could make the operation more difficult. 
* 	 Given the frequent problems of long distances traveled by patients and 
the limited availability of transportation, we recommend the following 
procedures. It is desirable to take a Pap smear before surgical 
sterilization. If tlh, results are available on the same day and are 
negative, you can perform the sterilization. If the results are unavailable 
that day -and the cervix does not show any suspicious lesions, surgery 
can be performed. However, if suspicious lesions are observed, you 
should await the results from the Pap smear before going ahead with 
the sterilization. 
* 	 Take into consideration that women can become pregnant while wait­
ing to return for another visit to obtain the test results and/or 
sterilization. In fact, they may be discouraged from returning at all. 
Therefore, it is preferable to perform the sterilization, and-if the test 
results later turn out positive-to perform a second surgical procedure, 
if necessary, thereby avoiding the possibility of the woman's becoming 
pregnant while she has cervical neoplasia. 
FIGURE 21.2 Incision site fora mini-laparotornY tubal figation. 
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Post-partumincision andmini-laparotom yprocedure
Sterile technique is used in performing both of these procedures. It is im­portant that the bladder be empty prior to the abdomiial incision. The site ofthe abdominal incision is cleaned arid draped. The skin is infiltrated with alocal anesthetic by the use of slow, careful, and deliberate movements
through each layer. Gentleness to avoid causing the patient pain is the key tothe success of this operation. No more than a total 300 mg of lidocaine with­out epinephrine is used. Alternatively, a spinal anesthetic or general anesthe­sia can be used, but a local anesthetic is usually preferred. A small, 2- to 3-cmtransverse incision is made, about 3 centimeters above the pubis in nonpreg­nant patients (see Figure 2 1.2) or subumbilically in post-partumn patients (seeFigure 21.3). If the operation is performed within a day of delivery, a subum­
bilical incision should be adequate. If the operation is performed later, thefundus may have ieduced in size, thereby requiring a small midline incision.
Since thrombophlebitis is more common following a post-partum procedure,do not use estrogens to suppress lactation 18). In the interval procedure, the cornua is brought into view by manipulating the uterus with the uterineelevator. (See Figure 21.4.) In the post-parturn procedure, the cornua should 
already be in view. 
FIGURE21.3 Incisionsite forpost-partum tubal lIgation. 
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FIGURE 21.4 Uterine elevation. In performing a mini-laparotomy tubal 
iigation, a sound is used to elevate the uterus so that the uterus and the 
tubes will be closer to the abdominal wall. 
The fallopian tube is grasped with an atraumatic instrument, then a liga­
ture of plain catgut is placed around the tube. The tube is occluded with a 
-lip, ring, or band, or by ligation, coagulation, or resection. Each layer is 
closed with an absorbable suture. For 2 days, the patient should rest at 
home or at the hospital. If she is post partum, she should avoid stienuous 
lifting for 1 week. (See Appendix D for kit of mini-laparotomy equipment.) 
Complications 
The low rate of complications makes this operation quite desirable. 
Complications, ranging between 0.4% to 1%, include wound infections, 
hematoma, uterine perforation with the elevating instrument, bladder iljury, 
and rterilization failure (19). These complications can, for the most part, be 
prevented by careful attention to surgical techniques during the operation. 
Re versibilit y 
With ligation or mechanical occlusion of the tube, careful microsurgical 
techniques can have a 50% to 70% rate of reversal. This high success rate, 
however, reflects reports from experts operating on selected patients. Once 
again, the point needs to be emphasized that reversal proceddres require spe­
cialized training and expensive equipment, and even sterilization performed 
by mini-laparotomy method should be considered permanent. 
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Laparost-opyprocedure
Laparoscopic sterilizations can be performed using general anesthesia orlocal anesthesia. If local anesthesia is used, patients should be adequatelysedated beforehand. The pelvic area is cleaned: then the abdominal site iscleaned and draped. Occasionally, it is necessary to catheterize the bladder.The cervix is stabilized with a cervical cannula, which will also permit manipu­lation of the uterus. A small, subumbilical incision is made. With careful out­ward traction on abdominal muscles, a Veress needle is inserted and directedtoward the pelvis and away from the great blood vessels. After the needlehas been placed in a safe position, roughly 3 liters of room air,carbon dioxide(CO), or nitrous oxide (N20) are infused into the peritoneal cavity. Currently,the low cost and convenience of using room air favor this substance. Insuffla­tion should be sufficient to assure visualization, but not so excessive as to in­terfere with respiration. The needle is withdrawn and the trocar placed intothe same incision. The incision is widened to 1 centimeter to accept thetrocar. The trocar is directed toward the pelvis and away from the greatvessels. The obturator ic, removed, and the laparoscope is placed so that asecond incision can be made under direct vision. Either through the second in­cision or alongside the laparoscope (depending upon the laparoscope used),the forceps are inserted to grasp the oviduct. If no other structures are closeto the oviduct, the tube is occluded. If coagulation is used, 2 centimeters ofthe oviduct are coagulated at midpoint and, if desired, transected. If clips areused, they are placed at the isthmic or proximal one-third of the tube (20). Ifbands are used, they are applied 3 centimeters from the cornual area (21).After both tubes are occluded, the pelvic organs are inspected for bleeding orir.iury, then the instruments removed, and the ncision closed. 
Complications 




The rate of complications following laparoscopy is strongly influenced by
the skill of the surgeon. Surgeons who have performed fewer than 100 casesa year may have a higher complication rate than surgeons who have hadmore experience (22). It is the use of coagulation that prirlarily results in
bowel burns or perforations. Unipolar coagulation carries 
a greater risk forelectrical accidents than other techniques; bipolar coagulation is a safer tech­nique than unipolar coagulation (23). The risk of burns has influenced manylaparoscopists to switch to rings, bands, or clips.Over the past few years, studies have shown that the risk of dying from alaparoscopic procedure is low. Currently, 'he mortality rate is 6 to 15 deaths 
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per 100,000 procedures (22,24). The pregnancy rate following laparoscopic 
sterilization has been reported to be about 2.5 per 1,000 procedures over a 
4-year period (25). 
TABLE 21.3 Major complications of laparoscopy for sterilization 
reported by mem.'-ers of the American Association of Gynecologic 





Total 	 76,842 
Failed attempts 	 513 6.7 
Laparotomies: 
Bowel trauma 	 67 0.9 
Hemorrhage 	 142 1.8 
Other 	 115 1.4 
Total 324 	 4.1 
Reversibility 
Again, tubal sterilization should be considered irreversible. However,rever­
sal is more likely if only minimal tubal destruction occurs. Coagulation, espe­
cially when unipolar electrodes have been used, offers a poor chance for 
reversal because of the amount of tubal destruction it causes. 
Patient Instructions 
Preoperative 
1. 	Depending on the exact procedure you are to have performed, you may 
need to bathe before the sterilization proceduro. 
2. 	Have someone come with you to the clinic or hospital where your surg­
ery will be performed so that the individual may accompany you home 
after the procedure. 
3. 	You will experience some pain after your procedure. Because it is 
desirable that you rest for several days and not be involved in any 




1. 	Following the operation, rest for about 2 days. You may then resume 
your normal activities when you are comfortable. 
2. 	Avoid intercourse until it is comfortable to begin again. 
3. 	Avoid strenuous lifting for about a week to allow the abdominal inci­
sions time to heal. 
4. Call upon your physician promptly if you develop
 




c) abdor,,inalpain that is persistent or increasing, or
 
d) bleeding from incision sites.
 






The absence of a visible scar, the ease of peritoneal entry, and the uncom­
plicated rapid recovery combine to make the vaginal approach to the ligation
of the oviducts very attractive (26,27). However, certain complications make 
these approaches less attractive than the abdominal ones. 
* Colpotomy 
The classic "vaginal tubal ligation" has enjoyed much popularity in India 
and the United States, where surgeons have been trained and encouraged to
perform vaginal surgerV. In 1980, the International Planned Parenthood Fed­
eration Family Planning Handbook stated that colpotomy is "preferred in 
some cultures because it does not involve an abdominal incision." (28).
However, the mini-laparotomy is now tile favored method in the eyes of 
many inter-,ational experts. 
Procedure. With tile patient in the lithotomy position after administering
either general, spinal, or local anesthesia, the cul-de-sac is entered through a
small incision. Each oviduct is brought into view, ligated, and cut. The incision 
is closed with absorbable suture. The patient can go home on the same day.
Complications. Several reports attest to the effectiveness (0.1 -2.91 fail­
ure rate) and relative safety (2.3'.-13.3,' minor complications) of the proce­
dure (26). Nevertheless, a major disadvantage of the colpotomy is that 
complication rates are reported to be approximately twice as high as rates 
reported in various studies of mini-laparatomy procedures and laparoscopic
tubal sterilizations. The higher rates are attributable to infection and 
hemorrhage. With proper patient selection (short vagina, pelvic relaxation, no




pelvic surgery, adequate equipment, 
anesthesia, these complications can be 
minimized. 
* Culdoscopy 
This procedure employs the endoscopic approach through the cul-de-sac 
and requires special skill and training. With the advent of the abdominal en­
doscopic approach, culdoscopy is seldom performed (27). 
Hysterectomy 
There is a significant debate as to the advisability of performing a hyster­
ectomy for sterilization purposes. Some argue that the possibility of cervical 
and/or endometrial malignancy, abnormal uterine bleeding, myomata, pelvic
relaxation, and other uterine problems that will eventually require a
hysterectomy, make hysterectomy a more attractive contraceptive proce­
dure for certain women than tubal ligation. 
Many clinicians, however, do not feel that the hysterectomy can be justi­
fied when the primary goal of surgery is sterilization because: 
1. The mortality for patients having a hysterectomy (62.5 per 100,000 
procedures) is six times greater than the mortality for women having 
laparoscopic tubal ligations (29, 30). 
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2. 	The cost and time for recovery from a hysterectomy are much greater 
than for recovery from a tubal ligation (31 ). 
3. 	The potential psychological impact of a hysterectomy is greater than 
that of atubal ligation. 
Refer to Table 2 1.4 for a review of the advantages, disadvantages, and 
the rates of failure, reversibility, complication, and mortality for the major 
methods of stei ilization discussed above. 
Othermethodsof tubal sterilization under research 
A potentially promising alternative to the previously mentioned steriliza­
tion techniques is that of hysteroscopy. Silver nitrate, zinc chloride, phenol,
 
cauterization with heat, cryosurgery, plastic occlusives, and tissue adhesives
 
have all been used in attempts to produce tubal occlusion when placed tran­








Vasectomy Lap.roscopy Laparotomy Colpotomy Culdoscopy 
Advantages Safe slghtm. Low rIt Of Can tI don,.as Leaves rio I saves no abdoirrnal 
yhiaity. catfllicalol OLtlatil-lrirrt Short procir tri' abdomirral scar, scar, brieftakes about 
io mortlity; re.COury le0, W in 0tiil eastly 1iterrriinrlrort0rinutes 
sirile rerqtunrn' n fi:orVty anesthsia. short wormn ofhothr -ti l 
inirraa ,tta r1 , !Ot .nd tcro I-Jr party., bef takes.tl lrae. 
Itraiing for phy Skills Crl be user for .qu.,i n,coIt, about 5.15 minutes 
claOs rn.pr r'rdor i creti,igrrosis rr'litrol y Sysofor les postop-lfIversivr e nos n 
hiroirI lrlivs rrstiurrrentscorlparnl, with iisrnc las to trrrir parr. ptiatlrlrss 
femlali. Styllljt Ilavei scar us s a nr1pO i it, . -reap.'eII -tYt Sr l i 0 
brief- lakes about rrrrirs anl usually avd­
1015 rminutes able 
Disadvantagas Not effective 111)until 
 1c1 -Ihtt ,1tes1 DlIcult ti oth .s lt Hgher coniptrcatron Rlequires greitsr 
s)r"t in 
1 Pptr11-l1ct1c.t,nrirPi-atr' piatnts local rate surgical skill tin 
sys a atel'Ci Iltnar-il qulriirtri ld at5esl hlrS3 fots-11rri 1iparotomy. 
Iateil., oicri nral 1ielilrli all p ,literi 9 In) ihents 
Cnirtic,itioiii 5uCrn 
irlfectioi 
Faiurlfalr,' 0t1',.1 2'. 2'0 02106% 01,, Ot055.' 0 a 0055% 
enersibility 5'. 701, 10%o50%oAb(to About 10o-50% About 10'-50' About 10%.50, 
Complications 5% to 7%0 1% 0tO65.. 16. to 133% 1.6'. to 13 3% 
Mortality Arrnytn 0 Low Low 	 LowLoW 

Skill requrreil uqerl Stprahst General General Specialist 
'ictilininr' practitioner or practitioner or 
specialist specialist 
Type of Local General or Local Loeal General or Local Genaral o Local 
anesthesia 
Equipent Easy Difficult Moderate M'derate Difficult
 
maintenance 
Recoverytime 1-5 days 	 1.5days1-5days 	 1.14 days 1.14days 
Facility Outpatient Outpatient or OUtpaient roonOperating Operating room or 
operating loerm or outpatent oulpatienl 
'Failure satesand the potential for succussful reversal depends primarily on the type of tual occlusionmethod Reversibility also 
depends upon reversal techniques used 
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THE ROLE OF STERILIZATION WORLDWIDE 
AND IN AFRICA 
Voluntary sterilization is one of the most popular methods of contracep­
tion in the world. (See Table 21.5.) About 100 million people huve had a ste­
rilization operation. In Africa, however, the rate of voluntary sterilization is 
one of the lowest in the world (33). (See Table 21.6.) 
TABLE 21.5 Estimated number of couples using birth control, 
worldwide, by method, 1970 and 1977 (8) 
1970 1977 
millions millions 
Voluntary sterilization 20 80 
Oral contraceptives 30 55 
Condoin 25 35 
IUD 12 15 
Other Methods 60 65 
Total 147 250 
Abortion (annual incidence) 40 40 
There is some evidence, however, that the demand for sterilization ser­
vices may be great among African women. For example, physicians at 
Kenyatta National Hospital in Nairobi, Kenya, asked women who had five or 
more children and who had just delivered if they would like a sterilization op­
eration performed. Fifty-nine percent said that they would (34). 
In some cultures, laws or regulations may restrict sterilization. However, 
such statutes, laws, and regulations have undergone many changes over the 
past few years. Most countries now have no laws specifically covering volun­
tary sterilization as a contraceptive method. Thus, legal authorities generally 
believe that whatever is not expressly prohibited is permitted. 
Each voluntary sterilization is estimated to avert 1 .5 to 2.5 births. This is a 
higher number than provided by the continued use of any other contraceptive 
method (35,36). Sterilization is also easier for the patient, who does not need 
to obtain resupplies or visit the provider at regular intervals. In the long run, 
the individual may find that sterilization is less costly in terms of the amount 
of money and time that family planning generally requires. 
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TABLE 21.6 Estimated number (in millions) of couples controlling fertility by 
voluntary sterilization, by country or continent (33) 
Year 
Country or Continent 1970 1975 1977 1978 1980 
China 4 30 35 36 40 
India 7 17 22 22 24 
Asia (excluding China, India) 1 2 3.5 4 5 
United States 3 8 9.5 12 13 
Europe 3 4.5 5.5 10 11 
Latin America 1 2 3 4.5 4.5 
Canada 0.5 0.5 1 1 1 
AfriLa 0.5 0.5 0.5 1 1 
Estimated World Total 20 65 80 90 100 
COUNSELING OF PATIENT WHO REQUESTS 
STERILIZATION 
In no other phase of family planning is it more important that decisions be 
based on clear, complete information. Individuals must be told repeatedly 
that, at present, sterilization procedures for both men and women are to be 
considered irreversible. Couples wishing to maintain the option of having 
children should be encouraged to use other approaches to birth control. 
Information pertaining to permanent methods of contraception should be 
provided through discussions witn individuals early in their reproductive 
years. The following guidelines for counseling are helpful in any discussion of 
sterilization. We have developed the BRAIDED mnemonic for remembering 
them. 
B enefits: permanent; effective; repeated decisions or costs unnecessary. 
R isks: surgery may lead to morbidity and mortality; expensive in short 
run; not 100% effective (slight chance of becoming pregnant in the 
future); operations to reverse procedure are expensive and may not be 
successful. 
A Iternatives: all reversible contraceptives and sterilization of the partner. 
inquiries: patient should be encouraged to ask questions; my'ths and mis­
information should be cleared up. 
Decision to change: patient should always feel she/he can freely decide 
not to undergo sterilization if he/she wishes, without experiencing clini­
cian's hostility or punishment by society (e.g., withdrawal of social welfare 
benefits). 269 
Explanation: the entire procedure arid its possible side effects should be 
explained in detail. Clearly emphasize the permanence of the procedure
along with accurate estimates of chances of reversal. Explain available 
data regarding potential psychologic and/or physiologic effects on
hormones, weight, menses, and sexual response. It is also important that 
the patient be aware of the costs of the procedure and where it can be 
performed. It is important that the patient understand that operations at­
tempting to reverse sterilization are major surgical procedures; the tubes 
cannot simply be untied. 
D ocumentation: the patient's chart should note the method and timing of
sterilization, any complications that occurred during or after the 
procedure, and the treatment and outcome of complications. 
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RELATIONSHiPS BETV EEN FAMILY PLANNING 
WORKERS AND USERS 
Family planning is only as successful as the delivery of its services.
 
The key aims of service delivery are:
 
* 	 gaining new acceptors of family planning, 
* 	 encouraging current users to continue planning their families through 
the effective use of safe methods, 
* providing a reliable source of contraceptive supplies and information, 
* identifying and dealing with complications effectively. 
Your success in achieving each of these objectives will depend largely on 
the quality of the relationships established between your users and you and 
your colleagues. This chapter examines different aspects of the user-provider 
relationship, consolidating recommendations made throughout this book 
with others based on the authors' experiences. We hope that you find these 
suggestions to be constructive. 
A good relationship between family planning workers and users is needed 
at all times: when educating the users (promotion and counseling), determin­
ing and providing the correct method, instructing the user in its use, and 
providing timely followup services. Developing and maintaining a good rela­
'ionship takes time. But by investing it, you will help couples understand and 
feel comfortable with their method of choice, thereby inc.-easing the likeli­
hood that they will continue to plan their families. Poor care from an unmo­
tivated family planning worker will not encourage a patient to return. The gui­
delines presented below are important to good working relationships in both 
the most and least sophisticated service delivery settings. 
EDUCATION 
Education, whether of family planning workers or users, has three 
purposes: 1) exposing people to alternative ways of identifying and solving 
problems, 2) exploring with them the relationship between these problems 
and family planning, and 3) instructing the individual woman about her own 
personai care. Community education is often achieved through women's and 
men's groups, schools, respected peers, the use of field educators, and 
media (music, drama, radio, newspapers). Teaching must be kept relevant to 
the individual; you must show how family plann!ig affects the family on a 
daily basis, using words and ideas that mean something to the user. 
CHOICE OF CONTRACEPTIVE METHOD 




her medical background, her plans for future pregnancies, her living
conditions, pressures placed on ier by her family or community, and her ac­
ceptance of the particular method. 
To provide family planning services, you must have adequate supplies. Al­
though another worker may he responsible for managing supplies, as a 
family planning worker, you must play a part inl deciding what supplies are 
needed. (See Chapter 23) 
Determine if the woman haLc my contramindications to using the Pill (see 
Chapters 11 and 1 2), tIe IUD (see Chapter 13), the ijectables (see Chapter 
12), arid the nonrnedical methods (see Chapters 2, 3, 14-1 8) Help her ex­
plore tier reprodiictive life plan as outlined in Chapter 9 :riod her feelings about 
the methods you nay have helped her select. 
Because pregna ,y test reagents are costly aind iII short supply in Africa, 
many providers request thai their users coMe during neistrus3il b-Oding as a 
sign that they are not pregciant. (See Chapters 11 12.) Howavet,; do not let 
this rule become i harrier to service delivery. It is sometimes appropriate to 
give a wornan Pills or i;n IUD when she is not bleeding since tie distances be­
tweei the woman's home and the service delivery point are often too great to 
force her to return another time. When appropriate, trust the woman's ac­
count of her history and, for example, instruct tier to take the Pills on the fifth 
day of her next period. When appropriate, perforn a pregnancy test to facili­
tate your clecision to insert an IUD or to i(if nister an injection at times other 
than durin( the menstrual flow. (See Chapter 20.) 
In some systems ol armily planning delivery, physical examinations are not 
practical or possible--nor are they always necessary (1). Through tria usC of 
a checklist of controindications for the Pill, IUD, and injectables (see Chapters 
11, 1 2, and 13), it is possihle to assess without a thorough physical examina­
tion whethefr ofr not n woman ishealthy iid can use family planning methods 
that trave lw oMrridity rates. 
Keep in iiiiri(I that tte iiue of contraceptives has a lower 
morbidity mortality rat( than pregnancy (2). Since mortality related to 
pregnancy mid childhirlh is nitich higher iII developiag countries than in de­
veloped couritrire;, the uJSe Of Contraceptives is an ev,,t safer option by 
comparison, Further, these roajor side effects of tl.e P;i reportel from West­
ern studies (cairdiovajscular ones) are believed to he tar smaller problems in 
developing(countriesuclias;those ii Africa (3) (See Chapters 1 ,12.) 
Howevei, in clinics whee other health needs are assessed and ministered 
to, physical eximinatios are fregrueritly performed and are very beneficial. 
The physical exarnimiatons may include a rea;st exarlinationi for lumps, in­
structiori about hi east exaiirtion (seon Figiures 22 1-22 3), anid a complete 
pelvic examination. When possible, the examnination can include a blood pres­
sure rearliig, ii check for urine protein arid glucose, a Pan srmear, a VD check, 
and a hiema-tocrlt ir hemoglobin test 
Gi,,e special emphasis to the methods ihat Lire-aid will continue to 
be-available and that are best adapted to the needs, beliefs, and characteris­
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FIGURE 22. 1 Teach women to use the flatpart of their fingertips to feel each 
area of the breast. 
FIGURE 22.2 Women should repeat the breast 
examination in a standing or sitting position. 
FIGURE 22.3 Most breast cancer occurs in the upper outer quadrant of the 
breast. 
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tics of the user. (See Chapter 2.) After the choice has been made, clearly ex­
plain how to use the method. 
PROVIDING GUIDANCE TO USERS 
Instruction: Individual instruction is provided at the time tile user seeks 
services. Explain each m-ethod-the Pill, injections, IUD, spermicides, natural 
methods, etc. Tell her how each works. Take apos~tive tone to explain the ad­
vantages of each but eXplain the side effects and disadvantag. ,as well. Tell 
her what side effects she might have and what signs are indications that she 
needs to return. (Refer to Chapters 11 -14, 16, and 19-21 .) Explain that 
some side effects cause changes but not .roblems, such as a change in the 
menstrual flow or pattern. Ask what concerns and lUeStions she has. Correct 
2ay misconceptions and fears she may have 
Followup In a clinic setting, have the user return so you can check how 
well she is doing with the family planning method, but remember that too 
many visits will decrease her cooperation. In both the comniLuiity-based pro­
gram" and clinic settings, the user needs to be instructed to recognize the 
danger signs of her contraceptive method. (See Chapters 1 1 -13.) Emphasize 
how important it is for her to return to the community distributor or the clinic 
if she has problems or (luestions or needs resupplies. Also empliasize the im­
portance of resumringq [he use of family pl nning methods after childbirth. 
Referral What should you do if the woman has a problem caused by the 
use of her family planning method that you cannot handle by yourself and 
that requires equipment or supplies that are unavailable to you? For such 
purposes, organized and direct lines of referral must be established. Some 
examples of good referral practices include: 
o 	 Arranging for wornen who are experiencing side effects to be seen by 
your supervisor during the next scheduled visit. 
* 	 Communicating (by word of mouth, two-way radio, written message, 
telephone, or by other rneans) with a nearby clinic or hospital to receive 
guidance about users' problems. 
" 	 Sending women to a nearby clinic or hospital for diagnosis and treat­
merint of problens that cannot be handled by the above approaches. 
Note that each of these approaches involvcs recognizing the problem, 
communicating it, getting the advice of professionals with more know!edge 
or experience, arid following up on the users' needs. 
After a woni has been referred elsewhere, follow up to see low 
well her problem is being managed. 
'Services provided by trairlle(J villa(,rs selected front tlte c, mmininity who are supervised by 
medical professionals 
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By referring problems, your skills, confidence, and effectiveness are 
enhanced. An added advantage is that nonfamily-planning problems expe­
rienced by women and their families are sometimes identified and resolved. 
In summary, whether you are educat;ng the user, helping her to choose a 
method, instructing her in the effective use of the method, or helping her deal 
with side effects or other problems as they arise, the quality of your relation­
ship with each woman will depend on your ability to: 
* demonstrate to her that you care about what she is experiencing, 
* communicate relevant facts clearly,
 
* 
 test whether the woman understands everything you feel she needs to 
understand, 
* keep a record of the woman's family planning experiences and refer to 
it so that you can take into account the past in dealing with the present. 
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APPROACHES TO DELIVERY OF FAMILY 
PLANNING SERVICES 
What are some of the key barriers to making -.he practice of family plan­
iing widespread? Most often they are misinformnation, lack of motivation, 
and problems in distribution of supplies (1). This entire book addresses the 
barrier of misinforriation. Chapter 22 deals specifically with motivating 
users and indirectly with motivating family plannng workers. In this chapter, 
we will examine the advantages and disadvantages of alternative delivery 
strategies for distributing supplies and providing services under varying 
circumstances. 
How do the family planning services offered in the health system you work 
in respond to your users' needs? Do you reach the right users with the right 
contraceptive methods and provide medical care in case there are 
complications? The range of health services offered within Africa differs tre­
mendously from country to country. Some countries offer family planning 
services through well-developed clinic se-vices with well-thought-out routes 
of referral. Some countries have establishvd clinic-based systems but find 
that shortages in medical personnel and money prevent them from reaching 
remote populations. Therefore, these countries have begun to experiment 
with community-based approaches to providing health services, including 
family planning and/or commercial distribution of contraceptives (2). Some 
countries are in the process of developing basic health services and, hence, 
have not yet found an effective way to deliver family-planning services. The 
answer to providing family planning services lies not in just one approach to 
delivery, but more likely, in a combination of strategies, each of which pro­
vides for referral. Some basic strategies are examined below. 
ALTERNATIVE DELIVERY STRATEGIES 
The strategies used in Africa and other parts of the world for delivering 
family planning services are and must be varied (2). Several African nations 
have had some degree of success with family planning delivery strategies 
(2-10). See Appendix E for a description of some of these experiences. 
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Typicall,, delivery strategies need to be a,,ered to meet the needs of different 
populations: couples living in urban areas, rural towns, villag.,s, and remote 
and inaccessible areas. In urban areas and rural towns, family planning is 
most often made available in clinics (CLINIC-BASED SERVICES, CBS) that 
offer family planning services alone or incoihination with other health ser­
vices for women and children (See Figure 231 )1n villagas and other remote 
and inaccessible areas and ill urban sectors that do noi have clinics, family 
planning may be riade available through COMMUNITY-BASED DISTRIBU-
TION systems. Also, in these same areas or in areas where people are recep­
tive to obtaining contraceptives from sources outside of the health care 
systems, commercial outlets may provide family planning (COMMERCIAL 
RJ-TAIL SALES, CRS). A more detailed discussion of these three basic strate­
gies is presented in Table 23.1. 
MIX OF CONTRACEPTIVE WIMI HIODS USED 
IN A PROGRAM 
Ideally, each family planning program should offer a balanced array of 
methods. However, the methods offered by a program are influenced a great 
FIGURE23.1 In many countries, familyplanning is primarily offered to moth­
ers who make use ofmaternal-chid health clinics. 
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TABLE 23. 1 Characteristics of principal approaches to providing 
family planning services 
DESCRIPTION 
I. COMMUNITY-BASED 
Local volunteers, usually 
village womern, are recluited 
to educate their neighbors. 
The . DIlunteers are also 
responsible for distribUtloyt 
the farily planninginiethods 
to users. In their training, the 
volunteers learm the har:ic 
concepts o farnily plil ing, 
how each rethor must be 
used, what the cortraiiidic;i-
tions and adverse effects ari 
for each rirethod, and iow to 
maintain simple data collec-
tioris systenis. A pf'ysicuin, 
midwife, or faimily planrmig 
nurse supervises the volrin­
teer's activities to nianagie any 
problems that tray OCCUr 
I. COMMERCIAL 
DISTRIBUTION 
Commercial distribution was 
berijun with the knowledLIU 
that renrote areas having no 
access to medical care sirne-
flow seeir to have otlher types 
of consurnrer itirniS avaailahle 
inl retail outlets. If other sup-
plies can reach tleise very 
rurriote areas, then so can 
family planning supplies. Most 
countries iout comnmercial 
distribution of oral crintiacep-
tives to rharniacies. Barrier 
methods, howeverr, ire sorlid in 
nearly every place. tnrrcerieo. 
nmarkets, and streets try 
hawkers. 
11. CLINIC-BASED SERVICES 
Clittc-based servicie Is a 
reasonable approacfh iII are ns 
where health workmr; ar.-
available turd users fo not live 
far from the clinic With sonie 
physician supervision, trainemd 
nurses and midwivis esarnlirre 
women, prescribe the alrpu-
priate family planning 
methods, and rian(e 
problems. 
ADVANTAGES 
Users can obtain 'rethods 
more cheaply 
More convenient for patients, 
who need rot travol Jorim 
distances. 
SuL)plies are distributed hy 
somleolle the patient knows 
alid t(iotS, 
Post-partum miothers can he 
Identifiedi aud visited, 
I-Ollowili edsJWr.i e 
User tnotivation is miaintained 
at high level through con-
tinuoUs interaction witfh 
voIunteer. 
Can reach very remote areas 
not reached fy other 
prugrairts. 
Uriers leed not travel long 
distances. 
Distributors are rrotivatedi try 
profit front sales. 
Availability of methods is well 
publiciled 
User does not need to wait ill 
lines to receive nrethods. 
User has privacy. 
Cost-; to the givernrent :a:i 
bre low, 
Usually resuipply to ,histrilir­
tmin poitts is leliable. 
PItients ale seen it each v:it 
by health care protessronals. 
Probleirs call bie spottillldand 
treated at visit 
A switch in contraceptivt! 
niethod can hequickly rne 
at the clinic 
Start-up costs low if 'aterrnl 
Child Health services (MCH) 
already avtailable. 





Initial program costs per user 
'Ire high. 
rull naternal ind child health 
fanily planning services are 
not offered. 
No nirnedicate access to 
clin cal staff for rlanagerneit 
of problerns. 
Some heIth ptrofessionals 
resist volunteers Offering 
services. 
User imay lack confidentiality. 
User may lack confidence in 
nonnredical worker, 
Patients must go to clinic for 
management of problems. 
It can he costly to start a 
program. 
Full services are not offered. 
Promotion arid advertising of 
contraceptives may bie 
subject to criticisms. 
Public Iealth officials do not 
hav control over resupply 
sysleilr 
Patients are prnarily limited 
to those living close by. 
Fillowup depends il1)On user's 
rettrn;.ig to chnic, 
The nurse or rnidwife may nout 
bn farilih-n to the patient. 
Patients are expected to come 
on their own initiative. 
Patients rrlay have to wait in 
long lines. 
The noctor or nurseriay be it 
rnal, whicfh would net be
 
acceptable to women in
 
sons1 cultures. 
TABLE 23.1 Characteristics of principalapproaches to providing family plan­
ning services- Continued 
DESCRIPTION 
a) MATERNAL CHILD 
HEALTH FAMILY 
PLANNING SERVICES 
As a starting point, the 
Maternal Child Health Family 
Planning program is preferred 
by many African governments 
because mothers can obtain 
several related serviccs at one 
site, thus providing continuity 
of care, and because family 
planning can be provided for 
child spacing as part of 
materrral and child care, and 
not as a measure to "control 
fertility." 
b) FAMILY-PLANNING-ONLY 
Clinics offering only family 
planning services are often 
established in urban areas or 
large towns to meet an exist-




Can attract large numbers of 
mothers coming forother 
services, 
Users can receive pediatric, 
obstetric, and gynecologic 
care in one setting, along 
with family planning ser-
vices, 
In theory, it offers an easier 
transition from post parturl 
to family planning, and the 
reverse. 

Patients uncomfortable with 

the social stigma of birth 
control are not so easily 
identified as users of family
planning. 
Family planning can be estab-
lished as an important 
element in the healtlhof 
w:men and children. 
The family planning workers 

are more motivater to de- 

liver family planning. 

More time can be spent 
counseling and educating 
each user. 
GenLrally, a better worker-to-
user ratio exists for family 
planning, 
Workers who have received 
special training in family 
planning may be more ef-
fective. 
Unmarried womn without 
children are more corn-
fortable in thistype of 
facility. 
DISADVANTAGES 
Family planning users are seen 
only after child and maternal 
health problems are 
attended to, 
Workers may be overworked 
and understaffed. 
Administrative functions are 
more complicated, especially 
if the resupply and reporting 
of service statistics for 
family planning services are 
not in.egrated with the 
support systems of the MCH 
program. 
Workers not always specific­
ally trained in family plan. 
ning may lack needed skills 
and motivation.
 
The physical facility (clinic,
 
health center) may not be 
able to accommodate the 
integration of family plan­
ning services. 
Users must be motivated to 
come or. their own for family
planning services. 
A smooth transition does not 
exist from the post-partum 
period to the time a woman 
needs family planning 
services or to the time when 
she needs antenatal care. 
Women must visit othier 
facilities to receive other 
health services, 
Clinics lack thtu additional 
incentive of offering ser­
vices that attract many 
mothers. 
deal by the system in which they are distributed, as well as by the prevalence 
of different diseases in an area (see Chapters 5, 6, and 9), cultural or religious 
preferences, and the prospects for a reliable logistics system. We suggest 
the following in Table 23.2 as a guideline: 
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TABLE 23.2 Guidelines for Use of Contraceptive Methods with 
Alternative Delivery Strategies 
Clinic Community Commercially 
Based Based Distributed 
Three types of oral contraceptives: 0.50 mg X X X 
estrogen, sub-0.50 mg estrogen, and progestin 
only. The varying doses of estrogen ca:i be 
tailored to overcome certain side effects such 
as spotting or bloating that occur in some 
women in response to a particular dose Pill. 
(See Chapters 11 and 12.) 
Two types of IUD's: a copper, medicated IUD, X X 
and the full range of sizes of the Lippes Loop," 
or the Saf-T-CoiV' , .Some women respond 
better to one IUD than another. (See Chapter 
13.) If the IUD is used in community-based 
programs, appropriately trained staff must in­
sert the IUD and be available for followup. 
An injectable: Depo-Provera ' ",or norethindrone X X 
enanthate. In countries where the injectables 
are approved for use, women who benefit from 
this method include: women who desire no 
more children but do not want to make tho 
final decision to have a sterilization; women 
who live a distance from medical dispensaries; 
and women who find a visit every 3 months 
most convenient. (See Chapter 12.) 
A complete sct of nonmedius' methods: con- X X X 
doms, foaming tablets, foams, creams, jellies, 
diaphragms. Individuals who find these suit­
able are breast-feeding mothers; women who, 
for medical reasons, cannot use other me­
thods; and women who are waiting to begin 
other methods of family planning. (See Chap­
ters 2, 3, 14, 15, 16.) 
Instruction in natural family planning methods: X x 
i.e., timing of ovulation, abstinence. These are 
good for women who find the other methods 
unsuitable. (See Chapters 2, 3, 17, 18.) 
Sterili4 iion services: Where practical, these X 
should he made available for women or men who 
desire to have no more children, especially 
those who have had frequent, short-interval 
births, or women whose lives may be endan­
gered by pregnancy. (See Chapter 21.) 
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ORDERING, MAINTAINING, AND STORING SUPPLIES 
To provide family planning services, you must have adequate supplies. Al­
though another worker may be responsible for managing supplies, you as a 
provider must play a part in deciding what is needed. Consider what supplies 
you want, how many users use the supplies, how frequently you receive 
shipments, and how much storage space you have. 
1.Compute the supplies you will use for 1year. Use the following guidelines: 
Pills: 
13 cycles per continuing user per year or 6.5 cycles per new user per 
year (assumes that not all new users will start on day 1 of the year) 
Condoms: 
144 (1 gross) per continuing user per year or 72 per new user per year
Foamn: 
2.5 bottles per continuing user per year (about 60 applications per 
bottle) or 2 bottles per new user per year 
Jelly: 
6 tubes per continuing user per year (about 25 applications per tube) or 
3 tubes per new user per year 
Diaphragms: 
generally need only 1 per person, but quality of diaphragm should be 
checked about once every 2 years and replacement may be necessary 
IUD's: 
guideline is to stock 3 IUD's for every 2 acceptors- this allows for ex­
pulsion and periodic replacement 
Sterilization kits: 
a general rule-of-thumb is 2 per doctor 
2. Calculate the size of reserve stocks. This is the amount of supplies you 
should have on hand to keep from running short if demand is higher than ex­
pected or if shipments are late. A handy formula is: 
FREQUENCY OF SHIPMENT + TRANSPORT TIME 
(Example: If shipments are delivered every 12 months, and time from 




3. Store the supplies in a well-ventilated arid dry area. (See Figure 23.2.) The 
temperature should not exceed 24" centigrade, and supplies should be pro­
tected from sunlight. Do riot stack the boxes more than 8 feet (2.4 m) high. 
Keep supplies 1 f .. )t (30 cm) away from the wall and 4 inches (10 cm) off the 
floor. The oldest supplies should be given out before newer supplies. Make 
certain the supplies are not outdated (11 ). 
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Pills: 5 years from date of manufacture; indicated on package 
Foam: 5 years from date of manufacture; date not on package 
Jelly: 5 years from date of manufacture; date not on package 
Condoms: 3 years from date of manufacture; indicated on package 
Diaphragms: indefinite, but probably about 5 years in hot, humid climate 
IUD's: no time limitation 
OBSTACLES AND POSSIBLE SOLUTIONS 
TO SERVICE DELIVERY 
The discussions presented both in Chapter 22 and this one are simplifica­
tions of what actually happens when providing family planning services. 
Regardless of the delivery strategy used, all programs confront problems and 
constraints. A number of these, along with possible solutions, are included in 
Table 23.3. 
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PROTECTION FROI SUN AND RAIN 
GUIDELINES FOR PROPER STORAGE 
1. CLEAN ROOM AND WHITEWASH WALLS. 
2. CHECK ROOF FOR WATER LEAKAGES. 
V3. NO DIRECT SUNLIGHT ON THE SUPPLIES.-VFNrILATIO I'VFNTILATIO 4. STOREROOM NOT SUBJECT TO WATER PENETRATION. 
5. SUPPLiES TO BE STACKED AT LEAST 4 INCHFS(IO cm) FROM FLOOR 
(Arrange dunnage of wood or steel).
T 6. SUPPLIES TO BE STACKED AT LEAST 1 FOOT(30 cn) FROM ANY WALL. 
7. SEPARATE STACKS ACCESSIBLE FOR "FIRST IN FIPST OUT" (FIFO), 
COUNTING, AND GENERAL MANAGEMENT. 
8. STACKS NOT MORE THAN 8 FEET HIGH (2.4 I). 
00 Y99. IDENTIFICATION MARKS AND OTHER LABELS VISIBLE. 
10. CUPPLIES 10 BE ISSUED BY CARTON OR BOX LOT. IF POSSIBLE. 
ARRIVAL 11. WELL VENTILATED.
 
DATS-GH 
 12. WELL LIGHTED. 
2c) 13. FIRE EXTINGUISHERS NOT BLOCKED. 
14 VACCINES AND SERAS M.,UST BE STORED IN,; REFRIGERATOR. 
15 OLD FILES, INFORMATION MATERIAL OFFICE SUPPLIES. ETC.. 
SHOULD BE STORED SEPARATELY. 
16 INSECTICIDES AND OTHER CHEMICALS NOT TO BE STORED TOGETHER 
WITH CONTRACEPTIVES AND MEDICAL SUPPLIES. 
-- * 17. STOREROOM TO BE DISINFECTED AND SPRAYED AGAINST INSECTS 
EVERY THIRD MONTH. 
(%"]S 18. DAMAGED AND CONDEMNED SUPPLIES TO BE SEPARATED AND 
(IOm) DISPOSED OF WITHOUT DELAY 
PA ETTE 19. STORE KEYS MUST BE AVAILABLE AT ALL TIMES. 




FIGURE 23.2 Guidelines for storing con tracep tives. 
TABLE 23.3 Dealing with obstacles to the delivery of services 
Problems and Constraints 
1. 	Lack of services {particularly in rural 
areas but also in urban ones) 
2. 	 Resistance of women to the concept 
of family planning 
3. 	 Male opposition to birth control and 
to the concept of women playing an 
important role in decisions governing 
how many children a couple should 
have 
Solutions 
a) 	Increase policymakers' knowledge of 
the health and economic benefits of 
family planning. 
b) 	 Increase the priority given to family 
planning in maternal child health 
units, particularly among nurses and 
nurse midwives. 
c) 	 Place higher priority on family plan­
ning in training of physicians and 
nurses. 
d) 	 Strengthen staffing and outreach 
services in clinics already offering 
family planning. 
e) 	 Develop, improve, or expand com­
munity-based and or commercial re­
tail distribution systems. 
a) 	Compare contraceptive complications 
with risks of pregnancy: allay fears 
of contraception. 
b) 	 Provide higher quality, more com­
prehensive family planning services. 
c) 	 Use child health and well-baby clinics 
as sources of referrals for family 
planning services. 
d) 	 Emphasize the health benefits of 
family planning and its voluntary 
nature. 
a) 	 Educate community leaders about 
benefits of family planning. 
(See Chapter 10.) 
b) 	Involve important men in the initial 
planning and promotion of contra­
ceptive services. 
c) 	 Provide methods women can use 
without knowledge of men if neces­
sary. 
d) 	 Educate schoolchildren about the 
family in today's society and the 
importance of planning it. 
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TABLE 23.3 Dedling with obstacles to the delivery of services- Continued 
Problems and Constraints 
4. 	Destruction of traditional institutions 
that encouraged effective methods 
of birth control 
5. 	Lack of trained backup medical per-
sonnel in staff, hospital, and clinics 
and a lack of trained lower-level 
staff to act as village educators,
recruiters, and distributors of 
contraceptives, 
6. 	Privacy is unavailable in certain clinic 
settings 
Solutions 
W Retain those traditional approaches 
that are safe and effeciive. 
I) Explain carefully tile reasons why 
some traditional approaches may not 
he safe or effective. 
c) 	 Encourage local involvemient in 
establishing effective child-spacing 
services. 
d1) Use neighbors in community-based 
distribution programs who can ef­
fectively communicate family plan­
ning concepts. 
a) Retrain physicians ises, and mid­
wives in family planning skills through 
intensive, short programs. 
b) 	Encourage and train nurses and mid­
wives to then train community-based 
paramedical personnel (121. 
c) 	Emphasize family planning in training 
programs for midwives, nurses, arid 
doctors. 
d) Thoroughly train supervisors of 
maternal-child health family planning 
workers to manage problems and 
reinforce training of lower-level 
family planning workers 
'0 	 Provision of services in a private 
setting. 
b) Alter the flow of patients in maternal­
child health family planning clinics 
in order to shorten waiting periods
by changing staffing patterns, clinic 
hours, or the appointment system. 
c) 	Initiate commercial distribution (in­
cluding the use of street vendors) of 
certain contraceptives. 
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TABLE 23.3 Dealing with obstacles to the delivery ofservices- Continued 
Problems and Constraints 
7. 	Inaccessability and lack of accepta-
bility in some quarters of sterilization 
services 
8. 	Failure of influential leaders to rec-
ognize the importance of voluntary 
means of child spacing to the health 
of the individual and society as a 
whole 
9. 	Laws prohibiting or customs dis-
couraging the provision of voluntary 
contraceptive services for unmarried 
women 
Solutions 
a) Training of nurse midwives, physi­
cians, and health assistants to per­
form mini-laparotomy procedures. 
b) Acquire necessary equipment. 
c) 	Set up a system to insure a constant 
supply of spare parts ind other 
needed supplies for laparoscopic 
equipment. (See Chapter 22.) 
a) 	Explain to leaders the health benefits 
of family planning. (See Chapter 1.) 
b) 	Demonstrate that family planning 
leads to reduced health care costs. 
c) 	Increase the education of politicians 
on the implications of rapid popula­
tion growth. 
a) Initiate services tha;t do not conflict 
directly with laws or customs of the 
land. 
b) Develop public information programs 
regarding health and social conse­
quences of adolescent pregnancies. 
c) 	Ask national leaders to interpret laws 
according to present conditions and 




Fr 'those of you who are responsible for developing and managing family planning programsand thus need in-depth information about the topics introduced in this chapter, we recommend 
these readifnq materials: 
1. BARNES, E. F. (Editor). Ambulatory Maternal Health Care and Famly Planning Services.
Crawfordsville, Indiana, R.R. Donelley and Sons Company, 1978.2. 	 FOREI, J. R, GOROSH, M. Community-based ard commercial contraceptive distribution: 
an inventory and appraisal Popula 'an Reports Series J,No. 19, 19783. 	 INTERNATIONAL FEDERATION OF GYNAECOLOGY AND OBSTETRICS INTERNATIONAL
CONFEDERATION OF MIDWIVES. Matrnity Care in 	 the World International Survey ofMidwifery Practice and Training. Winchester, Hampshire, England, C.M. Printing Seivi,, s 
1976. 
4. 	 INTERNATIONAL PLANNED PARENTHOOD FEDERAIION. Family Planning Handbook Fur
Doctors. Hertford, England, Stephen Austin and Sons Ltd., 1980,5. U. S. PUBLIC HEALTH SERVICE. Logistics Guidelines for Family Planning Programs. Depart­ment of Health and Human Services, Public Health Service, Centers forDisease Control,Center for Health Promotion and Education, Family Plnning Evaluation Division, 1981.6. 	 WORLD HE,LTH ORGANIZAT ION. The Fraditional Birth Attendant in Maternal and ChildHealth and Family Planning: a Guide to Her Training and Utilization Geneva, World Health 
Organization, 1975. 
REFERENCES1. WESTINGHOIJSE POPULATION CENTER. Contraceplive Distribution in the CommercialSector of Selected Developing Countries: Summary Report Columbia, Maryland, Westing­
house Populaticn Center, 1974. 
2. 	 RINEHART, W., PIOTROW, P. T. OC's - update m usage, safety, and side effects. Popula­
ticn Reports. January lA-5): 133-187, 1979
3. 	 FOREIT, J. R., GOROSH, M. E., GILLESPIE, D. G.,MERRITT, C. G Comniunity-based andcommercial contraceptive distribution: an 	 inventory and appraisal Plilih ion Reports,
March (J-19): 1-29, 1978. 
4. AMPOFO, D. A., NICHOLAS, D. D., OFOSU-AMAAH, S, BLUMENFELD, S., NEUMANN, A.K The Danfa family planning program in rural Ghana Studies inFamily Planning 7. 10: 
266-274, 1976. 
5. 	 INTERNATIONAL FERTILITY RESEARCH PROGRAM. Household distribution of contracep­
tives in Marrakech proves successful. Network 2: 2, 1981
6. 	 NICHOLS, D. J.,LABBOK M. Household distribution of contraceptives in Marrakech 
Morocco. December 1980 (unpublished).
7. INTERNATIONAL FERTILITY RESEARCH PROGRAM. Household distribution of contracep­
tives in Bir Ali ben Khalifa, Tunisia. Planning Familial a Domicile, July 1979.8. U. S. AGENCY FOR INI ERNATIONAL DEVELOPMENT. USAID Operations Research ProjectSummary. Increasing the Availability and Acceptability of Contraceptives ThroughCommunity-based Outreach in the Region of Bas, Zaire. January 1981 (unpublished).9. U. S. AGENCY FOR INTERNATIONAL DEVELOPMENT. USAID Operations Research Project
Summary. Community-based Distribution of Low Cost Family Planniig and Maternal-Child
Health Services in Rural Nigeria. February 1981 (unpublished).
10. 	WESTINGHOUSE 
 HEALTH SYSTEMS. Contraceptive retail sales prograrn-Ghana. West­inghouse Health Systems, Contract No. AID,,pha-C- 1145. September 1980.11. HOWELL, B. B., NOVELLI, W. D. Technical rssistance report on the "Family of the Future"co:ltraceptive sales program. Cairo, Eg' American Public Health Association, Interna­lional Health Programs. Supported by L'1 1D(AID/DSPE-C-0053). January 1981.12. ROSENFIELD, A, MAINE, D., GOROSI ,1.E. Nonclinical distribution of the pill in the devel­oping world. International Family Pla .ing Perspectives 6:130-136, December 1980. 
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CHAPTER 24 
INTEGRATION WITH OTHER FAMILY 
HEALTH SERVICES 
Programs that provide only family planning services and those that offer 
family planning together with other health services both have their place. 
(See Chapter 23.) The purpose of this chapter is not to advocate an integrat­
ed approach but to provide a working definition of integration. We hopu that 
this definition will help those of you who are developuing a program to deter­
mine which approach (or combination of approaches) will best serve your 
users' needs (1-3). For those of you who already have an integrated program, 
we hope that this working definition will help you to identify ways in which 
your program can be improved to meet the needs of your users more 
efficiently. 
HIGHLIGHTS OF AN INTEGRATED APPROACH 
TO PROVIDING FAMILY PLANNING SERVICES 
The perspective of an m-tegiated program is to serve the family as a whole 
by providing all basic health scrvlces io all family members in one setting. In a 
clinic setting, this can l.e achieved by the following: 
1. Training all staff members in family planning. 
2. 	Training staff together so that they feel confident in each other'%; 
abilities, make more use of one another (by referriiig cases to col­
leagues with special skills), and are able to stand in for colleagues, 2tc. 
3. 	Having one person supervise all staff members; sp6cialists can assist, 
when necessary. 
4. 	Providing a dependable supply of medicines, contraceptive supphes, 
and vaccines through one channel. 
5. 	Referring all difficult cases to specialists and following through on the 
results of the referral. 
6. 	Documenting family services so that a complete history of the family's 
health is maintained and available as a reference to all staff members. 
7. 	Reporting all activities and outcomes in one document and reviewing 
the information as a team for the purpose of improving services. 
SERVING THE HEALTH NEEDS OF THE FAMILY 
All couples want to have a healthy family. An integrated family health pro­
gram is one way of helping coup'3s maintain the health of their families. 
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Listed below are several services that may be offered by such a family health 
program: 
Objective 
1.Help the couple conceive wnen 
they a.a ready to have achild. 
2. Help the mother have a healthy 
pregnancy. 




4. 	Help the mother regain 
strength, offer good nur'uring 
tc the infant. 




6. 	 Help family members regain 
health after illness. 
7. Help the couple terminate 
childbearing when satisfied 
with family size. 
Servics Needed to Meet Objective
Reproductive education, use of 













Well-baby examinations and 
immunizations, delaying next 
pregnancy (use of contraceptives). 
Curative care. 
Sterilization. 
STAFF TRAINING AND RESPONSIBILITY 
How might a successfully integrated family health program function? Forthis discussion, we will present an idealized setting. This hypothetical clinic isstaffed 
 by physicians, nurse-midwives, nursing sisters,educator/nutritionist, 	 a health an 	 environmental sanitation worker, atechnician, 	 laboratorya person responsible for dispensing medicines and managingsupplies, and a registrarsecretary/rec,,rdkeeper.
All staff members are trained in family planning. All recognize how familysize, birth interval, post-partum abstinence, and the use of contraceptivescan affect the health and well-being of each family member. In addition, allstaff members understand the menstrual cycle, the basics of reproductivephysiology, and how the different contraceptive methodscenter work. 	 offered by theThey refer a user to someone more knowledgeable if theycannot fully answer aquestion. 
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All medical personnel (physicians, nurse-midwives, nursin'* sisters) re­
ceive specialized training in examining, educating, and advising users. They 
understand both the basis for each contraindication to use of the Pill, IUD, 
and injectable contraceptives and the predisposing factors that can be identi­
lied during a physical exanination, from the woman's history, or from labora­
tory test results. Each medical staff member has been ot)served by a supervi­
sor and colleague during counseling sessions with users and has worked at 
improving listening and explaining skills. Each medical staff member has also 
assisted in childbirths, inserted IUD's, and managed with a collague and su­
pervisor a vairi,ty of complications Irom the use of different methods. The in­
dividuals in this clinic know themselves and their colleagues to te skilled. 
They also know who does what best and are riot aslqmed to rtefer a user to a 
colleague or supervisor 
The staff works as a teani. All of the team ment)ers have scheduled out­
reach activities. The staff members have divided the week into a schedule of 
clinics to orgjanize their time and expertse: maternal care (prenatal, 
postnatal), well-baby, family planning, general morbidity, general community 
outreach, etc. Unlike some clinics, this hypothetical clinic is busy all week 
long. Most of tile )eo)ple who use the clinic are mothers aid their small 
children. The majority live within a few kilometers of the clinic, yet a number 
of people who use the clinic conie from I 5 to 35 kilometers away, often by 
foot. The staff rniembers know that if, during well-baby clinic, they are exam­
ining the children of a wonian who has corne frori 1 8 kilometers away and 
she expresses interest in the Pill, they will be ,ible to help tier to determine if 
this is the right method for her, etc. As a result, the woman does not need to 
be told to come back on aday when family plannig services are offered 
Conversely, while staff members satisfy a inother's need for fv:mily 
planning, they may also detect illnesses inher chidren and treat them on the 
spot. Often, the clinicians are able to identify signs of malnutrition. The clini­
cians can call upon the health educator mitritionist to help the family estab­
lish a healthy diet. 
The clinicians may call upon the environmental sanitaton worker if they 
detect medical problems related to water supply or sanitationi. 
SUPPORT SERVICES 
For the clinical aspects of the family health progrom to function 
successfully, administrative and technical support must be dependable. 
In the idealized clinic we have just described, medicines, vaccines, and 
contraceptive supplies are periodically delivered. If supplies run short because 
of a crisis, the dispenser, supply officer can send in an emeigency request 
and receive a special delivery. The staff rnermbers know that if women go 
away empty-handed or with a second-choice method, they may never come 
back. 
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Unless the staff members make a special request for assistance, their su­pervisor comes to the clinic once every 3 months. The supervisor is knowl.edgeable about and experienced in several aspects of family nealth, includingfamily planning. When tile team makes a special request, the supervisorbrings along a colleague who is more skilled in a particular area (e.g.,obstetrics, gynecology, nutrition, sanitary engineering, pediatrics) Staffmembers keep a record of difficult cases and other problems to discussduring their next visit with the supervisor Occasionmlly, they schedule users'followup visits to coincide with their supervisor's visits. In this way, womencan avoid making a journey to the hospital where the supervisor and other ex­
perts work. 
All aspects or the family are documented in one file family composi tion,reproductive health history, vaccination history, medical consultations, well­baby history, home environment, nutritional practices, deficiencies,interventions, etc. Since the same patient consultation form is used for familyplanning complications as for other forms of morbidity and tile form is addedto the family file, the amount of paperwork is kept to a minimum.
The clinic team 
benefits from the reporting system. On a monthly basis,the team members fill in one summary form that reports tile number of per­sons served by type of service and the comnodities consumed during thereporting period. This can provide the public health workers vi") a means ofevalu3ting how effective the program has been.
The staff uses the reporting information at weekly meetings todifficult or special cases, 2) 
1) review 
look at questions of clinica! management andprevention, 3) examine the caseload, numbertht i and types of referralsmade and the results of the referrals, 4) evaluate and plan outreachactivities, and 5) assess requirements for changes in use of staff time or forcommodities Periodically, tile staff members reevaluate the program by
asking the questions isted below. 
EVALUATING THE NEED FOR INTEGRATION 
The idealized situation described above may not exist anywhere.However, you may already use some of the principles and practices presentedabove in your own program, whether it provides only family planning services 
or integrated family health services. 
How well would integrated family planning services work within the con­text of your present program? The answer depends on the needs of yourusers, the availability of trained personnel and other resources, and the poli­cies arid ideologies of your government. Ask yourself the following questionsto evaluate whether your present program needs some change:
1. How many people live in the area served by my program? 
2. Where do they live? 
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3. 	Can I reach them with my system of services as it exists today? 
4. What do people need most today? 
5. 	What will people accept today, tomorrow, if more information is 
made available to them? 
6. 	What resources, both from my program and from the community, 
are available to meet the needs of the people? 
7. 	 Are they willing to come to my clinic or outreach sessions? 
8. 	Are there people who are reluctant to use services because of how 
they are offered? E,,amples: Married women who don't want to go 
tc family-planning-only clinics. Single women who don't want to go 
to clinics for mothers and their children. 
9. 	Am I making the best use of my own time, the time of my colleagues 
and staff? 
10. Are there ways in which I could reorganize my staff and resources to 
provide better services to more people? 
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CHAPTER 25 
KEEPING FAMILY PLANNING VOLUNTARY 
InI much of the world, people fee! that it is extrernely important that family 
planning decisions be individual decisions, made without strong pressure 
from forces beyond the individual woman or couple. In other ,societies, partic­
ularly in countries that are already very clowded or ar( island nations, society 
as a wh.le has tended to determine the ideal family size for the average 
couple When a society-tirough its; political institutions, the media, the 
medical establishment, oi the e lucational process-attempts to determine 
the number of children a couple sthould have, the individuml man and woman 
lose a part of their freedorn to make a voluntary decisionr as to tlheir reproduc­
five destiny. 
Many of is would like to be able to determine what career we are to work 
in, whom we are to nuirr y, where we are to live, what religion we are going to 
participate ili. and how we are to spend our leisure. time. Moreover, many cou­
ples thlroighiotJ the world would like to he able to determrine fcr themselves 
how ruarly clhildrenr they would like 1o have aid when they would like to have 
them. 
When a couitry adol)ts im altternative to tile volunlary practice of family 
planning, authorities carefully examine the nito's n)atural resources, its 
population, tile availabibity of productive land, migration patterns, tile antic­
ipated level of capital formation, educational opportunities, existing stan­
rJards of living, rnedicul resources, and tile cutLIrat heritage of a society. From 
these estimates, officials determine an acceptable population size and 
growth rate with respect to their development objectives and the resources 
available to the country Based on desired popul,,tion size and growth rate, 
officials then arrive at a desirable family size in order to maximize the quality 
of life for everyone ifnthat society. It is likely that the individual preferences of 
some couples regarcing ideal family size will come into conflict with the 
social norm. 
Autiorities can attempt to irifluenice couples' decisionmiakinig about tile 
desired size of a complete family in two ways. First, they car use positive in­
centives to erncourage couples to have smaller families, such as giving am 
annual bonus or job promotion to each family that has only one or two 
children. Tile second major approach involves lhe use of disincentives. For 
example, couples may suffer a loss of medical care, loss of housing, or loss of 
educational opportunities for their offspring should they have more children 
than the number the authorities have established as appropriate. 
While the population is growing rapidly inmost areas of Africa, there are 
still broad expanses of unsettled land and many untapped resources. For 
these reasons, most African qovernments have not set policies directed at 
limitinci population growth. On the other hand, many African nations-aware 
299 
,',6 ; Z :, .2"
 
of the potential effects on the quality of life of rapid population growth-are
beginning to encourage voluntary family planning through maternal and child 
health programs. 
Since voluntary family planning is new to most of Africa, it is too early to 
determine whether it will succeed in helping ccuples and countries to meet 
their respective objectives. For voluntary family planning to be given an op­
portunity to succeed, several conditions must be rn, t:
 
1) Contraceptives must be made available on a 
toluntary basis at all post­
partum clinics. 
2) Voluntary contraceptive services must be made available to all who are 
sexually active and who do not wish to become pregnant. This includes 
adolescent as well as older women, and Unmarried as well as married 
women. 
3) Voluntary contraceptive and sterilization services must be made availa­
ble to nulliparous couples as well as to high-parity women. 
4) Voluntary sterilization services must be made available to all meii as 
well as all women, and to rural as well as urban couples. 
The authors of this book hope that Contraceptive Technology: Africa can 
play a small role in improving the level of understanding of modr;rn contracep­
tives and that the availability of birth control methods will irmprove so that 
African couples will continue to be able to make decisions about childbearing 

































Pregnancy RatePearl M thod 
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from NFP centers 
Age: 20-39 
Medical: lovulatory 




users with monthly 
329 3,354 
Cycles 





follow-up by NFP 
center. Age: 19-48, 
Prospective study 




209 20.4 1.2 19.3 15.8 40.8 
users at NFP clinic. 
Age: < 18=8%, 
18-39=80-,. 
: 40=1 1-














176 5.3 0.1 5.2 5.7 12-8 










of new users. 
277(5) 1,967 
Months 
61 3. R N 227. 
3-5 months training,
monthly follow-up.Age: 18-39, 
mean 27(3). 130(6) 1,064 30 33.8 NR NR 24.2 60.1 
Months 
APPENDIX A Selected studies of !he effectiveness of the cervical mucous (Billings) method, 
Pregnancy Rate Discontinu-
Author No. of Pearl Method Life Table ation Rate 
Date & Type of Study No. Length Unplanned Per 100 Woman-Years % at Life Table 
Reference & Description of of Obser- Preg- Method User 12 Months % at 
Number Place of Participants Women vation nancies Total Failure(l) Failure(l) Total 12 Months 
Wade etal. USA Randomized, 573(5) 3,232 94 34.9 NR NR 22.4 73.7 
1980 prospective study Months 
of new users. 191(6) 1.269 42 39.7 5.7 34.0 26.7 73.7 
3-5 months training, Months 
monthly follow-up.







Weissman Tonga Prospective study 282 2.503 53 25.4(7) 0.5(7) 24.9(7) NR NR 
at al. of new zcceptors. Months 
1972 Age: mean 33. 
WHO El Salvador Prospective study 869(8) 2,701 45 21.6 0.5 21.1 NR NR 
1981 	 India, of new users. Cycles

Ireland. 3 cycles training, 725(6) 7.514 130 22.5 2.8 19.7 19.6 35.6
 
New monthly follow-up. Cycles

Zealand, Age: 20-38. mean 30. 869(9) 10,215 175 22.3 2.2 20.1 23.9 45.9 
Philiopines Medical: ovulating. Cycles (at 16 (at 16 








NR = not reported 
NFP = Natural Family Planning 
"Modification of Table 1 inReference 1. 
(1)Causes of failures generally as classified by authors. Method and user failure pregnancy rates may not equal total pregnancy rates because totals sometimes include
 




(2)Sum of method and user failure pregnancy rates does not equa! total because total includes 8 pregnancies following coitus on days of -sticky. cloudy mucus* taught
 
as permissable by some study centers but not permitted under the protocol.
 
13)Description covers alarger group than that reported; description of actual participants only isnot reported.
 
(4)Sum of method and user failure pregnancy rates does not equal t,albecause total includes 6 pregnancies classified as undetermined 
(5)Year beginning with startof training. 
(6)Year beginning with end of training and start of followup. 
17)As recalculated by Marshall. Mosley,and Rochat. 
8) Training period. 
19)Total. including training and followup periods 
APPENDIX B How to calculate the interval of fertility, using the "shortest minus 20,
longest minus 10" calculation 
Shortest Cycle Longest Cycle
(Minus 20) (Minus 10) 
If Your Shortest 
Cycle Has been 
Your First Fertile 
(Unsafe) Day is 
If Your Longest 
Cycle Has Been 
Your First Postovula­



































































Instrument pan and cover 

Control syringes, 5cc Luer-Lok 

Needles, hypodermic, 22g, 1/2" long 

Needles, hypodermic, 25g, 1/4" long 

Forceps, Halsted, mosquito, curved 5" 
stainless steel 
Forceps, Allis intestinal, 5 x 6 teeth 6" 
Needle holder, Collier, 5" 
Blades, carbon steel, N/S Blades, sz 10 
Handle, surgical knife, B-P No. 1030 No. 3 
Forceps, hemostat, straight, 5-1/2", Kelly 
Scissors, suture, standard 5-1/2" angled on 
flat stain!,.;ss 
Needles, taper point, mayo, 1/2" circle, 
sz. 6 
Needle, skin suture, straight, triangular 
point, 2-1/2" 






















Surgical blades, size 10 
Backhaus towel clamps, 14cm 
Allis clamp, 19 cm 
10-ml control syringe 
10-ml hypodermic syringes 
20-gauge hypodermic needles, 4 cm 
Dressing forceps, 14 cm 
Tissue forceps, standard, 14 cm 
Curved Halsted mosquito forceps, 13 cm 
Straight Pean artery forceps, 15.5 cm 
Babcock tissue forceps, 19.5 cm 
Curved artery forceps, 20 cm 
Bozeman dressing forceps, 25 cm 
Surgical knifa handle 

Mayo-Hegar needle holder, 17.5 cm 





Mayo taper point needles, size 6 





Ramathibodi uterine elevator 
Ramathibodi tubal hook 
Stainless steel sponge bowl 
Richardson-Eastman retractors 
Abdominal retractor 
Graves vaginal speculum (medium) 
Suture scissors 
Straight operating scissors, 15 cm 
Curved Metzenbaum scissors, 17.5 cm 


































An Inventory of Village and Household Contraceptive Delivery Projects, 1962-1979 






Dates Sponsors Potential Users Products Sold Retail Outlets Wholesaler and Promotion 
AFRICA 
"Ghana (11.3) Government Urban and Conoom Ghana National Ghana N3tional Consumer. POP-displays;
Start: 1970 Ghana National semi-urban (Sultan Trading Corporation Trading Corporation Media-comprehensive cam-
Product FP Program married Pressu,ized stores 'government (government dis- paign planned to include 
C. launched couples foam (Emko o tributorl press, radio, cinema, TV,wredl 

4 6 1971, 
 Licensed pharmacies Billboards. All oromotion 
program cur- stopped after 10 c ays of 
tailed and press ads. Retailer:
modified 7 1971 none. RP: none. 
Ghana (11.3) Government 7.5% of nonpregnant Condom Cordoms, foaming Commercial distrib- Condoms, foaming tablets: 
Start: 71976 and women age 15-44 who are (Panther . tablets: retail utor Consumer POP-countertop
Product Westinghouse not using contracep- SSSI) shops, dance halls, disolays, posters, door-
launched Health Systems tion, not living in Foaming tab- bars, "mammy way banners; Medin-p-ess.
11979 rural areas, and do not lets (Coral traders" (women radio; Other-billboarcs 
Panther. wish to become pregnant OC (Floril') ztreet vendors) OC: Consumer; posters in 
SSS. 11 1979 (N-62.250) OC- pharmacies clinics, pharmacies,



















Dates Sponsors Potential Users Products Sold Retail Outlets Wholesaler 
Publicity, Advertising 
and Promotion Total Sales 
AFRICA 
Kenya (15.4) 
Star: 3 1972; 
Product launch: 







One-half of "at risk" 
males age 18-30 with 
disposable cash in Meru 
test area (N = 50,000) 
Condom 
King ) 
All retail outlets, 





van, and sound 
equipment); mail-
Consumer: POP-dispen-
sers, metal shop signs, 







order samples, field educator; 
Other; leaflets, pamph­
lets. Retailer: field 
educator salesman, 
printed training ma­
terials. PR: day-long 
picnic seminar for 350local leaders 
Kenya (15.4) 
Start: 8 1974; 
End: 3 1976 


























groups in greater Cairo 
area: 100,000 new 










utor; 4 field 
supervisors also 





lets, list of partici­




ing of physicians lets, sampling. Re­
for IUD insertion tailer: samples, dis­
counts, training. PR: 
radio, press. TV. 




Dates Sponsors Potential Users Products Sold Retail Outlets Wholesaler 
Publicity. Advertising 
and Promotion Total Sales 
MIDDLE EAST 
Morocco (19.4j Government 
Start: 4 1969 
End: 7 1970 





































FP =family planning 
IPPF= International Planned ParenthLood Federation 
OC's = oral contraceptives 
POP = point of purchase 
PR - public relations 
PSI - Population Services International 
Source: Population Reports. Family planning programs. Social marketing: does it work? 1980 Jan; Series J,21. 
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W 	 in Cairo; 
Ministries of Health 








Ministries of Health 

and of Social Affairs 

Project Descriptioh~b 
(1974-1976); In Shanawan Area; 
household canvassing with 
village resupply employing 
local, salaried residents. 
All supplies provided free. 
Population: 14,000. 
(1974-Pres.); In Menoufia 
Governorate: household canvassing 
with village-level resupply; em-
ploying local salaried residents; 
initiai supplies free, resupply 
free of charge. Population: 
200.000. 
7
(19 8-Presl): In Menoufia 
Governorate; integrating and cp-
grading existing delivery systems 
of family planning, health and 
social services, and training 
mediczl, paramedical, and social 
welfare- personnel and local 
leaders to stimulate necessary 
community action for sustaining 
the level of contraceptive preva­
lence initiated to distribute 
contraceptives to households. 
Population: 1.4 million in 302 
rural villages. 
Evaluat:on Design' 
Baseline canvass provided 
estimates of use. Preva-
lencc surveys and service 
statistics provided impact 
assessment. 
Four experimental treatment 
groups compare effects of 
resupply through clinic village 
depots and free supplies 
vs pa-,ing for periodic contra-
ceptive Pre -rice surveys and 
service S:dtistIcs. 
Before and after social, demo-
graphic, health, and contiacepti ,e 
prevalence surveys; service 


















health and family 
planning services 
*;esults' 
One year after initial distribution, 
prevalence of contraceptive use 
increased from 18.4*. to 31%, a 68% 
increase. Service statistics indi­
cate that current prevalence of con­
traceptive use is 35%. 
One year after distribution of 
contraceptives, prevalence of use 
increased from 19% to 27.6%, a 45% 
increase. Project expanded to popu­
lation of 1.4 million. 









Ministry of PuL'ic 
Health (MOPH; 
Tunisia 
National Office of 
" Family Planning 
and Population (ONPFP); 
Sfax Governorate 
II. VILLAGE-BASED DISTRIBUTION (Continued) 
Project Cescription b Evaluation Design' 
(1977-Pr-,.); City of Marrakuch; Pre- and post-delivery 

household canvassing; MOPH contraceptive prevalence 

fieldworkers provide free OC' 
 surveys; comparison of rural 
and concoms on two successive and urban areas and male vs. 




Population: 1.2 millon. 
(1976-Pres.); PFAD project: Service statistics client 

household distribution, using records, evaluation survey. 

young local women, of free OC's 

(6 cycles) and resupply (9 

cycles). Referrals and transpor-

tation arranged for IUD's and fe-

male sterilization. Ultimte re-
supply through clinics and nurse­
hygienists. Designed to test basic
 
feasibility of household delivery
 





















Limited distribution canvass of urban 
and semi-urban areas showed that 
36.1%o of eligible women were already 
,ising contraception. An additional 
20% accepted pills or condoms as e 
result of canvass. Rerults are 
pending firr,- evaluation analysis. 
One year after initial distribution, 
contraceptive prevalence among 
married women of reproductive age 
iMWRA) increased from 5.9% to 
15.3%. Introduction of IUD's and tubal 
ligations has further increased all 
method prevalence. 
APPENDIX E II. VILLAGE-BASED DISTRIBUTION (Continued) 
vices. Population: 140,000. 
Country,
Implementing 







1977-Pres i, PFPC project, house 
hold distribution bv local women, 
free OC's (9 cycles;. condoms. 
foams, jellies; limited resupply 
free with various permanent re-
supply systens to be tested. Re-
ferrals made for :UD's and ster-
v:tion. Study ,.ill also compare 











Initial household visits in first 
delegation (pop: 41,802) provided 
estimate of 15.5'. MWRA as current 
users; and additional 33.3% of 
MWRA accepted free supplies and 
services. 
cc,, effectiveness of OC's on!y 
vs fami, planning with basic 
maternal child health (MCH) ser­
aThis column shows the country and the organizction resporsible for implementing "The first services listed pertain to tnse directly related to nonclinical fertility
the projects, according to available documentation, regulation. Next, the existence of a referral system is noted. A referral system 
iThis 	 i;dicates that distributors actively engage in promoting such service (e.g., trans­column provides brief information on the project's genera: ,haracter'stics. portation, scheduled appointments). Lastly, other services in which the agents
The dates in parentheses tel; when the proert began and ended, !f no are actively involved are indicated (e.g., maternal child care (MCH1 improvedtermination ,'ar appears, the project is assumed still active Insufficient in- nutrition, accinations, parasite treatment, etc.)
formation for a "umber of projects accounts for some incomplete blocks. 
"The strongest results known are stressed. This means that actual measures'This column focuses upon the kinds of information that are or will be of fertility reduction wiil appear, if available. Intermediate measures suchga:"ered. eithp' as part of project activities or independent: assessment as prevaience of contraceptive use will also appear if such information isefforts. Some '.rojects in:lude "treatment" and comparison groups in an a.,ailable. Weaker
experimental design. Since man/ ccmmunity-based distribution (CBDI) 
measures like acceptor rates may be all that are available. 
When none of the above is available, the "Results"projects currently provide minimal 	 may shuw simpleentries in the "Res-ults" column, this numerator data, or only administrative information such as number ofinformation can help anticipate the type of data and analysis that may retail outlets, agents trained, or commodity flow. Some projects have noteventually be reported, reported results at this time. 
Source: 	 Population Reports. Family planning programs. 
Community-based and commercial distribution: an inventory and appraisal. 






anuria and, 250 
 f'rtility rates of. 47-48
 
bleeding and, 248-249 
 injectable contraccptives and, 
chloroquine poisoning and 250 162 
complications of, 246-247 medical and social risks of pregnancy
complications of and for, 1,4 7
 
hospital admissions for, moitdlity and. 47
 
244-245 
 pregnancy and, 1,47
contraception information and, reproductive line plan arid, 1 13-114 
246 traditional coritra:eptive practices of, 
costs to health system, 15-16 47-48 
danger signa9ls. 251 Agglutination, Pregnancy Tests and,
ectopic pregnancy and, 247-250 100- 103 
ergonovine poi~oning and, 250 Allergic Reactions
 
gonorrhea and, 251 
 condoms and, 215-216
infections arid, 247-248 diaphragm.- and. 202, 205
 
infertility related to, 250 
 foams. 220-221
 
kidney damage and. 250 
 injectable contrr-eptives

liver damage and, 250 
 arid, 164
 




cervical damage, 249-250 causes of. 97
 
infection, 247-248 
 injectable contraceptives and,
retained pregnancy tissue, 248 159-160, 163 
toxic reactions, 250 menopause and. 97-98
 
uterine damage, 249-250 Mini-Pill and, 168
 
maternal mortality and, 15- 16 post-partum, 32-33
 
oligura arid, 250 
 pregnancy tests arid, 99
 
oxytocics arid. 248 
 primary, 97
 
parametritis and, 247 
 secondary, 18, 97 
pregnancy outcomes (adverse) temporary infertility arid, 66-67 
related to, 251 Ampicillin, see also Sexually 
pregnancy tests and, 105-109 Transmitted Diseases, 78. 80, 83, 86-87 
public impact of, 243-246 Anemia 
quinine poisoning arid. 250 child spacing, lactation,

retained pregnancy tissue and, and, 41
 
248 
 injectable contraceptives and,

risks of. 251 
 160. 164-165 
salpingitis and, 247 iron-deficiency. 17-18 
Abstinence IUD's -od, 175, 186
 
among ethnic groups, 24-25 lactation and, 39, 41
 
breastfeeding and, 23-25 
 maternal depletion syndrome, 39, 41 
lactation arid, 31-36 menstruation arid, 98
 
Natural Family Planning arid. Pill and, 130, 148
 
225-227, 230-231, 233-235 Anesthasia
 
poM-partum, 22-24, 31-36 
 female sterilization, 260, 262, 
Acne 264,266
 
Mini-Pill and, 16 7 IUD insertion arid, 181, 185 
Pill and, 135, 145-146 male sterilization, 256 
post-partum tubal ligation (incision),
Adolescents see alsoTubal Ligation, 37child spacing and, 47-49, 51 Anuria and Abortion, 250
 
contraceotives and, see also specific Appetite and Pill,
145-147 
methods, 49-50 Arcing Spring Rim, see also Diaphragm,
counseling of, 48-52 types of, 202-204 
educational programs for,48-52 Asherman's Syndrome arid IUD. 196-197 
examination of, 50 Asthma and Pill, 135
 
fertility awareness methods and, 
 Azoospernia. see also Infertility, causes 
226 315 of, 61,71 
31
 
Barrier Methods, see also 
adolescents and, 49-50 

Natural Family Planning and, 234 

specific contraceptive methods, 36 

Basal Body Temperature Method (BBT),

See also Natural Family Planning 

Methods, 225, 230-231 









coitus inter crura. 23 

coitus inter femora, 23 

coitus interruptus, 23 











polygy..-, (polygamy), 23 

service delivery, effect of, 
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voluntary family planning, 

attitudes toward, 299 

Billings Ovulation Method, 

see Cervical Mucous Method, 





Birth Defects, see Maternal Age

Birth or Interpregnancy Interval, 5 

abortions and, 7. 9 

child mortality and, 10-1 1 

children's intelligence and, 12 

infant mortality arid,7, 10 

lactation and, 42-44 

nutrition and, 42-44 

pregnancy wastage and, 7, 9 

stillbirths arid, 7, 9 

Birth Order, 5 

abortion arid, 8 

children's intelligence -and, 12 

fetal deaths arid, 5-6 

infant mortality arid, 8. 10 

maternal mortality -ind. 13-14, 16 

nutrition, child mortality and, 11 

pregnancy wastage and, 8 

stillbirths arid, 8 

Blood Clots, see Pulmonary Embolism 

Blood Pressure. see Hypertension 

BRAIDED Mnemonic, 124 

Brain, Functions of 









Pill arid, 145-146 

Breast Disease, Benign 
injectable contraceptives and, 
161. 163
 
























C.albicans, see Sexually 
Transmitted Diseases 
Calendar Method, 
see Natural Family Planning
Calendar-Thernal Method, 
see Natural Family Planning 
Cancer
 
cervical and IUD's, 173, 186
 


























































see Natural Family Planning
 










birth interval and, 10-11 

nutrition, birth order, arid, 11 

Child Spacing, see Family Planning 











Mini-Pill an:!, 167 

Pill and, 135, 143, 145-146 

Clilojoquine Poisoning aid Abortion, 250 

Cholestic Jaundice and Pill, 146 

Choosing a Contraceptive Method 

access to source, 117, 120 

BRAIDED mnemonic, 124 

breast self-examination, 276-277 

competence for choosing, 124 

contraindications, 119, 276 

costs of, 117-120 





effectiveness, 115- 116 

family environment, 276 

how to choose. 113- 124 

ideal method, 113-114 

individual accepiance, 1 17-122 

informed choice. 113, 123-124 

medical care and, 117-120 

menstrual cycle and, 91, 97 

method failure arid, 115-116, 123 

morbidity arid, 276 

mortality and, 1 18, 121. 276 

physical examinations, 276 

pregnancy, determination of, 276 

program considerations in, 122-123 

religion and, 117 





societal attitudes arid, 113, 117 

voluntary choice, 113 

Clinic-Based Services, see also Service 
Delivery, 282-285 

Coagulation anu Sterilization, 259 

Coagulation Responses arid IUD's, 175 

Coil Spring Rim Diaphragm, see also 

Diaphragm, types of, 202-203 

Coitus Inter Crura, 23 

Coitus Inter Femora, 23 







Combined Pills, see Pill
 
Commercial Retail Sales of 

C'ntracentives, see also Service 

Delivery 232-283, 285 

Community-Based Distribution of 














































Contrace;ptive Methods and Menstruation,
 






Methods, see specific methods 
Copper-7" (Gravigard'), see also
 


















choosing a contraceptive, 113-126
 








infertility, 57, 65, 68-7 1, 73-74
 
male sterilization, 255, 258, 269-270
 















Cystocele and Diaphragms, 202
 
















Lactation and, 36 







injectable contraceptives aJnd, 164 

Pill and, 135, 143-148 













Mini-Pill and, 167 





availability of, 202-204 

checking position of, 207 





educational programs, 206-208 

effectiveness of, 201 

fitting for, 202-205 

graduated fitting rings, 204-205 

health benefits of, 18 

history of, 201 

insertion of, 206-207 





jelly or cream arid, 206-207
 
mechanism of action, 201-202 

noncontraceptive benefits, 205 

removal of, 208 

sexually transmitted diseases and, 18 

side effects and complications, 205 





types of, 202-204 

Diarrhea and Pill, 156 





infertility arid, 69 

Down's Syndrome. 7. 9 

Dutch Cap, see Diaphragm 









IUD's arid, 175, 187 

Mini-Pill arid, 168 

Pill and, 145-146 

Dyspareunia and Pill, 146 

Ectopic Pregnancy. 17 

abortion and, 247, 250 

diagnosis of. 105-109 















































Epilepsy and Pill, 135
 




effects of, 133. 144. 146
 
menstrual cycle and, 91-95
 
potency in Pill, 138-139
 
side effects of, 146
 
Evaluation of Service Delivery. 296-297
 
Eye Pain and Pill. 145-146
 




I-allopius arid Condom, 21 3
 






















family benefits of, 18-19
 
health benefits of, 5-18
 
political support for, 291
 


























Fertility Awareness Methods, 





Fertility Control, 22-25 

Fertilization of Ovum, see also 





birth order and, 5-6 





infertility arid, 63 

Flat Spring Rim Diaphragm, see 







allergic reactions to, 221 

availability of, 219 

effectiveness of, 219-220 













uses of, 221 





Pill and, 131 

Follicle-Stimulating Hormone Releasing 

Factor (FSH-RF). 93 

Follicular Phase, see also 

Menstrual Cycle, 91-92. 94 

Follow-up, User or Patient, set. also 

Service Delivery, 278 





FSH, see Follicle-StirnulatinC Hormone
 
FSH-RF, see Follicle-Stimulating Hormone 

Releasing Factor 




Gardenerella vaginalis, see 

Sexually Transm;tted Diseases 

Gilbert's Disease and Pill, 135 

Gonorrhea, see also Sexually 

Transmitted Diseases, 18 

abortion and, 251 

IUD's and, 173. 195-196 

spermicides and, 221 









Graefenberg, Dr.Ernst, 171 

Gravigard', seeCopper-7, Linder 

Intrauterine Devices, types of 
Hasse, C., 201 
HCG, see Human Chorionic Gonadotropin 
Headacnes 















Hepatitis and Pill, 135
 






High-Dose Estrogens, see Postcoital
 
Contraception 












menstruation and, 9 1-95
 






















Idiopathic Thrombocytopenic Purpura 
(ITP)
 




Immunoassay Pregnancy Test, see also
 
Pregnancy Test, 101 - 1 J4
 
two-minute slide test, 101 - 104
 
two-hour tube test, 102-104
 
Infant Mortality, 5-8, 10
 
birth interval and, 7, 10
 
birth order and, 8, 10
 






















alcohol and, 70 

athletic activities and, 70 

attitudes towards, 55-56 

causes cf, 59-64, 71 

clothing ',d. 70 

condoms and, 215-216 

counseling, 57, 65, 68-71, 73-74 

definition of, 56 

DES arid, 69 

diagnosis of, 61.65, 73-74 

douching arid, 69 

effects of, 55-56 

epidemiology of. 57-58 

family planners and, 55, 57, 65-66 

female circumcision arid. 64 

female infertility, 59-61, 64 

filariasis and, 63 





irradiation arid, 69 

IUD's and, 65-66 

lubricants and, 69 

male infertility, 59, 61-64 

marijuana arid, 70 

medications and, 69 

multiple sex partners arid, 70-71 

nutrition and, 70 

occupation and, 70 

physiology of, 59-62 

PID and, 58, 61, 65-66 

Pill arid, 65-66 

pollution arid, 70 

pregnancy wastage and, 56-57 

prevention of. 65, 74 

primary, 56, 58 

secondary, 56, 58 

sexually transmitted diseases arid, 5 7-58,

61, 63, 65, 77 

smoking and, 70 

spermicides and, 69 

sterilization and, 67 

stress and, 65. 69, 73-74 





endometrial biopsy, 73 

history taking and 









semen analysis, 71-72 

Sims-Huhner (postcoital), 71, 73 

tubal patency, 73 

treatment of, 68, 74 

Informed Choice, 113, 123-124 

Injectable Contraceptives, 129 

adolescents and, 162 





amenorrhea and, 160, 163
 
anemia arid, 160, 164-165
 
as temporary method, 161-162
 
breakthrough bleeding and, 163
 






















fertility (return of), 161
 












iron-deficiency anemia and, 18
 





































Interpregnancy Interval, see Birth Interval
 
Intrauterine Devices (IUD's), see also
 














Asherman's Syndrome and, 196-197
 
cervical cancer and, 173, 186
 






choosing an IUD, 176-179
 




Intrauterine Devices (IUD's) (Cent) 

continuation rates with, 174 

contraindications, 173, 175 

Copper-7" (Gravigardi), see 

Intrauterine Devices, types of 

Copper-T (Tatum-T'), see 

Intrauterine Devices, types of 

cramps and, 187 

Dalkon Shield', see Inirauterine 

Device, types of 

danger signals, 197 

dysmenorrhea and, : 75, 187 









endometritis and, 173, 186, 194 

expulsion of, 174, 179, 186-190 

fitting for, 178-179, 187
 
gonorrhea and, 173, 195-196 







infertility and, 65-66, 175 

in.;ertion of, 177, 180-186 





















Leiomyomata and, 186 

Lippes Loop , see Intrauterine 

Devices, types of 

lost strings, 188-190 





menorrhagia and, 175 

menstruation and, 97-98 









peritonitis and, 194 





perforation during insertion of, 







pregnancy and, 173 

Progestasert-T", see Intrauterine 





removal of, 174, 184, 190-193 

Intrauterine Devices (UD's) (Cont.)
 






sexually transmitted diseases and,
 
78, 173, 195-1 j6
 





types of, 172, 174-1 16
 
uterine bleeding and, i 75, 186
 
Iron-Deficiency Anemia, see Anemia
 




IUD's, see Intrauterine Devices
 














barrier methods and, 36
 
child health and, 31, 41-43
 
child spacing and, 31-34
 




contraceptive selection during, 36-39
 






fertility control and, 31
 
infant health and, 31, 41 .43
 




















noncontraceptive benefits of, 41
 




Pills and, 37-39, 135, 146
 












traditional practice of, 31-32
 







 Maternal Mortality (Cont.)

Laws child spacing and, 12
 
service delivery and, 291 
sterilizat;on and, 268 
family planning services and, 12 
hemorrhage, 14, 16
Let-down Reflex, 186 
Leukorrhea and Pill, 146 
nutritior al depletion, susceptibility 
ano, 16Pulmonary embolism, 14, 16LH-RF, see Luteinizing Hornone-Releasing reies, 16 
Factor

Libido sepsis, 16 
fertility awareness methods and, toxemia, 14, 16 
225 
.'lechanical Ouclusion (Sterilization), 




Pill and, 145-146 z"ee Depo-Provera',MenopauseLife Expectancy at Birth, 5-6 amenorrhea and, 97- 98MenoauseLigation arid Division (Sterilization) iMenorrhagia259
 
Ligation, Division, and Separation 
 injectabe contracptives
(Sterilization), 259 IUD'sand,and,163186Lippes Loop', see alsolntrauterine Mensigna, Wilhelm PDevices, types of J. 201 Menstrual Cycle, 91-98
lactation and, 36 Mens a
r , 9-98Liver Damage and Abortion, 250 amenorrhea, 97-98Liver Disease anemia and, 98Pill arid, 134-135 choosing a contraceptive, 91. 96-97Luteal Phase, see a/so MenstrualCycle, , s a4 chronology of, 95 
Clezg H cramping, menstrual pain, ore R. adysmenorrhea,Luteinizing Hormone P: 92, 96-97siiq Factor determining fertile days, 225-226, 228,ILH-RF), 93, 95L.iteinizing Hormones ILH), 33, 92-95 2023 0230-233, 304Pill and, 131 endometrium or endometrial 
Luteolysis lining, 91-95
 
Pill and, 131 
 effects of contraceptives on,
96-98 
Malnutrition egg, see Menstrual Cycle. ovum
birth order arid, 11-12 fallopian tube, 93
 
child development and, 1 . fertility and, 91, 98
firtilization of ovum, 91-93,
maternal dplotion and, 16, 19 95
susceptib:ty and, 11 9 2 
Marasmus, 42-43 follicles, 92-95Maternal Age, 5abortions and, 7-8 follicular phase, 9 1, 94 functions of brain, 93-95
birth defects and, 79 HOG, 91, 93, 94fetal deaths and, 5, 7 hormones, 91-95IUD insertion arid, 177, 180pregnancy wastage and, 7-8 
 length of cycle. 91, 96, 98
stillbirths and, 7-8 
Maternal-Child Health (MCH) Clinics, 
lutcal phase, 91, 94 
menstrual bleeding or menstruation,see also Service Delivery, 284 91-95Maternal Depletion Syndrome, see Anemia Pill and, 146, 148Maternal Health
family planning (child spacing) missed periods, Pill and, 143,145-147and , 12 m e e r l e 2
 
lactation and, 41-42 
 model menstrual cycle, 230 
Maternal Mortality ovtjrian cycle, 91-93 
abortion, 15-16 ovary, 92-94 
adolescents and, 47 ovulation, 91-95
 
associated with childboaring, 13 ovum or egg, 91-95
physiology of, 91-95birth order and, 13-14, 16 premenstrual symptoms, 92, 94-96 
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Menstrual Cycle (Cont., 

symptoms of, 94, 96, 97 

taking a menstrujal history, 96 

uterine cycle, G1-92, 94 

Metonidazole, see alsoSexually 





injectable contraceptives, 163 





Mini-Pill, 129, 143-145, 147
acne29,67 

adolescents and, 50 

amenorrhea and, 168 











ectopic pregnancy and, 167




failure rates of, 166-167 

headaches and, 167-168 

history of, 166 

instructions to users orpatients, 168 

lactation and, 167 





menstruation and, 97-98 

monilia vaginitis and, 167 

mononucleosis arid, 167 

noncontraceptive benefits of, 168 

safety of. 166 

side effects arid complications, 168 

spotting arid, 168 

thrombophlebitis and, 168 












Mongolism, see Down's Syndrome 
Monilia, see Sexually 
Transmitted Diseases 
Monilia Vaginitis
Diaphragm and, 205 

Mini-Pill and, 167 





Mini-Pill and, 167 







contraceptive use and, 118, 121 

























see Natural Family Planning
 






advantages of, 234- 235
 




















International Federation of 


















































mechanism of action, 232-233
 


















Nausea and Pill, 143, 145-147

Norethindrone Enanthate (NET), 
see Injectable Contraceptives
Nutrition, see Malnutrition 
Oily Skin 




Oliguria and Abortion, 250 

Osyris wightiana, 22 

Ovarian Cancer, 17 

Pill and, 130 





Ovarian Cysts, 17 





fertility awareness methods 









abortion and, 248 

lactation arid, 34 





Pelvic Inflammatory Disease 
infertility and, 58, 61, 65-66 

IUD's, infertility, and, 65-66, 

173, 187, 192, 194-196 

morning-after IUD's and, 241 

Pill and, 17-18, 130, 148 

Pharaonic circumcision 
 see Female 
Circumcision 
Pill, see also Postcoital Contraception 

acne and, 135, 145-146 

adolescents and, 50 

anemia and, 130, 14 :
appetite and, 145-147 

asthma and, 135 

availability in Africa, 138 

benefits of, 130 











breast cancer and, 130 

breast disease (benign) and, 148 

capacitation, 13 1 






















cholestic jaundice and, 146
 








danger signals, 142, 153-1 94
 




















effects of, 133, 144, 146
 
side effects of, 146
 




gallbladder disease and, 134. 145
Gilbert's Disease and, 135
 
headaches and, 134, 143
 
health benefits of, 17-18
 




















instructions for user ri
patient, 149-156
 














men (Pill and), 155
 
management of Pill dosage, 141-142
 
mechanism of action, 131, 133
 

















mononucleosis and, 135 

mortality and, 130 

nausea and, 143, 146-147 

noncontraceptive benefits, 148-149 

oily skin and, 146-147 

ovarian cancer and, 131 

ovarian cysts and, 130, 148 

ovulation and, 131 

overview of, 129-131 

PID and, 130, 148 

PID, infertility, and, 66-67 











effect of, 133 

estrogenic effect of, 140 

potency in, 138-139 









pruritis and, 146 

relative potency of estrogen 

and progestin, 138-141 

rheumatoid arthritis and, 148 

sexually transmitted diseases, 77 













prugressive over time, 144-145 

smoking and, 121, 135 

spotting arid, 134, 143-147 









cancer and, 130 

fibromyomata and, 135 

prolapse and, 146 









varicose veins and, 135, 146 

vasomotor symptoms and, 145-146 






menstral cycle ad, 93-95 

mestral cycle arilactation 
Plants as Contraceptives, 22 

see also Traditional Practices 

Political Support for Family Planning, 
291
 
















testing for, see Pregnancy Tests
 
Pregnancy Order, see Birth Order 
Pregnancy Tests, 99-111
 










costs of, 101, 104
 
disadvantages of, 101-106, 109
 








immunoassay tests, 101 - 104
 
two-minute slide test, 101 - 104 
two-hour tube test, 102-104
 




performing, 99. 102, 109
 
radioimmunoassay tests, 101, 104, 109
 
radioreceptorassay tests, 101, 105
 










trophoblastic disease arid, 100
 










Premenstrual Symptoms. 92, 94-96
 










menstrual cycle and, 91 -95
 














potency in Pill, 138-139
 




Prolactin Reflex, 33-35 





Menstrual Cycle 	 etfect of,290Pruritis and Pill, 146 family health and, 293-294Pubic lice, see Sexually integration of family planningTransmitted Diseases with family health, 293-297Pulmonary Embolism and other laws and, 291maternal-child health (MCH) clinicsThromboembolic Disorde , 14, 16 and, 284injectable contraceptives and,

161, 164 objectives of, 275
Mini-Pill and, 167 obstacles and solutions to, 287,Pill arid, 134, 143, 145 290-291 
political support for, 291 
records, 293, 296r p rts, 293,296 
Quinine Poisoning and Abortion,250 
 referral of users or 
patients, 278-279, 293 
Radioimmunoassay Pregnancy Tests, 101, 
staff 
responsibilities of, 294-295103-104, 109 
Radioreceptorassay Pregnancy Tests, 
team approach to service, 295
training of. 293, 294-295101, 105 
supcrvision and support services,Records (Service Delivery), 293, 296 293, 295-296Rectocele and Diaphragms, 202 
 supplies (ordering, maintaining,
Referral of Users or Patients, see storing), 276, 286-288, 293also Service Delivery and Integration
of Services, 278-279, 293 	
storage guidelines, 288 
target populations meeting needsReports (Service Delivery), 293, 296 of, 282-284
Reproductive Life Plan, 113-114, 122 
 evaluation of, 296-297
Retained Pregnmancy Tissue and Abortion,
248 	 Sexually Transmitted Diseases (orRheumatoid Arthritis, 17 
 Sexually Transmitted Infections)
Pill and, 148 
ba;,ie. methods arid, 77Rhythm Method, see Natural C. albicans. 77Family Planning C. trachotnatis, 77Ruta gra veolens,22 chancroid. 77, 79-81 
chlarnydia, 77, 79. 82-84 
condoms arid, 18, 213-216 
Safe-T-Coil r	 condylomata accuninata, 86-87, see also Intrauterine contraceptive methods and, 77-78Devices, types of C~sbiis, 86-87lactation and, 36 diagnosis of, 79-87Safety of Contraceptives, see also diaphragms and, 1Uspecific methods, 118-I 19, 121 
 ectopic pregnancy and, 77
Sai, Fred T., 113
Salpingitis and Abortion, 247 	 effect.- of, 77 family planning workers arid, 77-78Sanger, Margaret, 2 19 Gardnerella vagirnalis, 84-85Saponaria offkinl~ais, (also gonorrhea, 77, 79-81Enterolobium cyclocarpui),22Secretory Phase, see Luteal Phase 	
herpes genitalis, 84-85 
IUD's, infertility and, 57-58, 61, 63,Service
Sepsis, 
Delivery16 
lerviceaDiverymemonilia, 65-66, 173, 195-196 
77-78, 84-35aiternative methods for (advantages pelvic inflarnmatory disease, 77-81and disadvantages), 28 1-284 Pill arid, 77examples of (Appendix C), 307-312
clinic-based services, 282-285 
pubic lice, 86-87 
spermicidal foam and, 77commercial retail sales, 282-283, spermicides arid, 18, 221285 
syphilis, 77, 82-84community-based distribution, T palidum,77282-285 
T vagina/is, 77 
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treatment and management of,78-87 









Short, Roger. 31 

S'ckle Cell Disease 





Pill and, 135 





Sims-Huhner Test (Postcoital Test) 









adolescents arid, 49 

allergic reactions to, 220-22, 

availability of. 219 





effectiveness of, 219-220 





lactation and, 36 

mechanism of action, 219 

reasons for failure, 220 













menstrual cycle and, 92, 94 





Mini-Pill and, 168 

Pill and, 134, 143-147 

Staff (Service Delivery) 

responsibilities of, 294-295 

team approach, 295 

traiting of, 293, 294-295 

Steri;ization 
abdominal approaches (female), 
260-265 

instructions to user or 



































advantages of, 253-254, 267
 




attitudes tcward, 255, 268
 
















effectiveness of, 253, 267
 
factors affecting use of, 267
 
female (tubal sterilization), see also
 




advantages of, 253-254, 266-267
 

















































































male, 257, 267 
















instructions to c!inicians, 




kit (Appendix A), 303 






side effects arid coinpli catioins 
256-257256-257 1Infertility,
Subfertility, se al..o Infetility, 56, 58 





Supplies, see also Service Delivery and
 
Integration of Services, 293
maintaining stock, 276 





availability of, 223 

effectiveness of, 219-220, 223 












Syphilis, see alsoSexually 

Transmitted Diseases. 18 

7palfidum, see Sexually 
Transmitted Diseases
T vaginalis, see Sexually 
Transmitted Diseases 
Tetracycline, see also Sexually






























lactation as contraceptive, 22-24, 31-32
 
modernization and, 24-25, 27
 
plants as abortifaciernis, 22
plants as fertility-controlling agents, 22
 
safety of, 2 1, 28
 
Userattitudess ud sarid, 27-28








spermicidal foamns and, 221








Tubal Patency Test, see also
 











Uterine Cycle, see Menstrual Cycle

Uterine Fibromyomata and Pill, 135
 




















Pill and, 135, 145-146
 








Vaginal Rings, 169 

Vaginal Septa and Diaphragms, 202 

Vaginal Suppositories, see Suppositories,
 
Creams, and Jellies (Spermicidal) 
Varicose Veins 

Mini-Pill and, 167 













attitudes toward, 299 

benefits of, 299 

Voluntary Family Planning (Cont.)
 



































The authors of Family Planning Methods and Practice. Africa are com­
mitted to producing the best family planning training and reference materials
 
possible for your personal use and for the benefit of your program and
 
clients. To do this, we need your assessment of the book. What you tell us
 
will be used in developing other training materials as well as any future edi­
tions of Family Planning Methods and Practice. Africa. All iniormation will
 




SOMETHING ABOUT YOU 
Name: 	 Date: 
Address: 	 Job Title: 
Employer: 
-	 , Profession: 
SNumber of years of professional Professional Training: 
experience: 
Are you personally providing family planning services to couples? 
Yes - - -- No 
YOUR REACTIONS TO THE BOOK 
1.What did you find to be most useful in your own day-to-day work? 
2.Did you find statements or facts that do not correspond to your profes­
sional experience? If so, please explain: 
3. 	As a result of reading the book, have you done anything differently in your 
personal life or work? If so, please explain: 
4. 	Have you found any of the information, illustrations, or tables to be useful 
during training programs, client counseling sessions, or presentations to 
colleagues? If so, please specify what materials were used, in what kind of 
setting, and for whom. 
2 
5. Are you aware of studies, projects, or clinical experiences from your coun­
try that would improve the value of the book? If so, please identify these
studies or experiences, who was responsible for them, how we can con­
tact them, and send us any information you may have about them. 
6. If you were free to change the book in any way that you saw fit, how would 
you improve it? 
7. Was the book easy to read and understand? If not, please explain how it 
can be improved, citing examples. 
8. To whom would you recommend the book? How might these individuals 
use the book? 
I would appreciate receiving up to._free copies of the book Family Plan­
ning Methods and Practice: Africa to be distributed to • 
Please send copies to this address: 
Mail this evaluation to: Centers for Disease Control 
ATTN: CHPE, Division of Reproductive Health 
U.S. Public Health Service 
Department of Health and Human Services 
Atlanta, Georgia 30333 
U.S.A. 
'Number of free copies available dependent on current inventory. 
